Abcd1tm1Kan/Y
Gt(ROSA)26Sortm2.1(CAG-ELOVL1)Geno/Gt(ROSA)26Sor+
Tg(CMV-cre)1Cgn/0
involves: 129 * BALB/cJ * C57BL/6J * Swiss
|
increased fatty acids level |
J:257393
|
|
lethality, incomplete penetrance |
J:257393
|
Abcd1tm1Kan/Y
Gt(ROSA)26Sortm2.1(CAG-ELOVL1)Geno/Gt(ROSA)26Sor+
Cnptm1(cre)Kan/Cnp+
involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6J
|
increased fatty acids level |
J:257393
|
Acvr1tm1Glh/Acvr1+
Gt(ROSA)26Sortm1.2(CAG-EGFP)Glh/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
involves: 129S6/SvEvTac * C57BL/6J * FVB/N * SJL
|
abnormal response to injury |
J:257905
|
|
increased bone ossification |
J:257905
|
Acvr1tm1Glh/Acvr1+
Gt(ROSA)26Sortm1.2(CAG-EGFP)Glh/Gt(ROSA)26Sor+
Tg(Pdgfra-cre)1Clc/0
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * FVB/N
|
abnormal response to injury |
J:257905
|
|
increased bone ossification |
J:257905
|
Acvr1tm1Glh/Acvr1tm1Vk
Gt(ROSA)26Sortm1.2(CAG-EGFP)Glh/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
involves: 129 * C57BL/6 * FVB/N * SJL
|
abnormal response to injury |
J:257905
|
|
increased bone ossification |
J:257905
|
Acvr1tm1Mak/Acvr1+
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Olig2tm1.1(cre)Wdr/Olig2+
involves: 129 * C57BL/6
|
increased oligodendrocyte number |
J:285841
|
Acvr1tm1Mak/Acvr1+
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Olig2tm1.1(cre)Wdr/Olig2+
involves: 129 * C57BL/6 * FVB/N
|
increased brain tumor incidence |
J:285841
|
|
increased glioma incidence |
J:285841
|
Acvr1tm1Mak/Acvr1+
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
H3c2tm1Mak/H3c2+
Olig2tm1.1(cre)Wdr/Olig2+
involves: 129 * C57BL/6 * FVB/N
|
increased brain tumor incidence |
J:285841
|
|
increased glioma incidence |
J:285841
|
Acvr1tm2.1Vlcg/Acvr1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(tetO-cre)1Jaw/0
involves: 129 * 129S4/SvJae * C57BL/6 * C57BL/6NTac
|
abnormal motor capabilities/coordination/movement |
J:239136
|
|
increased bone ossification |
J:239136
|
Acvr1tm2.1Vlcg/Acvr1+
Gt(ROSA)26Sortm3.1(cre/ERT2)Vlcg/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6NTac
|
increased bone ossification |
J:234069
|
Acvrl1tm2.1Spo/Acvrl1tm2.1Spo
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129 * 129S1/Sv * 129X1/SvJ
|
abnormal lung vasculature morphology |
J:154620
|
|
anemia |
J:154620
|
|
arteriovenous malformation |
J:154620
|
|
cachexia |
J:154620
|
|
decreased hematocrit |
J:154620
|
|
enlarged heart |
J:154620
|
|
gastrointestinal arteriovenous malformation |
J:154620
|
|
internal hemorrhage |
J:154620
|
|
lung hemorrhage |
J:154620
|
|
melena |
J:154620
|
|
premature death |
J:154620
|
Adamts9tm1.1Cvrk/Adamts9tm1.1Cvrk
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Mitf-cre)7114Gsb/0
involves: 129S6/SvEvTac * C3HeB/FeJ * C57BL/6N * CBA
|
abnormal melanoblast morphology |
J:262498
|
|
increased melanoblast apoptosis |
J:262498
|
Adgra2tm1.1Vlcg/Adgra2tm2.1Vlcg
Gt(ROSA)26Sortm3.1(cre/ERT2)Vlcg/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NTac
|
abnormal brain vasculature morphology |
J:200671
|
Adgrg6em2Jlp/Adgrg6em2Jlp
Edil3Tg(Sox2-cre)1Amc/Edil3+
Gt(ROSA)26Sortm1(ADGRG6)Jlp/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * CBA
|
embryonic lethality during organogenesis, complete penetrance |
J:315981
|
|
lethality throughout fetal growth and development, incomplete penetrance |
J:315981
|
|
normal
nervous system phenotype |
J:315981
|
Adgrg6em2Jlp/Adgrg6em2Jlp
Gt(ROSA)26Sortm1(ADGRG6)Jlp/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * SJL
|
embryonic lethality during organogenesis, complete penetrance |
J:315981
|
Afg3l1tm1.1Arte/Afg3l1tm1.1Arte
Afg3l2tm1Arte/Afg3l2tm1Arte
Gt(ROSA)26Sortm1Lrsn/Gt(ROSA)26Sor+
Tg(Plp1-cre/ERT)3Pop/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N
|
abnormal dermal layer morphology |
J:237410
|
|
abnormal melanoblast morphology |
J:237410
|
|
abnormal mitochondrial physiology |
J:237410
|
|
abnormal oligodendrocyte morphology |
J:237410
|
|
abnormal oligodendrocyte physiology |
J:237410
|
|
abnormal Schwann cell morphology |
J:237410
|
|
abnormal sciatic nerve morphology |
J:237410
|
|
decreased melanocyte number |
J:237410
|
|
demyelination |
J:237410
|
|
dilated mitochondrion |
J:237410
|
Afg3l2tm1Arte/Afg3l2tm1Arte
Gt(ROSA)26Sortm1Lrsn/Gt(ROSA)26Sor+
Tg(Pcp2-cre)2Mpin/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal nervous system electrophysiology |
J:193564
|
|
abnormal Purkinje cell mitochondrial morphology |
J:193564
|
Afg3l2tm1Arte/Afg3l2tm1Arte
Gt(ROSA)26Sortm1Lrsn/Gt(ROSA)26Sor+
Tg(Plp1-cre/ERT)3Pop/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
|
abnormal mitochondrial shape |
J:237410
|
|
dilated mitochondrion |
J:237410
|
Agr2tm1.1Lpkn/Agr2tm1.1Lpkn
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129 * 129S6/SvEvTac * C57BL/6
|
abnormal enterocyte morphology |
J:156704
|
|
abnormal enterocyte proliferation |
J:156704
|
|
abnormal intestinal goblet cell morphology |
J:156704
|
|
colitis |
J:156704
|
|
increased enterocyte apoptosis |
J:156704
|
|
increased Paneth cell number |
J:156704
|
Agr2tm1Lex/Agr2tm1Lex
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * 129S5/SvEvBrd * C57BL/6
|
increased cell proliferation |
J:195573
|
Aicdatm1(cre)Mnz/Aicda+
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0
involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J
|
increased B cell derived lymphoma incidence |
J:153656
|
|
increased follicular lymphoma incidence |
J:153656
|
|
increased hemolymphoid system tumor incidence |
J:153656
|
|
increased leukemia incidence |
J:153656
|
|
increased medulloblastoma incidence |
J:153656
|
|
increased skin squamous cell carcinoma incidence |
J:153656
|
|
increased T cell derived lymphoma incidence |
J:153656
|
|
increased tumor incidence |
J:153656
|
|
premature death |
J:153656
|
Akt1tm1Mjl/Akt1+
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm1(cre/ERT)Nat
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6
|
abnormal blood vessel morphology |
J:293971
|
|
abnormal mammary gland duct morphology |
J:293971
|
|
abnormal mammary gland stroma morphology |
J:293971
|
|
biliary cyst |
J:293971
|
|
dilated bile duct |
J:293971
|
|
mammary gland alveolar hyperplasia |
J:293971
|
|
mammary gland hyperplasia |
J:293971
|
Albtm1(cre/ERT2)Mtz/Alb+
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6
|
increased cholangiocarcinoma incidence |
J:192740
|
Aldh1a1tm1Gdu/Aldh1a1tm1Gdu
Aldh1a2tm1.1Mbp/Aldh1a2tm1.1Mbp
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
abnormal spermatogenesis |
J:324715
|
|
azoospermia |
J:324715
|
|
male infertility |
J:324715
|
Alx1em1Jian/Alx1em1Jian
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * CBA/J
|
normal
embryo phenotype |
J:320497
|
Amotl1tm1Laho/Amotl1tm1Laho
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Cdh5-cre/ERT2)1Rha/0
involves: 129X1/SvJ * C57BL/6
|
abnormal pericyte morphology |
J:253854
|
|
abnormal retina blood vessel morphology |
J:253854
|
|
abnormal retina vasculature morphology |
J:253854
|
Angpt1tm1.1Seq/Angpt1tm1.1Seq
Angpt2tm1c(KOMP)Seq/Angpt2tm1c(KOMP)Seq
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/?
Tg(tetO-cre)1Jaw/0
involves: 129 * C57BL/6NCr
|
abnormal anterior eye segment morphology |
J:217296
|
|
abnormal cornea morphology |
J:217296
|
|
abnormal eye morphology |
J:217296
|
|
abnormal eye physiology |
J:217296
|
|
abnormal intraocular pressure |
J:217296
|
|
abnormal lymphatic vessel morphology |
J:217296
|
|
abnormal retina layer morphology |
J:217296
|
|
abnormal retina nerve fiber layer morphology |
J:217296
|
|
absent Schlemm's canal |
J:217296
|
|
buphthalmos |
J:217296
|
|
cornea vascularization |
J:217296
|
|
decreased visual acuity |
J:217296
|
|
increased cornea size |
J:217296
|
|
increased eye anterior chamber depth |
J:217296
|
|
thin retina ganglion layer |
J:217296
|
|
thin retina inner nuclear layer |
J:217296
|
|
thin retina outer nuclear layer |
J:217296
|
Angpt1tm1.1Yona/Angpt1tm1.1Yona
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae
|
abnormal retina blood vessel morphology |
J:213456
|
|
decreased astrocyte number |
J:213456
|
|
increased susceptilbility to retina ischemic injury |
J:213456
|
|
increased vascular permeability |
J:213456
|
ApcMin/Apc+
Gt(ROSA)26Sor/Gt(ROSA)26Sor+
B6.Cg-Gt(ROSA)26Sor ApcMin
|
abnormal tumor susceptibility |
J:66060
|
|
decreased alimentary system tumor incidence |
J:66060
|
|
decreased incidence of tumors by chemical induction |
J:66060
|
|
decreased mammary gland tumor incidence |
J:66060
|
ApcMin/Apc+
Gt(ROSA)26Sortm2(Rnf187)Jhai/Gt(ROSA)26Sor+
Tg(Vil1-cre)20Syr/0
involves: 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased gastrointestinal tumor incidence |
J:173145
|
|
increased tumor growth/size |
J:173145
|
ApcMin/Apc+
Col1a1tm9(tetO-Dnmt3b_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
abnormal DNA methylation |
J:127808
|
|
increased intestinal adenoma incidence |
J:127808
|
|
increased tumor growth/size |
J:127808
|
ApcMin/Apc+
Col1a1tm10(tetO-Dnmt3b_i3)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
normal
neoplasm |
J:127808
|
ApcMin/Apc+
Col1a1tm11(tetO-Dnmt3b_i6)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
normal
neoplasm |
J:127808
|
ApcMin/Apc+
Col1a1tm12(tetO-Dnmt3a_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
normal
neoplasm |
J:127808
|
ApcMin/Apc+
Dclk1tm1.1(cre/ERT2)Seno/Dclk1+
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1(HBEGF)Awai
involves: 129S4/SvJaeSor * C57BL/6
|
abnormal tumor morphology |
J:193873
|
|
normal
digestive/alimentary phenotype |
J:193873
|
|
normal
endocrine/exocrine gland phenotype |
J:193873
|
Apoetm1Unc/Apoetm1Unc
Atictm1c(EUCOMM)Hmgu/Atictm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * C57BL/6N
|
decreased circulating cholesterol level |
J:338121
|
|
decreased susceptibility to atherosclerosis |
J:338121
|
|
normal
homeostasis/metabolism phenotype |
J:338121
|
|
increased circulating triglyceride level |
J:338121
|
Arid1atm1.1Mag/Arid1a+
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * CD-1
|
abnormal ovary morphology |
J:219794
|
|
normal
neoplasm |
J:219794
|
Arid1atm1.1Mag/Arid1atm1.1Mag
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * CD-1
|
hemorrhagic ascites |
J:219794
|
|
increased interleukin-6 secretion |
J:219794
|
|
increased metastatic potential |
J:219794
|
|
increased ovarian carcinoma incidence |
J:219794
|
|
increased ovary tumor incidence |
J:219794
|
Arid1atm1.1Mag/Arid1atm1.1Mag
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S4/SvJaeSor * C57BL/6J * CBA/J
|
abnormal cardiac neural crest cell migration |
J:231470
|
|
abnormal cardiac outflow tract development |
J:231470
|
|
abnormal conotruncus septation |
J:231470
|
|
abnormal neural crest cell migration |
J:231470
|
Arih1em3Gpt/Arih1em3Gpt
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6JGpt
|
decreased interferon-beta secretion |
J:330879
|
|
decreased interleukin-6 secretion |
J:330879
|
|
increased susceptibility to Herpesvirales infection |
J:330879
|
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality |
J:330879
|
Arpc3tm1Ssod/Arpc3tm1Ssod
Gt(ROSA)26Sortm2(CAG-tdTomato)Fawa/Gt(ROSA)26Sor+
Tg(Thy1-cre/ERT2,-EYFP)VGfng/0
involves: C57BL/6 * SJL
|
abnormal dendritic spine morphology |
J:196577
|
Ascl1tm1And/Ascl1tm1And
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Ascl1-EGFP,-cre)1Jejo/0
involves: 129 * 129X1/SvJ * C57BL/6 * DBA
|
abnormal dorsal interneuron morphology |
J:98830
|
Atf5tm1(KOMP)Vlcg/Atf5tm1(KOMP)Vlcg
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Or4e5tm1(cre)Rax/Or4e5+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NCr * C57BL/6NTac
|
abnormal olfactory receptor morphology |
J:205214
|
Atg3tm1.1Ywh/Atg3tm1.1Ywh
Fnip1m1Btlr/Fnip1m1Btlr
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6J
|
abnormal autophagy |
J:234285
|
|
absent B cells |
J:234285
|
Atg3tm1.1Ywh/Atg3tm1.1Ywh
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJaeSor * C57BL/6
|
abnormal T cell morphology |
J:172749
|
|
increased T cell apoptosis |
J:172749
|
Atictm1c(EUCOMM)Hmgu/Atictm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6J * C57BL/6N
|
abnormal cell cycle |
J:338121
|
|
abnormal vascular wound healing |
J:338121
|
|
decreased vascular smooth muscle cell proliferation |
J:338121
|
|
normal
homeostasis/metabolism phenotype |
J:338121
|
Atmtm1Shzh/Atmtm2.1Fwa
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
involves: 129 * 129S6/SvEvTac
|
abnormal class switch recombination |
J:191288
|
|
chromosomal instability |
J:191288
|
Atoh1tm3Hzo/Atoh1+
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
involves: 129 * 129S7/SvEvBrd * 129X1/SvJ
|
abnormal cerebellum external granule cell layer morphology |
J:155047
|
|
abnormal cerebellum morphology |
J:155047
|
|
abnormal neuronal precursor proliferation |
J:155047
|
|
irregular external granule cell layer thickness |
J:155047
|
Atoh1tm3Hzo/Atoh1tm1Hzo
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129 * 129S7/SvEvBrd
|
thin external granule cell layer |
J:155047
|
Atoh1tm3Hzo/Atoh1tm1Hzo
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
involves: 129 * 129S7/SvEvBrd * 129X1/SvJ
|
abnormal neuronal precursor proliferation |
J:155047
|
|
cerebellum atrophy |
J:155047
|
|
thin external granule cell layer |
J:155047
|
Atoh7tm1Gla/Atoh7tm1Gla
Tg(Crx-Atoh7,-cre)60Gla/0
Gt(ROSA)26Sortm1Sho/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * SJL
|
abnormal optic nerve innervation |
J:186563
|
|
abnormal retina nerve fiber layer morphology |
J:186563
|
Atoh7tm1Gla/Atoh7tm1Gla
Tg(Crx-Atoh7,-cre)251Gla/0
Gt(ROSA)26Sortm1Sho/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * SJL
|
abnormal optic nerve innervation |
J:186563
|
|
abnormal optic nerve morphology |
J:186563
|
|
abnormal retina ganglion layer morphology |
J:186563
|
|
abnormal retina nerve fiber layer morphology |
J:186563
|
Aurkatm1.1Tvd/Aurkatm1.1Tvd
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129 * 129P2/OlaHsd * C57BL/6J
|
abnormal mitosis |
J:145744
|
|
increased apoptosis |
J:145744
|
|
increased mitotic index |
J:145744
|
Aurkatm1.1Tvd/Aurkatm1.1Tvd
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm1Sor
involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J
|
abnormal cell nucleus morphology |
J:145744
|
|
abnormal chromosome number |
J:145744
|
|
abnormal mitosis |
J:145744
|
|
decreased cell proliferation |
J:145744
|
|
increased mitotic index |
J:145744
|
Bap1tm1.1Geno/Bap1+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
abnormal hematopoietic system morphology/development |
J:187380
|
Bap1tm1.1Geno/Bap1tm1.1Geno
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
abnormal bone marrow cell physiology |
J:187380
|
|
abnormal cardiac thrombosis |
J:187380
|
|
abnormal erythrocyte morphology |
J:187380
|
|
abnormal erythropoiesis |
J:187380
|
|
abnormal granulocyte morphology |
J:187380
|
|
abnormal hematopoietic stem cell physiology |
J:187380
|
|
abnormal myelopoiesis |
J:187380
|
|
abnormal neutrophil morphology |
J:187380
|
|
anemia |
J:187380
|
|
anisopoikilocytosis |
J:187380
|
|
cardiac muscle necrosis |
J:187380
|
|
enlarged spleen |
J:187380
|
|
extramedullary hematopoiesis |
J:187380
|
|
giant platelets |
J:187380
|
|
heart inflammation |
J:187380
|
|
increased hematopoietic stem cell number |
J:187380
|
|
increased leukemia incidence |
J:187380
|
|
increased leukocyte cell number |
J:187380
|
|
increased monocyte cell number |
J:187380
|
|
increased neutrophil cell number |
J:187380
|
|
increased nucleated erythrocyte cell number |
J:187380
|
|
myeloid hyperplasia |
J:187380
|
|
thrombocytopenia |
J:187380
|
Bcl10tm1Mak/Bcl10tm1Mak
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd
|
normal
immune system phenotype |
J:228288
|
|
normal
mortality/aging |
J:228288
|
Bcl11atm1Pwt/Bcl11atm1Pwt
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
involves: 129X1/SvJ * C57BL/6 * CBA
|
abnormal dendritic cell differentiation |
J:207383
|
|
decreased B cell number |
J:207383
|
|
decreased dendritic cell number |
J:207383
|
|
decreased plasmacytoid dendritic cell number |
J:207383
|
Bcl11atm2.1Peli/Bcl11atm2.1Peli
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv
|
abnormal common lymphocyte progenitor cell morphology |
J:194616
|
|
abnormal hematopoietic stem cell physiology |
J:194616
|
|
abnormal immune system morphology |
J:194616
|
|
abnormal T cell differentiation |
J:194616
|
|
decreased B cell number |
J:194616
|
|
decreased DN2 thymocyte number |
J:194616
|
|
decreased hematopoietic stem cell number |
J:194616
|
|
decreased immature B cell number |
J:194616
|
|
decreased pre-B cell number |
J:194616
|
|
decreased pro-B cell number |
J:194616
|
|
increased B cell apoptosis |
J:194616
|
Bcl11atm2.1Peli/Bcl11atm2.1Peli
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv
|
abnormal hematopoietic stem cell physiology |
J:194616
|
|
decreased hematopoietic stem cell number |
J:194616
|
|
normal
hematopoietic system phenotype |
J:194616
|
|
normal
immune system phenotype |
J:194616
|
Bcl11btm1Peli/Bcl11btm1Peli
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6J
|
abnormal NK cell differentiation |
J:161373
|
|
decreased metastatic potential |
J:161373
|
Bhlha15tm3(cre/ERT2)Skz/?
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/?
Trip11tm1.1Psmi/Trip11tm1.2Psmi
involves: 129/Sv * C57BL/6
|
no abnormal phenotype detected |
J:253969
|
Bhlhe22tm3.1(cre)Meg/Bhlhe22+
Gata3tm1Jfz/Gata3tm2Gsv
Gt(ROSA)26Sortm1(CAG-Mafb,-tdTomato)Good/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
abnormal cochlear ganglion morphology |
J:207904
|
|
abnormal inner hair cell synaptic ribbon morphology |
J:207904
|
Bhlhe22tm3.1(cre)Meg/Bhlhe22tm1Meg
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129/Sv * 129X1/SvJ
|
abnormal spinal cord dorsal horn morphology |
J:158273
|
Bhlhe22tm3.1(cre)Meg/Bhlhe22tm1Meg
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129/Sv * 129S4/SvJaeSor
|
abnormal spinal cord dorsal horn morphology |
J:158273
|
|
decreased neuron number |
J:158273
|
Bmi1tm1(cre/ERT)Mrc/Bmi1+
Gt(ROSA)26Sortm1(DTA)Mrc/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal duodenum crypts of Lieberkuhn morphology |
J:138364
|
|
abnormal jejunum crypts of Lieberkuhn morphology |
J:138364
|
|
premature death |
J:138364
|
|
slow postnatal weight gain |
J:138364
|
Bmi1tm1Sgon/Bmi1tm1Sgon
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
decreased hematopoietic stem cell number |
J:221849
|
|
decreased lymphocyte cell number |
J:221849
|
|
decreased spleen weight |
J:221849
|
|
normal
hematopoietic system phenotype |
J:221849
|
|
normal
immune system phenotype |
J:221849
|
|
normal
mortality/aging |
J:221849
|
|
premature death |
J:221849
|
Bmp2tm1Jfm/Bmp2tm1Jfm
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J * CBA/J
|
normal
craniofacial phenotype |
J:274818
|
|
normal
embryo phenotype |
J:274818
|
Bmp4tm2(tetO-Bmp4,lacZ)Jfm/Bmp4+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129/Sv * C57BL/6J * CBA/J
|
abnormal craniofacial bone morphology |
J:181229
|
|
abnormal eye distance/ position |
J:181229
|
|
abnormal frontal bone morphology |
J:181229
|
|
abnormal mandible morphology |
J:181229
|
|
abnormal maxilla morphology |
J:181229
|
|
abnormal nasal cartilage morphology |
J:181229
|
|
absent frontal bone |
J:181229
|
|
absent nasal bone |
J:181229
|
|
cleft palate |
J:181229
|
|
enlarged Meckel's cartilage |
J:181229
|
|
round head |
J:181229
|
|
short face |
J:181229
|
|
short mandible |
J:181229
|
|
short maxilla |
J:181229
|
|
small frontal bone |
J:181229
|
|
small mandibular coronoid process |
J:181229
|
|
small nasal bone |
J:181229
|
Bmp4tm2(tetO-Bmp4,lacZ)Jfm/?
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/?
Tg(Mef2c-cre)2Blk/?
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ
|
abnormal heart right ventricle morphology |
J:169047
|
|
abnormal heart ventricle outflow tract morphology |
J:169047
|
|
thick myocardium |
J:169047
|
Bod1lem1Bltn/Bod1lem1Bltn
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6J * C57BL/6NTac
|
abnormal class switch recombination |
J:337726
|
|
decreased IgG1 level |
J:337726
|
Braftm1Mmcm/Braf+
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Mitf-cre)7114Gsb/0
STOCK Braftm1Mmcm Gt(ROSA)26Sortm14(CAG-tdTomato)Hze Tg(Mitf-cre)7114Gsb/Cvrk
|
abnormal cell physiology |
J:312561
|
|
increased tail pigmentation |
J:312561
|
Braftm1Tuv/Braftm1Tuv
Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+
Tg(Tyr-cre/ERT2)13Bos/0
TgTn(sb-T2/Onc)#Dla/0
involves: 129S6/SvEvTac * FVB/N
|
increased melanoma incidence |
J:177503
|
Btnl1tm1(KOMP)Mbp/Btnl1tm1(KOMP)Mbp
Gt(ROSA)26Sortm1(rtTA*M2)Jae/0
Tg(tetO-Btnl1)#Ahay/0
involves: 129S4/SvJae * C57BL/6 * C57BL/6N
|
decreased gamma-delta intraepithelial T cell number |
J:236526
|
Capzbtm1c(EUCOMM)Wtsi/Capzbtm1c(EUCOMM)Wtsi
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Atoh1-cre)1Bfri/0
involves: 129S6/SvEvTac * C57BL/6N * CBA * SJL
|
abnormal cochlea morphology |
J:246055
|
|
abnormal cuticular plate morphology |
J:246055
|
|
abnormal vestibular hair cell stereociliary bundle morphology |
J:246055
|
|
cochlear hair cell degeneration |
J:246055
|
|
decreased cochlear hair cell stereocilia number |
J:246055
|
|
short vestibular hair cell stereocilia |
J:246055
|
Card11tm1.1Litt/Card11tm1.1Litt
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Tg(TcraTcrb)425Cbn/?
involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6
|
abnormal T cell activation |
J:180410
|
Cbx8tm1Hko/Cbx8tm1Hko
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129 * C57BL/6 * C57BL/6NTac
|
abnormal cell physiology |
J:178955
|
|
normal
hematopoietic system phenotype |
J:178955
|
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
decreased tumor growth/size |
J:280854
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:280854
|
|
premature death |
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
premature death |
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
increased pancreatic intraepithelial neoplasia incidence |
J:280854
|
|
premature death |
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
premature death |
J:280854
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd
|
decreased B cell number |
J:92789
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(CTNNB1)Nerl/Gt(ROSA)26Sortm1(CTNNB1)Nerl
involves: 129P2/OlaHsd * BALB/c
|
normal
immune system phenotype |
J:112660
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:113365
|
|
abnormal splenic cell ratio |
J:113365
|
|
decreased B cell apoptosis |
J:113365
|
|
increased B cell number |
J:113365
|
|
increased cell proliferation |
J:113365
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6
|
normal
immune system phenotype |
J:113365
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1Uzs/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * BALB/c
|
normal
immune system phenotype |
J:130768
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm5(Map3k14)Rsky/Gt(ROSA)26Sortm5(Map3k14)Rsky
involves: 129P2/OlaHsd * C57BL/6
|
enlarged lymph nodes |
J:139293
|
|
enlarged spleen |
J:139293
|
|
increased marginal zone B cell number |
J:139293
|
|
increased mature B cell number |
J:139293
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm5(Map3k14)Rsky/Gt(ROSA)26Sortm5(Map3k14)Rsky
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6
|
decreased lymphocyte cell number |
J:139293
|
|
decreased mature B cell number |
J:139293
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm6(Map3k14*)Rsky/Gt(ROSA)26Sortm6(Map3k14*)Rsky
involves: 129P2/OlaHsd * C57BL/6
|
abnormal Peyer's patch morphology |
J:139293
|
|
abnormal spleen B cell follicle morphology |
J:139293
|
|
decreased B-1 B cell number |
J:139293
|
|
enlarged lymph nodes |
J:139293
|
|
enlarged spleen |
J:139293
|
|
increased mature B cell number |
J:139293
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm6(Map3k14*)Rsky/Gt(ROSA)26Sortm6(Map3k14*)Rsky
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6
|
increased lymphocyte cell number |
J:139293
|
|
increased mature B cell number |
J:139293
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(Cd74/MOG)Awai/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:140751
|
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:140751
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(Cd74/MOG)Awai/Gt(ROSA)26Sor+
Il10tm1Roer/Il10tm1Roer
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:140751
|
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:140751
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd
|
abnormal T cell activation |
J:160931
|
|
cachexia |
J:160931
|
|
enlarged spleen |
J:160931
|
|
increased T cell derived lymphoma incidence |
J:160931
|
|
increased T cell proliferation |
J:160931
|
|
premature death |
J:160931
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd
|
abnormal B cell activation |
J:228288
|
|
abnormal bone marrow cell number |
J:228288
|
|
abnormal plasmablast number |
J:228288
|
|
abnormal spleen morphology |
J:228288
|
|
enlarged lymph nodes |
J:228288
|
|
enlarged spleen |
J:228288
|
|
increased B cell derived lymphoma incidence |
J:228288
|
|
increased B cell number |
J:228288
|
|
increased B cell proliferation |
J:228288
|
|
increased plasma cell number |
J:228288
|
|
postnatal lethality, complete penetrance |
J:228288
|
|
spleen hyperplasia |
J:228288
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
Malt1tm1Mak/Malt1tm1Mak
involves: 129P2/OlaHsd
|
normal
immune system phenotype |
J:228288
|
|
normal
mortality/aging |
J:228288
|
Cd19tm1(cre)Cgn/?
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sortm1(HBEGF)Awai
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell morphology |
J:131076
|
|
abnormal bone marrow cell number |
J:131076
|
|
abnormal lymph node cell ratio |
J:131076
|
|
abnormal lymphocyte cell number |
J:131076
|
|
abnormal lymphocyte morphology |
J:131076
|
|
abnormal splenic cell ratio |
J:131076
|
|
absent immature B cells |
J:131076
|
|
absent mature B cells |
J:131076
|
Cd28tm1.1Huen/Cd28tm1.1Huen
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
abnormal regulatory T cell physiology |
J:191101
|
|
decreased regulatory T cell number |
J:191101
|
Cd79atm1(cre)Reth/Cd79a+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129X1/SvJ * BALB/c * C57BL/6
|
abnormal enzyme/coenzyme activity |
J:113645
|
Cdc25atm1Hpw/Cdc25atm1.1Hpw
Cdc25btm1Pjd/Cdc25btm1Pjd
Cdc25ctm1Hpw/Cdc25ctm1Hpw
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6
|
abnormal small intestinal villus morphology |
J:145768
|
|
abnormal small intestine crypts of Lieberkuhn morphology |
J:145768
|
|
decreased small intestinal villus height |
J:145768
|
|
decreased small intestine length |
J:145768
|
|
premature death |
J:145768
|
|
weight loss |
J:145768
|
Cdc25atm1Hpw/Cdc25atm1.1Hpw
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6
|
normal
digestive/alimentary phenotype |
J:145768
|
Cdc42tm1Brak/Cdc42tm1Brak
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6
|
abnormal crypts of Lieberkuhn morphology |
J:184563
|
|
abnormal intestinal epithelium morphology |
J:184563
|
|
abnormal small intestinal villus morphology |
J:184563
|
|
absent Paneth cells |
J:184563
|
|
increased small intestinal crypt cell apoptosis |
J:184563
|
Cdcp1tm1.2Moas/Cdcp1tm1.2Moas
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Tg(KRT14-cre/ERT)20Efu/0
involves: 129X1/SvJ * C57BL/6 * CD-1 * FVB/N * SJL
|
abnormal skin condition |
J:194368
|
|
abnormal skin morphology |
J:194368
|
|
focal hair loss |
J:194368
|
|
hunched posture |
J:194368
|
|
increased tumor growth/size |
J:194368
|
|
increased tumor incidence |
J:194368
|
|
premature death |
J:194368
|
|
thick epidermis |
J:194368
|
|
thick skin |
J:194368
|
Cdh1tm1.1Mpst/Cdh1tm2Kem
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tg(Vil1-cre)20Syr/0
involves: 129 * C57BL/6 * DBA/2
|
no abnormal phenotype detected |
J:163273
|
Cdk1tm3Kald/Cdk1+
Fbxo43tm1.2Kald/Fbxo43tm1.2Kald
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL
|
arrest of male meiosis |
J:251984
|
|
azoospermia |
J:251984
|
|
increased male germ cell apoptosis |
J:251984
|
|
premature death |
J:251984
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Gt(ROSA)26Sortm1.1(MYC/ERT2)Gev/Gt(ROSA)26Sortm1.1(MYC/ERT2)Gev
involves: 129X1/SvJ * C57BL/6 * FVB/N
|
increased cell proliferation |
J:142030
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
involves: 129 * C57BL/6J * SJL
|
increased fibrosarcoma incidence |
J:146617
|
|
increased sarcoma incidence |
J:146617
|
|
intestinal fibrosis |
J:146617
|
|
skeletal muscle interstitial fibrosis |
J:146617
|
|
skin fibrosis |
J:146617
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptentm1Rdp/Ptentm1Rdp
Tg(tetO-BRAF*V600E)29Lc/0
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129/Sv * C57BL/6J * FVB * SJL
|
increased melanoma incidence |
J:221902
|
Cdx1tm1Pgr/Cdx1tm1Pgr
Gt(ROSA)26Sortm1(en/Cdx1,-EGFP)Npln/Gt(ROSA)26Sor+
Tg(Pax3-cre)1Joe/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal hypoglossal nerve morphology |
J:231654
|
|
abnormal melanoblast migration |
J:231654
|
|
belly spot |
J:231654
|
|
fused dorsal root ganglion |
J:231654
|
|
white spotting |
J:231654
|
Celf2tm1Yjin/Celf2tm1Yjin
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Pvalbtm1(cre)Arbr/Pvalb+
involves: 129P2/OlaHsd * 129S6/SvEvTac * BALB/c * C57BL/6NCrl
|
abnormal neuron physiology |
J:269731
|
Cep55tm1c(EUCOMM)Hmgu/Cep55tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6N * C57BL/6NTac
|
increased cell nucleus count |
J:287102
|
Cflartm1Ywh/Cflartm1Ywh
Gt(ROSA)26Sortm16(cre)Arte/Gt(ROSA)26Sor+
Ripk3tm2Vmd/Ripk3tm2Vmd
involves: 129S6/SvEvTac * C57BL/6N * C57BL/6NTac
|
embryonic lethality prior to tooth bud stage |
J:209137
|
Chattm2(cre)Lowl/Chat+
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Sema6aGt(KST069)Byg/Sema6aGt(KST069)Byg
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NCr
|
abnormal inhibitory postsynaptic currents |
J:202884
|
Chd7Gt(S20-7E1)Sor/Chd7tm1.1Dmm
Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze/Gt(ROSA)26Sor+
Tg(Neurog1-cre)1Jejo/0
involves: 129S * C57BL/6 * SJL/J
|
abnormal vestibulocochlear ganglion morphology |
J:310063
|
Chd7tm1.1Dmm/Chd7tm1.1Dmm
Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze/Gt(ROSA)26Sor+
Shhtm1(EGFP/cre)Cjt/Shh+
involves: 129S1/SvlmJ * 129S6/SvEvTac * C57BL/6J * SJL/J
|
normal
hearing/vestibular/ear phenotype |
J:310063
|
Chd7tm1.1Dmm/Chd7tm1.1Dmm
Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze/Gt(ROSA)26Sor+
Tg(Atoh1-cre)1Bfri/0
involves: 129 * C57BL/6 * C57BL/6NCrl * CBA
|
normal
hearing/vestibular/ear phenotype |
J:310063
|
Chd7tm2a(EUCOMM)Wtsi/Chd7tm2a(EUCOMM)Wtsi
E2f1Tg(Wnt1-cre)2Sor/E2f1+
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
involves: 129 * C3H * C57BL/6 * C57BL/6N
|
abnormal conotruncal ridge morphology |
J:298597
|
|
abnormal cranial neural crest cell migration |
J:298597
|
|
abnormal embryonic tissue physiology |
J:298597
|
|
abnormal pharyngeal arch morphology |
J:298597
|
|
double outlet right ventricle |
J:298597
|
|
impaired cranial neural crest cell differentiation |
J:298597
|
|
interrupted aortic arch, type b |
J:298597
|
|
perinatal lethality, complete penetrance |
J:298597
|
|
pulmonary trunk hypoplasia |
J:298597
|
|
small frontal bone |
J:298597
|
|
small mandible |
J:298597
|
|
small maxilla |
J:298597
|
|
ventricular septal defect |
J:298597
|
Chuktm1Lex/Chuktm1Lex
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S/Sv * 129S/SvEvBrd * C57BL/6
|
abnormal fibroblast migration |
J:159873
|
|
decreased fibroblast cell migration |
J:159873
|
|
decreased fibroblast chemotaxis |
J:159873
|
Ciao3tm1.1Fsl/Ciao3tm1.1Fsl
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
premature death |
J:170523
|
Cmiptm1.1Ics/Cmiptm1.1Ics
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
B6.Cg-Cmiptm1.1Ics Gt(ROSA)26Sortm1(cre/ERT)Nat
|
normal
renal/urinary system phenotype |
J:313623
|
Col1a1tm1(tetO-CTNNB1)Tcd/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
abnormal crypts of Lieberkuhn morphology |
J:193365
|
|
abnormal enterocyte apoptosis |
J:193365
|
|
abnormal enterocyte proliferation |
J:193365
|
|
abnormal intestine development |
J:193365
|
|
decreased body weight |
J:193365
|
|
normal
digestive/alimentary phenotype |
J:193365
|
|
increased enterocyte apoptosis |
J:193365
|
Col1a1tm1(tetO-Cyp26b1)Mfra/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal lymphatic vessel morphology |
J:206581
|
Col1a1tm1(tetO-Deptor)Dmsa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6 * C57BL/6J
|
hepatic steatosis |
J:187378
|
|
increased circulating leptin level |
J:187378
|
|
increased liver weight |
J:187378
|
|
increased susceptibility to diet-induced obesity |
J:187378
|
|
increased triglyceride level |
J:187378
|
|
increased white adipose tissue amount |
J:187378
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
decreased fibroblast proliferation |
J:194505
|
|
increased sarcoma incidence |
J:194505
|
|
premature death |
J:194505
|
|
tumor regression |
J:194505
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Tg(CAG-cat,-lacZ)11Miya/0
involves: 129S4/SvJae * C57BL/6 * CBA/J * DBA/2
|
increased sarcoma incidence |
J:194505
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(Mpz-cre)94Imeg/0
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6
|
increased sarcoma incidence |
J:194505
|
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Alb1-cre)7Gsc/0
involves: 129 * C57BL/6 * FVB/N
|
abnormal liver morphology |
J:210545
|
|
premature death |
J:210545
|
Col1a1tm1(tetO-GFP/RNAi:luc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
no abnormal phenotype detected |
J:171191
|
Col1a1tm1(tetO-GFP/RNAi:Rad21)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal bone marrow cell number |
J:229031
|
|
abnormal definitive hematopoiesis |
J:229031
|
|
abnormal hematopoietic stem cell morphology |
J:229031
|
|
decreased B cell number |
J:229031
|
|
extramedullary hematopoiesis |
J:229031
|
|
increased hematopoietic stem cell number |
J:229031
|
|
increased myeloid cell number |
J:229031
|
Col1a1tm1(tetO-Irf4)Sing/Col1a1tm1(tetO-Irf4)Sing
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Irf4tm1Mak/Irf4+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal class switch recombination |
J:203903
|
|
abnormal plasma cell differentiation |
J:203903
|
Col1a1tm1(tetO-Irf4)Sing/Col1a1tm1(tetO-Irf4)Sing
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Irf4tm1Mak/Irf4tm1Mak
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal class switch recombination |
J:203903
|
|
abnormal plasma cell differentiation |
J:203903
|
Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal bone marrow cell morphology/development |
J:179085
|
|
abnormal bone marrow cell physiology |
J:179085
|
|
abnormal proerythroblast morphology |
J:179085
|
|
decreased bone marrow cell number |
J:179085
|
|
decreased erythrocyte cell number |
J:179085
|
|
decreased hematopoietic cell number |
J:179085
|
|
decreased lymphocyte cell number |
J:179085
|
|
decreased megakaryocyte cell number |
J:179085
|
|
macrocytosis |
J:179085
|
|
normal
mortality/aging |
J:179085
|
|
postnatal growth retardation |
J:179085
|
|
reticulocytopenia |
J:179085
|
|
thrombocytosis |
J:179085
|
Col1a1tm1(tetO-RNAi:Rps19)Karl/Col1a1tm1(tetO-RNAi:Rps19)Karl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal bone marrow cell morphology/development |
J:179085
|
|
abnormal bone marrow cell physiology |
J:179085
|
|
abnormal large intestine morphology |
J:179085
|
|
abnormal proerythroblast morphology |
J:179085
|
|
decreased bone marrow cell number |
J:179085
|
|
decreased erythrocyte cell number |
J:179085
|
|
decreased hematopoietic cell number |
J:179085
|
|
decreased lymphocyte cell number |
J:179085
|
|
decreased megakaryocyte cell number |
J:179085
|
|
decreased neutrophil cell number |
J:179085
|
|
macrocytosis |
J:179085
|
|
postnatal growth retardation |
J:179085
|
|
premature death |
J:179085
|
|
reticulocytopenia |
J:179085
|
|
thrombocytopenia |
J:179085
|
|
thrombocytosis |
J:179085
|
Col1a1tm1(tetO-SOX2)Mjm/Col1a1+
Gt(ROSA)26Sortm1(tTA)Roos/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2J
|
abnormal ileum crypts of Lieberkuhn morphology |
J:199754
|
|
abnormal intestine physiology |
J:199754
|
|
ectopic Paneth cells |
J:199754
|
|
increased cell proliferation |
J:199754
|
Col1a1tm1(tetO-Stat1)Biat/Col1a1tm1(tetO-Stat1)Biat
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Stat1tm1Dlv/Stat1tm1Dlv
involves: 129S/SvEv * 129S4/SvJae * C57BL/6
|
abnormal susceptibility to infection induced morbidity/mortality |
J:212694
|
Col1a1tm1(tetO-Tcfap2c)Hsc/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal circulating enzyme level |
J:174049
|
|
abnormal enterocyte proliferation |
J:174049
|
|
abnormal hepatocyte mitochondrial morphology |
J:174049
|
|
abnormal hepatocyte morphology |
J:174049
|
|
abnormal intestinal mucosa morphology |
J:174049
|
|
abnormal intestine development |
J:174049
|
|
abnormal pancreas physiology |
J:174049
|
|
abnormal small intestine morphology |
J:174049
|
|
decreased liver glycogen level |
J:174049
|
|
dehydration |
J:174049
|
|
normal
immune system phenotype |
J:174049
|
|
increased circulating alanine transaminase level |
J:174049
|
|
increased circulating alkaline phosphatase level |
J:174049
|
|
increased circulating amylase level |
J:174049
|
|
increased circulating aspartate transaminase level |
J:174049
|
|
increased circulating lactate dehydrogenase level |
J:174049
|
|
increased hepatocyte apoptosis |
J:174049
|
|
increased hepatocyte proliferation |
J:174049
|
|
lethargy |
J:174049
|
|
liver failure |
J:174049
|
|
microvesicular hepatic steatosis |
J:174049
|
|
premature death |
J:174049
|
|
weight loss |
J:174049
|
Col1a1tm1(tetO-U2AF1*S34F)Mjwa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6
|
abnormal definitive hematopoiesis |
J:221403
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:222916
|
|
increased prostate gland tumor incidence |
J:222916
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(KRT14-cre)1Amc/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA
|
abnormal epidermal layer morphology |
J:171057
|
|
abnormal epidermal stem cell morphology |
J:171057
|
|
abnormal hair growth |
J:171057
|
|
abnormal tongue epithelium morphology |
J:171057
|
|
hyperkeratosis |
J:171057
|
|
increased cell proliferation |
J:171057
|
|
increased skin squamous cell carcinoma incidence |
J:171057
|
|
thick epidermis |
J:171057
|
|
thick skin |
J:171057
|
|
wrinkled skin |
J:171057
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal enterocyte proliferation |
J:141457
|
|
abnormal intestinal epithelium morphology |
J:141457
|
|
abnormal intestinal goblet cell morphology |
J:141457
|
|
absent Paneth cells |
J:141457
|
|
decreased alkaline phosphatase activity |
J:141457
|
|
enlarged pancreas |
J:141457
|
|
increased cell proliferation |
J:141457
|
|
increased pancreatic acinar cell number |
J:141457
|
|
pancreatic acinar-to-ductal metaplasia |
J:141457
|
|
premature death |
J:141457
|
|
thick skin |
J:141457
|
Col1a1tm1(tetO-Yap1*)Lrsn/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
premature death |
J:185310
|
Col1a1tm1(tetO-Yod1*)Hpl/Col1a1tm1(tetO-Yod1*)Hpl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:194608
|
|
abnormal professional antigen presenting cell physiology |
J:194608
|
|
normal
immune system phenotype |
J:194608
|
Col1a1tm1(tetO-Yod1*)Hpl/Col1a1tm1(tetO-Yod1*)Hpl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Tap1tm1Arp/Tap1tm1Arp
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
|
abnormal professional antigen presenting cell physiology |
J:194608
|
Col1a1tm2(tetO-CTNNB1*)Hoch/Col1a1tm2(tetO-CTNNB1*)Hoch
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6
|
abnormal crypts of Lieberkuhn morphology |
J:191050
|
|
abnormal intestinal epithelium morphology |
J:191050
|
|
abnormal intestinal goblet cell morphology |
J:191050
|
|
abnormal large intestine crypts of Lieberkuhn morphology |
J:191050
|
|
abnormal small intestine crypts of Lieberkuhn morphology |
J:191050
|
Col1a1tm2(tetO-GFP/RNAi:Smc1a)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal bone marrow cell number |
J:229031
|
|
abnormal definitive hematopoiesis |
J:229031
|
|
abnormal hematopoietic stem cell morphology |
J:229031
|
|
decreased B cell number |
J:229031
|
|
decreased hematopoietic stem cell number |
J:229031
|
|
enlarged spleen |
J:229031
|
|
extramedullary hematopoiesis |
J:229031
|
|
increased bone marrow cell number |
J:229031
|
|
increased granulocyte monocyte progenitor cell number |
J:229031
|
|
increased hematopoietic stem cell number |
J:229031
|
|
increased myeloid cell number |
J:229031
|
|
increased neutrophil cell number |
J:229031
|
|
increased spleen red pulp amount |
J:229031
|
|
myeloid hyperplasia |
J:229031
|
|
myeloid metaplasia |
J:229031
|
Col1a1tm2(tetO-GFP/RNAi:Smc1a)Iaai/Col1a1tm3(tetO-GFP/RNAi:Stag2)Iaai
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal definitive hematopoiesis |
J:229031
|
|
abnormal spleen morphology |
J:229031
|
|
anemia |
J:229031
|
|
decreased B cell number |
J:229031
|
|
enlarged spleen |
J:229031
|
|
myeloid hyperplasia |
J:229031
|
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Flt3tm1.1Dosm/Flt3tm1.1Dosm
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129 * C57BL/6
|
increased leukemia incidence |
J:210097
|
|
premature death |
J:210097
|
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
involves: 129S4/SvJae * C57BL/6
|
abnormal hematopoietic stem cell proliferation |
J:210097
|
|
enlarged spleen |
J:210097
|
|
extramedullary hematopoiesis |
J:210097
|
|
normal
hematopoietic system phenotype |
J:210097
|
|
increased hematopoietic stem cell proliferation |
J:210097
|
|
increased leukemia incidence |
J:210097
|
|
normal
neoplasm |
J:210097
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Cdh16-cre)91Igr/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * ICR
|
normal
renal/urinary system phenotype |
J:211179
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Wt1tm2(cre/ERT2)Wtp/Wt1+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
abnormal kidney mesenchyme morphology |
J:211179
|
|
delayed kidney development |
J:211179
|
|
increased kidney tumor incidence |
J:211179
|
|
kidney cyst |
J:211179
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Six2-EGFP/cre)1Amc/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CD-1
|
kidney cyst |
J:211179
|
|
normal
neoplasm |
J:211179
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * CD-1
|
decreased susceptibility to diet-induced obesity |
J:177113
|
|
hypoglycemia |
J:177113
|
|
improved glucose tolerance |
J:177113
|
|
increased insulin sensitivity |
J:177113
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Foxd1tm1(GFP/cre)Amc/Foxd1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
hydronephrosis |
J:211179
|
|
normal
neoplasm |
J:211179
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * CD-1
|
normal
homeostasis/metabolism phenotype |
J:177113
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Wt1tm2(cre/ERT2)Wtp/Wt1+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
small kidney |
J:211179
|
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal cell proliferation |
J:98920
|
|
abnormal epidermal layer morphology |
J:98920
|
|
abnormal forestomach morphology |
J:98920
|
|
abnormal hair follicle morphology |
J:98920
|
|
abnormal intermediate gastric gland morphology |
J:98920
|
|
abnormal intestinal epithelium morphology |
J:98920
|
|
abnormal small intestine morphology |
J:98920
|
|
abnormal stomach epithelium morphology |
J:98920
|
|
abnormal stomach glandular epithelium morphology |
J:98920
|
|
abnormal stomach mucosa morphology |
J:98920
|
|
dehydration |
J:98920
|
|
increased skin tumor incidence |
J:98920
|
|
lethargy |
J:98920
|
|
premature death |
J:98920
|
|
spleen atrophy |
J:98920
|
|
stomach epithelial hyperplasia |
J:98920
|
|
thymus atrophy |
J:98920
|
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(tTA)Roos/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2J
|
abnormal intestine physiology |
J:199754
|
|
abnormal small intestine crypts of Lieberkuhn morphology |
J:199754
|
|
increased cell proliferation |
J:199754
|
Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
decreased erythrocyte cell number |
J:179085
|
|
decreased hematopoietic cell number |
J:179085
|
|
decreased lymphocyte cell number |
J:179085
|
|
macrocytosis |
J:179085
|
|
normal
mortality/aging |
J:179085
|
|
postnatal growth retardation |
J:179085
|
|
reticulocytopenia |
J:179085
|
|
thrombocytopenia |
J:179085
|
|
thrombocytosis |
J:179085
|
Col1a1tm2(tetO-RNAi:Rps19)Karl/Col1a1tm2(tetO-RNAi:Rps19)Karl
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
decreased erythrocyte cell number |
J:179085
|
|
decreased hematopoietic cell number |
J:179085
|
|
decreased lymphocyte cell number |
J:179085
|
|
decreased neutrophil cell number |
J:179085
|
|
macrocytosis |
J:179085
|
|
postnatal growth retardation |
J:179085
|
|
premature death |
J:179085
|
|
reticulocytopenia |
J:179085
|
|
thrombocytopenia |
J:179085
|
|
thrombocytosis |
J:179085
|
Col1a1tm2(tetO-U2AF1)Mjwa/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/0
involves: 129S4/SvJae * C57BL/6
|
normal
hematopoietic system phenotype |
J:221403
|
Col1a1tm3(tetO-Fosl1,-DsRed)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal skeleton morphology |
J:213764
|
|
ascites |
J:213764
|
|
enlarged spleen |
J:213764
|
|
lethargy |
J:213764
|
|
liver fibrosis |
J:213764
|
|
weight loss |
J:213764
|
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal forelimb morphology |
J:171191
|
|
abnormal hair follicle morphology |
J:171191
|
|
abnormal hindlimb morphology |
J:171191
|
|
decreased body size |
J:171191
|
|
delayed endochondral bone ossification |
J:171191
|
|
excessive hair |
J:171191
|
|
failure of endochondral bone ossification |
J:171191
|
|
fetal growth retardation |
J:171191
|
|
hydrops fetalis |
J:171191
|
|
increased leukemia incidence |
J:171191
|
|
increased lymphoma incidence |
J:171191
|
|
increased T cell derived lymphoma incidence |
J:171191
|
|
polydactyly |
J:171191
|
|
postnatal growth retardation |
J:171191
|
|
premature death |
J:171191
|
|
progressive hair loss |
J:171191
|
|
short snout |
J:171191
|
Col1a1tm3(tetO-GFP/RNAi:Stag2)Iaai/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal definitive hematopoiesis |
J:229031
|
|
abnormal hematopoietic stem cell morphology |
J:229031
|
|
decreased B cell number |
J:229031
|
|
decreased hematopoietic stem cell number |
J:229031
|
|
increased myeloid cell number |
J:229031
|
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * CD-1
|
decreased body size |
J:177113
|
|
impaired glucose tolerance |
J:177113
|
|
increased circulating glucose level |
J:177113
|
|
increased circulating insulin level |
J:177113
|
|
postnatal growth retardation |
J:177113
|
Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/?
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
decreased primordial germ cell number |
J:196313
|
Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
no abnormal phenotype detected |
J:157298
|
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal hair follicle morphology |
J:171191
|
|
decreased body size |
J:171191
|
|
excessive hair |
J:171191
|
|
increased leukemia incidence |
J:171191
|
|
increased lymphoma incidence |
J:171191
|
|
increased T cell derived lymphoma incidence |
J:171191
|
|
postnatal growth retardation |
J:171191
|
|
premature death |
J:171191
|
|
progressive hair loss |
J:171191
|
|
short snout |
J:171191
|
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6
|
cachexia |
J:171191
|
|
increased lung adenoma incidence |
J:171191
|
|
increased tumor incidence |
J:171191
|
|
premature death |
J:171191
|
|
respiratory distress |
J:171191
|
Col1a1tm5(tetO-Jun/Fos)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Alb1-cre)7Gsc/0
involves: 129 * C57BL/6 * FVB/N
|
abnormal liver morphology |
J:210545
|
|
premature death |
J:210545
|
Col1a1tm6(tetO-MSI2)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal bone marrow cell morphology/development |
J:163322
|
|
abnormal erythrocyte morphology |
J:163322
|
|
abnormal leukocyte morphology |
J:163322
|
|
abnormal myelopoiesis |
J:163322
|
|
decreased common myeloid progenitor cell number |
J:163322
|
|
decreased lymphocyte cell number |
J:163322
|
|
decreased neutrophil cell number |
J:163322
|
|
enlarged spleen |
J:163322
|
|
increased bone marrow cell number |
J:163322
|
|
increased erythrocyte cell number |
J:163322
|
|
increased hematocrit |
J:163322
|
|
increased hematopoietic stem cell number |
J:163322
|
|
increased leukemia incidence |
J:163322
|
|
increased leukocyte cell number |
J:163322
|
|
increased liver weight |
J:163322
|
|
increased mean corpuscular volume |
J:163322
|
|
increased spleen weight |
J:163322
|
|
increased susceptibility to induced morbidity/mortality |
J:163322
|
|
spleen hyperplasia |
J:163322
|
|
thrombocytopenia |
J:163322
|
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI
|
abnormal cell cycle |
J:171348
|
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm8(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal cell cycle |
J:171348
|
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm9(tetO-GFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
chimera involves: 129S4/SvJae * C57BL/6
|
infertility |
J:171348
|
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal cell cycle |
J:171348
|
|
early cellular replicative senescence |
J:171348
|
|
neonatal lethality, complete penetrance |
J:171348
|
|
no abnormal phenotype detected |
J:171348
|
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm10(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal small intestinal crypt cell physiology |
J:171348
|
|
abnormal small intestinal crypt cell proliferation |
J:171348
|
|
decreased erythroid progenitor cell number |
J:171348
|
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal cell cycle |
J:171348
|
|
early cellular replicative senescence |
J:171348
|
|
neonatal lethality, complete penetrance |
J:171348
|
|
no abnormal phenotype detected |
J:171348
|
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CMV-rtTA)4Bjd/0
involves: 129S4/SvJae * C57BL/6 * NMRI
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm11(tetO*-RFP/RNAi:Rpa3)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129S4/SvJae * C57BL/6
|
abnormal small intestinal crypt cell physiology |
J:171348
|
|
abnormal small intestinal crypt cell proliferation |
J:171348
|
|
decreased erythroid progenitor cell number |
J:171348
|
|
premature death |
J:171348
|
|
weight loss |
J:171348
|
Col1a1tm17(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal small intestinal crypt cell physiology |
J:222595
|
|
abnormal small intestinal crypt cell proliferation |
J:222595
|
|
ectopic Paneth cells |
J:222595
|
Col1a1tm18(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
normal
digestive/alimentary phenotype |
J:222595
|
Col1a1tm19(tetO-GFP,-cas9*)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal small intestinal crypt cell physiology |
J:222595
|
|
abnormal small intestinal crypt cell proliferation |
J:222595
|
|
ectopic Paneth cells |
J:222595
|
Col1a1tm20(tetO-GFP,-cas9*D10A)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal small intestinal crypt cell physiology |
J:222595
|
|
abnormal small intestinal crypt cell proliferation |
J:222595
|
|
ectopic Paneth cells |
J:222595
|
Col4a3tm1Jhm/Col4a3tm1Jhm
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(tetO-COL4A3/Col4a3)#aJhm/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA
|
increased renal glomerulus basement membrane thickness |
J:207595
|
|
normal
renal/urinary system phenotype |
J:207595
|
Cpa3tm3(icre)Hrr/Cpa3+
Gt(ROSA)26Sortm1Hjf/?
Notch1tm1Agt/Notch1tm1Agt
involves: 129 * C57BL/6
|
abnormal dendritic cell differentiation |
J:143731
|
|
abnormal T cell receptor beta chain V(D)J recombination |
J:143731
|
Crls1tm1Geno/Crls1tm1Geno
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
decreased oxygen consumption |
J:266083
|
Ctdnep1tm3Ryn/Ctdnep1tm3Ryn
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Six2tm1(tTA,tetO-EGFP/cre)Amc/Six2+
involves: 129X1/SvJ * C57BL/6 * C57BL/6J
|
decreased kidney apoptosis |
J:205755
|
Ctnna1em1Xjz/Ctnna1tm1Efu
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * C57BL/6J * C57BL/6NCrl * CBA
|
abnormal retina development |
J:328283
|
|
decreased angiogenesis |
J:328283
|
|
hemorrhage |
J:328283
|
Ctnna1tm1Efu/Ctnna1tm1Efu
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * C57BL/6NCrl * CBA
|
abnormal retina development |
J:328283
|
|
decreased angiogenesis |
J:328283
|
|
decreased body size |
J:328283
|
|
hemorrhage |
J:328283
|
|
impaired blood-brain barrier function |
J:328283
|
|
increased angiogenesis |
J:328283
|
|
microphthalmia |
J:328283
|
|
persistence of hyaloid vascular system |
J:328283
|
|
postnatal lethality, complete penetrance |
J:328283
|
|
slow postnatal weight gain |
J:328283
|
Ctnnb1tm1Mmt/Ctnnb1+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Prom1tm1(cre/ERT2)Gilb/Prom1+
involves: 129S6/SvEvTac * 129X1/SvJ
|
increased intestinal adenocarcinoma incidence |
J:144215
|
|
premature death |
J:144215
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Gt(ROSA)26Sortm2(Sp8)Lma/Gt(ROSA)26Sor+
Tg(Msx2-cre)5Rem/0
involves: 129X1/SvJ * C57BL/6 * CBA
|
normal
limbs/digits/tail phenotype |
J:223057
|
Ctnnb1tm2Kem/Ctnnb1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Col2a1-cre)1Bhr/0
Tg(tetO-Vegfa)90Ala/0
involves: 129 * C57BL/6 * FVB/N * ICR * SJL
|
increased hemangioma incidence |
J:156474
|
|
normal
skeleton phenotype |
J:156474
|
Ctnnb1tm2Kem/Ctnnb1tm2.1Kem
Corintm2(cre)Bamo/Corin+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * FVB/N
|
abnormal auchene hair morphology |
J:160311
|
|
abnormal awl hair morphology |
J:160311
|
|
abnormal hair cycle anagen phase |
J:160311
|
|
abnormal hair cycle catagen phase |
J:160311
|
|
abnormal hair cycle telogen phase |
J:160311
|
|
abnormal hair follicle physiology |
J:160311
|
|
abnormal hair shaft morphology |
J:160311
|
|
abnormal zigzag hair morphology |
J:160311
|
|
decreased guard hair length |
J:160311
|
|
delayed hair regrowth |
J:160311
|
|
increased hair follicle apoptosis |
J:160311
|
Ctnnb1tm2Kem/Ctnnb1tm2.1Kem
Gt(ROSA)26Sortm1(Ctnnb1)Kem/Gt(ROSA)26Sor+
Tg(Zp3-cre)93Knw/0
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6J
|
abnormal embryonic tissue morphology |
J:187739
|
|
abnormal germ layer development |
J:187739
|
|
failure to gastrulate |
J:187739
|
|
prenatal lethality, complete penetrance |
J:187739
|
Ctnnb1tm2Kem/Ctnnb1tm2.1Kem
Gt(ROSA)26Sortm1(Ctnnb1)Kem/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6J * CBA/J
|
abnormal brain morphology |
J:187739
|
|
abnormal craniofacial morphology |
J:187739
|
|
prenatal lethality, complete penetrance |
J:187739
|
Ctnnb1tm2Kem/Ctnnb1tm2.1Kem
Gt(ROSA)26Sortm1(Ctnnb1)Kem/Gt(ROSA)26Sor+
Tg(Foxn1-cre)1Tbo/0
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6
|
decreased body size |
J:187739
|
|
focal hair loss |
J:187739
|
|
normal
integument phenotype |
J:187739
|
Ctnnb1tm2Kem/Ctnnb1tm2.1Kem
Gt(ROSA)26Sortm1(Ctnnb1)Kem/Gt(ROSA)26Sor+
Tg(Cdx1-cre)23Kem/0
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * FVB
|
caudal body truncation |
J:187739
|
|
prenatal lethality, complete penetrance |
J:187739
|
|
truncated tail bud |
J:187739
|
Ctnnb1tm2Kem/Ctnnb1tm2.1Kem
Gt(ROSA)26Sortm1(Ctnnb1)Kem/Gt(ROSA)26Sortm1(Ctnnb1)Kem
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6J * CBA/J
|
neonatal lethality, complete penetrance |
J:187739
|
Ctnnb1tm2Kem/Ctnnb1tm2.1Kem
Gt(ROSA)26Sortm1(Ctnnb1)Kem/Gt(ROSA)26Sortm1(Ctnnb1)Kem
Tg(Cdx1-cre)23Kem/0
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * FVB
|
abnormal digit morphology |
J:187739
|
|
abnormal hindlimb morphology |
J:187739
|
|
abnormal neural tube morphology |
J:187739
|
|
abnormal rib morphology |
J:187739
|
|
abnormal sex gland morphology |
J:187739
|
|
abnormal vertebrae morphology |
J:187739
|
|
absent hindlimb |
J:187739
|
|
absent tail |
J:187739
|
|
brachydactyly |
J:187739
|
|
normal
embryo phenotype |
J:187739
|
|
fused phalanges |
J:187739
|
|
open neural tube |
J:187739
|
|
perinatal lethality, complete penetrance |
J:187739
|
|
persistent cloaca |
J:187739
|
|
rib fusion |
J:187739
|
|
short ribs |
J:187739
|
|
small adrenal glands |
J:187739
|
|
small kidney |
J:187739
|
|
small vertebrae |
J:187739
|
|
vertebral fusion |
J:187739
|
Ctnnb1tm2Kem/Ctnnb1tm2.1Kem
Gt(ROSA)26Sortm1(Ctnnb1)Kem/Gt(ROSA)26Sortm1(Ctnnb1)Kem
Tg(Foxn1-cre)1Tbo/0
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6
|
decreased body size |
J:187739
|
|
normal
integument phenotype |
J:187739
|
|
sparse hair |
J:187739
|
Ctnnb1tm2Kem/Ctnnb1tm2.1Kem
Gt(ROSA)26Sortm1(Ctnnb1)Kem/Gt(ROSA)26Sortm1.1(Ctnnb1)Kem
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * CBA
|
abnormal embryonic tissue morphology |
J:187739
|
|
abnormal germ layer development |
J:187739
|
|
failure to gastrulate |
J:187739
|
|
prenatal lethality, complete penetrance |
J:187739
|
Ctnnb1tm2Kem/Ctnnb1tm2Kem
Gt(ROSA)26Sortm1(Fgf8)Lma/Gt(ROSA)26Sor+
Tg(Msx2-cre)5Rem/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA
|
abnormal autopod morphology |
J:223057
|
|
abnormal hindlimb morphology |
J:223057
|
|
abnormal ulna morphology |
J:223057
|
|
normal
limbs/digits/tail phenotype |
J:223057
|
Ctnnb1tm2Kem/Ctnnb1tm2Kem
Gt(ROSA)26Sortm1(Fgf8)Lma/Gt(ROSA)26Sor+
Shhtm1(EGFP/cre)Cjt/Shh+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal reproductive system development |
J:223057
|
|
abnormal tail development |
J:223057
|
|
normal
reproductive system phenotype |
J:223057
|
Ctnnb1tm2Kem/Ctnnb1tm2Kem
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129 * C57BL/6 * CBA/J
|
absent hindbrain |
J:178971
|
|
absent mandible |
J:178971
|
|
absent maxilla |
J:178971
|
|
absent midbrain |
J:178971
|
|
absent midbrain-hindbrain boundary |
J:178971
|
|
small pharyngeal arch |
J:178971
|
Ctnnb1tm2Kem/Ctnnb1tm3Kba
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129 * C57BL/6 * CBA/J
|
abnormal cerebellum development |
J:178971
|
|
abnormal craniofacial bone morphology |
J:178971
|
|
absent midbrain-hindbrain boundary |
J:178971
|
Ctps1tm1c(KOMP)Wtsi/Ctps1tm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
B6.Cg-Ctps1tm1c(KOMP)Wtsi Gt(ROSA)26Sortm1(cre/ERT2)Tyj
|
abnormal intestinal epithelium morphology |
J:348981
|
|
abnormal small intestinal villus morphology |
J:348981
|
|
abnormal small intestine crypts of Lieberkuhn morphology |
J:348981
|
|
abnormal spleen morphology |
J:348981
|
|
abnormal thymus physiology |
J:348981
|
|
decreased erythrocyte cell number |
J:348981
|
|
decreased germinal center B cell number |
J:348981
|
|
decreased hemoglobin content |
J:348981
|
|
decreased IgM level |
J:348981
|
|
decreased lymphocyte cell number |
J:348981
|
|
decreased small intestinal villus height |
J:348981
|
|
decreased T cell proliferation |
J:348981
|
|
decreased T follicular helper cell number |
J:348981
|
|
impaired humoral immune response |
J:348981
|
|
increased CD8-positive, alpha-beta T cell number |
J:348981
|
|
reticulocytopenia |
J:348981
|
|
small thymus |
J:348981
|
|
thymus hypoplasia |
J:348981
|
|
weight loss |
J:348981
|
Cyp11b2tm1.1(cre)Brlt/Cyp11b2+
Nr0b1tm1Lja/Y
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
normal
endocrine/exocrine gland phenotype |
J:204614
|
Daam1tm1.1Tpy/Daam1tm1.1Tpy
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Nkx2-5tm1(cre)Rjs/Nkx2-5+
involves: 129S1/Sv * 129S4/SvJaeSor * 129S7/SvEvBrd
|
abnormal cardiac muscle tissue morphology |
J:228507
|
Ddrgk1tm1c(EUCOMM)Hmgu/Ddrgk1tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/6N
|
abnormal embryonic erythropoiesis |
J:231701
|
|
abnormal hematopoietic stem cell physiology |
J:231701
|
|
decreased erythrocyte cell number |
J:231701
|
|
decreased granulocyte number |
J:231701
|
|
decreased hemoglobin content |
J:231701
|
|
decreased lymphocyte cell number |
J:231701
|
|
decreased monocyte cell number |
J:231701
|
|
pancytopenia |
J:231701
|
|
premature death |
J:231701
|
|
weight loss |
J:231701
|
Ddx5tm1.1Arte/Ddx5tm1.1Arte
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6N * C57BL/6NTac
|
increased cellular sensitivity to gamma-irradiation |
J:191933
|
Dhcr24tm1c(EUCOMM)Wtsi/Dhcr24tm1c(EUCOMM)Wtsi
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J * C57BL/6N
|
abnormal bile composition |
J:304449
|
|
abnormal sterol level |
J:304449
|
|
decreased circulating cholesterol level |
J:304449
|
Dis3tm1.1Uba/Dis3tm1.1Uba
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac
|
abnormal B cell morphology |
J:302856
|
|
abnormal class switch recombination |
J:302856
|
Dll4tm2.1Vlcg/Dll4+
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NTac
|
abnormal induced retina neovascularization |
J:177797
|
|
abnormal vascular regression |
J:177797
|
Dll4tm2.1Vlcg/Dll4tm2.1Vlcg
Gt(ROSA)26Sortm3.1(cre/ERT2)Vlcg/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NTac
|
abnormal retina vasculature morphology |
J:200671
|
Dll4tm3.1Vlcg/Dll4+
Gt(ROSA)26Sortm3.1(cre/ERT2)Vlcg/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NTac
|
no abnormal phenotype detected |
J:200671
|
Dnai1tm1.1Leo/Dnai1tm1.1Leo
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129 * C57BL/6
|
abnormal mucociliary clearance |
J:155730
|
|
abnormal respiratory system physiology |
J:155730
|
|
normal
nervous system phenotype |
J:155730
|
|
rhinosinusitis |
J:155730
|
Dnajc10tm1Tiw/Dnajc10tm1Tiw
Gt(ROSA)26Sortm1.2Tiw/Gt(ROSA)26Sor+
involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6
|
abnormal salivary gland physiology |
J:159968
|
|
normal
endocrine/exocrine gland phenotype |
J:159968
|
|
increased endoplasmic reticulum stress |
J:159968
|
Dnmt3atm1Jae/Dnmt3atm1Jae
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Nkx2-2tm2.1Suss/Nkx2-2tm2.1Suss
Tg(Ins2-cre)23Herr/0
involves: 129S/Sv * Black Swiss * C57BL/6 * CBA/J * SJL
|
abnormal pancreatic beta cell differentiation |
J:177838
|
Dnmt3atm1Trow/Dnmt3a+
Gt(ROSA)26Sortm3(CAG-flpo/ERT2)Alj/Gt(ROSA)26Sor+
Npm1tm1Trow/Npm1+
Tg(Mx1-cre)1Cgn/0
B6.Cg-Gt(ROSA)26Sortm3(CAG-flpo/ERT2)Alj Npm1tm1Trow Dnmt3atm1Trow Tg(Mx1-cre)1Cgn
|
abnormal bone marrow cell physiology |
J:272803
|
Dph1tm1.1Cmch/Dph1tm1.1Cmch
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J
|
small nasal bone |
J:214744
|
Dph1tm2Bhr/Dph1+
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Mesp1tm2(cre)Ysa/Mesp1+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj
|
embryonic lethality, complete penetrance |
J:214744
|
Dph1tm2Bhr/Dph1+
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6J * CBA/J
|
acephaly |
J:214744
|
Dph1tm2Bhr/Dph1tm2Bhr
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Mesp1tm2(cre)Ysa/Mesp1+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6J * C57BL/6NCrlj * CBA/JNCrlj
|
normal
mortality/aging |
J:214744
|
Dph1tm2Bhr/Dph1tm2Bhr
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6J * CBA/J
|
normal
growth/size/body region phenotype |
J:214744
|
Droshatm1.1Vlcg/Droshatm3Vlcg
Gt(ROSA)26Sortm3.1(cre/ERT2)Vlcg/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NTac
|
decreased body size |
J:200671
|
|
normal
mortality/aging |
J:200671
|
Droshatm1Litt/Droshatm1.1Litt
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N
|
abnormal interferon-gamma secretion |
J:138683
|
Dscamtm1Pfu/Dscamtm1Pfu
Gt(ROSA)26Sortm3(CAG-EGFP/Dsred2)Luo/?
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal amacrine cell morphology |
J:179393
|
|
abnormal axon fasciculation |
J:179393
|
Dvl3tm1Awb/Dvl3tm1Awb
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S/Sv * Black Swiss * C57BL/6J * CBA/J
|
normal
nervous system phenotype |
J:142392
|
Dvl3tm1Awb/Dvl3tm1Awb
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Isl1tm1(cre)Sev/Isl1+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * Black Swiss
|
normal
cardiovascular system phenotype |
J:142392
|
E2f4tm2.1Lees/E2f4tm2.1Lees
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6
|
abnormal respiratory motile cilium morphology |
J:241925
|
Ednrbtm1Nrd/Ednrbtm1Nrd
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA/J
|
abnormal enteric neural crest cell migration |
J:140320
|
|
aganglionic megacolon |
J:140320
|
|
distended abdomen |
J:140320
|
|
premature death |
J:140320
|
|
slow postnatal weight gain |
J:140320
|
|
white spotting |
J:140320
|
Ednrbtm1Nrd/Ednrbtm1Nrd
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * CBA/J
|
abnormal mature B cell number |
J:233811
|
|
abnormal Peyer's patch morphology |
J:233811
|
|
abnormal spleen morphology |
J:233811
|
|
abnormal splenic cell ratio |
J:233811
|
|
decreased B cell number |
J:233811
|
|
decreased germinal center B cell number |
J:233811
|
|
decreased IgA level |
J:233811
|
|
decreased marginal zone B cell number |
J:233811
|
|
decreased spleen red pulp amount |
J:233811
|
|
decreased spleen weight |
J:233811
|
|
decreased spleen white pulp amount |
J:233811
|
|
large intestinal inflammation |
J:233811
|
|
small Peyer's patches |
J:233811
|
|
small spleen |
J:233811
|
Ednrbtm1Nrd/Ednrbtm1Nrd
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6J
|
abnormal coat/hair pigmentation |
J:231435
|
|
abnormal hair follicle melanocyte morphology |
J:231435
|
|
abnormal melanocyte proliferation |
J:231435
|
|
absent hair follicle melanin granules |
J:231435
|
|
decreased melanocyte number |
J:231435
|
|
reduced hair shaft melanin granule number |
J:231435
|
Eedtm1Sho/Eedtm1Sho
Eportm1.1(EGFP/icre)Uk/Epor+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sortm1(EYFP)Cos
involves: 129S1/Sv * 129X1/SvJ * BALB/cJ
|
abnormal erythropoiesis |
J:154730
|
Eef1a1tm2Arge/Eef1a1+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
abnormal bone marrow cell physiology |
J:196407
|
Egln1tm2.1Fsl/Egln1tm2.1Fsl
Epas1tm1Mcs/Epas1tm1Mcs
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Egln1tm2.1Fsl Epas1tm1Mcs
|
normal
hematopoietic system phenotype |
J:202737
|
|
premature death |
J:202737
|
Egln1tm2.1Fsl/Egln1tm2.1Fsl
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Egln1tm2.1Fsl
|
extramedullary hematopoiesis |
J:202737
|
|
increased erythropoietin level |
J:202737
|
|
increased hematocrit |
J:202737
|
|
increased spleen weight |
J:202737
|
|
polycythemia |
J:202737
|
|
premature death |
J:202737
|
Egln1tm2.1Fsl/Egln1tm2.1Fsl
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Hif1atm3Rsjo/Hif1atm3Rsjo
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Egln1tm2.1Fsl Hif1atm3Rsjo
|
extramedullary hematopoiesis |
J:202737
|
|
increased erythropoietin level |
J:202737
|
|
increased hematocrit |
J:202737
|
|
increased spleen weight |
J:202737
|
|
premature death |
J:202737
|
Egln1tm2Fong/Egln1tm2Fong
Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6
|
abnormal blood vessel morphology |
J:133568
|
|
abnormal capillary branching pattern |
J:133568
|
|
abnormal capillary morphology |
J:133568
|
|
abnormal definitive hematopoiesis |
J:132720
|
|
abnormal kidney vasculature morphology |
J:133568
|
|
abnormal liver morphology |
J:132720
|
|
abnormal lung vasculature morphology |
J:133568
|
|
abnormal renal glomerulus morphology |
J:133568
|
|
abnormal splenic cell ratio |
J:132720
|
|
decreased survivor rate |
J:132720
|
|
dilated liver sinusoidal space |
J:133568
|
|
dilated vasculature |
J:133568
|
|
enlarged liver |
J:132720
|
|
enlarged spleen |
J:132720
|
|
extramedullary hematopoiesis |
J:132720
|
|
increased angiogenesis |
J:133568
|
|
increased circulating erythropoietin level |
J:132720
|
|
increased hematocrit |
J:132720
|
|
increased hemoglobin content |
J:132720
|
|
increased leukocyte cell number |
J:132720
|
|
polycythemia |
J:132720
|
|
premature death |
J:132720
|
|
reddish skin |
J:132720
|
Egr2tm2(cre)Pch/Egr2+
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/?
involves: 129S2/SvPas * C57BL/6
|
abnormal myelination |
J:207470
|
Egr2tm2(cre)Pch/Egr2+
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/?
Ptpn11tm1.1Wbm/Ptpn11tm1.1Wbm
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
abnormal myelination |
J:207470
|
Egr2tm2(cre)Pch/Egr2+
Gt(ROSA)26Sortm8(Map2k1*,EGFP)Rsky/?
involves: 129S2/SvPas * C57BL/6
|
abnormal myelin sheath morphology |
J:207470
|
|
abnormal nerve conduction |
J:207470
|
|
abnormal sciatic nerve morphology |
J:207470
|
|
hypermyelination |
J:207470
|
|
increased myelin sheath thickness |
J:207470
|
|
increased nerve conduction velocity |
J:207470
|
|
tomacula |
J:207470
|
Egr2tm2(cre)Pch/Egr2+
Gt(ROSA)26Sortm8(Map2k1*,EGFP)Rsky/?
Ptpn11tm1.1Wbm/Ptpn11tm1.1Wbm
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
hypermyelination |
J:207470
|
Egr2tm2(cre)Pch/?
Gt(ROSA)26Sortm5(CAG-EGFP,-lacZ)Dym/?
Tg(Fev-flpe)1Dym/?
involves: 129S2/SvPas
|
no abnormal phenotype detected |
J:136096
|
Egr3tm1Jmi/Egr3tm1Jmi
Gt(ROSA)26Sortm1(CAG-taulacZ)Bene/Gt(ROSA)26Sor+
Tg(Dbh-cre)KH212Gsat/0
involves: C57BL/6 * FVB/NTac
|
abnormal sympathetic neuron morphology |
J:196371
|
|
normal
nervous system phenotype |
J:196371
|
Elavl1tm1Thla/Elavl1tm1Thla
Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+
involves: 129
|
abnormal B cell physiology |
J:155109
|
|
abnormal colon morphology |
J:155109
|
|
abnormal crypts of Lieberkuhn morphology |
J:155109
|
|
abnormal definitive hematopoiesis |
J:155109
|
|
abnormal intestinal epithelium morphology |
J:155109
|
|
abnormal intestinal goblet cell morphology |
J:155109
|
|
abnormal intestinal mucosa morphology |
J:155109
|
|
abnormal myeloid leukocyte morphology |
J:155109
|
|
cachexia |
J:155109
|
|
decreased B cell apoptosis |
J:155109
|
|
decreased bone marrow cell number |
J:155109
|
|
decreased cell proliferation |
J:155109
|
|
decreased common myeloid progenitor cell number |
J:155109
|
|
decreased double-positive T cell number |
J:155109
|
|
decreased erythroid progenitor cell number |
J:155109
|
|
decreased granulocyte number |
J:155109
|
|
decreased leukocyte cell number |
J:155109
|
|
distended stomach |
J:155109
|
|
increased granulocyte number |
J:155109
|
|
increased T cell apoptosis |
J:155109
|
|
intestinal obstruction |
J:155109
|
|
lymph node hypoplasia |
J:155109
|
|
premature death |
J:155109
|
|
small intestinal villus atrophy |
J:155109
|
|
spleen hypoplasia |
J:155109
|
|
thymus hypoplasia |
J:155109
|
Emx1tm1(cre)Ito/?
Gt(ROSA)26Sortm1(HD*103Q)Xwy/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
normal
nervous system phenotype |
J:99759
|
En1tm1Alj/En1tm8.1Alj
En2tm1Alj/En2tm6Alj
Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+
involves: 129S2/SvPas * 129S6/SvEvTac * Swiss Webster
|
abnormal cerebellar foliation |
J:156169
|
|
abnormal cerebellar granule cell precursor proliferation |
J:156169
|
|
abnormal cerebellum development |
J:156169
|
|
abnormal cerebellum external granule cell layer morphology |
J:156169
|
|
abnormal cerebellum fissure morphology |
J:156169
|
|
abnormal cerebellum morphology |
J:156169
|
|
abnormal cerebellum posterior vermis morphology |
J:156169
|
|
abnormal cerebellum vermis lobule morphology |
J:156169
|
|
abnormal cerebellum vermis morphology |
J:156169
|
|
abnormal midbrain morphology |
J:156169
|
|
cerebellum vermis hypoplasia |
J:156169
|
|
decreased anterior vermis size |
J:156169
|
|
perinatal lethality, complete penetrance |
J:156169
|
|
small cerebellum |
J:156169
|
|
thin external granule cell layer |
J:156169
|
En1tm1Alj/En1tm8.1Alj
En2tm1Alj/En2tm7.1Alj
Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S2/SvPas * 129S6/SvEvTac * 129X1/SvJ * Swiss Webster
|
abnormal cerebellar foliation |
J:156169
|
|
abnormal cerebellum hemisphere lobule morphology |
J:156169
|
|
abnormal cerebellum vermis lobule morphology |
J:156169
|
En1tm1Alj/En1tm8.1Alj
En2tm6Alj/En2+
Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * Swiss Webster
|
abnormal cerebellar foliation |
J:156169
|
|
abnormal cerebellum vermis lobule morphology |
J:156169
|
|
decreased anterior vermis size |
J:156169
|
En1tm2(cre)Gld/En1+
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv
|
abnormal CNS synaptic transmission |
J:106437
|
|
abnormal ventral interneuron 1 morphology |
J:106437
|
En1tm2(cre)Wrst/?
Gt(ROSA)26Sortm5(CAG-EGFP,-lacZ)Dym/?
Nkx2-2tm1Jlr/Nkx2-2tm1Jlr
Tg(Fev-flpe)1Dym/?
involves: 129S1/Sv * 129X1/SvJ
|
abnormal rhombomere morphology |
J:136096
|
En1tm2(cre)Wrst/?
Gt(ROSA)26Sortm5(CAG-EGFP,-lacZ)Dym/?
Tg(Fev-flpe)1Dym/?
involves: 129S1/Sv * 129X1/SvJ
|
no abnormal phenotype detected |
J:136096
|
En1tm7(cre/ESR1)Alj/En1+
En2tm2Alj/En2tm2Alj
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJaeSor * 129S6/SvEvTac * 129X1/SvJ * Swiss Webster
|
abnormal cerebellum morphology |
J:134516
|
|
abnormal cerebellum vermis morphology |
J:134516
|
|
abnormal tectum morphology |
J:134516
|
|
decreased midbrain size |
J:134516
|
|
decreased rhombomere 1 size |
J:134516
|
En1tm7(cre/ESR1)Alj/0
Fgf8tm1.3Mrt/Fgf8tm2.1Jyhl
Gt(ROSA)26Sortm1Sor/0
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
normal
growth/size/body region phenotype |
J:156717
|
|
normal
nervous system phenotype |
J:156717
|
En1tm8.1Alj/En1+
En2tm6Alj/En2+
Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * Swiss Webster
|
abnormal cerebellar foliation |
J:156169
|
|
abnormal cerebellum fissure morphology |
J:156169
|
|
abnormal cerebellum posterior vermis morphology |
J:156169
|
En2tm1Alj/En2tm6Alj
Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+
involves: 129S2/SvPas * 129S6/SvEvTac * Swiss Webster
|
abnormal cerebellar foliation |
J:156169
|
|
abnormal cerebellum hemisphere lobule morphology |
J:156169
|
|
abnormal cerebellum vermis lobule morphology |
J:156169
|
En2tm5.1Alj/En2tm5.1Alj
Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+
involves: 129S2/SvPas * Swiss Webster
|
normal
nervous system phenotype |
J:156169
|
Engtm2.1Hma/Engtm2.1Hma
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
abnormal vascular wound healing |
J:212952,
J:227170
|
|
arteriovenous malformation |
J:212952,
J:227170
|
|
decreased locomotor activity |
J:227170
|
|
dehydration |
J:227170
|
|
diarrhea |
J:227170
|
|
hemorrhage |
J:212952
|
|
moribund |
J:227170
|
Eomestm1Rob/Eomestm1.1Rob
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA
|
abnormal endoderm development |
J:131055
|
|
abnormal visceral endoderm morphology |
J:131055
|
Epotm1Knni/Epotm1Knni
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S/Sv * C57BL/6
|
abnormal erythropoiesis |
J:165479
|
|
decreased erythrocyte cell number |
J:165479
|
|
decreased hematocrit |
J:165479
|
|
decreased hemoglobin content |
J:165479
|
Epxtm1.1(cre)Jlee/Epx+
Gt(ROSA)26Sortm1(DTA)Lky/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6
|
decreased eosinophil cell number |
J:198489
|
Erbb3tm3Cbm/Erbb3tm3Cbm
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/?
Tg(Dhh-cre)1Mejr/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
|
abnormal myelination |
J:207470
|
Erbb3tm3Cbm/Erbb3tm3Cbm
Gt(ROSA)26Sortm8(Map2k1*,EGFP)Rsky/?
Tg(Dhh-cre)1Mejr/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
|
abnormal myelination |
J:207470
|
|
decreased myelin sheath thickness |
J:207470
|
|
hypermyelination |
J:207470
|
Errfi1tm1Jwj/Errfi1tm1Jwj
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
increased skin papilloma incidence |
J:153715
|
|
normal
respiratory system phenotype |
J:153715
|
|
uterus hyperplasia |
J:153715
|
Espl1tm1.1Kna/Espl1tm1.2Kna
Wapltm1.1Jmpt/Wapltm1.2Jmpt
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac * SJL
|
abnormal mitosis |
J:205429
|
Ets1tm2Jml/Ets1tm2Jml
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Pax3tm1(cre)Joe/Pax3+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6J * C57BL/6NCrl
|
abnormal cardiac neural crest cell migration |
J:334073
|
|
abnormal cardiac outflow tract development |
J:334073
|
|
abnormal conotruncal ridge morphology |
J:334073
|
|
abnormal neural crest cell physiology |
J:334073
|
|
double outlet right ventricle |
J:334073
|
Ezh2tm1Yugo/Ezh2tm1Yugo
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S/Sv * C57BL/6
|
abnormal neuron differentiation |
J:154927
|
Fbxo43tm1.1Kald/Fbxo43tm1.2Kald
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL
|
increased male germ cell apoptosis |
J:251984
|
|
male infertility |
J:251984
|
Fevtm1Esd/Fevtm2Esd
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Fev-cre)1Esd/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal action potential |
J:165266
|
|
abnormal innervation |
J:165266
|
|
abnormal nervous system electrophysiology |
J:165266
|
|
abnormal serotonergic neuron morphology |
J:165266
|
|
abnormal somatosensory cortex morphology |
J:165266
|
Fgf8tm1.3Mrt/Fgf8tm1.4Mrt
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Nkx2-5tm1(cre)Rjs/Nkx2-5+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S7/SvEvBrd
|
abnormal heart development |
J:109474
|
|
abnormal splanchnic mesoderm morphology |
J:109474
|
Fgf10tm1.1(cre/ERT2)Sbel/Fgf10tm1Sms
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6
|
abnormal cecum development |
J:187831
|
|
abnormal lung bud morphology |
J:187831
|
|
interdigital webbing |
J:187831
|
Fgf10tm1Ska/Fgf10tm1Sms
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Twist2tm1(cre)Dor/Twist2+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * CBA
|
abnormal lung development |
J:150706
|
|
abnormal lung lobe morphology |
J:150706
|
|
abnormal right lung accessory lobe morphology |
J:150706
|
|
abnormal right lung cranial lobe morphology |
J:150706
|
|
abnormal right lung middle lobe morphology |
J:150706
|
|
impaired branching involved in bronchus morphogenesis |
J:150706
|
|
lung hemorrhage |
J:150706
|
|
pulmonary hypoplasia |
J:150706
|
|
small lung |
J:150706
|
|
small lung lobe |
J:150706
|
Fgf15tm1Sms/Fgf15tm1Sms
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * CBA
|
abnormal cardiac neural crest cell migration |
J:97317
|
|
abnormal cardiac outflow tract development |
J:97317
|
|
decreased cardiac neural crest cell number |
J:97317
|
Fgfr1tm1.1Jpa/Fgfr1+
Gt(ROSA)26Sortm5(Etv4/en,-GFP)Amc/Gt(ROSA)26Sor+
Tg(Prrx1-cre)1Cjt/0
involves: 129 * C57BL/6 * CBA * SJL/J * Swiss Webster
|
abnormal limb development |
J:149478
|
Fgfr1tm1Jpa/Fgfr1tm1Jpa
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J * CBA/J
|
decreased maxillary shelf size |
J:298139
|
|
small frontonasal prominence |
J:298139
|
Fgfr1tm1Upir/Fgfr1tm1Upir
Fgfr2tm1Dor/Fgfr2tm1Dor
Gt(ROSA)26Sortm1(Cdkn1b,EGFP)Dor/Gt(ROSA)26Sor+
Myl2tm1(cre)Krc/Myl2+
involves: 129/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
heart hypoplasia |
J:131577
|
|
thin ventricular wall |
J:131577
|
Fh1tm1Pjp/Fh1tm1Pjp
Gt(ROSA)26Sortm1(CAG-FH)Pjp/Gt(ROSA)26Sor+
Tg(Cdh16-cre)91Igr/0
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * C57BL/6J * ICR
|
normal
homeostasis/metabolism phenotype |
J:198486
|
|
normal
renal/urinary system phenotype |
J:198486
|
Fh1tm1Pjp/Fh1tm1Pjp
Gt(ROSA)26Sortm2(CAG-FH*)Pjp/Gt(ROSA)26Sor+
Tg(Cdh16-cre)91Igr/0
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * C57BL/6J * ICR
|
normal
homeostasis/metabolism phenotype |
J:198486
|
|
normal
renal/urinary system phenotype |
J:198486
|
Fis1tm1Dcc/Fis1tm1.1Dcc
Gt(ROSA)26Sortm1.1(CAG-COX8A/Dendra2)Dcc/Gt(ROSA)26Sor+
Tg(Stra8-icre)1Reb/0
involves: 129S6/SvEvTac * C57BL/6 * FVB/NJ
|
abnormal spermatid morphology |
J:309044
|
|
azoospermia |
J:309044
|
|
decreased testis weight |
J:309044
|
|
impaired autophagy |
J:309044
|
|
increased male germ cell apoptosis |
J:309044
|
|
increased mitochondrial number |
J:309044
|
|
multinucleated giant male germ cells |
J:309044
|
|
small testis |
J:309044
|
Flt1tm1.1Fong/Flt1tm1.1Fong
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NCr * CD-1
|
decreased body size |
J:202202
|
|
decreased myocardial infarct size |
J:202202
|
|
increased angiogenesis |
J:202202
|
|
increased endothelial cell proliferation |
J:202202
|
|
increased macrophage cell number |
J:202202
|
|
increased vascular permeability |
J:202202
|
Flt1tm1.1Fong/Flt1tm1.1Fong
Kdrtm1Jrt/Kdr+
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
involves: 129 * C57BL/6NCr * CD-1
|
increased angiogenesis |
J:202202
|
Foxa2tm1.1(rtTa)Moon/Foxa2tm1.1(rtTa)Moon
Gt(ROSA)26Sortm1Sor/?
Tg(tetO-cre)1Jaw/?
involves: C57BL/6 * SJL
|
no abnormal phenotype detected |
J:119721
|
Foxa2tm2.1(cre/Esr1*)Moon/Foxa2tm2.1(cre/Esr1*)Moon
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor
|
no abnormal phenotype detected |
J:130990
|
Foxg1tm1(cre)Skm/?
Gt(ROSA)26Sorem1(ptxA)Btar/?
involves: 129P2/OlaHsd * C57BL/6J
|
abnormal cochlear hair cell stereociliary bundle morphology |
J:236519
|
|
neonatal lethality, complete penetrance |
J:236519
|
Foxg1tm1.1(cre)Ddmo/Foxg1+
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1a(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N
|
telencephalon hypoplasia |
J:335489
|
Foxg1tm1.1(cre)Ddmo/Foxg1+
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1c(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N
|
telencephalon hypoplasia |
J:335489
|
Foxg1tm1.1(cre)Ddmo/Foxg1+
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1d(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N
|
telencephalon hypoplasia |
J:335489
|
Foxg1tm1.1(cre)Ddmo/0
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1aem1Knwea/Polr1atm1c(EUCOMM)Hmgu
involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N
|
telencephalon hypoplasia |
J:335489
|
Foxl2tm2.1Tre/Foxl2tm2.1Tre
Gt(ROSA)26Sortm9(cre/ESR1)Arte/?
involves: 129S/Sv * C57BL/6
|
abnormal ovarian follicle morphology |
J:157008
|
|
abnormal ovary morphology |
J:157008
|
|
primary sex reversal |
J:157008
|
Foxn1tm1.1Cbln/Foxn1tm1Tbo
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6
|
normal
immune system phenotype |
J:177992
|
Foxn1tm3(cre)Nrm/Foxn1+
Gt(ROSA)26Sortm1(Tbx1)Rche/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NHsd
|
abnormal third pharyngeal pouch morphology |
J:214094
|
|
abnormal thymus development |
J:214094
|
|
abnormal thymus epithelium morphology |
J:214094
|
|
decreased thymocyte number |
J:214094
|
|
thymus hypoplasia |
J:214094
|
Foxo1tm1Flv/Foxo1tm1Flv
Gt(ROSA)26Sortm1(CAG-FOXO1,GFP)Moli/Gt(ROSA)26Sor+
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:189962
|
|
normal
mortality/aging |
J:189962
|
Fzd4tm1Nat/Fzd4tm2.1Nat
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ
|
small kidney |
J:170839
|
Fzd5tm1Nat/Fzd5tm2Nat
Gt(ROSA)26Sortm1(cre/ERT)Nat/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL
|
abnormal thalamus morphology |
J:136390
|
Gas2l2tm1c(KOMP)Wtsi/Gas2l2tm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N
|
neonatal lethality, incomplete penetrance |
J:277289
|
Gas2l3tm1c(EUCOMM)Hmgu/Gas2l3tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N
|
abnormal fetal cardiomyocyte morphology |
J:244087
|
|
abnormal fetal cardiomyocyte proliferation |
J:244087
|
|
abnormal mitotic cytokinesis |
J:244087
|
|
normal
cardiovascular system phenotype |
J:244087
|
Gata6osem1Zfa/Gata6osem1Zfa
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6
|
abnormal enterocyte physiology |
J:268724
|
Gata6osem3Zfa/Gata6osem3Zfa
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6
|
abnormal enterocyte proliferation |
J:268724
|
Gbx2tm1.1(cre/ERT2)Jyhl/Gbx2tm1.1Mrt
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
|
abnormal telencephalon development |
J:147282
|
|
abnormal thalamus morphology |
J:147282
|
Gbx2tm1.1(cre/ERT2)Jyhl/Gbx2tm1Mrt
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
|
abnormal thalamus morphology |
J:147282
|
Gdf11tm1Sjl/Gdf11tm1Sjl
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tg(Cdx2-cre/ERT)#Mllo/0
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ
|
abnormal tail morphology |
J:272567
|
Gdnftm1(cre/ERT2)Cos/Gdnf+
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6J
|
abnormal kidney development |
J:206853
|
|
absent kidney |
J:206853
|
|
decreased renal glomerulus number |
J:206853
|
|
small kidney |
J:206853
|
Gdnftm1(cre/ERT2)Cos/Gdnf+
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Spry1tm1.1Jdli/Spry1+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6J
|
small kidney |
J:206853
|
Gdpd5tm1Itl/Gdpd5tm1.1Itl
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129/Sv * 129X1/SvJ * C57BL/6J
|
abnormal neuron differentiation |
J:178550
|
|
decreased motor neuron number |
J:178550
|
|
normal
nervous system phenotype |
J:178550
|
Gja10tm1.1(icre)Aah/Gja10+
Gt(ROSA)26Sortm1(CAG-cas9*,-EGFP)Fezh/?
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
abnormal retina horizontal cell morphology |
J:333740
|
Gli1tm3(cre/ERT2)Alj/Gli1+
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * 129X1/SvJ
|
normal
respiratory system phenotype |
J:264185
|
Gli1tm3(cre/ERT2)Alj/Gli1+
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
involves: 129S6/SvEvTac * 129X1/SvJ
|
increased medulloblastoma incidence |
J:139574
|
|
premature death |
J:139574
|
Gli1tm3(cre/ERT2)Alj/Gli1+
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Tnntm1b(KOMP)Wtsi/Tnntm1b(KOMP)Wtsi
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6N
|
abnormal tooth development |
J:302206
|
Gli2tm1(cre/ERT2)Tipe/Gli2+
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
involves: 129X1/SvJ
|
abnormal bronchioalveolar stem cell morphology |
J:264185
|
|
abnormal pulmonary alveolus morphology |
J:264185
|
|
decreased type II pneumocyte number |
J:264185
|
|
emphysema |
J:264185
|
|
overexpanded pulmonary alveolus |
J:264185
|
Gli3Xt-J/Gli3Xt-J
Gt(ROSA)26Sortm2(Gli2*)Flng/Gt(ROSA)26Sor+
Ihhtm1Amc/Ihhtm1Amc
Tg(Col2a1-cre)3Amc/0
involves: 129S1/Sv * 129X1/SvJ * C3H/HeJ
|
abnormal long bone diaphysis morphology |
J:154905
|
|
decreased body size |
J:154905
|
|
perinatal lethality, complete penetrance |
J:154905
|
|
short limbs |
J:154905
|
|
normal
skeleton phenotype |
J:154905
|
Gm30731tm1.1Dalm/Gm30731tm1.1Dalm
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NCrl
|
abnormal neuronal stem cell physiology |
J:281278
|
Gnai2tm2.1Rneu/Gnai2tm2.1Rneu
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
B6.Cg-Gt(ROSA)26Sortm1(cre/ert2)Tyj Gnai2tm2.1Rneu
|
abnormal response to cardiac infarction |
J:217517
|
|
decreased myocardial infarct size |
J:217517
|
Gnastm5.1Lsw/Gnastm5.1Lsw
Gt(ROSA)26Sortm1(CAG-Mapt/GFP)Uboe/Gt(ROSA)26Sor+
Or8a1tm28(cre)Mom/Or8a1tm27Mom
involves: 129P2/OlaHsd * 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6J
|
normal
taste/olfaction phenotype |
J:233447
|
Gnaztm1Lfb/Gnaz+
Grhl3tm1(cre)Cgh/Grhl3+
Gt(ROSA)26Sortm1(ptxA)Cgh/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
exencephaly |
J:157446
|
|
spina bifida |
J:157446
|
Gnaztm1Lfb/Gnaztm1Lfb
Grhl3tm1(cre)Cgh/Grhl3+
Gt(ROSA)26Sortm1(ptxA)Cgh/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
exencephaly |
J:157446
|
|
spina bifida |
J:157446
|
Gpx4tm1.1Qra/Gpx4tm1.1Qra
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * SJL
|
abnormal cellular respiration |
J:183246
|
|
astrocytosis |
J:183246
|
|
cachexia |
J:183246
|
|
increased hepatocyte apoptosis |
J:183246
|
|
lethality, complete penetrance |
J:183246
|
|
lethargy |
J:183246
|
|
neurodegeneration |
J:183246
|
Grhl3tm1(cre)Cgh/Grhl3+
Gt(ROSA)26Sortm1(ptxA)Cgh/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
abnormal neural tube closure |
J:157446
|
|
exencephaly |
J:157446
|
Grhl3tm1(cre)Cgh/Grhl3+
Gt(ROSA)26Sortm1(ptxA)Cgh/Gt(ROSA)26Sor+
Rac1tm1Djk/Rac1tm1Djk
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * SJL
|
exencephaly |
J:157446
|
|
spina bifida |
J:157446
|
Grin1tm1c(EUCOMM)Wtsi/Grin1tm1c(EUCOMM)Wtsi
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Slc6a4-cre)ET127Gsat/0
involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL
|
abnormal innervation |
J:193625
|
Grin1tm1c(EUCOMM)Wtsi/Grin1tm2.1Stl
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Slc6a4-cre)ET127Gsat/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N * SJL
|
abnormal innervation |
J:193625
|
Gt(ROSA)26Sor/Gt(ROSA)26Sor
involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6J
|
no abnormal phenotype detected |
J:39814
|
Gt(ROSA)26Sor/Gt(ROSA)26Sor
Igs4tm1Hsas/Igs4tm1Hsas
involves: 129S4/SvJae * 129S7/SvEvBrd
|
abnormal cell physiology |
J:192826
|
Gt(ROSA)26Sor/Gt(ROSA)26Sor
Igs4tm1Hsas/Igs4tm1Hsas
Tg(CAG-cre)13Miya/0
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6
|
normal
cellular phenotype |
J:192826
|
Gt(ROSA)26Sorem1(CAG-cas9*,-EGFP)Rsky/Gt(ROSA)26Sor+
C57BL/6N-Gt(ROSA)26Sorem1(CAG-cas9*,-EGFP)Rsky
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sorem1(CAG-TMEM14B,-EGFP)Xqw/Gt(ROSA)26Sor+
Tg(Nes-cre)1Kln/0
involves: C57BL/6 * SJL
|
abnormal brain morphology |
J:253976
|
|
abnormal cortical intermediate zone morphology |
J:253976
|
|
abnormal cortical plate morphology |
J:253976
|
|
abnormal embryonic/fetal subventricular zone morphology |
J:253976
|
|
abnormal neocortex morphology |
J:253976
|
|
increased brain size |
J:253976
|
|
increased neocortex size |
J:253976
|
|
thickened cerebral cortex |
J:253976
|
Gt(ROSA)26Sorem1(CAG-Zbtb21,-GFP)Jhan/Gt(ROSA)26Sor+
Tg(Nes-cre)1Kln/0
B6.Cg-Gt(ROSA)26Sorem1(CAG-Zbtb21,-GFP)Jhan Tg(Nes-cre)1Kln
|
abnormal CNS synaptic transmission |
J:351206
|
|
abnormal excitatory postsynaptic potential |
J:351206
|
|
abnormal postsynaptic density morphology |
J:351206
|
|
abnormal spatial reference memory |
J:351206
|
|
decreased dendritic spine density |
J:351206
|
|
impaired contextual conditioning behavior |
J:351206
|
|
impaired spatial learning |
J:351206
|
|
reduced long-term potentiation |
J:351206
|
Gt(ROSA)26Sorem1(CAG-Zbtb21,-GFP)Jhan/Gt(ROSA)26Sor+
Tg(Camk2a-cre)T29-1Stl/0
B6.Cg-Gt(ROSA)26Sorem1(CAG-Zbtb21,-GFP)Jhan Tg(Camk2a-cre)T29-1Stl
|
abnormal CNS synaptic transmission |
J:351206
|
|
abnormal excitatory postsynaptic potential |
J:351206
|
|
abnormal spatial reference memory |
J:351206
|
|
decreased dendritic spine density |
J:351206
|
|
impaired spatial learning |
J:351206
|
|
reduced long-term potentiation |
J:351206
|
Gt(ROSA)26Sorem1(CAG-Zbtb21,-GFP)Jhan/Gt(ROSA)26Sor+
Aldh1l1em1(cre/ERT2)Nju/Aldh1l1+
Not Specified
|
normal
behavior/neurological phenotype |
J:351206
|
|
normal
nervous system phenotype |
J:351206
|
Gt(ROSA)26Sorem1(CAG-Zfas1)Cya/Gt(ROSA)26Sor+
Tg(Myh6-cre)#Cya/0
involves: C57BL/6J
|
abnormal calcium ion homeostasis |
J:294533
|
|
decreased cardiac muscle contractility |
J:294533
|
|
dilated heart left ventricle |
J:294533
|
|
increased cardiomyocyte apoptosis |
J:294533
|
Gt(ROSA)26Sorem1(DPP4)Yowa/Gt(ROSA)26Sorem1(DPP4)Yowa
C57BL/6-Gt(ROSA)26Sorem1(DPP4)Yowa
|
gliosis |
J:279060
|
|
increased susceptibility to Coronaviridae infection |
J:279060
|
Gt(ROSA)26Sorem1(ptxA)Btar/?
Tg(Atoh1-cre)1Bfri/?
B6.Cg-Gt(ROSA)26Sorem1(ptxA)Btar Tg(Atoh1-cre)1Bfri/Btar
|
abnormal cochlear hair cell stereociliary bundle morphology |
J:236519
|
|
abnormal inner hair cell stereociliary bundle morphology |
J:236519
|
|
abnormal vestibular hair cell stereociliary bundle morphology |
J:236519
|
|
deafness |
J:236519
|
|
increased or absent threshold for auditory brainstem response |
J:236519
|
|
short inner hair cell stereocilia |
J:236519
|
Gt(ROSA)26Sorem1(Tbc1d15)Jren/Gt(ROSA)26Sorem1(Tbc1d15)Jren
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+
involves: C57BL/6N * FVB/N
|
abnormal mitochondrial physiology |
J:341775
|
|
decreased myocardial infarct size |
J:341775
|
|
decreased susceptibility to myocardial ischemic injury |
J:341775
|
Gt(ROSA)26Sorem1(Tor1b)Wtd/Gt(ROSA)26Sor+
Tg(Nes-cre)1Kln/0
involves: 129 * C57BL/6 * SJL
|
normal
behavior/neurological phenotype |
J:288753
|
|
decreased body weight |
J:288753
|
|
normal
mortality/aging |
J:288753
|
|
normal
nervous system phenotype |
J:288753
|
Gt(ROSA)26Sorem1(Tor1b)Wtd/Gt(ROSA)26Sor+
Tor1atm1Wtd/Tor1atm3.1Wtd
Tg(dlx5a-cre)1Mekk/0
involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6J * CD-1
|
normal
behavior/neurological phenotype |
J:288753
|
|
normal
nervous system phenotype |
J:288753
|
Gt(ROSA)26Sorem1(Tor1b)Wtd/Gt(ROSA)26Sor+
Tor1atm1Wtd/Tor1atm3.1Wtd
Tg(Nes-cre)1Kln/0
involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6J * SJL
|
no abnormal phenotype detected |
J:288753
|
Gt(ROSA)26Sorem1(Tor1b)Wtd/Gt(ROSA)26Sor+
Tor1atm2Wtd/Tor1atm3.1Wtd
Tg(Nes-cre)1Kln/0
involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6J * SJL
|
normal
behavior/neurological phenotype |
J:288753
|
|
normal
growth/size/body region phenotype |
J:288753
|
|
normal
nervous system phenotype |
J:288753
|
Gt(ROSA)26Sorem1(Tor1b)Wtd/Gt(ROSA)26Sor+
Tg(dlx5a-cre)1Mekk/0
involves: 129 * C57BL/6 * CD-1
|
normal
behavior/neurological phenotype |
J:288753
|
Gt(ROSA)26Sorem1(Ube2s)Chaw/?
involves: C57BL/6
|
decreased interferon level |
J:306461
|
|
increased susceptibility to Picornaviridae infection induced morbidity/mortality |
J:306461
|
Gt(ROSA)26Sorem2(Mios)Bcgen/Gt(ROSA)26Sor+
Miostm1Pfw/Miostm1Pfw
Olig2tm2(TVA,cre)Rth/Olig2+
involves: 129 * C57BL/6
|
normal
nervous system phenotype |
J:320720
|
Gt(ROSA)26Sorem5(CAG-KANK4,-tdTomato)Bcgen/Gt(ROSA)26Sor+
Tg(Cdh5-cre/ERT2)1Rha/0
Not Specified
|
abnormal artery morphology |
J:326312
|
|
abnormal blood circulation |
J:326312
|
|
abnormal vascular development |
J:326312
|
|
decreased capillary density |
J:326312
|
Gt(ROSA)26Sorem#(CAG-Fstl5)Jrio/Gt(ROSA)26Sor+
Tg(Prrx1-cre)1Cjt/0
involves: C57BL/6J * C57BL/6N * SJL/J
|
abnormal bone mineral density |
J:301587
|
|
decreased bone mineral density of femur |
J:301587
|
|
short femur |
J:301587
|
|
short tibia |
J:301587
|
Gt(ROSA)26Sortm1(ACTB-Map2k5*/EGFP)Zxi/Gt(ROSA)26Sortm1(ACTB-Map2k5*/EGFP)Zxi
Tg(Nes-cre/Esr1*)4Ynj/0
involves: 129S6/SvEvTac * C57BL/6NCr
|
abnormal dentate gyrus morphology |
J:206948
|
|
abnormal long-term spatial reference memory |
J:206948
|
|
abnormal neuron physiology |
J:206948
|
|
abnormal spatial reference memory |
J:206948
|
|
enhanced long-term object recognition memory |
J:206948
|
|
enhanced spatial learning |
J:206948
|
Gt(ROSA)26Sortm1(ACTB-Map2k5*/EGFP)Zxi/Gt(ROSA)26Sortm14(CAG-tdTomato)Hze
Tg(Nes-cre/Esr1*)4Ynj/0
involves: 129S6/SvEvTac * C57BL/6NCr
|
abnormal dendrite morphology |
J:206948
|
|
abnormal dendritic spine morphology |
J:206948
|
|
abnormal dentate gyrus morphology |
J:206948
|
|
normal
nervous system phenotype |
J:206948
|
Gt(ROSA)26Sortm1(Actb-Met)Fmai/?
Tg(Nes-cre)1Kln/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
normal
vision/eye phenotype |
J:173661
|
Gt(ROSA)26Sortm1(Actb-T,-GFP)Dalco/Gt(ROSA)26Sortm1(Actb-T,-GFP)Dalco
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm1(ADGRG6)Jlp/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * SJL
|
no abnormal phenotype detected |
J:315981
|
Gt(ROSA)26Sortm1(Akt1/EGFP)Glas/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
decreased total body fat amount |
J:94134
|
|
increased muscle weight |
J:94134
|
|
increased skeletal muscle fiber size |
J:94134
|
|
increased skeletal muscle size |
J:94134
|
Gt(ROSA)26Sortm1(B4galt1)Clib/Gt(ROSA)26Sortm1(B4galt1)Clib
Tg(Nes-cre)Wme/?
involves: 129S6/SvEvTac * C57BL/6 * CBA
|
abnormal gut flora balance |
J:209737
|
|
abnormal homeostasis |
J:209737
|
|
abnormal Paneth cell morphology |
J:209737
|
|
decreased acute inflammation |
J:209737
|
|
decreased circulating interleukin-6 level |
J:209737
|
|
decreased susceptibility to induced colitis |
J:209737
|
|
decreased susceptibility to induced morbidity/mortality |
J:209737
|
|
normal
digestive/alimentary phenotype |
J:209737
|
|
normal
hematopoietic system phenotype |
J:209737
|
Gt(ROSA)26Sortm1(Bcor*A)Vjba/Gt(ROSA)26Sor+
Tmem163Tg(ACTB-cre)2Mrt/Tmem163+
involves: 129S1/Sv * FVB/N
|
abnormal eye morphology |
J:296645
|
|
abnormal forelimb morphology |
J:296645
|
|
abnormal hindbrain morphology |
J:296645
|
|
embryonic lethality during organogenesis, complete penetrance |
J:296645
|
|
short mandible |
J:296645
|
|
short snout |
J:296645
|
Gt(ROSA)26Sortm1(Bcor*A)Vjba/Gt(ROSA)26Sortm1(Bcor*A)Vjba
involves: 129S1/Sv
|
abnormal bone marrow cell physiology |
J:231455
|
|
decreased cell proliferation |
J:231455
|
Gt(ROSA)26Sortm1(Bmi1)Aiwa/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal hematopoietic stem cell physiology |
J:198331
|
|
normal
hematopoietic system phenotype |
J:198331
|
|
increased hematopoietic stem cell number |
J:198331
|
|
increased hematopoietic stem cell proliferation |
J:198331
|
Gt(ROSA)26Sortm1(Cacna1c*)Red/Gt(ROSA)26Sor+
Foxg1tm1(cre)Skm/Foxg1+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
abnormal neuron morphology |
J:199433
|
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sor+
Tg(Osr1-cre)4Mrt/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N
|
increased malignant tumor incidence |
J:234601
|
|
increased prostate gland adenocarcinoma incidence |
J:234601
|
|
increased prostate intraepithelial neoplasia incidence |
J:234601
|
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sortm1(CAG-AR)Zsu
Tg(Osr1-cre)4Mrt/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N
|
increased prostate gland adenocarcinoma incidence |
J:234601
|
|
increased prostate intraepithelial neoplasia incidence |
J:234601
|
Gt(ROSA)26Sortm1(CAG-Bcl3,-EGFP)Hoev/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd
|
abnormal B cell differentiation |
J:208980
|
|
abnormal B-2 B cell morphology |
J:208980
|
|
abnormal class switch recombination |
J:208980
|
|
abnormal follicular B cell morphology |
J:208980
|
|
abnormal Peyer's patch germinal center morphology |
J:208980
|
|
abnormal transitional stage T3 B cell morphology |
J:208980
|
|
absent marginal zone B cells |
J:208980
|
|
decreased B cell apoptosis |
J:208980
|
|
decreased B cell proliferation |
J:208980
|
|
decreased B-1 B cell number |
J:208980
|
|
decreased B-1a cell number |
J:208980
|
|
decreased IgG1 level |
J:208980
|
|
decreased IgG2b level |
J:208980
|
|
decreased IgG3 level |
J:208980
|
|
decreased IgM level |
J:208980
|
|
decreased immature B cell number |
J:208980
|
|
decreased marginal zone B cell number |
J:208980
|
|
decreased transitional stage T1 B cell number |
J:208980
|
|
enlarged spleen |
J:208980
|
|
increased lymphocyte cell number |
J:208980
|
Gt(ROSA)26Sortm1(CAG-Bgeo,-Insc/GFP)Jakn/Gt(ROSA)26Sortm1(CAG-Bgeo,-Insc/GFP)Jakn
Tg(Nes-cre)1Wmz/0
involves: C57BL/6
|
abnormal brain development |
J:178712
|
|
abnormal cerebral cortex morphology |
J:178712
|
|
abnormal cortical intermediate zone morphology |
J:178712
|
|
abnormal cortical plate morphology |
J:178712
|
|
abnormal neuron morphology |
J:178712
|
|
abnormal neuronal precursor proliferation |
J:178712
|
|
abnormal radial glial cell morphology |
J:178712
|
|
abnormal stratification in cerebral cortex |
J:178712
|
|
increased neuron number |
J:178712
|
|
seizures |
J:178712
|
|
thickened cerebral cortex |
J:178712
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Rb1tm2Brn/Rb1tm2Brn
Tg(Gfap-cre)2Brn/0
either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased pituitary gland tumor incidence |
J:187257
|
|
normal
neoplasm |
J:187257
|
|
premature death |
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased carcinoma incidence |
J:187257
|
|
increased medulloblastoma incidence |
J:187257
|
|
increased pituitary gland tumor incidence |
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Ptentm1Mro/Pten+
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N
|
increased prostate gland adenocarcinoma incidence |
J:184533
|
|
increased prostate intraepithelial neoplasia incidence |
J:184533
|
|
urinary bladder obstruction |
J:184533
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N
|
increased prostate intraepithelial neoplasia incidence |
J:184533
|
|
normal
neoplasm |
J:184533
|
|
prostate gland hyperplasia |
J:184533
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Tg(Gfap-cre)2Brn/0
either: (involves: 129P2/OlaHsd * FVB/N) or (involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence |
J:187257
|
|
increased pituitary gland tumor incidence |
J:187257
|
|
increased tumor incidence |
J:187257
|
|
premature death |
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmpr1a)Que/Gt(ROSA)26Sor+
Shhtm1(EGFP/cre)Cjt/?
Not Specified
|
abnormal esophageal epithelium morphology |
J:166768
|
|
abnormal forestomach morphology |
J:166768
|
|
preweaning lethality, complete penetrance |
J:166768
|
Gt(ROSA)26Sortm1(CAG-CAMK2G*T287D,-EGFP)Whua/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
|
normal
digestive/alimentary phenotype |
J:243363
|
Gt(ROSA)26Sortm1(CAG-CAMK2G*T287D,-EGFP)Whua/Gt(ROSA)26Sor+
Tg(Vil1-cre)997Gum/0
involves: 129 * C57BL/6
|
decreased susceptibility to induced colitis |
J:243363
|
|
normal
digestive/alimentary phenotype |
J:243363
|
|
increased incidence of tumors by chemical induction |
J:243363
|
Gt(ROSA)26Sortm1(CAG-cas9*,-EGFP)Fezh/Gt(ROSA)26Sortm1(CAG-cas9*,-EGFP)Fezh
B6;129-Gt(ROSA)26Sortm1(CAG-cas9*,-EGFP)Fezh
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm1(CAG-cas9*,-EGFP)Fezh/?
Tmem258tm1.1(KOMP)Vlcg/Tmem258+
involves: C57BL/6NTac
|
increased cell death |
J:240635
|
|
increased endoplasmic reticulum stress |
J:240635
|
Gt(ROSA)26Sortm1(CAG-CHRM4*,-mCitrine)Ute/Gt(ROSA)26Sor+
B6.129-Gt(ROSA)26Sortm1(CAG-CHRM4*,-mCitrine)Ute/J
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm1(CAG-COP4*E123T*H134R,-tdTomato)Gfng/Gt(ROSA)26Sortm1(CAG-COP4*E123T*H134R,-tdTomato)Gfng
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
|
no abnormal phenotype detected |
J:179349
|
Gt(ROSA)26Sortm1(CAG-ECFP/EYFP*)Phep/Gt(ROSA)26Sortm1(CAG-ECFP/EYFP*)Phep
B6.Cg-Gt(ROSA)26Sortm1(CAG-ECFP/EYFP*)Phep
|
no abnormal phenotype detected |
J:82809
|
Gt(ROSA)26Sortm1(CAG-EGFP)Blh/?
involves: C57BL/6
|
no abnormal phenotype detected |
J:149822
|
Gt(ROSA)26Sortm1(CAG-EGFP)Luo/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ
|
no abnormal phenotype detected |
J:98961
|
Gt(ROSA)26Sortm1(CAG-EGFP/Rpl10a,-birA)Wtp/Gt(ROSA)26Sortm1(CAG-EGFP/Rpl10a,-birA)Wtp
involves: 129S4/SvJae * C57BL/6J
|
no abnormal phenotype detected |
J:201159
|
Gt(ROSA)26Sortm1(CAG-EGFP/Vamp2)Ggc/Gt(ROSA)26Sor+
Tg(Syn1-cre)671Jxm/0
involves: C57BL/6 * CBA
|
no abnormal phenotype detected |
J:206865
|
Gt(ROSA)26Sortm1(CAG-Errfi1)Jwj/?
Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
no abnormal phenotype detected |
J:218222
|
Gt(ROSA)26Sortm1(CAG-Errfi1)Jwj/?
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
abnormal uterus physiology |
J:218222
|
|
endometrium hyperplasia |
J:218222
|
|
increased papilloma incidence |
J:218222
|
|
increased uterus weight |
J:218222
|
|
premature death |
J:218222
|
Gt(ROSA)26Sortm1(CAG-Etv2,-GFP)Hkata/Gt(ROSA)26Sor+
Commd10Tg(Vav1-icre)A2Kio/Commd10+
involves: C57BL/6NCrlj * C57BL/10 * CBA/Ca * CBA/JNCrlj
|
abnormal bone marrow cell morphology/development |
J:203163
|
|
abnormal hematopoietic system morphology/development |
J:203163
|
|
anemia |
J:203163
|
|
decreased common myeloid progenitor cell number |
J:203163
|
|
decreased erythroid progenitor cell number |
J:203163
|
|
preweaning lethality, incomplete penetrance |
J:203163
|
Gt(ROSA)26Sortm1(CAG-Etv2,-GFP)Hkata/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * SJL
|
abnormal definitive hematopoiesis |
J:203163
|
|
abnormal vitelline vasculature morphology |
J:203163
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:203163
|
|
hemorrhage |
J:203163
|
Gt(ROSA)26Sortm1(CAG-Etv2,-GFP)Hkata/Gt(ROSA)26Sor+
Meox1tm1(cre)Jpa/Meox1+
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:203163
|
Gt(ROSA)26Sortm1(CAG-Etv2,-GFP)Hkata/Gt(ROSA)26Sor+
Sox1tm1(cre)Take/Sox1+
involves: C57BL/6NCrlj * CBA/JNCrlj
|
normal
cardiovascular system phenotype |
J:203163
|
|
normal
embryo phenotype |
J:203163
|
|
normal
hematopoietic system phenotype |
J:203163
|
|
normal
mortality/aging |
J:203163
|
Gt(ROSA)26Sortm1(CAG-Etv2,-GFP)Hkata/Gt(ROSA)26Sor+
Sox17tm1(icre)Heli/Sox17+
involves: 129S2/SvPas * C57BL/6NCrlj * CBA/JNCrlj
|
normal
embryo phenotype |
J:203163
|
|
normal
mortality/aging |
J:203163
|
Gt(ROSA)26Sortm1(CAG-Etv2,-GFP)Hkata/Gt(ROSA)26Sortm1(CAG-Etv2,-GFP)Hkata
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:203163
|
Gt(ROSA)26Sortm1(CAG-Foxn1/ERT2,-GFP)Cbln/Gt(ROSA)26Sor+
Foxn1tm3(cre)Nrm/Foxn1+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal thymus involution |
J:208852
|
|
normal
endocrine/exocrine gland phenotype |
J:208852
|
|
increased T cell number |
J:208852
|
Gt(ROSA)26Sortm1(CAG-Foxo1*)Jcbr/Gt(ROSA)26Sor+
Pdpk1tm1Jcbr/Pdpk1tm1Jcbr
Tg(Pomc1-cre)16Lowl/0
involves: C57BL/6 * FVB/N
|
decreased circulating corticosterone level |
J:134336
|
|
decreased corticotroph cell number |
J:134336
|
|
normal
homeostasis/metabolism phenotype |
J:134336
|
Gt(ROSA)26Sortm1(CAG-FOXO1,GFP)Moli/Gt(ROSA)26Sor+
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:189962
|
Gt(ROSA)26Sortm1(CAG-GCaMP5)Ryba/Gt(ROSA)26Sor+
Hnrnputm1.1Tman/Hnrnputm1.1Tman
Tg(Ckmm-cre)5Khn/0
involves: 129S4/SvJaeSor * FVB
|
decreased cardiac muscle contractility |
J:223139
|
Gt(ROSA)26Sortm1(CAG-GFP/Eif2c2)Zjh/Gt(ROSA)26Sortm1(CAG-GFP/Eif2c2)Zjh
involves: C57BL/6 * NZB
|
no abnormal phenotype detected |
J:179351
|
Gt(ROSA)26Sortm1(CAG-Kcnj11*,-GFP)Nich/Gt(ROSA)26Sor+
Tg(Ins2-cre)23Herr/0
involves: C57BL/6 * CBA/J
|
abnormal circulating glucagon level |
J:146650
|
|
abnormal circulating glucose level |
J:146650
|
|
abnormal pancreas morphology |
J:146650
|
|
abnormal pancreatic alpha cell morphology |
J:146650
|
|
abnormal pancreatic beta cell physiology |
J:146650
|
|
abnormal pancreatic islet morphology |
J:146650
|
|
decreased circulating glucagon level |
J:146650
|
|
decreased circulating insulin level |
J:146650
|
|
decreased insulin secretion |
J:146650
|
|
decreased pancreas weight |
J:146650
|
|
decreased pancreatic alpha cell number |
J:146650
|
|
decreased pancreatic beta cell number |
J:146650
|
|
decreased pancreatic islet number |
J:146650
|
|
hyperglycemia |
J:146650
|
|
increased circulating glucagon level |
J:146650
|
|
slow postnatal weight gain |
J:146650
|
|
small pancreatic islets |
J:146650
|
Gt(ROSA)26Sortm1(CAG-Kcnj11*,-GFP)Nich/?
Tg(CAG-Bgeo/GFP)21Lbe/0
Tg(Pmch-cre)1Lowl/0
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * FVB/NJ
|
abnormal single cell response |
J:167906
|
|
normal
homeostasis/metabolism phenotype |
J:167906
|
|
impaired glucose tolerance |
J:167906
|
Gt(ROSA)26Sortm1(CAG-LMNA*)Cyh/Gt(ROSA)26Sor+
Tg(Ckmm-cre)5Khn/0
involves: C57BL/6JNarl * FVB
|
abnormal cell nucleus morphology |
J:284048
|
|
abnormal endoplasmic reticulum morphology |
J:284048
|
|
abnormal mitochondrial crista morphology |
J:284048
|
|
abnormal skeletal muscle morphology |
J:284048
|
|
abnormal white adipose tissue morphology |
J:284048
|
|
centrally nucleated skeletal muscle fibers |
J:284048
|
|
decreased basal metabolism |
J:284048
|
|
decreased body fat mass |
J:284048
|
|
decreased body size |
J:284048
|
|
decreased body temperature |
J:284048
|
|
decreased carbon dioxide production |
J:284048
|
|
decreased grip strength |
J:284048
|
|
decreased heart rate |
J:284048
|
|
decreased locomotor activity |
J:284048
|
|
decreased oxygen consumption |
J:284048
|
|
decreased skeletal muscle fiber diameter |
J:284048
|
|
decreased skeletal muscle mass |
J:284048
|
|
dystrophic muscle |
J:284048
|
|
increased circulating creatine kinase level |
J:284048
|
|
increased endoplasmic reticulum stress |
J:284048
|
|
increased respiratory quotient |
J:284048
|
|
jerky movement |
J:284048
|
|
kyphosis |
J:284048
|
|
premature death |
J:284048
|
|
prolonged QT interval |
J:284048
|
Gt(ROSA)26Sortm1(CAG-Lmx1b,ALPP)Rjo/Gt(ROSA)26Sor+
Tg(Prrx1-cre)1Cjt/0
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL/J
|
abnormal ankle joint morphology |
J:158676
|
|
abnormal foot pad morphology |
J:158676
|
|
abnormal skeleton morphology |
J:158676
|
|
abnormal tendon morphology |
J:158676
|
|
decreased skeletal muscle mass |
J:158676
|
Gt(ROSA)26Sortm1(CAG-Lmx1b,ALPP)Rjo/Gt(ROSA)26Sor+
Sox9tm3(cre)Crm/Sox9+
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6
|
abnormal ankle joint morphology |
J:158676
|
|
abnormal foot pad morphology |
J:158676
|
|
abnormal skeleton morphology |
J:158676
|
|
abnormal tendon morphology |
J:158676
|
|
decreased skeletal muscle mass |
J:158676
|
Gt(ROSA)26Sortm1(CAG-Mafb,-tdTomato)Good/Gt(ROSA)26Sor+
Tg(Neurog1-cre)1Jejo/0
involves: 129S4/SvJae * C57BL/6J * SJL/J
|
abnormal cochlear ganglion morphology |
J:207904
|
|
abnormal inner hair cell synaptic ribbon morphology |
J:207904
|
|
normal
nervous system phenotype |
J:207904
|
|
postnatal lethality, incomplete penetrance |
J:207904
|
Gt(ROSA)26Sortm1(CAG-MAP2K7*/MAPK8,-EGFP)Ftw/Gt(ROSA)26Sor+
Tg(Ckmm-cre)5Khn/0
involves: C57BL/6 * FVB
|
normal
growth/size/body region phenotype |
J:195844
|
|
normal
homeostasis/metabolism phenotype |
J:195844
|
Gt(ROSA)26Sortm1(CAG-MFN2*T105M)Dple/Gt(ROSA)26Sor+
Tg(Nes-cre)1Kln/0
involves: C57BL/6 * SJL
|
abnormal skeletal muscle fiber morphology |
J:251584
|
|
abnormal skeletal muscle fiber type ratio |
J:251584
|
|
abnormal soleus morphology |
J:251584
|
|
decreased mitochondrial number |
J:251584
|
|
decreased skeletal muscle fiber diameter |
J:251584
|
|
normal
nervous system phenotype |
J:251584
|
|
short stride length |
J:251584
|
|
skeletal muscle fiber atrophy |
J:251584
|
Gt(ROSA)26Sortm1(CAG-MFN2*T105M)Dple/Gt(ROSA)26Sor+
Tg(CAG-cre/Esr1*)5Amc/0
involves: C57BL/6 * CBA
|
abnormal hair follicle morphology |
J:251584
|
|
abnormal mitochondrial morphology |
J:251584
|
|
abnormal motor capabilities/coordination/movement |
J:251584
|
|
abnormal myelination |
J:251584
|
|
ascites |
J:251584
|
|
premature death |
J:251584
|
|
respiratory distress |
J:251584
|
Gt(ROSA)26Sortm1(CAG-Mir21)Jake/Gt(ROSA)26Sor+
Tg(Gfap-cre)#Mvs/0
involves: BALB/c * C57BL/6 * C57BL/6NHsd
|
abnormal astrocyte morphology |
J:192021
|
|
abnormal astrocyte physiology |
J:192021
|
|
abnormal response to injury |
J:192021
|
|
increased susceptibility to injury |
J:192021
|
Gt(ROSA)26Sortm1(CAG-Mir182)Dgk/Gt(ROSA)26Sortm1(CAG-Mir182)Dgk
involves: 129/Sv * C57BL/6
|
no abnormal phenotype detected |
J:217635
|
Gt(ROSA)26Sortm1(CAG-Mir182)Dgk/Gt(ROSA)26Sortm1(CAG-Mir182)Dgk
Krastm4Tyj/Krastm4Tyj
Trp53tm1Brn/Trp53tm1Brn
involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased metastatic potential |
J:217635
|
Gt(ROSA)26Sortm1(CAG-Mlip)Dzw/Gt(ROSA)26Sor+
Tg(Tnnt2-cre)5Blh/0
involves: C57BL/6 * DBA/2
|
normal
cardiovascular system phenotype |
J:227485
|
|
decreased response of heart to induced stress |
J:227485
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1+
Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased prostate gland tumor incidence |
J:307910
|
|
premature death |
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1tm2Brn
Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased metastatic potential |
J:307910
|
|
increased prostate gland tumor incidence |
J:307910
|
|
premature death |
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased prostate intraepithelial neoplasia incidence |
J:307910
|
|
premature death |
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Tg(Dbh-icre)1Gsc/0
involves: 129S6/SvEvTac * C57BL/6
|
adrenal medulla hyperplasia |
J:222527
|
|
increased neuroblastoma incidence |
J:222527
|
Gt(ROSA)26Sortm1(CAG-NPM1*)Geno/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
involves: C57BL/6 * CBA
|
abnormal megakaryocyte differentiation |
J:196690
|
|
abnormal platelet morphology |
J:196690
|
|
enlarged spleen |
J:196690
|
|
increased megakaryocyte cell number |
J:196690
|
|
myeloid hyperplasia |
J:196690
|
|
thrombocytopenia |
J:196690
|
Gt(ROSA)26Sortm1(CAG-NPM1*)Geno/Gt(ROSA)26Sortm1(CAG-NPM1*)Geno
Tg(Mx1-cre)1Cgn/0
involves: C57BL/6 * CBA
|
abnormal megakaryocyte differentiation |
J:196690
|
|
abnormal platelet morphology |
J:196690
|
|
enlarged spleen |
J:196690
|
|
increased megakaryocyte cell number |
J:196690
|
|
thrombocytopenia |
J:196690
|
Gt(ROSA)26Sortm1(CAG-NR2F1)Mjts/Gt(ROSA)26Sor+
Nr2f2tm2.1Tsa/Nr2f2tm2.1Tsa
Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ
|
normal
reproductive system phenotype |
J:162256
|
Gt(ROSA)26Sortm1(CAG-Nr2f2)Tsa/Gt(ROSA)26Sor+
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+
involves: 129S1/Sv * 129X1/SvJ * FVB/N
|
abnormal cardiovascular system physiology |
J:227012
|
|
abnormal cell physiology |
J:227012
|
|
abnormal mitochondrial inner membrane morphology |
J:227012
|
|
abnormal mitochondrial physiology |
J:227012
|
|
abnormal mitochondrial shape |
J:227012
|
|
abnormal oxidative phosphorylation |
J:227012
|
|
abnormal respiratory electron transport chain |
J:227012
|
|
decreased cardiac muscle contractility |
J:227012
|
|
decreased fatty acid oxidation |
J:227012
|
|
decreased oxygen consumption |
J:227012
|
|
dilated cardiomyopathy |
J:227012
|
|
enlarged heart |
J:227012
|
|
premature death |
J:227012
|
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+
Tg(MMTV-cre)7Mul/0
involves: BALB/c * FVB/N
|
increased mammary adenocarcinoma incidence |
J:173655
|
|
premature death |
J:173655
|
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+
Tg(Wap-cre)1Gsc/0
involves: BALB/c * C57BL/6 * FVB/N
|
abnormal involution of the mammary gland |
J:173655
|
|
increased mammary adenocarcinoma incidence |
J:173655
|
|
increased mammary gland tumor incidence |
J:173655
|
Gt(ROSA)26Sortm1(CAG-PLS3,-GFP)Bwir/Gt(ROSA)26Sor+
Mnx1tm4(cre)Tmj/Mnx1+
involves: 129S1/Sv * 129S4/SvJae * BALB/cJ * C57BL/6
|
normal
muscle phenotype |
J:193844
|
|
normal
nervous system phenotype |
J:193844
|
Gt(ROSA)26Sortm1(CAG-PSTPIP1)Dtg/Gt(ROSA)26Sor+
Commd10Tg(Vav1-icre)A2Kio/Commd10+
involves: C57BL/6 * C57BL/10 * CBA/Ca
|
no abnormal phenotype detected |
J:196002
|
Gt(ROSA)26Sortm1(CAG-PTPN1,-EGFP)Mtr/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2
|
increased prostate intraepithelial neoplasia incidence |
J:231906
|
|
prostate gland anterior lobe hyperplasia |
J:231906
|
Gt(ROSA)26Sortm1(CAG-RABVgp4,-TVA)Arenk/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd
|
no abnormal phenotype detected |
J:206510
|
Gt(ROSA)26Sortm1(CAG-Rheb*)Pfw/Gt(ROSA)26Sor+
Rhebtm1Pfw/Rhebtm1Pfw
Tg(Nes-cre)1Kln/0
involves: C57BL/6 * SJL
|
normal
nervous system phenotype |
J:168571
|
Gt(ROSA)26Sortm1(CAG-Rheb*)Pfw/Gt(ROSA)26Sortm1(CAG-Rheb*)Pfw
Tg(Nes-cre)1Kln/0
involves: C57BL/6 * SJL
|
abnormal cerebral cortex morphology |
J:168571
|
|
hypermyelination |
J:168571
|
|
increased brain size |
J:168571
|
|
increased brain weight |
J:168571
|
|
increased oligodendrocyte number |
J:168571
|
|
neuron hypertrophy |
J:168571
|
|
thickened cerebral cortex |
J:168571
|
Gt(ROSA)26Sortm1(CAG-Rhoj,-EGFP)Auem/Gt(ROSA)26Sor+
Tg(Tek-cre)2352Rwng/0
involves: C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
abnormal retina vasculature morphology |
J:191977
|
Gt(ROSA)26Sortm1(CAG-Rhoj,-EGFP)Auem/Gt(ROSA)26Sortm1(CAG-Rhoj,-EGFP)Auem
Tg(CAG-cre/Esr1*)1Egwa/0
involves: C57BL/6 * CBA * DBA/2
|
abnormal induced retina neovascularization |
J:173943
|
Gt(ROSA)26Sortm1(CAG-Rhoj,-EGFP)Auem/Gt(ROSA)26Sortm1(CAG-Rhoj,-EGFP)Auem
Tg(Tek-cre)#Rwng/0
involves: C57BL/6 * CBA
|
abnormal vascular development |
J:173943
|
|
embryonic growth retardation |
J:173943
|
|
prenatal lethality, complete penetrance |
J:173943
|
Gt(ROSA)26Sortm1(CAG-Slc39a14*L438R)Wvh/Gt(ROSA)26Sor+
Tg(Ctsk-cre)1Rda/0
involves: C57BL/6
|
abnormal compact bone morphology |
J:261326
|
|
abnormal tibia morphology |
J:261326
|
|
normal
craniofacial phenotype |
J:261326
|
|
decreased bone ossification |
J:261326
|
|
decreased bone trabecular spacing |
J:261326
|
|
increased bone mineralization |
J:261326
|
|
increased bone trabecula number |
J:261326
|
|
increased trabecular bone thickness |
J:261326
|
|
increased trabecular bone volume |
J:261326
|
Gt(ROSA)26Sortm1(CAG-Slc39a14*L438R)Wvh/Gt(ROSA)26Sor+
Tg(Runx2-icre)1Jtuc/0
involves: FVB/N
|
abnormal compact bone morphology |
J:261326
|
|
abnormal osteoblast physiology |
J:261326
|
|
normal
craniofacial phenotype |
J:261326
|
|
decreased bone mineralization |
J:261326
|
|
decreased bone trabecula number |
J:261326
|
|
decreased diameter of femur |
J:261326
|
|
decreased diameter of tibia |
J:261326
|
|
decreased femur stiffness |
J:261326
|
|
decreased trabecular bone connectivity density |
J:261326
|
|
decreased trabecular bone mass |
J:261326
|
|
decreased trabecular bone volume |
J:261326
|
|
fragile skeleton |
J:261326
|
|
increased bone mineralization |
J:261326
|
|
increased bone ossification |
J:261326
|
|
increased bone trabecular spacing |
J:261326
|
|
increased femur compact bone thickness |
J:261326
|
|
increased osteoclast cell number |
J:261326
|
Gt(ROSA)26Sortm1(CAG-SNCA)Tanj/Gt(ROSA)26Sortm1(CAG-SNCA)Tanj
Tg(Plp1-cre/ERT)3Pop/0
involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl * DBA/2
|
abnormal glial cell morphology |
J:283567
|
|
abnormal neuron morphology |
J:283567
|
|
alpha-synuclein inclusion body |
J:283567
|
|
decreased locomotor activity |
J:283567
|
|
impaired coordination |
J:283567
|
|
normal
nervous system phenotype |
J:283567
|
|
premature death |
J:283567
|
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sor+
Tg(Sftpc-cre)1Blh/0
involves: 129S/SvEv * C57BL/6 * DBA/2
|
abnormal lung morphology |
J:161806
|
|
bronchial epithelial hyperplasia |
J:161806
|
|
bronchiolar epithelial hyperplasia |
J:161806
|
|
increased lung adenocarcinoma incidence |
J:161806
|
|
lung epithelium hyperplasia |
J:161806
|
|
premature death |
J:161806
|
|
respiratory distress |
J:161806
|
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sor+
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
involves: 129S6/SvEv * C57BL/6
|
bronchial epithelial hyperplasia |
J:161806
|
|
normal
neoplasm |
J:161806
|
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
involves: 129S6/SvEv * C57BL/6
|
bronchial epithelial hyperplasia |
J:161806
|
|
increased lung adenocarcinoma incidence |
J:161806
|
Gt(ROSA)26Sortm1(CAG-tdTomato*,-EGFP*)Ees/Gt(ROSA)26Sortm1(CAG-tdTomato*,-EGFP*)Ees
involves: 129S6/SvEvTac * C57BL/6NCr
|
no abnormal phenotype detected |
J:199711
|
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
involves: C57BL/6 * CBA
|
abnormal hematopoietic system physiology |
J:158953
|
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sor+
Tg(Nes-cre)1Wme/0
involves: C57BL/6 * CBA
|
abnormal hematopoietic system physiology |
J:158953
|
|
normal
hematopoietic system phenotype |
J:158953
|
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sortm1(cre/ERT)Nat
involves: 129 * C57BL/6
|
abnormal hematopoietic system physiology |
J:158953
|
|
normal
hematopoietic system phenotype |
J:158953
|
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sortm1(cre/ERT)Nat
Tg(H2-K-BCL2)1Josd/0
involves: 129 * C3H * C57BL/6
|
abnormal hematopoietic system physiology |
J:158953
|
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sortm1(cre/ERT)Nat
Trp53tm1Tyj/Trp53+
involves: 129 * 129S2/SvPas * C57BL/6
|
normal
hematopoietic system phenotype |
J:158953
|
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sortm1(cre/ERT)Nat
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129 * 129S2/SvPas * C57BL/6
|
normal
hematopoietic system phenotype |
J:158953
|
Gt(ROSA)26Sortm1(CAG-Wnt5a,-AcGFP)Skde/Gt(ROSA)26Sor+
Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal embryo attachment |
J:233595
|
|
abnormal embryo development |
J:233595
|
|
abnormal maternal decidual layer morphology |
J:233595
|
|
abnormal placenta morphology |
J:233595
|
|
abnormal trophoblast giant cell proliferation |
J:233595
|
|
abnormal uterine-embryonic axis |
J:233595
|
|
abnormal uterus morphology |
J:233595
|
|
decreased litter size |
J:233595
|
|
decreased placental labyrinth size |
J:233595
|
|
impaired embryo implantation |
J:233595
|
|
impaired spacing of implantation sites |
J:233595
|
|
reduced female fertility |
J:233595
|
|
normal
reproductive system phenotype |
J:233595
|
|
twin decidual capsule |
J:233595
|
Gt(ROSA)26Sortm1(CARD14*)Ribt/Gt(ROSA)26Sor+
Tg(KRT14-cre/ERT)20Efu/0
involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1
|
acanthosis |
J:292094
|
|
decreased body weight |
J:292094
|
|
decreased circulating glucose level |
J:292094
|
|
hyperkeratosis |
J:292094
|
|
increased dendritic cell number |
J:292094
|
|
increased keratinocyte proliferation |
J:292094
|
|
increased neutrophil cell number |
J:292094
|
|
parakeratosis |
J:292094
|
|
premature death |
J:292094
|
|
psoriasis |
J:292094
|
|
skin inflammation |
J:292094
|
|
thick epidermis |
J:292094
|
Gt(ROSA)26Sortm1(CARD14*)Ribt/Gt(ROSA)26Sor+
Tg(KRT5-cre)5132Jlj/0
involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl * DBA/2J
|
normal
integument phenotype |
J:292094
|
|
neonatal lethality, complete penetrance |
J:292094
|
Gt(ROSA)26Sortm1(CARD14*)Ribt/Gt(ROSA)26Sor+
Malt1tm1c(EUCOMM)Hmgu/Malt1tm1c(EUCOMM)Hmgu
Tg(KRT5-cre)5132Jlj/0
involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCrl * DBA/2J
|
normal
mortality/aging |
J:292094
|
Gt(ROSA)26Sortm1(CARD14*)Ribt/Gt(ROSA)26Sor+
Malt1tm1c(EUCOMM)Hmgu/Malt1tm1c(EUCOMM)Hmgu
Tg(KRT14-cre/ERT)20Efu/0
involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1
|
decreased body weight |
J:292094
|
|
increased dendritic cell number |
J:292094
|
|
increased neutrophil cell number |
J:292094
|
|
psoriasis |
J:292094
|
|
skin inflammation |
J:292094
|
|
thick epidermis |
J:292094
|
Gt(ROSA)26Sortm1(Cdkn1b,EGFP)Dor/Gt(ROSA)26Sor+
Myl2tm1(cre)Krc/Myl2+
involves: 129/Sv * 129S4/SvJae * C57BL/6
|
heart hypoplasia |
J:131577
|
|
thin ventricular wall |
J:131577
|
Gt(ROSA)26Sortm1(Cdkn1b,EGFP)Dor/Gt(ROSA)26Sortm1(Cdkn1b,EGFP)Dor
Myl2tm1(cre)Krc/Myl2+
involves: 129/Sv * 129S4/SvJae * C57BL/6
|
heart hypoplasia |
J:131577
|
|
thin ventricular wall |
J:131577
|
Gt(ROSA)26Sortm1(Cdkn1c)Jfpa/Gt(ROSA)26Sor+
Myl2tm1(cre)Krc/Myl2+
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal heart left ventricle pressure |
J:197451
|
|
decreased myocardial infarct size |
J:197451
|
|
increased coronary flow rate |
J:197451
|
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Kat8tm1Thl/Kat8+
involves: 129S1/Sv
|
abnormal DNA repair |
J:128936
|
|
decreased fibroblast proliferation |
J:128936
|
|
increased cellular sensitivity to ionizing radiation |
J:128936
|
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Kat8tm1Thl/Kat8tm1Thl
involves: 129S1/Sv
|
decreased fibroblast proliferation |
J:128936
|
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Mcl1tm1Ywh/Mcl1tm1Ywh
involves: 129/Sv * 129S6/SvEvTac * C57BL/6
|
increased T cell apoptosis |
J:137400
|
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Id1tm3Bene/Id1tm3Bene
Id2tm1Xdz/Id2tm1Xdz
Id3tm1Zhu/Id3tm1Zhu
involves: 129S4/SvJaeSor * C57BL/6
|
premature neuronal precursor differentiation |
J:185426
|
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Pknox1tm1.1Rygo/Pknox1tm1.1Rygo
involves: 129 * C57BL/6 * C57BL/6JJcl
|
abnormal spermatogonia morphology |
J:258387
|
|
arrest of spermatogenesis |
J:258387
|
|
azoospermia |
J:258387
|
|
decreased male germ cell number |
J:258387
|
|
increased testis apoptosis |
J:258387
|
|
normal
reproductive system phenotype |
J:258387
|
|
seminiferous tubule degeneration |
J:258387
|
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sortm1(Tcfe2a/Tal1)Xhsu
involves: 129/Sv * C57BL/6
|
abnormal lymphopoiesis |
J:144569
|
|
abnormal myelopoiesis |
J:144569
|
Gt(ROSA)26Sortm1(cre/ERT2)Thl/0
Picalmtm1.1Tmae/Picalmtm1.1Tmae
involves: 129 * C57BL/6 * SJL
|
abnormal erythropoiesis |
J:220728
|
|
diluted coat color |
J:220728
|
|
hypochromic microcytic anemia |
J:220728
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
|
increased T cell derived lymphoma incidence |
J:179414
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3tm1.2Tno
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
|
decreased lymphoma incidence |
J:179414
|
|
increased T cell derived lymphoma incidence |
J:179414
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Rad50tm3Jpt/Rad50tm4.1Jpt
involves: 129/Sv * C57BL/6
|
abnormal intestine morphology |
J:209141
|
|
postnatal lethality, complete penetrance |
J:209141
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tg(CAG-ANGPT1*)5Yo/0
involves: 129S4/SvJae * C57BL/6NCrlj * CBA/JNCrlj
|
abnormal retina blood vessel morphology |
J:213456
|
|
decreased susceptilbility to retina ischemic injury |
J:213456
|
|
decreased vascular permeability |
J:213456
|
|
increased astrocyte number |
J:213456
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Rdh10tm1c(KOMP)Wtsi/Rdh10tm1c(KOMP)Wtsi
involves: 129S4/SvJae * C57BL/6N * FVB/NJ
|
abnormal spontaneous fetal mouth movement |
J:278485
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Rdh10tm1c(KOMP)Wtsi/Rdh10tm1d(KOMP)Wtsi
involves: 129S4/SvJae * C57BL/6N * FVB/NJ
|
abnormal cricoid cartilage morphology |
J:278485
|
|
abnormal hyoid bone morphology |
J:278485
|
|
abnormal hypoglossal nerve morphology |
J:278485
|
|
abnormal motor neuron morphology |
J:278485
|
|
abnormal palatal shelf elevation |
J:278485
|
|
abnormal thyroid cartilage morphology |
J:278485
|
|
abnormal tongue muscle morphology |
J:278485
|
|
abnormal tongue position |
J:278485
|
|
cleft secondary palate |
J:278485
|
|
normal
craniofacial phenotype |
J:278485
|
|
decreased palatine bone horizontal plate size |
J:278485
|
|
decreased tongue size |
J:278485
|
|
palatal shelves fail to meet at midline |
J:278485
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Hprt1tm6(CAG-fat-1)Geno/Hprt1tm6(CAG-fat-1)Geno
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal fatty acids level |
J:213660
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Sprtntm1.1Yjm/Sprtntm1.1Yjm
involves: 129S/SvEv * 129S4/SvJae
|
chromosomal instability |
J:297179
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Secisbp2tm1.1Amdu/Secisbp2tm1.2Amdu
B6(129S4)-Gt(ROSA)26Sortm1(cre/ERT2)Tyj Secisbp2tm1.1Amdu Secisbp2tm1.2Amdu
|
abnormal enzyme/coenzyme activity |
J:251875
|
|
abnormal pituitary gland physiology |
J:251875
|
|
abnormal thyroid hormone level |
J:251875
|
|
decreased body weight |
J:251875
|
|
decreased triiodothyronine level |
J:251875
|
|
increased circulating thyroid-stimulating hormone level |
J:251875
|
|
increased thyroxine level |
J:251875
|
|
infertility |
J:251875
|
|
premature death |
J:251875
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Supt5tm1.1Rrp/Supt5tm1.2Rrp
involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6
|
abnormal fibroblast physiology |
J:319843
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sortm1(cre/ERT2)Tyj
Nus1tm1.1Qrm/Nus1tm1.1Qrm
involves: 129 * C57BL/6 * SJL
|
abnormal lipid homeostasis |
J:243753
|
|
hepatic steatosis |
J:243753
|
|
increased liver free fatty acids level |
J:243753
|
|
increased liver triglyceride level |
J:243753
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sortm1(Grem1)Svok
involves: 129S1/Sv * 129S4/SvJae
|
abnormal digit morphology |
J:214075
|
|
polydactyly |
J:214075
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sortm1(Pyy)Paba
involves: 129S4/SvJae
|
abnormal bone mineralization |
J:189512
|
|
abnormal bone structure |
J:189512
|
|
abnormal osteoclast morphology |
J:189512
|
|
decreased bone mineral density of femur |
J:189512
|
|
decreased bone strength |
J:189512
|
|
decreased compact bone area |
J:189512
|
|
decreased lean body mass |
J:189512
|
|
decreased trabecular bone volume |
J:189512
|
|
increased osteoclast cell number |
J:189512
|
|
short femur |
J:189512
|
|
small vertebrae |
J:189512
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/0
Smc5tm1c(KOMP)Wtsi/Smc5tm1d(KOMP)Wtsi
involves: 129S4/SvJae * C57BL/6N * CBA
|
abnormal cell cycle |
J:240155
|
|
abnormal cell differentiation |
J:240155
|
|
abnormal mitosis |
J:240155
|
|
abnormal mitotic spindle assembly checkpoint |
J:240155
|
|
abnormal mitotic spindle morphology |
J:240155
|
|
normal
cellular phenotype |
J:240155
|
|
increased cell death |
J:240155
|
|
increased mitotic index |
J:240155
|
|
mitotic nondisjunction |
J:240155
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
Trp53tm5Tyj/Trp53tm5Tyj
involves: 129S4/SvJae * C57BL/6
|
tumor regression |
J:118233
|
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
Trp53bp2tm2Xlu/Trp53bp2tm2Xlu
involves: 129P2/OlaHsd
|
abnormal kidney physiology |
J:162396
|
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
Lin9tm1.1Sgau/Lin9+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal mitotic spindle assembly checkpoint |
J:162678
|
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
Lin9tm1.1Sgau/Lin9tm1.1Sgau
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal cell nucleus morphology |
J:162678
|
|
abnormal centrosome morphology |
J:162678
|
|
abnormal mitosis |
J:162678
|
|
abnormal small intestinal crypt cell proliferation |
J:162678
|
|
abnormal small intestinal villus morphology |
J:162678
|
|
abnormal small intestine morphology |
J:162678
|
|
decreased fibroblast proliferation |
J:162678
|
|
premature death |
J:162678
|
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
Ppp1r13ltm1Xlu/Ppp1r13ltm1Xlu
involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J
|
abnormal cell cycle |
J:177360
|
|
abnormal keratinocyte differentiation |
J:177360
|
|
decreased fibroblast proliferation |
J:177360
|
|
early cellular replicative senescence |
J:177360
|
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sortm1(cre/ERT)Brn
Pou5f1tm1Jnic/Pou5f1tm1Jnic
involves: 129P2/OlaHsd
|
abnormal inner cell mass morphology |
J:208425
|
|
abnormal primitive endoderm morphology |
J:208425
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
involves: 129 * 129S4/SvJae * BALB/c * C57BL/6
|
decreased tumor-free survival time |
J:130367
|
|
endometrium hyperplasia |
J:130367
|
|
increased gastrointestinal tumor incidence |
J:130367
|
|
increased incidence of tumors by chemical induction |
J:130367
|
|
increased prostate gland tumor incidence |
J:130367
|
|
increased prostate intraepithelial neoplasia incidence |
J:130367
|
|
increased skin squamous cell carcinoma incidence |
J:130367
|
|
increased T cell derived lymphoma incidence |
J:130367
|
|
increased tumor incidence |
J:130367
|
|
intestine polyps |
J:130367
|
|
prostate gland hyperplasia |
J:130367
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Ikbkbtm1Lex/Ikbkbtm1Lex
involves: 129S/SvEvBrd
|
abnormal fibroblast migration |
J:159873
|
|
decreased fibroblast cell migration |
J:159873
|
|
decreased fibroblast chemotaxis |
J:159873
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Lhx2tm1Monu/Lhx2tm1Monu
involves: 129 * 129P2/OlaHsd * C57BL/6
|
abnormal cerebral cortex morphology |
J:130167
|
|
abnormal telencephalon development |
J:130167
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+
involves: 129 * C57BL/6
|
abnormal cecum morphology |
J:146617
|
|
abnormal small intestine morphology |
J:146617
|
|
cardiac fibrosis |
J:146617
|
|
glomerulosclerosis |
J:146617
|
|
increased sarcoma incidence |
J:146617
|
|
intestinal fibrosis |
J:146617
|
|
intestine polyps |
J:146617
|
|
premature death |
J:146617
|
|
pulmonary fibrosis |
J:146617
|
|
renal glomerulus fibrosis |
J:146617
|
|
renal glomerulus hypertrophy |
J:146617
|
|
renal interstitial fibrosis |
J:146617
|
|
skeletal muscle interstitial fibrosis |
J:146617
|
|
tight skin |
J:146617
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm13Sor/Pdgfra+
involves: 129S4/SvJaeSor * C57BL/6
|
cardiac fibrosis |
J:146617
|
|
glomerulosclerosis |
J:146617
|
|
intestinal fibrosis |
J:146617
|
|
intestine polyps |
J:146617
|
|
renal glomerulus hypertrophy |
J:146617
|
|
skeletal muscle interstitial fibrosis |
J:146617
|
|
tight skin |
J:146617
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Tardbptm1.1Pcw/Tardbp+
involves: 129 * C57BL/6 * SJL
|
abnormal respiratory quotient |
J:164406
|
|
decreased body weight |
J:164406
|
|
decreased total body fat amount |
J:164406
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Tardbptm1.1Pcw/Tardbptm1.1Pcw
involves: 129 * C57BL/6 * SJL
|
abnormal food intake |
J:164406
|
|
abnormal lipid oxidation |
J:164406
|
|
abnormal respiratory quotient |
J:164406
|
|
abnormal survival |
J:164406
|
|
decreased body weight |
J:164406
|
|
decreased total body fat amount |
J:164406
|
|
normal
homeostasis/metabolism phenotype |
J:164406
|
|
weight loss |
J:164406
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Il1r2tm1.1Mchc/Il1r2tm1.1Mchc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6NTac
|
abnormal adaptive immunity |
J:347877
|
|
increased IgG level |
J:347877
|
|
increased spleen germinal center size |
J:347877
|
|
increased T follicular helper cell number |
J:347877
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm1(cre/ERT)Nat
B6.129-Gt(ROSA)26Sortm1(cre/Esr1)Nat
|
no abnormal phenotype detected |
J:84747
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
involves: 129 * 129S1/Sv * 129X1/SvJ
|
increased sarcoma incidence |
J:147728
|
|
increased tumor incidence |
J:147728
|
|
premature death |
J:147728
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
decreased litter size |
J:194308
|
|
increased sarcoma incidence |
J:217462
|
|
increased tumor incidence |
J:194308
|
|
increased tumor latency |
J:194308
|
|
postnatal growth retardation |
J:194308
|
|
premature death |
J:194308
|
Gt(ROSA)26Sortm1(Crh)Jde/Gt(ROSA)26Sortm1(Crh)Jde
Tg(Camk2a-cre/ERT2)2Gsc/0
involves: 129S2/SvPas * C57BL/6J * FVB/N
|
increased anxiety-related response |
J:176339
|
Gt(ROSA)26Sortm1(Crh)Jde/Gt(ROSA)26Sortm1(Crh)Jde
Tg(Nes-cre)1Kln/0
involves: 129S2/SvPas * C57BL/6 * SJL
|
abnormal seizure response to pharmacological agent |
J:140968
|
|
decreased susceptibility to neuronal excitotoxicity |
J:140968
|
Gt(ROSA)26Sortm1(CTNNB1)Nerl/Gt(ROSA)26Sortm1(CTNNB1)Nerl
Tg(Mx1-cre)1Cgn/0
involves: 129P2/OlaHsd * BALB/c * C57BL/6 * CBA
|
abnormal bone marrow cell number |
J:112660
|
|
abnormal proerythroblast morphology |
J:112660
|
|
anemia |
J:112660
|
|
arrested T cell differentiation |
J:112660
|
|
decreased double-negative T cell number |
J:112660
|
|
decreased erythrocyte cell number |
J:112660
|
|
decreased granulocyte number |
J:112660
|
|
decreased hemoglobin content |
J:112660
|
|
decreased leukocyte cell number |
J:112660
|
|
impaired myelopoiesis |
J:112660
|
|
premature death |
J:112660
|
|
thrombocytopenia |
J:112660
|
|
thymus hypoplasia |
J:112660
|
Gt(ROSA)26Sortm1(Dkk1)Flng/Gt(ROSA)26Sor+
Rac1tm1Djk/Rac1+
Tg(Msx2-cre)5Rem/0
involves: 129S4/SvJae * 129X1/SvJ
|
absent hindlimb |
J:145305
|
|
short forelimb |
J:145305
|
Gt(ROSA)26Sortm1(Dkk1)Flng/Gt(ROSA)26Sortm1(Dkk1)Flng
Tg(Msx2-cre)5Rem/0
involves: 129X1/SvJ
|
absent hindlimb |
J:145305
|
|
short forelimb |
J:145305
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Mesp1tm2(cre)Ysa/Mesp1+
involves: 129S/SvEv * C57BL/6NCrlj * CBA/JNCrlj
|
embryonic lethality, complete penetrance |
J:214744
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
either: (involves: 129S/SvEv * C57BL/6 * CBA) or (involves: 129S/SvEv * C57BL/6 * CBA * CD-1)
|
absent midbrain-hindbrain boundary |
J:103417
|
|
decreased midbrain size |
J:103417
|
|
open neural tube |
J:103417
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Tg(Plp1-cre/ERT)3Pop/0
involves: 129S/SvEv * C57BL/6 * DBA/2
|
abnormal brain white matter morphology |
J:234435
|
|
abnormal motor coordination/balance |
J:234435
|
|
abnormal nervous system morphology |
J:234435
|
|
ataxia |
J:234435
|
|
autoimmune response |
J:234435
|
|
axon degeneration |
J:234435
|
|
CNS inflammation |
J:234435
|
|
decreased myelin sheath thickness |
J:234435
|
|
decreased oligodendrocyte number |
J:234435
|
|
demyelination |
J:234435
|
|
increased activated T cell number |
J:234435
|
|
lymph node inflammation |
J:234435
|
|
premature death |
J:234435
|
|
seizures |
J:234435
|
|
weight loss |
J:234435
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Nkx2-5tm1(cre)Rjs/Nkx2-5+
either: (involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6) or (involves: 129S/SvEv * 129S7/SvEvBrd * CD-1)
|
absent heart |
J:103417
|
|
decreased embryo size |
J:103417
|
|
embryonic lethality during organogenesis, complete penetrance |
J:103417
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Hcn4tm1(cre/ERT2)Anlu/Hcn4+
involves: 129S/SvEv
|
abnormal sinoatrial node morphology |
J:186021
|
|
atrioventricular block |
J:186021
|
|
cardiac fibrosis |
J:186021
|
|
decreased heart rate |
J:186021
|
|
increased heart rate variability |
J:186021
|
|
irregular heartbeat |
J:186021
|
|
premature death |
J:186021
|
|
prolonged PR interval |
J:186021
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Tg(Smad7-cre)1Sjc/0
involves: 129S/Sv * C3HeB/FeJ
|
abnormal blood vessel morphology |
J:150864
|
|
abnormal dorsal aorta morphology |
J:150864
|
|
abnormal vitelline vasculature morphology |
J:150864
|
|
absent atrioventricular cushions |
J:150864
|
|
atrioventricular cushion hypoplasia |
J:150864
|
|
normal
cardiovascular system phenotype |
J:150864
|
|
embryonic lethality during organogenesis, complete penetrance |
J:150864
|
|
hemorrhage |
J:150864
|
|
pharyngeal arch hypoplasia |
J:150864
|
|
small heart |
J:150864
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Tg(Slc16a8-cre/ERT2,-EGFP)1Moss/0
involves: 129S/SvEv * C57BL/6 * CBA
|
abnormal retina pigment epithelium morphology |
J:154671
|
|
abnormal rod electrophysiology |
J:154671
|
|
retina fold |
J:154671
|
|
retina pigment epithelium atrophy |
J:154671
|
|
normal
vision/eye phenotype |
J:154671
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Tg(Trpv1-cre)1Hoon/0
involves: 129S1/Sv
|
abnormal body temperature homeostasis |
J:169256
|
|
abnormal chemical nociception |
J:169256
|
|
normal
behavior/neurological phenotype |
J:169256
|
|
decreased inflammatory response |
J:169256
|
|
decreased pruritus |
J:169256
|
|
decreased sensory neuron number |
J:169256
|
|
increased thermal nociceptive threshold |
J:169256
|
|
normal
nervous system phenotype |
J:169256
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Calcatm1.1(cre/ERT2)Ptch/Calca+
involves: 129P2/OlaHsd * 129S/SvEv
|
abnormal club cell morphology |
J:190366
|
|
abnormal pulmonary neuroendocrine body morphology |
J:190366
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+
Kittm1(cre/ERT2)Dsa/Kit+
involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6
|
abnormal gastrointestinal motility |
J:204737
|
|
abnormal intestinal peristalsis |
J:204737
|
|
abnormal intestinal transit time |
J:204737
|
|
abnormal synaptic transmission |
J:204737
|
|
impaired gastric peristalsis |
J:204737
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sortm1(DTA)Jpmb
either: (involves: 129S/SvEv * C57BL/6) or (involves: 129S/SvEv * CD-1)
|
no abnormal phenotype detected |
J:103417
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sortm1(DTA)Jpmb
Tg(KRT14-cre/ERT)20Efu/?
involves: 129S/SvEv * CD-1
|
abnormal stomach epithelium morphology |
J:173368
|
Gt(ROSA)26Sortm1(DTA)Kio/Gt(ROSA)26Sor+
Tg(Tnfrsf4-cre)1Nik/0
B6.129-Tnfrsf4tm2(cre)Nik Gt(ROSA)26Sortm1(DTA)Kio
|
decreased body size |
J:203905
|
|
exocrine pancreas atrophy |
J:203905
|
|
postnatal growth retardation |
J:203905
|
Gt(ROSA)26Sortm1(DTA)Lky/Gt(ROSA)26Sor+
Myf5tm3(cre)Sor/Myf5+
involves: 129P2/OlaHsd * 129S4/SvJaeSor
|
abnormal levator veli palatini muscle morphology |
J:310908
|
|
abnormal palatopharyngeus muscle morphology |
J:310908
|
|
abnormal soft palate morphology |
J:310908
|
|
abnormal soft palate muscle morphology |
J:310908
|
|
abnormal superior pharyngeal constrictor muscle morphology |
J:310908
|
|
abnormal tensor veli palatini muscle morphology |
J:310908
|
|
decreased palatal shelf size |
J:310908
|
|
lethality throughout fetal growth and development, complete penetrance |
J:310908
|
Gt(ROSA)26Sortm1(DTA)Lky/Gt(ROSA)26Sor+
Il13tm1(YFP/cre)Lky/Il13tm1(YFP/cre)Lky
involves: 129P2/OlaHsd * 129S4/SvJae
|
decreased eosinophil cell number |
J:178986
|
|
decreased IgG1 level |
J:178986
|
|
decreased interleukin-5 secretion |
J:178986
|
|
decreased interleukin-13 secretion |
J:178986
|
|
increased susceptibility to parasitic infection |
J:178986
|
Gt(ROSA)26Sortm1(DTA)Lky/Gt(ROSA)26Sor+
Tg(LHX3-cre)#Sjr/0
involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6
|
abnormal adenohypophysis morphology |
J:211401
|
|
abnormal spinal cord morphology |
J:211401
|
|
decreased body size |
J:211401
|
|
decreased gonadotroph cell number |
J:211401
|
|
normal
endocrine/exocrine gland phenotype |
J:211401
|
|
lethality throughout fetal growth and development, incomplete penetrance |
J:211401
|
|
male infertility |
J:211401
|
Gt(ROSA)26Sortm1(DTA)Lky/Gt(ROSA)26Sortm1(DTA)Lky
involves: 129P2/OlaHsd
|
abnormal cell death |
J:133382
|
Gt(ROSA)26Sortm1(DTA)Lky/Gt(ROSA)26Sortm1(DTA)Lky
Tg(Cd4-cre)1Cwi/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:133382
|
|
abnormal CD8-positive, alpha-beta T cell differentiation |
J:133382
|
|
abnormal lymph node T cell domain morphology |
J:133382
|
|
abnormal spleen morphology |
J:133382
|
|
abnormal T cell receptor V(D)J recombination |
J:133382
|
|
decreased CD4-positive, alpha-beta T cell number |
J:133382
|
|
decreased CD8-positive, alpha-beta T cell number |
J:133382
|
|
decreased double-positive T cell number |
J:133382
|
|
decreased lymphocyte cell number |
J:133382
|
|
decreased NK T cell number |
J:133382
|
|
decreased regulatory T cell number |
J:133382
|
|
normal
immune system phenotype |
J:133382
|
|
increased susceptibility to parasitic infection |
J:133382
|
Gt(ROSA)26Sortm1(DTA)Lky/?
Il5tm1.1(icre)Lky/Il5+
Rag1tm1Mom/Rag1tm1Mom
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
|
abnormal immune system physiology |
J:206097
|
Gt(ROSA)26Sortm1(DTA)Mrc/Gt(ROSA)26Sor+
Olig1tm1(cre)Rth/Olig1+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
absent oligodendrocytes |
J:105927
|
|
decreased motor neuron number |
J:105927
|
|
lethality throughout fetal growth and development, complete penetrance |
J:105927
|
Gt(ROSA)26Sortm1(DTA)Mrc/Gt(ROSA)26Sor+
Myf6tm1(cre)Mrc/Myf6+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal myogenesis |
J:133338
|
|
abnormal skeletal muscle fiber morphology |
J:133338
|
|
neonatal lethality, complete penetrance |
J:133338
|
Gt(ROSA)26Sortm1(DTA)Mrc/Gt(ROSA)26Sor+
Myf5tm1(cre)Mrc/Myf5+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal rib morphology |
J:133338
|
|
asymmetric sternocostal joints |
J:133338
|
|
normal
mortality/aging |
J:133338
|
|
rib fusion |
J:133338
|
Gt(ROSA)26Sortm1(DTA)Mrc/Gt(ROSA)26Sor+
Myf5tm1.1(cre)Mrc/Myf5+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal rib morphology |
J:133338
|
|
normal
muscle phenotype |
J:133338
|
|
neonatal lethality, complete penetrance |
J:133338
|
Gt(ROSA)26Sortm1(DTA)Mrc/Gt(ROSA)26Sor+
Chrna7tm2.1(cre)Swr/Chrna7+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal abdominal wall morphology |
J:223063
|
|
abnormal craniofacial morphology |
J:223063
|
|
abnormal dorsal root ganglion morphology |
J:223063
|
|
abnormal limb bone morphology |
J:223063
|
|
abnormal retina pigment epithelium morphology |
J:223063
|
|
abnormal rostral-caudal axis patterning |
J:223063
|
|
abnormal tail morphology |
J:223063
|
|
anemia |
J:223063
|
|
delayed caudal neuropore closure |
J:223063
|
|
dorsal root ganglion hypoplasia |
J:223063
|
|
normal
embryo phenotype |
J:223063
|
|
enlarged liver |
J:223063
|
|
enlarged pancreas |
J:223063
|
|
enlarged salivary gland |
J:223063
|
|
flat head |
J:223063
|
|
hunched posture |
J:223063
|
|
macrodontia |
J:223063
|
|
omphalocele |
J:223063
|
|
perinatal lethality, complete penetrance |
J:223063
|
|
short mandible |
J:223063
|
|
spina bifida |
J:223063
|
Gt(ROSA)26Sortm1(DTA)Mrc/Gt(ROSA)26Sortm1(DTA)Mrc
Myf5tm1(cre)Mrc/Myf5tm1(cre)Mrc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
decreased body size |
J:120967
|
|
weakness |
J:120967
|
Gt(ROSA)26Sortm1(DTA)Mrc/?
Tg(Rlbp1-cre/ERT2,-EGFP)1Wshn/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA
|
abnormal blood-retina barrier function |
J:192243
|
|
abnormal cone electrophysiology |
J:192243
|
|
abnormal eye electrophysiology |
J:192243
|
|
abnormal Muller cell morphology |
J:192243
|
|
abnormal retina blood vessel morphology |
J:192243
|
|
abnormal retina cone cell outer segment morphology |
J:192243
|
|
abnormal retina inner limiting membrane morphology |
J:192243
|
|
abnormal retina morphology |
J:192243
|
|
abnormal retina outer limiting membrane morphology |
J:192243
|
|
abnormal retina pigment epithelium morphology |
J:192243
|
|
abnormal retina vasculature morphology |
J:192243
|
|
abnormal rod electrophysiology |
J:192243
|
|
disorganized photoreceptor outer segment |
J:192243
|
|
retina neovascularization |
J:192243
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
Relnrl/Reln+
Wnt3atm1(cre)Eag/Wnt3a+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
decreased Cajal-Retzius cell number |
J:153209
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
Relnrl/Reln+
Trp73tm1(cre)Agof/Trp73+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
decreased Cajal-Retzius cell number |
J:153209
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
Relnrl/Reln+
Trp73tm1(cre)Agof/Trp73+
Wnt3atm1(cre)Eag/Wnt3a+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
decreased Cajal-Retzius cell number |
J:153209
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
Tg(Alb1-cre)7Gsc/0
involves: 129P2/OlaHsd
|
increased circulating alanine transaminase level |
J:92789
|
|
increased circulating aspartate transaminase level |
J:92789
|
|
liver degeneration |
J:92789
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
Neurod6tm1(cre)Kan/Neurod6+
involves: 129P2/OlaHsd
|
abnormal cerebral cortex morphology |
J:92789
|
|
neonatal lethality, complete penetrance |
J:92789
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
Cnptm1(cre)Kan/Cnp+
involves: 129P2/OlaHsd
|
absent oligodendrocytes |
J:92789
|
|
axon degeneration |
J:92789
|
|
demyelination |
J:92789
|
|
paraparesis |
J:92789
|
|
postnatal lethality, complete penetrance |
J:92789
|
|
tremors |
J:92789
|
|
weight loss |
J:92789
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
Tg(Pomc-EGFP)1Low/0
Tg(Gnrh1-cre)1Dlc/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA
|
decreased neuron number |
J:199640
|
|
decreased uterus weight |
J:199640
|
|
increased abdominal adipose tissue amount |
J:199640
|
|
small ovary |
J:199640
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
Trp73tm1(cre)Agof/Trp73+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
decreased Cajal-Retzius cell number |
J:153209
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
Kiss1tm1.1(cre)Uboe/Kiss1+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * C57BL/6J
|
abnormal vagina development |
J:173936
|
|
decreased ovary weight |
J:173936
|
|
increased body weight |
J:173936
|
|
normal
mortality/aging |
J:173936
|
|
normal
reproductive system phenotype |
J:173936
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
Kiss1rtm1.1(cre)Uboe/Kiss1r+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal vagina development |
J:173936
|
|
decreased neuron number |
J:173936
|
|
decreased ovary weight |
J:173936
|
|
normal
reproductive system phenotype |
J:173936
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sortm1(DTA)Riet
involves: 129P2/OlaHsd
|
abnormal skeleton morphology |
J:110983
|
|
increased susceptibility to age-related retinal degeneration |
J:110983
|
|
premature death |
J:110983
|
|
vestigial tail |
J:110983
|
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sortm1(DTA)Riet
Tg(Rorc-cre)1Litt/?
involves: 129P2/OlaHsd
|
abnormal effector T cell morphology |
J:137020
|
Gt(ROSA)26Sortm1(DTA)Vlcg/Gt(ROSA)26Sortm1(DTA)Vlcg
involves: 129S1/Sv
|
no abnormal phenotype detected |
J:201507
|
Gt(ROSA)26Sortm1(DTA)Vlcg/Gt(ROSA)26Sortm1(DTA)Vlcg
Tg(BGLAP-cre/ERT2)#Stko/0
involves: 129S1/Sv * FVB/N
|
abnormal glucose homeostasis |
J:201507
|
|
abnormal hormone level |
J:201507
|
|
abnormal lipid homeostasis |
J:201507
|
|
abnormal lipid level |
J:201507
|
|
decreased adiponectin level |
J:201507
|
|
decreased bone mass |
J:201507
|
|
decreased bone ossification |
J:201507
|
|
decreased bone volume |
J:201507
|
|
decreased circulating insulin level |
J:201507
|
|
decreased circulating osteocalcin level |
J:201507
|
|
decreased circulating testosterone level |
J:201507
|
|
decreased gonadal fat pad weight |
J:201507
|
|
decreased insulin secretion |
J:201507
|
|
decreased lean body mass |
J:201507
|
|
decreased locomotor activity |
J:201507
|
|
decreased osteoblast cell number |
J:201507
|
|
decreased pancreatic beta cell mass |
J:201507
|
|
decreased pancreatic beta cell proliferation |
J:201507
|
|
decreased white fat cell number |
J:201507
|
|
hyperglycemia |
J:201507
|
|
impaired glucose tolerance |
J:201507
|
|
increased apoptosis |
J:201507
|
|
increased bone resorption |
J:201507
|
|
increased carbon dioxide production |
J:201507
|
|
increased circulating glucose level |
J:201507
|
|
increased energy expenditure |
J:201507
|
|
increased food intake |
J:201507
|
|
increased oxygen consumption |
J:201507
|
|
insulin resistance |
J:201507
|
Gt(ROSA)26Sortm1(DUX4)Sqh/Gt(ROSA)26Sor+
Tg(ACTA1-cre)79Jme/0
involves: 129S6/SvEvTac * C57BL/6J * SJL
|
prenatal lethality |
J:268959
|
Gt(ROSA)26Sortm1(DUX4)Sqh/Gt(ROSA)26Sor+
Tg(ACTA1-rtTA,tetO-cre)102Monk/0
involves: 129S6/SvEvTac * C3H * C57BL/6
|
decreased survivor rate |
J:268959
|
Gt(ROSA)26Sortm1(DUX4)Sqh/Gt(ROSA)26Sor+
Tg(ACTA1-cre/Esr1*)2Kesr/0
involves: 129S6/SvEvTac * C3H * C57BL/6
|
abnormal acute inflammation |
J:268959
|
|
abnormal gait |
J:268959
|
|
centrally nucleated skeletal muscle fibers |
J:268959
|
|
decreased locomotor activity |
J:268959
|
|
decreased skeletal muscle fiber diameter |
J:268959
|
|
decreased skeletal muscle mass |
J:268959
|
|
decreased vertical activity |
J:268959
|
|
muscle weakness |
J:268959
|
|
skeletal muscle fiber degeneration |
J:268959
|
Gt(ROSA)26Sortm1(Eif1a-tTA,tetO-mCherry/HTR4*D100A)Conk/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal bone ossification |
J:193162
|
|
normal
mortality/aging |
J:193162
|
Gt(ROSA)26Sortm1(Eif1a-tTA,tetO-mCherry/HTR4*D100A)Conk/Gt(ROSA)26Sor+
Tg(Col1a1-tTA)139Niss/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
|
increased bone mineral density |
J:193162
|
|
normal
mortality/aging |
J:193162
|
Gt(ROSA)26Sortm1(en/Cdx1,-EGFP)Npln/Gt(ROSA)26Sor+
Pax3Sp/Pax3+
Tg(Pax3-cre)1Joe/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal coat/hair pigmentation |
J:231654
|
|
abnormal enteric ganglia morphology |
J:231654
|
|
abnormal tail hair pigmentation |
J:231654
|
|
belly spot |
J:231654
|
Gt(ROSA)26Sortm1(en/Cdx1,-EGFP)Npln/Gt(ROSA)26Sor+
Tg(Pax3-cre)1Joe/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal coat/hair pigmentation |
J:231654
|
|
abnormal hind foot hair pigmentation |
J:231654
|
|
abnormal tail hair pigmentation |
J:231654
|
|
absent gastric milk in neonates |
J:231654
|
|
belly spot |
J:231654
|
|
decreased body size |
J:231654
|
|
hydronephrosis |
J:231654
|
|
kinked tail |
J:231654
|
|
perinatal lethality, incomplete penetrance |
J:231654
|
|
postnatal growth retardation |
J:231654
|
|
postnatal lethality, incomplete penetrance |
J:231654
|
|
reduced fertility |
J:231654
|
Gt(ROSA)26Sortm1(en/Cdx1,-EGFP)Npln/Gt(ROSA)26Sor+
Tg(T-cre)1Lwd/0
involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6
|
abnormal cervical vertebrae morphology |
J:231654
|
|
abnormal vertebrae morphology |
J:231654
|
|
abnormal vertebral arch morphology |
J:231654
|
|
cervical vertebral transformation |
J:231654
|
|
decreased lumbar vertebrae number |
J:231654
|
|
decreased thoracic vertebrae number |
J:231654
|
|
rib fusion |
J:231654
|
|
vertebral fusion |
J:231654
|
|
vertebral transformation |
J:231654
|
Gt(ROSA)26Sortm1(ETV6/SYK)Hjum/Gt(ROSA)26Sor+
Cd79atm3(cre/ERT2)Reth/Cd79a+
involves: 129S6/SvEvTac * BALB/c
|
abnormal circulating chemokine level |
J:208904
|
|
abnormal cytokine level |
J:208904
|
|
abnormal plasma cell differentiation |
J:208904
|
|
enlarged lymph nodes |
J:208904
|
|
enlarged spleen |
J:208904
|
|
increased B cell apoptosis |
J:208904
|
|
increased B cell number |
J:208904
|
|
increased B cell proliferation |
J:208904
|
|
increased circulating interferon-gamma level |
J:208904
|
|
increased circulating interleukin-6 level |
J:208904
|
|
increased circulating interleukin-10 level |
J:208904
|
|
increased circulating tumor necrosis factor level |
J:208904
|
|
increased IgM level |
J:208904
|
|
increased interferon-gamma secretion |
J:208904
|
|
increased interleukin-10 secretion |
J:208904
|
|
increased tumor necrosis factor secretion |
J:208904
|
Gt(ROSA)26Sortm1(ETV6/SYK)Hjum/Gt(ROSA)26Sor+
Cd79atm3(cre/ERT2)Reth/Cd79a+
Tg(BCL2)22Wehi/0
involves: 129S6/SvEvTac * BALB/c * C57BL/6JWehi * SJL/JWehi
|
abnormal B cell physiology |
J:208904
|
|
abnormal plasma cell differentiation |
J:208904
|
|
enlarged lymph nodes |
J:208904
|
|
enlarged spleen |
J:208904
|
Gt(ROSA)26Sortm1(EWSR1/FLI1)Sbk/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/?
involves: 129S1/Sv * C57BL/6 * CBA
|
abnormal blood cell morphology/development |
J:129039
|
|
abnormal lymph node B cell domain morphology |
J:129039
|
|
abnormal myelopoiesis |
J:129039
|
|
anemia |
J:129039
|
|
decreased erythrocyte cell number |
J:129039
|
|
decreased hematocrit |
J:129039
|
|
enlarged liver |
J:129039
|
|
enlarged spleen |
J:129039
|
|
increased leukemia incidence |
J:129039
|
|
increased leukocyte cell number |
J:129039
|
|
increased spleen red pulp amount |
J:129039
|
|
premature death |
J:129039
|
|
thrombocytosis |
J:129039
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
Rev3ltm1.1Diaz/Rev3ltm1.1Diaz
involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac
|
abnormal class switch recombination |
J:188723
|
|
abnormal somatic hypermutation frequency |
J:188723
|
|
decreased B cell proliferation |
J:188723
|
|
normal
immune system phenotype |
J:188723
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Plcg1tm1Gcrp/Plcg1tm1Rwen
Tg(Cd4-cre)1Cwi/0
involves: 129X1/SvJ * C57BL/6 * DBA/2
|
abnormal CD4-positive T cell differentiation |
J:157757
|
|
abnormal CD8-positive, alpha-beta T cell differentiation |
J:157757
|
|
abnormal regulatory T cell physiology |
J:157757
|
|
abnormal T cell activation |
J:157757
|
|
alopecia |
J:157757
|
|
decreased body weight |
J:157757
|
|
decreased CD4-positive, alpha-beta T cell number |
J:157757
|
|
decreased CD8-positive, alpha-beta T cell number |
J:157757
|
|
decreased interferon-gamma secretion |
J:157757
|
|
decreased interleukin-2 secretion |
J:157757
|
|
decreased single-positive T cell number |
J:157757
|
|
decreased T cell number |
J:157757
|
|
decreased T cell proliferation |
J:157757
|
|
dermatitis |
J:157757
|
|
increased double-positive T cell number |
J:157757
|
|
increased T cell apoptosis |
J:157757
|
|
rectal prolapse |
J:157757
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA
|
increased susceptibility to induced pancreatitis |
J:289183
|
|
pancreatic acinar-to-ductal metaplasia |
J:289183
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trim29tm1c(EUCOMM)Wtsi/Trim29tm1c(EUCOMM)Wtsi
involves: 129 * C57BL/6 * CBA
|
decreased gland tumor incidence |
J:289183
|
|
normal
endocrine/exocrine gland phenotype |
J:289183
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trim29tm1c(EUCOMM)Wtsi/Trim29tm1c(EUCOMM)Wtsi
Trp53tm1Brn/Trp53+
involves: 129 * C57BL/6 * CBA
|
normal
endocrine/exocrine gland phenotype |
J:289183
|
|
normal
mortality/aging |
J:289183
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trp53tm1Brn/Trp53+
involves: 129 * C57BL/6 * CBA
|
increased pancreas tumor incidence |
J:289183
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:289183
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:289183
|
|
pancreatic acinar-to-ductal metaplasia |
J:289183
|
|
premature death |
J:289183
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:280854
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:280854
|
|
premature death |
J:280854
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N
|
premature death |
J:280854
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ilktm1Star/Ilktm1Star
Tg(Krt1-15-cre/PGR*)22Cot/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL/J
|
abnormal hair follicle development |
J:172933
|
|
abnormal wound healing |
J:172933
|
|
delayed wound healing |
J:172933
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
S1pr1tm2Rlp/S1pr1tm2Rlp
Tg(Cdh5-cre/ERT2)1Rha/0
involves: 129S6/SvEvTac * 129X1/SvJ
|
abnormal aorta morphology |
J:189010
|
|
abnormal retina vasculature morphology |
J:189010
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Pdx1-cre)89.1Dam/0
Trim29tm1c(EUCOMM)Wtsi/Trim29tm1c(EUCOMM)Wtsi
involves: 129 * C57BL/6 * CBA
|
normal
endocrine/exocrine gland phenotype |
J:289183
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
Prdm1tm2Masu/Prdm1tm2Masu
involves: 129P2/OlaHsd * 129X1/SvJ
|
abnormal germinal center B cell physiology |
J:167612
|
|
abnormal plasma cell differentiation |
J:167612
|
|
decreased IgG1 level |
J:167612
|
|
decreased survivor rate |
J:167612
|
|
enlarged liver |
J:167612
|
|
enlarged lymph nodes |
J:167612
|
|
enlarged spleen |
J:167612
|
|
increased B cell derived lymphoma incidence |
J:167612
|
|
increased germinal center B cell number |
J:167612
|
|
premature death |
J:167612
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Lhx6tm2Vpa/Lhx6tm2Vpa
Tg(Nkx2-1-cre)1Wdr/0
involves: 129P2/OlaHsd * 129X1/SvJ
|
abnormal brain interneuron morphology |
J:196342
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Plp1-Ncre)DFki/0
Tg(Plp1-Ccre)RFki/0
involves: 129X1/SvJ * FVB/N
|
no abnormal phenotype detected |
J:144851
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(GFAP-Ccre)FFki/0
Tg(GFAP-Ncre)VFki/0
involves: 129X1/SvJ * FVB/N
|
no abnormal phenotype detected |
J:144851
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Resttm1.1Jhsi/Resttm1.1Jhsi
Tg(Nes-cre/ERT2)KEisc/0
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * SJL
|
abnormal neuron differentiation |
J:174056
|
|
decreased neuron number |
J:174056
|
|
premature neuronal precursor differentiation |
J:174056
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Runx1tm2.1(cre/Esr1*)Ims/Runx1tm1Medv
B6.Cg-Gt(ROSA)26Sortm1(EYFP)Cos Runx1tm2.1(cre/Esr1*)Ims
|
abnormal hematopoietic system morphology/development |
J:182232
|
|
normal
hematopoietic system phenotype |
J:182232
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Hprt1tm1(Ins2-HBEGF)Herr/Y
Tg(Gcg-rtTA)#Herr/0
Tg(tetO-cre)1Jaw/0
involves: 129X1/SvJ * C57BL/6
|
abnormal pancreatic alpha cell differentiation |
J:159291
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Hprt1tm1(Ins2-HBEGF)Herr/Y
Tg(Ins2-cre/ERT)1Dam/0
involves: 129X1/SvJ * C57BL/6 * CBA
|
abnormal pancreatic islet morphology |
J:159291
|
|
normal
endocrine/exocrine gland phenotype |
J:159291
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Il22tm1.1(icre)Stck/Il22+
involves: 129X1/SvJ * C57BL/6N
|
abnormal susceptibility to bacterial infection |
J:220074
|
|
increased susceptibility to weight loss |
J:220074
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sortm1(EYFP)Cos
Pax7tm1(cre/ERT2)Gaka/Pax7tm1(cre/ERT2)Gaka
Paxbp1tm1.1Nju/Paxbp1tm1.1Nju
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6NCr
|
abnormal mitochondrial ATP synthesis coupled electron transport |
J:304562
|
|
abnormal mitochondrial morphology |
J:304562
|
|
abnormal oxidative phosphorylation |
J:304562
|
|
abnormal respiratory electron transport chain |
J:304562
|
|
decreased mitochondrial fission |
J:304562
|
|
impaired skeletal muscle regeneration |
J:304562
|
Gt(ROSA)26Sortm1(EYFP)Cos/?
Tg(Il17f-cre)1Awai/?
involves: 129X1/SvJ * C57BL/6 * DBA
|
no abnormal phenotype detected |
J:144336
|
Gt(ROSA)26Sortm1(EYFP)Cos/?
Tg(Lck-cre)548Jxm/0
involves: 129X1/SvJ * C57BL/6 * SJL
|
no abnormal phenotype detected |
J:117041
|
Gt(ROSA)26Sortm1(Fgf8)Lma/Gt(ROSA)26Sor+
Tg(Msx2-cre)5Rem/0
involves: C57BL/6 * CBA
|
abnormal calcaneum morphology |
J:223057
|
|
abnormal limb development |
J:223057
|
|
abnormal skeleton development |
J:223057
|
|
polydactyly |
J:223057
|
Gt(ROSA)26Sortm1(Fgf8)Lma/Gt(ROSA)26Sor+
Shhtm2(cre/ERT2)Cjt/Shh+
involves: 129S6/SvEvTac
|
abnormal genital tubercle morphology |
J:223057
|
|
abnormal reproductive system physiology |
J:223057
|
Gt(ROSA)26Sortm1(Fgf8)Lma/Gt(ROSA)26Sor+
Shhtm2(cre/ERT2)Cjt/Shhtm2(cre/ERT2)Cjt
involves: 129S6/SvEvTac
|
abnormal genital tubercle morphology |
J:223057
|
Gt(ROSA)26Sortm1(Fgf8)Lma/Gt(ROSA)26Sor+
Shhtm2(cre/ERT2)Cjt/Shhtm2(cre/ERT2)Cjt
Tg(Msx2-cre)5Rem/0
involves: 129S6/SvEvTac * C57BL/6 * CBA
|
abnormal limb development |
J:223057
|
Gt(ROSA)26Sortm1(Flt1,EGFP)Dlam/Gt(ROSA)26Sor+
Tg(Thy1-cre)1Dlam/0
involves: 129 * C57BL/6 * FVB
|
abnormal sensory capabilities/reflexes/nociception |
J:172783
|
Gt(ROSA)26Sortm1(Foxo1)Jnk/Gt(ROSA)26Sor+
Pdpk1tm1Maka/Pdpk1tm1Maka
Tg(CAG-cat,-lacZ)11Miya/0
Tg(Pomc1-cre)16Lowl/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
|
increased body weight |
J:162892
|
Gt(ROSA)26Sortm1(GAP43/EGFP)Gld/Gt(ROSA)26Sor+
Ngfrtm1Klee/Ngfrtm1Klee
Tg(Pax6-cre,GFP)2Pgr/0
involves: 129S1/Sv
|
abnormal retina ganglion cell morphology |
J:145459
|
|
abnormal superior colliculus morphology |
J:145459
|
|
normal
vision/eye phenotype |
J:145459
|
Gt(ROSA)26Sortm1(Gck)Ydor/Gt(ROSA)26Sor+
Trp53tm1Brn/Trp53tm1Brn
Tg(Ins2-cre)25Mgn/0
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
normal
endocrine/exocrine gland phenotype |
J:210493
|
|
hyperglycemia |
J:210493
|
|
postnatal lethality, incomplete penetrance |
J:210493
|
Gt(ROSA)26Sortm1(Gck)Ydor/Gt(ROSA)26Sor+
Tg(Ins2-cre)25Mgn/0
involves: C57BL/6 * DBA
|
decreased circulating insulin level |
J:210493
|
|
decreased pancreatic beta cell mass |
J:210493
|
|
hyperglycemia |
J:210493
|
|
postnatal lethality, incomplete penetrance |
J:210493
|
Gt(ROSA)26Sortm1(Gck)Ydor/Gt(ROSA)26Sor+
Tg(Pdx1-cre/Esr1*)#Dam/0
involves: C57BL/6 * CBA
|
abnormal pancreatic beta cell physiology |
J:210493
|
|
decreased fasting circulating glucose level |
J:210493
|
|
decreased pancreatic beta cell proliferation |
J:210493
|
|
increased circulating insulin level |
J:210493
|
|
increased oxygen consumption |
J:210493
|
Gt(ROSA)26Sortm1(Gck)Ydor/Gt(ROSA)26Sortm1(Kcnj11*V59M)Fmas
Tg(Pdx1-cre/Esr1*)#Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA
|
abnormal pancreatic beta cell physiology |
J:210493
|
|
hyperglycemia |
J:210493
|
Gt(ROSA)26Sortm1(Gli2)Jmao/Gt(ROSA)26Sor+
Smotm2Amc/Smotm2Amc
Nkx3-2tm1(cre)Wez/Nkx3-2+
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ
|
normal
digestive/alimentary phenotype |
J:199664
|
Gt(ROSA)26Sortm1(Gli2)Jmao/Gt(ROSA)26Sor+
Nkx3-2tm1(cre)Wez/Nkx3-2+
involves: 129S7/SvEvBrd
|
normal
digestive/alimentary phenotype |
J:199664
|
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sor+
C3FeJ.Cg-Gt(ROSA)26Sortm1(GNAQ*)Cvr
|
normal
pigmentation phenotype |
J:225597
|
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sor+
Tg(Tyr-cre/ERT2)13Bos/0
C3FeJ.Cg-Tg(Tyr-cre/ERT2)13Bos Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Cvrk
|
abnormal melanocyte morphology |
J:225597
|
|
normal
behavior/neurological phenotype |
J:225597
|
|
exophthalmos |
J:225597
|
|
hyperpigmentation |
J:225597
|
|
normal
neoplasm |
J:225597
|
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sor+
Tg(Mitf-cre)7114Gsb/0
C3FeJ.Cg-Gt(ROSA)26Sortm1(GNAQ*)Cvkr Tg(Mitf-cre)7114Gsb/Cvrk
|
abnormal anterior eye segment morphology |
J:225597
|
|
abnormal choroid pigmentation |
J:225597
|
|
abnormal coat/hair pigmentation |
J:225597
|
|
abnormal dermal pigmentation |
J:225597
|
|
abnormal epidermal pigmentation |
J:225597
|
|
abnormal extracutaneous pigmentation |
J:225597
|
|
abnormal eye pigmentation |
J:225597
|
|
abnormal Harderian gland pigmentation |
J:225597
|
|
abnormal leptomeninges pigmentation |
J:225597
|
|
abnormal melanocyte number |
J:225597
|
|
abnormal melanocyte proliferation |
J:225597
|
|
abnormal motor coordination/balance |
J:225597
|
|
abnormal otic pigmentation |
J:225597
|
|
abnormal skin pigmentation |
J:225597
|
|
abnormal spinal cord meninges morphology |
J:225597
|
|
abnormal uvea morphology |
J:225597
|
|
absent startle reflex |
J:225597
|
|
decreased body weight |
J:225597
|
|
dermal-epidermal separation |
J:225597
|
|
ectopic melanocytes |
J:225597
|
|
enlarged lymph nodes |
J:225597
|
|
exophthalmos |
J:225597
|
|
head tilt |
J:225597
|
|
head tossing |
J:225597
|
|
hyperpigmentation |
J:225597
|
|
increased foot pad pigmentation |
J:225597
|
|
increased intraocular melanoma incidence |
J:225597
|
|
increased metastatic potential |
J:225597
|
|
increased or absent threshold for auditory brainstem response |
J:225597
|
|
increased tail pigmentation |
J:225597
|
|
thick ears |
J:225597
|
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sor+
Tg(Dct-lacZ)A12Jkn/0
Tg(Mitf-cre)7114Gsb/0
C3FeJ.Cg-Gt(ROSA)26Sortm1(GNAQ*)Cvrk Tg(Dct-lacZ)A12Jkn Tg(Mitf-cre)7114Gsb/Cvrk
|
abnormal melanosome morphology |
J:225597
|
|
normal
pigmentation phenotype |
J:225597
|
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sortm1Sor
Tg(Mitf-cre)7114Gsb/0
C3FeJ.Cg-Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sortm1Sor Tg(Mitf-cre)7114Gsb/Cvrk
|
decreased melanocyte number |
J:225597
|
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sortm1Sor
Tg(Tyr-cre/ERT2)13Bos/0
STOCK Tg(Tyr-cre/ERT2)13Bos Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sortm1Sor/Cvrk
|
abnormal epidermal pigmentation |
J:312561
|
|
decreased melanocyte number |
J:312561
|
|
decreased skin pigmentation |
J:312561
|
|
decreased tail pigmentation |
J:312561
|
|
reduced hair shaft melanin granule number |
J:312561
|
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sortm14(CAG-tdTomato)Hze
Tg(Mitf-cre)7114Gsb/0
C3FeJ.Cg-Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sortm14(CAG-tdTomato)Hze Tg(Mitf-cre)7114Gsb/Cvrk
|
abnormal cell physiology |
J:312561
|
|
abnormal epidermal pigmentation |
J:312561
|
|
abnormal melanocyte morphology |
J:312561
|
|
abnormal melanocyte number |
J:312561
|
|
abnormal melanocyte proliferation |
J:312561
|
|
abnormal tail pigmentation |
J:312561
|
|
hypopigmentation |
J:312561
|
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal class switch recombination |
J:172031
|
|
absent spleen germinal center |
J:172031
|
|
decreased B cell apoptosis |
J:172031
|
|
decreased B cell number |
J:172031
|
|
decreased germinal center B cell number |
J:172031
|
|
decreased IgA level |
J:172031
|
|
decreased IgG1 level |
J:172031
|
|
decreased IgG2a level |
J:172031
|
|
decreased IgG3 level |
J:172031
|
|
decreased plasma cell number |
J:172031
|
|
decreased tumor-free survival time |
J:172031
|
|
enlarged spleen |
J:172031
|
|
increased B cell number |
J:172031
|
|
increased histiocytic sarcoma incidence |
J:172031
|
|
increased IgE level |
J:172031
|
|
increased macrophage cell number |
J:172031
|
|
increased marginal zone B cell number |
J:172031
|
|
increased sarcoma incidence |
J:172031
|
|
increased spleen weight |
J:172031
|
|
increased T cell number |
J:172031
|
|
increased tumor incidence |
J:172031
|
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal class switch recombination |
J:172031
|
|
absent spleen germinal center |
J:172031
|
|
decreased B cell number |
J:172031
|
|
decreased follicular B cell number |
J:172031
|
|
decreased germinal center B cell number |
J:172031
|
|
decreased IgA level |
J:172031
|
|
decreased IgG1 level |
J:172031
|
|
decreased IgG2a level |
J:172031
|
|
decreased IgG2b level |
J:172031
|
|
decreased IgG3 level |
J:172031
|
|
decreased plasma cell number |
J:172031
|
|
decreased tumor-free survival time |
J:172031
|
|
enlarged spleen |
J:172031
|
|
increased B cell number |
J:172031
|
|
increased histiocytic sarcoma incidence |
J:172031
|
|
increased IgE level |
J:172031
|
|
increased macrophage cell number |
J:172031
|
|
increased marginal zone B cell number |
J:172031
|
|
increased sarcoma incidence |
J:172031
|
|
increased spleen weight |
J:172031
|
|
increased tumor incidence |
J:172031
|
Gt(ROSA)26Sortm1(Gphb5)Lmac/Gt(ROSA)26Sor+
Not Specified
|
normal
cardiovascular system phenotype |
J:96633
|
|
decreased body weight |
J:96633
|
|
decreased circulating cholesterol level |
J:96633
|
|
decreased circulating glucose level |
J:96633
|
|
decreased circulating insulin level |
J:96633
|
|
decreased susceptibility to diet-induced obesity |
J:96633
|
|
decreased triglyceride level |
J:96633
|
|
increased circulating thyroxine level |
J:96633
|
|
increased circulating triiodothyronine level |
J:96633
|
|
increased oxygen consumption |
J:96633
|
|
short frontal bone |
J:96633
|
|
short nasal bone |
J:96633
|
|
short snout |
J:96633
|
Gt(ROSA)26Sortm1(Grem1)Svok/Gt(ROSA)26Sor+
Tg(Prrx1-cre)1Cjt/0
involves: 129S1/Sv * C57BL/6J * SJL/J
|
abnormal digit morphology |
J:214075
|
|
abnormal forelimb bud morphology |
J:214075
|
|
abnormal hallux morphology |
J:214075
|
|
abnormal hindlimb morphology |
J:214075
|
|
absent forelimb |
J:214075
|
|
brachydactyly |
J:214075
|
|
decreased apoptosis |
J:214075
|
|
forelimb oligodactyly |
J:214075
|
|
increased cell proliferation |
J:214075
|
|
polydactyly |
J:214075
|
|
syndactyly |
J:214075
|
|
triphalangia |
J:214075
|
Gt(ROSA)26Sortm1(Grem1)Svok/Gt(ROSA)26Sor+
Shhtm1(EGFP/cre)Cjt/0
involves: 129S1/Sv
|
polyphalangy |
J:214075
|
|
postaxial polydactyly |
J:214075
|
|
preaxial polydactyly |
J:214075
|
Gt(ROSA)26Sortm1(Grem1)Svok/Gt(ROSA)26Sor+
Tg(Hoxb6-cre/ERT)1Smac/0
involves: 129S1/Sv * FVB/N
|
abnormal digit morphology |
J:214075
|
|
absent hindlimb |
J:214075
|
|
brachydactyly |
J:214075
|
|
polydactyly |
J:214075
|
|
polyphalangy |
J:214075
|
Gt(ROSA)26Sortm1(Grem1)Svok/Gt(ROSA)26Sortm1(Grem1)Svok
Tg(Hoxb6-cre/ERT)1Smac/0
involves: 129S1/Sv * FVB/N
|
abnormal digit morphology |
J:214075
|
|
absent fibula |
J:214075
|
|
absent hindlimb |
J:214075
|
|
bowed femur |
J:214075
|
|
bowed tibia |
J:214075
|
|
brachydactyly |
J:214075
|
|
polydactyly |
J:214075
|
|
polyphalangy |
J:214075
|
|
short fibula |
J:214075
|
Gt(ROSA)26Sortm1(GRN)Pvd/Gt(ROSA)26Sor+
Tg(Pgk1-cre)1Lni/0
Tg(SOD1*G93A)1Gur/0
B6J.Cg-Tg(Pgk1-cre)1Lni Gt(ROSA)26Sortm1(GRN)Pvd Tg(SOD1*G93A)1Gur
|
impaired coordination |
J:211734
|
|
motor neuron degeneration |
J:211734
|
|
premature death |
J:211734
|
Gt(ROSA)26Sortm1(GRN)Pvd/Gt(ROSA)26Sortm1(GRN)Pvd
Tg(Pgk1-cre)1Lni/0
Tg(SOD1*G93A)1Gur/0
B6J.Cg-Tg(Pgk1-cre)1Lni Gt(ROSA)26Sortm1(GRN)Pvd Tg(SOD1*G93A)1Gur
|
impaired coordination |
J:211734
|
|
motor neuron degeneration |
J:211734
|
|
premature death |
J:211734
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Fxn)Dhg/Gt(ROSA)26Sor+
B6.129-Gt(ROSA)26Sortm1(H1/tetO-RNAi:Fxn)Dhg
|
abnormal axon morphology |
J:254962
|
|
abnormal enzyme/coenzyme activity |
J:254962
|
|
abnormal myocardial fiber morphology |
J:254962
|
|
abnormal retina pigment epithelium morphology |
J:254962
|
|
abnormal sarcomere morphology |
J:254962
|
|
absent P wave |
J:254962
|
|
ataxia |
J:254962
|
|
cardiac fibrosis |
J:254962
|
|
cardiomyopathy |
J:254962
|
|
decreased grip strength |
J:254962
|
|
decreased locomotor activity |
J:254962
|
|
decreased myelin sheath thickness |
J:254962
|
|
decreased survivor rate |
J:254962
|
|
disorganized mitochondrial cristae |
J:254962
|
|
dorsal root ganglion degeneration |
J:254962
|
|
impaired coordination |
J:254962
|
|
increased heart iron level |
J:254962
|
|
increased mitochondrial size |
J:254962
|
|
premature death |
J:254962
|
|
prolonged QT interval |
J:254962
|
|
retina photoreceptor degeneration |
J:254962
|
|
short stride length |
J:254962
|
|
weight loss |
J:254962
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Not Specified
|
abnormal glucose homeostasis |
J:170965
|
|
hyperglycemia |
J:170965
|
|
increased circulating insulin level |
J:170965
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
abnormal prostate gland physiology |
J:170965
|
|
enlarged prostate gland anterior lobe |
J:170965
|
|
increased prostate gland tumor incidence |
J:170965
|
|
increased prostate gland weight |
J:170965
|
|
prostate gland hyperplasia |
J:170965
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1.1Hwu/Pten+
involves: 129S4/SvJae * C57BL/6NTac
|
increased lymphoma incidence |
J:170965
|
|
increased thyroid adenoma incidence |
J:170965
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sortm9(cre/ESR1)Arte
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * C57BL/6
|
decreased B cell number |
J:170965
|
|
disheveled coat |
J:170965
|
|
enlarged lymph nodes |
J:170965
|
|
enlarged spleen |
J:170965
|
|
hunched posture |
J:170965
|
|
increased acute lymphoblastic leukemia incidence |
J:170965
|
|
increased memory B cell number |
J:170965
|
|
increased spleen weight |
J:170965
|
|
premature death |
J:170965
|
|
weight loss |
J:170965
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pion)Pggd/Gt(ROSA)26Sor+
Tg(APPswe,PSEN1dE9)85Dbo/0
involves: 129S6/SvEvTac * C3H * C57BL/6
|
amyloid beta deposits |
J:163997
|
Gt(ROSA)26Sortm1(HA)Libl/Gt(ROSA)26Sortm1(HA)Libl
Mogtm1(cre)Gkl/?
involves: 129/Sv * C57BL/6
|
normal
behavior/neurological phenotype |
J:137838
|
|
normal
immune system phenotype |
J:137838
|
Gt(ROSA)26Sortm1(HA)Libl/Gt(ROSA)26Sortm1(HA)Libl
Mogtm1(cre)Gkl/?
Tg(TcraCl4,TcrbCl4)1Shrm/0
involves: 129/Sv * BALB/c * C57BL/6
|
abnormal oligodendrocyte morphology |
J:137838
|
|
abnormal optic nerve morphology |
J:137838
|
|
brain inflammation |
J:137838
|
|
decreased locomotor activity |
J:137838
|
|
demyelination |
J:137838
|
|
impaired righting response |
J:137838
|
|
optic nerve inflammation |
J:137838
|
|
spinal cord inflammation |
J:137838
|
|
tremors |
J:137838
|
|
weight loss |
J:137838
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sor+
Tg(Krt1-15-cre/PGR*)22Cot/0
involves: C57BL/6J * SJL/J
|
abnormal esophageal epithelium morphology |
J:244536
|
|
increased cell proliferation |
J:244536
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sor+
Opn4tm1(cre)Sapa/Opn4+
involves: 129S * C57BL/6
|
abnormal circardian behavior entrainment |
J:137151
|
|
abnormal suprachiasmatic nucleus morphology |
J:137151
|
|
normal
behavior/neurological phenotype |
J:137151
|
|
decreased retina ganglion cell number |
J:137151
|
|
impaired pupillary reflex |
J:137151
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sor+
Tg(Adora2a-cre)2MDkde/0
involves: C57BL/6 * SJL
|
abnormal basal ganglion morphology |
J:150475
|
|
enhanced conditioned place preference behavior |
J:150475
|
|
hyperactivity |
J:150475
|
|
normal
nervous system phenotype |
J:150475
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sor+
Tg(Gh1-cre)bKnmn/0
involves: C57BL/6 * FVB/N
|
abnormal circulating hormone level |
J:169459
|
|
abnormal energy expenditure |
J:169459
|
|
abnormal gas homeostasis |
J:169459
|
|
abnormal glucose homeostasis |
J:169459
|
|
decreased body weight |
J:169459
|
|
decreased circulating glucose level |
J:169459
|
|
decreased circulating growth hormone level |
J:169459
|
|
decreased circulating insulin level |
J:169459
|
|
decreased circulating insulin-like growth factor I level |
J:169459
|
|
decreased energy expenditure |
J:169459
|
|
decreased fluid intake |
J:169459
|
|
decreased lean body mass |
J:169459
|
|
decreased liver triglyceride level |
J:169459
|
|
decreased liver weight |
J:169459
|
|
decreased oxygen consumption |
J:169459
|
|
decreased somatotroph cell number |
J:169459
|
|
impaired glucose tolerance |
J:169459
|
|
increased circulating leptin level |
J:169459
|
|
increased insulin sensitivity |
J:169459
|
|
increased respiratory quotient |
J:169459
|
|
increased retroperitoneal fat pad weight |
J:169459
|
|
increased subcutaneous adipose tissue amount |
J:169459
|
|
increased total body fat amount |
J:169459
|
|
small adenohypophysis |
J:169459
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sor+
Kiss1tm1.1(cre)Uboe/Kiss1+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL
|
abnormal estrous cycle |
J:173936
|
|
decreased neuron number |
J:173936
|
|
female infertility |
J:173936
|
|
prolonged diestrus |
J:173936
|
|
prolonged estrus |
J:173936
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sor+
Kiss1rtm1.1(cre)Uboe/Kiss1r+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL
|
decreased neuron number |
J:173936
|
|
normal
reproductive system phenotype |
J:173936
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sor+
Tg(Mrgpra3-GFP/cre)#Xzd/0
involves: C57BL/6
|
normal
behavior/neurological phenotype |
J:197482
|
|
decreased pruritus |
J:197482
|
|
decreased sensory neuron number |
J:197482
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sortm1(HBEGF)Awai
Mogtm1(cre)Gkl/?
involves: C57BL/6
|
abnormal immune system physiology |
J:131076
|
|
abnormal neuron morphology |
J:131076
|
|
astrocytosis |
J:131076
|
|
demyelination |
J:131076
|
|
hindlimb paralysis |
J:131076
|
|
increased neuron apoptosis |
J:131076
|
|
tremors |
J:131076
|
|
weight loss |
J:131076
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sortm1(HBEGF)Awai
Tg(Cd4-cre)1Cwi/0
involves: C57BL/6 * DBA/2
|
abnormal lymphocyte cell number |
J:131076
|
|
decreased single-positive T cell number |
J:131076
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sortm1(HBEGF)Awai
Tg(Gdf9-icre)5092Coo/0
involves: C57BL/6
|
abnormal female germ cell apoptosis |
J:157008
|
|
abnormal granulosa cell apoptosis |
J:157008
|
|
abnormal ovarian follicle morphology |
J:157008
|
|
abnormal ovary morphology |
J:157008
|
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sortm9(CAG-tdTomato)Hze
Oxttm1.1(cre)Dolsn/Oxt+
involves: 129S6/SvEvTac * C57BL/6
|
normal
behavior/neurological phenotype |
J:192007
|
|
decreased oxygen consumption |
J:192007
|
|
decreased response to leptin |
J:192007
|
|
normal
growth/size/body region phenotype |
J:192007
|
|
increased susceptibility to diet-induced obesity |
J:192007
|
|
increased total body fat amount |
J:192007
|
Gt(ROSA)26Sortm1(HD*103Q)Xwy/?
Tg(Nes-cre)1Kln/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal cerebral cortex pyramidal cell morphology |
J:99759
|
|
abnormal inhibitory postsynaptic currents |
J:99759
|
|
cerebral cortex pyramidal cell degeneration |
J:99759
|
|
decreased locomotor activity |
J:99759
|
|
gliosis |
J:99759
|
|
neurodegeneration |
J:99759
|
Gt(ROSA)26Sortm1(Hesx1)Jpmb/Gt(ROSA)26Sor+
Tmem163Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6 * SJL
|
exencephaly |
J:135132
|
Gt(ROSA)26Sortm1(Hesx1)Jpmb/Gt(ROSA)26Sor+
Hesx1tm1(cre)Jpmb/Hesx1tm1(cre)Jpmb
involves: 129S/SvEv * C57BL/6 * SJL
|
abnormal eye morphology |
J:135132
|
|
postnatal lethality, incomplete penetrance |
J:135132
|
Gt(ROSA)26Sortm1(Hesx1)Jpmb/Gt(ROSA)26Sortm1(Hesx1)Jpmb
Hesx1tm1(cre)Jpmb/Hesx1tm1(cre)Jpmb
involves: 129S/SvEv * C57BL/6 * SJL
|
abnormal eye morphology |
J:135132
|
|
anophthalmia |
J:135132
|
|
microphthalmia |
J:135132
|
|
normal
mortality/aging |
J:135132
|
Gt(ROSA)26Sortm1(Hesx1)Jpmb/Gt(ROSA)26Sortm1(Hesx1)Jpmb
Tmem163Tg(ACTB-cre)2Mrt/0
involves: 129S/SvEv * C57BL/6 * SJL
|
exencephaly |
J:135132
|
Gt(ROSA)26Sortm1(Hoxa2)Fmr/Gt(ROSA)26Sor+
Olig2tm2(TVA,cre)Rth/Olig2+
involves: 129P2/OlaHsd
|
abnormal brain development |
J:193058
|
|
decreased oligodendrocyte progenitor number |
J:193058
|
Gt(ROSA)26Sortm1(Irx3*)Hui/Gt(ROSA)26Sor+
Tg(Ins2-cre)25Mgn/0
involves: C57BL/6 * DBA
|
abnormal white adipose tissue physiology |
J:208887
|
|
normal
behavior/neurological phenotype |
J:208887
|
|
decreased body weight |
J:208887
|
|
decreased fat cell size |
J:208887
|
|
decreased percent body fat/body weight |
J:208887
|
|
improved glucose tolerance |
J:208887
|
|
increased energy expenditure |
J:208887
|
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
Tg(Cd4-cre)1Cwi/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
abnormal spleen morphology |
J:160931
|
|
abnormal T cell activation |
J:160931
|
|
abnormal T cell differentiation |
J:160931
|
|
cachexia |
J:160931
|
|
decreased double-positive T cell number |
J:160931
|
|
decreased single-positive T cell number |
J:160931
|
|
decreased T cell number |
J:160931
|
|
distended abdomen |
J:160931
|
|
enlarged spleen |
J:160931
|
|
hunched posture |
J:160931
|
|
normal
immune system phenotype |
J:160931
|
|
increased T cell derived lymphoma incidence |
J:160931
|
|
increased T cell proliferation |
J:160931
|
|
lethargy |
J:160931
|
|
premature death |
J:160931
|
Gt(ROSA)26Sortm1(JAG1)Xin/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)20Fwan/?
involves: 129S4/SvJae * C57BL/6 * FVB/NCrl
|
abnormal prostate gland morphology |
J:238768
|
|
increased prostate gland adenocarcinoma incidence |
J:238768
|
|
increased prostate intraepithelial neoplasia incidence |
J:238768
|
Gt(ROSA)26Sortm1(JAG1)Xin/Gt(ROSA)26Sor+
Tg(Pbsn-cre)20Fwan/?
involves: C57BL/6 * FVB/NCrl
|
normal
endocrine/exocrine gland phenotype |
J:238768
|
Gt(ROSA)26Sortm1(Kcnj11*V59M)Fmas/Gt(ROSA)26Sor+
Tg(Nes-cre)1Kln/0
involves: 129S4/SvJae * C57BL/6 * SJL
|
abnormal action potential |
J:162008
|
|
abnormal channel response |
J:162008
|
|
abnormal nervous system electrophysiology |
J:162008
|
|
decreased body weight |
J:162008
|
|
decreased grip strength |
J:162008
|
|
hyperactivity |
J:162008
|
|
impaired balance |
J:162008
|
|
impaired coordination |
J:162008
|
|
muscle weakness |
J:162008
|
|
perinatal lethality, incomplete penetrance |
J:162008
|
Gt(ROSA)26Sortm1(Kcnj11*V59M)Fmas/Gt(ROSA)26Sor+
Tg(Ins2-cre)23Herr/0
involves: 129S4/SvJae * C57BL/6
|
abnormal pancreatic alpha cell morphology |
J:144715
|
|
abnormal pancreatic beta cell morphology |
J:144715
|
|
abnormal pancreatic beta cell physiology |
J:144715
|
|
abnormal pancreatic islet morphology |
J:144715
|
|
decreased body weight |
J:144715
|
|
decreased circulating insulin level |
J:144715
|
|
decreased insulin secretion |
J:144715
|
|
decreased pancreatic beta cell number |
J:144715
|
|
increased circulating glucagon level |
J:144715
|
|
increased circulating glucose level |
J:144715
|
|
increased pancreatic alpha cell number |
J:144715
|
|
polyuria |
J:144715
|
Gt(ROSA)26Sortm1(Kcnj11*V59M)Fmas/Gt(ROSA)26Sor+
Tg(Pdx1-cre/Esr1*)#Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA
|
hyperglycemia |
J:210493
|
Gt(ROSA)26Sortm1(Kdm6b)Scla/Gt(ROSA)26Sor+
Kdm6bGt(XB814)Byg/Kdm6bGt(XB814)Byg
Tg(Pgk1-cre)1Lni/0
involves: 129P2/OlaHsd * BALB/c * C57BL/6
|
normal
mortality/aging |
J:196346
|
|
normal
nervous system phenotype |
J:196346
|
Gt(ROSA)26Sortm1(LDLR/avidin)Svo/Gt(ROSA)26Sortm1(LDLR/avidin)Svo
involves: 129
|
no abnormal phenotype detected |
J:187859
|
Gt(ROSA)26Sortm1(LRRK2*R1441C)Djmo/Gt(ROSA)26Sortm1(LRRK2*R1441C)Djmo
B6.129-Gt(ROSA)26Sortm1(LRRK2*R1441C)Djmo
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm1(LRRK2*R1441C)Djmo/Gt(ROSA)26Sortm1(LRRK2*R1441C)Djmo
Tg(Slc6a3-icre)1Fto/0
involves: 129 * C57BL/6J * FVB/N
|
abnormal dopaminergic neuron morphology |
J:218456
|
|
normal
behavior/neurological phenotype |
J:218456
|
|
normal
nervous system phenotype |
J:218456
|
|
normal
taste/olfaction phenotype |
J:218456
|
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * FVB/NJ
|
no abnormal phenotype detected |
J:92043
|
Gt(ROSA)26Sortm1(MAML1)Wsp/Gt(ROSA)26Sor+
Tg(Cd4-cre)1Cwi/0
B6.Cg-Tg(Cd4-cre)1Cwi Gt(ROSA)26Sortm1(MAML1)Wsp
|
abnormal immunoglobulin level |
J:113262
|
|
abnormal T-helper 1 physiology |
J:113262
|
|
abnormal T-helper 2 physiology |
J:113262
|
|
decreased susceptibility to parasitic infection |
J:113262
|
|
increased susceptibility to parasitic infection |
J:113262
|
Gt(ROSA)26Sortm1(MAML1)Wsp/Gt(ROSA)26Sor+
Pax3tm1(cre)Joe/Pax3+
Not Specified
|
abnormal neural tube morphology |
J:130251
|
|
decreased neuronal precursor cell number |
J:130251
|
|
loss of glutamate neurons |
J:130251
|
Gt(ROSA)26Sortm1(MAML1)Wsp/Gt(ROSA)26Sor+
Tg(Tagln-cre)1Jjl/0
involves: CD-1 * FVB/N
|
abnormal dermal layer morphology |
J:112093
|
|
abnormal hair growth |
J:112093
|
|
abnormal keratinocyte morphology |
J:112093
|
|
abnormal tail morphology |
J:112093
|
|
alopecia |
J:112093
|
|
decreased body size |
J:112093
|
|
dermal cyst |
J:112093
|
|
increased squamous cell carcinoma incidence |
J:112093
|
Gt(ROSA)26Sortm1(MAML1)Wsp/Gt(ROSA)26Sor+
Tg(KRT14-rtTA)F42Efu/0
Tg(tetO-cre)1Jaw/0
involves: 129 * C57BL/6 * FVB
|
abnormal conjunctiva goblet cell differentiation |
J:194073
|
|
abnormal conjunctival epithelium morphology |
J:194073
|
|
abnormal conjunctival sac morphology |
J:194073
|
|
abnormal cornea epithelium morphology |
J:194073
|
|
abnormal eye morphology |
J:194073
|
|
alopecia |
J:194073
|
|
conjunctivitis |
J:194073
|
|
cornea ulcer |
J:194073
|
|
cornea vascularization |
J:194073
|
|
decreased conjunctiva goblet cell number |
J:194073
|
Gt(ROSA)26Sortm1(Mib1*V943F)Jlp/Gt(ROSA)26Sor+
Tg(Myh6-cre)2182Mds/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal heart ventricle morphology |
J:338889
|
|
thin ventricle myocardium compact layer |
J:338889
|
Gt(ROSA)26Sortm1(Mir7-1,-EGFP)Horn/Gt(ROSA)26Sor+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S/SvEv * C57BL/6 * C57BL/6J * CBA
|
decreased glucagon secretion |
J:187631
|
|
decreased insulin secretion |
J:187631
|
Gt(ROSA)26Sortm1(Mirn155)Rsky/Gt(ROSA)26Sortm1(Mirn155)Rsky
involves: BALB/c * C57BL/6
|
abnormal humoral immune response |
J:121084
|
|
increased germinal center B cell number |
J:121084
|
|
normal
reproductive system phenotype |
J:121084
|
Gt(ROSA)26Sortm1(Myc)Rcse/Gt(ROSA)26Sortm1(Myc)Rcse
Tg(Wap-cre)11738Mam/0
involves: 129 * C57BL/6 * SJL
|
abnormal branching of the mammary ductal tree |
J:169403
|
|
abnormal chromosome number |
J:169403
|
|
abnormal mammary gland epithelium physiology |
J:169403
|
|
chromosomal instability |
J:169403
|
|
increased mammary gland apoptosis |
J:169403
|
|
normal
neoplasm |
J:169403
|
Gt(ROSA)26Sortm1(MYC/ERT2)Gev/Gt(ROSA)26Sortm1(MYC/ERT2)Gev
involves: C57BL/6 * FVB/N
|
preneoplasia |
J:142030
|
Gt(ROSA)26Sortm1(MYC/ERT2)Gev/Gt(ROSA)26Sortm1(MYC/ERT2)Gev
Krastm4Tyj/Krastm4Tyj
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
increased lung adenoma incidence |
J:142030
|
|
increased lung tumor incidence |
J:142030
|
Gt(ROSA)26Sortm1(Neurog3*S183A*S187A)Axbe/?
Krt19tm1(cre/ERT)Ggu/?
B6.Cg-Gt(ROSA)26Sortm1(Neurog3*S183A*S187A)Axbe Krt19tm1(cre/ERT)Ggu
|
increased pancreatic beta cell number |
J:215154
|
Gt(ROSA)26Sortm1(Neurog3*S183A*S187A)Axbe/?
Tg(Pdx1-cre)6Tuv/?
B6.Cg-Gt(ROSA)26Sortm1(Neurog3*S183A*S187A)Axbe Tg(Pdx1-cre)6Tuv
|
increased pancreatic beta cell number |
J:215154
|
Gt(ROSA)26Sortm1(Nfatc2*)Rao/Gt(ROSA)26Sor+
Tg(CMV-cre)1Cgn/0
involves: BALB/cJ
|
abnormal hematopoietic system morphology/development |
J:148341
|
|
prenatal lethality, incomplete penetrance |
J:148341
|
Gt(ROSA)26Sortm1(Nfatc2*)Rao/Gt(ROSA)26Sor+
Tg(Cd4-cre)1Cwi/0
involves: C57BL/6 * DBA/2
|
abnormal interferon level |
J:148341
|
|
abnormal T cell activation |
J:148341
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Lepob/Lepob
Tg(Adipoq-cre)1Evdr/0
involves: 129S4/SvJaeSor * C57BL/6J * FVB/NJ
|
normal
adipose tissue phenotype |
J:237232
|
|
hyperglycemia |
J:237232
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Adipoq-cre)1Evdr/0
involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/NJ
|
abnormal brown adipose tissue morphology |
J:237232
|
|
normal
homeostasis/metabolism phenotype |
J:237232
|
|
increased liposarcoma incidence |
J:237232
|
|
lipodystrophy |
J:237232
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJaeSor * C57BL/6 * CBA
|
decreased B cell number |
J:167000
|
|
enlarged spleen |
J:167000
|
|
increased leukemia incidence |
J:167000
|
|
increased leukocyte cell number |
J:167000
|
|
premature death |
J:167000
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Krastm4Tyj/Krastm4Tyj
Tg(Cela1-cre/ERT)1Dam/0
involves: 129S4/SvJae * 129S4/SvJaeSor
|
increased pancreatic intraepithelial neoplasia incidence |
J:142188
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre/Esr1*)35.10Dam/0
involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * CBA
|
increased pancreatic intraepithelial neoplasia incidence |
J:142188
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * ICR
|
abnormal endocrine pancreas morphology |
J:86975
|
|
abnormal exocrine pancreas morphology |
J:86975
|
|
abnormal pancreas development |
J:86975
|
|
decreased pancreatic alpha cell number |
J:86975
|
|
decreased pancreatic beta cell number |
J:86975
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJaeSor * C57BL/6 * CBA
|
abnormal pancreas development |
J:169830
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Pdx1-cre/Esr1*)35.10Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA
|
abnormal pancreas development |
J:86975
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Neurog3-cre/Esr1*)1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA
|
absent pancreatic alpha cells |
J:86975
|
|
embryonic lethality during organogenesis, complete penetrance |
J:86975
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Col1a1-cre)1Kry/0
involves: 129S4/SvJaeSor * C57BL/6 * FVB/N
|
abnormal bone marrow cavity morphology |
J:233131
|
|
abnormal skeleton morphology |
J:233131
|
|
abnormal trabecular bone morphology |
J:233131
|
|
decreased body weight |
J:233131
|
|
decreased bone trabecular spacing |
J:233131
|
|
increased bone mass |
J:233131
|
|
increased bone trabecula number |
J:233131
|
|
increased trabecular bone thickness |
J:233131
|
|
increased trabecular bone volume |
J:233131
|
|
kinked tail |
J:233131
|
|
osteosclerosis |
J:233131
|
|
postnatal growth retardation |
J:233131
|
|
thick neurocranium |
J:233131
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Neurog3-cre)C1Able/0
involves: 129S4/SvJaeSor
|
abnormal pancreas development |
J:190530
|
|
abnormal pancreatic duct morphology |
J:190530
|
|
absent pancreatic islets |
J:190530
|
|
decreased body weight |
J:190530
|
|
normal
endocrine/exocrine gland phenotype |
J:190530
|
|
hyperglycemia |
J:190530
|
|
postnatal lethality, complete penetrance |
J:190530
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Shhtm2(cre/ERT2)Cjt/Shh+
involves: 129S4/SvJaeSor * 129S6/SvEvTac
|
normal
vision/eye phenotype |
J:118372
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Rbpjtm1Hon/Rbpjtm1Hon
Tg(Col1a1-cre)1Kry/0
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N
|
normal
skeleton phenotype |
J:233131
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Six2tm1(tTA,tetO-EGFP/cre)Amc/Six2+
involves: 129S4/SvJaeSor * C57BL/6J
|
abnormal renal tubule morphology |
J:185844
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Hes1tm1(cre/ERT2)Lcm/Hes1+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ
|
abnormal pancreas development |
J:169830
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Adipoq-cre)1Evdr/0
involves: 129S4/SvJaeSor * C57BL/6J * FVB/NJ
|
abnormal white fat cell differentation |
J:237232
|
|
absent epididymal fat pad |
J:237232
|
|
decreased susceptibility to diet-induced obesity |
J:237232
|
|
hepatic steatosis |
J:237232
|
|
hyperglycemia |
J:237232
|
|
increased circulating insulin level |
J:237232
|
|
increased liposarcoma incidence |
J:237232
|
|
increased liver weight |
J:237232
|
|
insulin resistance |
J:237232
|
|
lipodystrophy |
J:237232
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Hes1tm1.1Frad/Hes1tm1.1Frad
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJaeSor * C57BL/6 * CBA
|
decreased B cell number |
J:167000
|
|
decreased lymphoma incidence |
J:167000
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Wt1-cre)#Jbeb/0
involves: 129S4/SvJaeSor
|
abnormal epicardium morphology |
J:178290
|
|
hemopericardium |
J:178290
|
|
lethality throughout fetal growth and development |
J:178290
|
|
thin myocardium compact layer |
J:178290
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Neurod1-cre)1Able/0
involves: 129S4/SvJaeSor * C57BL/6 * DBA/2
|
abnormal pancreas morphology |
J:190530
|
|
abnormal pancreatic islet morphology |
J:190530
|
|
normal
homeostasis/metabolism phenotype |
J:190530
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Tg(Neurog3-cre/ERT2)1Able/0
involves: 129S4/SvJaeSor * C57BL/6 * DBA/2
|
normal
endocrine/exocrine gland phenotype |
J:190530
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sortm1(Notch1)Dam
involves: 129S4/SvJae * C57BL/6
|
no abnormal phenotype detected |
J:86975
|
Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu/Gt(ROSA)26Sor+
Tg(Lck-cre)548Jxm/0
B6.Cg-Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu Tg(Lck-cre)548Jxm
|
increased T cell derived lymphoma incidence |
J:185287
|
|
premature death |
J:185287
|
Gt(ROSA)26Sortm1(NOTCH3)Sat/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6
|
no abnormal phenotype detected |
J:133358
|
Gt(ROSA)26Sortm1(NOTCH3)Sat/Gt(ROSA)26Sor+
Notch3Gt(PST033)Byg/Notch3Gt(PST033)Byg
Tg(Tagln-cre)1Her/0
involves: 129 * C57BL/6 * SJL
|
normal
nervous system phenotype |
J:171887
|
Gt(ROSA)26Sortm1(NOTCH3)Sat/Gt(ROSA)26Sor+
Notch3Gt(PST033)Byg/Notch3Gt(PST033)Byg
Tg(Tagln-cre)1Her/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL
|
decreased cerebral infarct size |
J:133358
|
Gt(ROSA)26Sortm1(Ntn4)Dyl/Gt(ROSA)26Sor+
Tg(KRT14-cre)1Amc/0
involves: 129/Sv * C57BL/6 * CBA
|
abnormal blood vessel morphology |
J:162807
|
|
abnormal cardiovascular system physiology |
J:162807
|
|
abnormal coat appearance |
J:162807
|
|
abnormal hair follicle morphology |
J:162807
|
|
abnormal lymphangiogenesis |
J:162807
|
|
abnormal lymphatic vessel morphology |
J:162807
|
|
abnormal skin vasculature morphology |
J:162807
|
|
abnormal tumor vascularization |
J:162807
|
|
decreased body size |
J:162807
|
|
increased metastatic potential |
J:162807
|
|
lymphatic vessel hyperplasia |
J:162807
|
|
reddish skin |
J:162807
|
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
|
abnormal circulating cytokine level |
J:260047
|
|
abnormal renal glomerulus morphology |
J:260047
|
|
anemia |
J:260047
|
|
decreased B cell number |
J:260047
|
|
decreased body size |
J:260047
|
|
decreased body weight |
J:260047
|
|
decreased hematocrit |
J:260047
|
|
decreased lymphocyte cell number |
J:260047
|
|
enlarged lymph nodes |
J:260047
|
|
enlarged spleen |
J:260047
|
|
glomerulonephritis |
J:260047
|
|
increased inflammatory response |
J:260047
|
|
increased monocyte cell number |
J:260047
|
|
increased neutrophil cell number |
J:260047
|
|
increased T cell number |
J:260047
|
|
joint inflammation |
J:260047
|
|
joint swelling |
J:260047
|
|
small intestinal inflammation |
J:260047
|
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
Pycardtm1Vmd/Pycardtm1Vmd
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J
|
normal
growth/size/body region phenotype |
J:260047
|
|
normal
immune system phenotype |
J:260047
|
|
increased circulating interferon-gamma level |
J:260047
|
|
increased circulating interleukin-6 level |
J:260047
|
|
increased circulating tumor necrosis factor level |
J:260047
|
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
Nlrc4tm1Vmd/Nlrc4tm1Vmd
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NCrl
|
normal
immune system phenotype |
J:260047
|
|
normal
skeleton phenotype |
J:260047
|
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+
Tg(Itgax-cre)1-1Reiz/0
involves: C3H * C57BL/6 * C57BL/6J
|
decreased body size |
J:260047
|
|
increased monocyte cell number |
J:260047
|
|
increased neutrophil cell number |
J:260047
|
|
normal
skeleton phenotype |
J:260047
|
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+
Tg(S100A8-cre,-EGFP)1Ilw/0
involves: C3H * C57BL/6 * C57BL/6J
|
abnormal circulating cytokine level |
J:260047
|
|
decreased body size |
J:260047
|
|
decreased body weight |
J:260047
|
|
increased circulating interleukin-18 level |
J:260047
|
|
increased monocyte cell number |
J:260047
|
|
increased neutrophil cell number |
J:260047
|
|
joint swelling |
J:260047
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP1)S1Brd/0
involves: 129S7/SvEvBrd * FVB
|
abnormal tumor susceptibility |
J:166063
|
|
increased carcinoma incidence |
J:166063
|
|
increased sarcoma incidence |
J:166063
|
|
premature death |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP1)S2Brd/0
involves: 129S7/SvEvBrd * FVB
|
abnormal tumor susceptibility |
J:166063
|
|
increased carcinoma incidence |
J:166063
|
|
increased sarcoma incidence |
J:166063
|
|
premature death |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP1)H5Brd/0
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal tumor susceptibility |
J:166063
|
|
prenatal lethality, incomplete penetrance |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP1)H12Brd/0
involves: 129S7/SvEvBrd * C57BL/6
|
prenatal lethality, incomplete penetrance |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP1)H8Brd/0
involves: 129S7/SvEvBrd * C57BL/6
|
prenatal lethality, complete penetrance |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP1)H39Brd/0
involves: 129S7/SvEvBrd * C57BL/6
|
prenatal lethality, complete penetrance |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)S2Brd/0
involves: 129S7/SvEvBrd * FVB
|
abnormal tumor susceptibility |
J:166063
|
|
increased leukemia incidence |
J:166063
|
|
increased lymphoma incidence |
J:166063
|
|
premature death |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)S1Brd/0
involves: 129S7/SvEvBrd * FVB
|
abnormal tumor susceptibility |
J:166063
|
|
increased leukemia incidence |
J:166063
|
|
increased lymphoma incidence |
J:166063
|
|
premature death |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)H27Brd/0
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal tumor susceptibility |
J:166063
|
|
increased leukemia incidence |
J:166063
|
|
increased lymphoma incidence |
J:166063
|
|
premature death |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)H32Brd/0
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal tumor susceptibility |
J:166063
|
|
increased leukemia incidence |
J:166063
|
|
increased lymphoma incidence |
J:166063
|
|
premature death |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP2)H31Brd/0
involves: 129S7/SvEvBrd * C57BL/6
|
prenatal lethality, incomplete penetrance |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP3)S1Brd/0
involves: 129S7/SvEvBrd * FVB
|
abnormal tumor susceptibility |
J:166063
|
|
premature death |
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+
TgTn(pb-sb-ATP3)S2Brd/0
involves: 129S7/SvEvBrd * FVB
|
prenatal lethality, complete penetrance |
J:166063
|
Gt(ROSA)26Sortm1(PDGFB)Cbet/Gt(ROSA)26Sor+
Pdgfbtm1Cbet/Pdgfbtm1Cbet
Tg(Fabp4-lacZ)4Mosh/0
Tg(Tek-cre)1Ywa/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N * SJL
|
abnormal blood vessel morphology |
J:166532
|
Gt(ROSA)26Sortm1(PDGFB)Cbet/Gt(ROSA)26Sor+
Pdgfbtm1Cbet/Pdgfbtm1Cbet
Tg(Tek-cre)1Ywa/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * SJL
|
abnormal astrocyte morphology |
J:166532
|
|
abnormal capillary morphology |
J:166532
|
|
abnormal pericyte morphology |
J:166532
|
|
decreased capillary density |
J:166532
|
|
impaired blood-brain barrier function |
J:166532
|
Gt(ROSA)26Sortm1(PDGFB)Cbet/Gt(ROSA)26Sortm1(PDGFB)Cbet
Pdgfbtm1Cbet/Pdgfbtm1Cbet
Tg(Fabp4-lacZ)4Mosh/0
Tg(Tek-cre)1Ywa/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N * SJL
|
normal
cardiovascular system phenotype |
J:166532
|
Gt(ROSA)26Sortm1(PDGFB)Cbet/Gt(ROSA)26Sortm1(PDGFB)Cbet
Pdgfbtm1Cbet/Pdgfbtm1Cbet
Tg(Tek-cre)1Ywa/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * SJL
|
abnormal astrocyte morphology |
J:166532
|
|
abnormal capillary morphology |
J:166532
|
|
abnormal pericyte morphology |
J:166532
|
|
decreased capillary density |
J:166532
|
|
impaired blood-brain barrier function |
J:166532
|
Gt(ROSA)26Sortm1(PDGFRA*)Hsc/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129/Sv * C57BL/6 * CBA
|
abnormal interfrontal bone morphology |
J:145520
|
|
abnormal intramembranous bone ossification |
J:145520
|
|
premature coronal suture closure |
J:145520
|
|
premature intramembranous bone ossification |
J:145520
|
|
premature metopic suture closure |
J:145520
|
|
short snout |
J:145520
|
Gt(ROSA)26Sortm1(Phc2*,EGFP)Hko/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ
|
normal
skeleton phenotype |
J:204987
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac
|
abnormal blood vessel morphology |
J:170898
|
|
premature death |
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * CD-1
|
abnormal ovary morphology |
J:219794
|
|
normal
neoplasm |
J:219794
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
increased lymphoma incidence |
J:170898
|
|
increased mammary gland tumor incidence |
J:170898
|
|
increased T cell derived lymphoma incidence |
J:170898
|
|
premature death |
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)1Mam/0
involves: 129S6/SvEvTac * FVB/N
|
increased mammary gland tumor incidence |
J:170898
|
|
increased tumor incidence |
J:170898
|
|
premature death |
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Olig2tm1.1(cre)Wdr/Olig2+
involves: 129 * C57BL/6 * FVB/N
|
normal
neoplasm |
J:285841
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)#Tfln/0
involves: 129S6/SvEvTac
|
increased mammary adenocarcinoma incidence |
J:170898
|
|
increased mammary gland tumor incidence |
J:170898
|
|
increased tumor incidence |
J:170898
|
|
premature death |
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)#Tfln/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
increased lymphoma incidence |
J:170898
|
|
increased mammary adenocarcinoma incidence |
J:170898
|
|
increased mammary gland tumor incidence |
J:170898
|
|
increased T cell derived lymphoma incidence |
J:170898
|
|
premature death |
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
H3c2tm1Mak/H3c2+
Olig2tm1.1(cre)Wdr/Olig2+
involves: 129 * C57BL/6 * FVB/N
|
normal
neoplasm |
J:285841
|
Gt(ROSA)26Sortm1(Pim1-E2F1)Rebr/Gt(ROSA)26Sor+
Tmem163Tg(ACTB-cre)2Mrt/0
involves: 129P2/OlaHsd * FVB * FVB/N
|
abnormal long bone epiphyseal plate proliferative zone |
J:83303
|
|
abnormal skeleton morphology |
J:83303
|
|
decreased body size |
J:83303
|
|
decreased width of hypertrophic chondrocyte zone |
J:83303
|
|
postnatal growth retardation |
J:83303
|
|
postnatal lethality, incomplete penetrance |
J:83303
|
Gt(ROSA)26Sortm1(Ptpn22*)Draw/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
enlarged spleen |
J:201448
|
|
expanded mesangial matrix |
J:201448
|
|
glomerulonephritis |
J:201448
|
|
increased anti-double stranded DNA antibody level |
J:201448
|
|
increased autoantibody level |
J:201448
|
|
increased B cell number |
J:201448
|
|
increased germinal center B cell number |
J:201448
|
|
spleen hyperplasia |
J:201448
|
Gt(ROSA)26Sortm1(ptxA)Cgh/Gt(ROSA)26Sor+
Tg(Ins2-cre)25Mgn/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
abnormal glucose homeostasis |
J:130781
|
|
normal
endocrine/exocrine gland phenotype |
J:130781
|
|
hypoglycemia |
J:130781
|
|
improved glucose tolerance |
J:130781
|
|
increased circulating insulin level |
J:130781
|
Gt(ROSA)26Sortm1(ptxA)Cgh/Gt(ROSA)26Sor+
Tg(Pdx1-cre)6Cvw/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
improved glucose tolerance |
J:130781
|
Gt(ROSA)26Sortm1(ptxA)Cgh/Gt(ROSA)26Sortm1(ptxA)Cgh
involves: 129P2/OlaHsd * C57BL/6
|
no abnormal phenotype detected |
J:130781
|
Gt(ROSA)26Sortm1(RAC1*)Jkis/Gt(ROSA)26Sor+
involves: 129
|
normal
neoplasm |
J:187582
|
Gt(ROSA)26Sortm1(RAC1*)Jkis/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
involves: 129S4/SvJae
|
increased lung adenocarcinoma incidence |
J:187582
|
|
increased tumor growth/size |
J:187582
|
Gt(ROSA)26Sortm1(RARA*)Clmd/Gt(ROSA)26Sor+
Tg(Hoxb7-cre)13Amc/0
Tg(Hoxb7-EGFP)33Cos/0
involves: 129/SvEv * C57BL/6 * CBA * Swiss Webster
|
impaired branching involved in ureteric bud morphogenesis |
J:157254
|
|
renal hypoplasia |
J:157254
|
Gt(ROSA)26Sortm1(RARA*)Clmd/Gt(ROSA)26Sortm1(RARA*)Clmd
Tg(Hoxb7-cre)13Amc/0
involves: 129/SvEv * C57BL/6 * Swiss Webster
|
abnormal kidney development |
J:157254
|
|
impaired branching involved in ureteric bud morphogenesis |
J:157254
|
|
renal hypoplasia |
J:157254
|
Gt(ROSA)26Sortm1(RARA*)Clmd/Gt(ROSA)26Sortm1(RARA*)Clmd
Tg(Hoxb7-cre)13Amc/0
Tg(Hoxb7-EGFP)33Cos/0
involves: 129/SvEv * C57BL/6 * CBA * Swiss Webster
|
absent kidney |
J:157254
|
|
impaired branching involved in ureteric bud morphogenesis |
J:157254
|
|
renal hypoplasia |
J:157254
|
|
small ureteric bud |
J:157254
|
Gt(ROSA)26Sortm1(RARA*)Soc/Gt(ROSA)26Sortm1(RARA*)Soc
Foxg1tm1(cre)Skm/Foxg1+
involves: 129P2/OlaHsd
|
abnormal medial ganglionic eminence morphology |
J:135403
|
|
telencephalon hypoplasia |
J:135403
|
Gt(ROSA)26Sortm1(RARA*)Soc/Gt(ROSA)26Sortm1(RARA*)Soc
Isl1tm1(cre)Tmj/Isl1+
involves: 129X1/SvJ
|
decreased motor neuron number |
J:135403
|
Gt(ROSA)26Sortm1(RICTOR)Jger/Gt(ROSA)26Sortm1(RICTOR)Jger
Tg(GFAP-cre)25Mes/0
involves: 129 * FVB/N
|
abnormal postnatal subventricular zone morphology |
J:192206
|
|
abnormal tumor vascularization |
J:192206
|
|
increased glioma incidence |
J:192206
|
|
increased oligodendroglioma incidence |
J:192206
|
|
premature death |
J:192206
|
Gt(ROSA)26Sortm1(RICTOR)Jger/Gt(ROSA)26Sortm1(RICTOR)Jger
Tg(GFAP-cre)25Mes/0
Tg(GFAP-EGFR*,-lacZ)#Agu/0
involves: 129S1/Sv * 129X1/SvJ * FVB/N
|
abnormal postnatal subventricular zone morphology |
J:192206
|
|
decreased tumor latency |
J:192206
|
|
increased astrocytoma incidence |
J:192206
|
|
increased glioma incidence |
J:192206
|
|
increased oligodendroglioma incidence |
J:192206
|
|
premature death |
J:192206
|
Gt(ROSA)26Sortm1(RNAi:Bmpr2)Dliu/Gt(ROSA)26Sor+
involves: 129 * C57BL/6J
|
abnormal blood vessel morphology |
J:145514
|
|
abnormal pulmonary artery morphology |
J:145514
|
|
abnormal spleen morphology |
J:145514
|
|
abnormal spleen white pulp morphology |
J:145514
|
|
anemia |
J:145514
|
|
cachexia |
J:145514
|
|
decreased angiogenesis |
J:145514
|
|
decreased erythrocyte cell number |
J:145514
|
|
enlarged spleen |
J:145514
|
|
extramedullary hematopoiesis |
J:145514
|
|
normal
homeostasis/metabolism phenotype |
J:145514
|
|
intestinal hemorrhage |
J:145514
|
|
intestine polyps |
J:145514
|
|
pallor |
J:145514
|
|
premature death |
J:145514
|
|
respiratory distress |
J:145514
|
|
reticulocytosis |
J:145514
|
|
normal
skeleton phenotype |
J:145514
|
|
vascular smooth muscle hypoplasia |
J:145514
|
Gt(ROSA)26Sortm1(RNAi:Bmpr2)Dliu/Gt(ROSA)26Sortm1(RNAi:Bmpr2)Dliu
involves: 129 * C57BL/6J
|
gastrointestinal hemorrhage |
J:145514
|
|
premature death |
J:145514
|
Gt(ROSA)26Sortm1(RNU6-RNAi:Rad18)Wbaa/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6
|
abnormal double-strand DNA break repair |
J:177475
|
|
abnormal spermatid morphology |
J:177475
|
|
abnormal synaptonemal complex |
J:177475
|
|
decreased body weight |
J:177475
|
|
decreased epididymis weight |
J:177475
|
|
decreased litter size |
J:177475
|
|
decreased testis weight |
J:177475
|
|
oligozoospermia |
J:177475
|
Gt(ROSA)26Sortm1(RNU6-RNAi:Rad18)Wbaa/Gt(ROSA)26Sortm1(RNU6-RNAi:Rad18)Wbaa
involves: 129S6/SvEvTac * C57BL/6
|
preweaning lethality, complete penetrance |
J:177475
|
Gt(ROSA)26Sortm1(RNU6-RNAi:Trpv1)Thch/Gt(ROSA)26Sor+
Not Specified
|
abnormal body temperature |
J:132700
|
|
abnormal chemical nociception |
J:132700
|
|
abnormal pain threshold |
J:132700
|
|
abnormal physiological response to xenobiotic |
J:132700
|
|
increased thermal nociceptive threshold |
J:132700
|
Gt(ROSA)26Sortm1(rtTA2S*M2)Whsu/Gt(ROSA)26Sortm1(rtTA2S*M2)Whsu
involves: 129S6/SvEvTac
|
no abnormal phenotype detected |
J:99718
|
Gt(ROSA)26Sortm1(rtTA)Awu/Gt(ROSA)26Sor+
Hif1atm3Rsjo/Hif1atm3Rsjo
Tg(tetO-cre)LC1Bjd/0
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
abnormal cell migration |
J:130751
|
Gt(ROSA)26Sortm1(rtTA)Awu/Gt(ROSA)26Sortm1(rtTA)Awu
Xisttm1Awu/Y
involves: 129S4/SvJae
|
abnormal B cell differentiation |
J:112954
|
|
abnormal definitive hematopoiesis |
J:112954
|
|
abnormal embryonic tissue morphology |
J:112954
|
|
abnormal erythropoiesis |
J:112954
|
|
abnormal myelopoiesis |
J:112954
|
|
abnormal T cell differentiation |
J:112954
|
|
abnormal thymus morphology |
J:112954
|
|
absent pre-B cells |
J:112954
|
|
anemia |
J:112954
|
|
decreased bone marrow cell number |
J:112954
|
|
decreased double-positive T cell number |
J:112954
|
|
decreased granulocyte number |
J:112954
|
|
decreased hematocrit |
J:112954
|
|
decreased immature B cell number |
J:112954
|
|
decreased macrophage cell number |
J:112954
|
|
decreased pro-B cell number |
J:112954
|
|
decreased thymocyte number |
J:112954
|
|
increased hematopoietic stem cell number |
J:112954
|
|
neonatal lethality |
J:112954
|
|
premature death |
J:112954
|
|
prenatal lethality |
J:112954
|
|
small thymus |
J:112954
|
|
thymus hypoplasia |
J:112954
|
|
weakness |
J:112954
|
Gt(ROSA)26Sortm1(rtTA)Awu/Gt(ROSA)26Sortm1(rtTA)Awu
Xisttm1Awu/Xisttm1Awu
involves: 129S4/SvJae
|
decreased bone marrow cell number |
J:112954
|
|
decreased hematocrit |
J:112954
|
|
premature death |
J:112954
|
|
small thymus |
J:112954
|
|
weakness |
J:112954
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Col2a1-cre)1Bhr/0
Tg(tetO-Vegfa)90Ala/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N * SJL
|
abnormal bone marrow morphology |
J:156474
|
|
abnormal bone ossification |
J:156474
|
|
abnormal bone structure |
J:156474
|
|
abnormal hematopoietic system morphology/development |
J:156474
|
|
abnormal long bone epiphyseal plate morphology |
J:156474
|
|
abnormal long bone metaphysis morphology |
J:156474
|
|
abnormal megakaryocyte progenitor cell morphology |
J:156474
|
|
abnormal osteoblast differentiation |
J:156474
|
|
abnormal skeleton development |
J:156474
|
|
abnormal trabecular bone morphology |
J:156474
|
|
abnormal vasculogenesis |
J:156474
|
|
decreased bone resorption |
J:156474
|
|
decreased long bone epiphyseal plate size |
J:156474
|
|
decreased osteoclast cell number |
J:156474
|
|
enlarged spleen |
J:156474
|
|
extramedullary hematopoiesis |
J:156474
|
|
increased hematopoietic stem cell number |
J:156474
|
|
increased megakaryocyte cell number |
J:156474
|
|
increased trabecular bone mass |
J:156474
|
|
myelofibrosis |
J:156474
|
|
thrombocytopenia |
J:156474
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Nes-cre)1Kln/0
Tg(tetO-Vegfa)90Ala/0
mixed
|
normal
behavior/neurological phenotype |
J:99607
|
|
intracranial hemorrhage |
J:99607
|
|
spinal hemorrhage |
J:99607
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Tg(tetO-Xbp1_is)#Pesch/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA * FVB
|
abnormal glucose homeostasis |
J:194290
|
|
abnormal liver morphology |
J:194290
|
|
decreased circulating insulin level |
J:194290
|
|
decreased fasting circulating glucose level |
J:194290
|
|
decreased liver glycogen level |
J:194290
|
|
decreased total body fat amount |
J:194290
|
|
enhanced lipolysis |
J:194290
|
|
hepatic steatosis |
J:194290
|
|
hypoglycemia |
J:194290
|
|
increased circulating free fatty acids level |
J:194290
|
|
increased insulin sensitivity |
J:194290
|
|
increased liver triglyceride level |
J:194290
|
|
increased respiratory quotient |
J:194290
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras2)12Hev/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N
|
increased pancreas tumor incidence |
J:184378
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:184378
|
|
increased susceptibility to injury |
J:184378
|
|
pancreatic acinar-to-ductal metaplasia |
J:184378
|
|
small pancreas |
J:184378
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras2)12Hev/0
Trp53tm1Tyj/Trp53+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:184378
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:184378
|
|
increased susceptibility to injury |
J:184378
|
|
premature death |
J:184378
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:186194
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:186194
|
|
pancreatic acinar-to-ductal metaplasia |
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Prrx1-cre)1Cjt/0
Tg(tetO-Gata6)1Abl/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL/J
|
oligodactyly |
J:205405
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Rbpjtm1Hon/Rbpjtm1Hon
Tg(tetO-cre)1Jaw/0
involves: 129 * C57BL/6
|
abnormal lung development |
J:155893
|
|
neonatal lethality, complete penetrance |
J:155893
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Nphs2-cre)1Seq/0
Tg(tetO-Vegfa)90Ala/0
involves: 129S1/Sv * 129X1/SvJ * FVB/N * ICR
|
albuminuria |
J:99607
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(CAG-cre)1Nagy/0
Tg(tetO-Vegfa)90Ala/0
involves: 129S1/Sv * 129X1/SvJ * FVB/N * ICR
|
edema |
J:99607
|
|
embryonic lethality during organogenesis, complete penetrance |
J:99607
|
|
enlarged lymph nodes |
J:99607
|
|
hepatic peliosis |
J:99607
|
|
premature death |
J:99607
|
|
reddish skin |
J:99607
|
|
thymus atrophy |
J:99607
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Sox9tm3(cre)Crm/Sox9+
Tg(tetO-Vegfa)1Kesh/0
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ
|
abnormal blood vessel morphology |
J:147285
|
|
increased vascular endothelial cell number |
J:147285
|
Gt(ROSA)26Sortm1(Rybp/EGFP)Cve/Gt(ROSA)26Sor+
Tmem163Tg(ACTB-cre)2Mrt/0
involves: 129S1/Sv * 129X1/SvJ * FVB/N
|
cornea vascularization |
J:134428
|
Gt(ROSA)26Sortm1(Rybp/EGFP)Cve/Gt(ROSA)26Sor+
Tg(Cryaa-cre)10Mlr/0
involves: 129S1/Sv * 129X1/SvJ
|
abnormal lens fiber morphology |
J:134428
|
|
cataract |
J:134428
|
Gt(ROSA)26Sortm1(Rybp/EGFP)Cve/Gt(ROSA)26Sortm1(Rybp/EGFP)Cve
Tmem163Tg(ACTB-cre)2Mrt/0
involves: 129S1/Sv * 129X1/SvJ * FVB/N
|
abnormal vitreous body morphology |
J:134428
|
|
absent eye anterior chamber |
J:134428
|
|
cataract |
J:134428
|
|
coloboma |
J:134428
|
|
cornea vascularization |
J:134428
|
|
retina fold |
J:134428
|
Gt(ROSA)26Sortm1(Sall1)Ryn/Gt(ROSA)26Sor+
Tg(CAG-cre)13Miya/0
involves: 129P2/OlaHsd * C57BL/6
|
decreased body weight |
J:162052
|
Gt(ROSA)26Sortm1(Sall1)Ryn/Gt(ROSA)26Sor+
Six2tm1(tTA,tetO-EGFP/cre)Amc/Six2+
involves: 129P2/OlaHsd * C57BL/6 * CD-1
|
no abnormal phenotype detected |
J:162052
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6057Njen/0
involves: C3H * C57BL/6
|
decreased embryo size |
J:102234
|
|
decreased fetal size |
J:102234
|
|
increased B cell derived lymphoma incidence |
J:102234
|
|
increased lymphoma incidence |
J:102234
|
|
increased medulloblastoma incidence |
J:102234
|
|
increased T cell derived lymphoma incidence |
J:102234
|
|
increased tumor incidence |
J:102234
|
|
lethality throughout fetal growth and development, incomplete penetrance |
J:102234
|
|
premature death |
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0
involves: C3H * C57BL/6
|
abnormal duodenum morphology |
J:102234
|
|
decreased embryo size |
J:102234
|
|
decreased fetal size |
J:102234
|
|
increased B cell derived lymphoma incidence |
J:102234
|
|
increased lymphoma incidence |
J:102234
|
|
increased medulloblastoma incidence |
J:102234
|
|
increased T cell derived lymphoma incidence |
J:102234
|
|
increased tumor incidence |
J:102234
|
|
lethality throughout fetal growth and development, incomplete penetrance |
J:102234
|
|
premature death |
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6113Njen/0
involves: C3H * C57BL/6
|
decreased embryo size |
J:102234
|
|
decreased fetal size |
J:102234
|
|
increased B cell derived lymphoma incidence |
J:102234
|
|
increased lymphoma incidence |
J:102234
|
|
increased T cell derived lymphoma incidence |
J:102234
|
|
increased tumor incidence |
J:102234
|
|
lethality throughout fetal growth and development, incomplete penetrance |
J:102234
|
|
pituitary gland hyperplasia |
J:102234
|
|
premature death |
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc3)12740Njen/0
involves: C3H * C57BL/6J
|
increased adenoma incidence |
J:153656
|
|
increased B cell derived lymphoma incidence |
J:153656
|
|
increased basal cell carcinoma incidence |
J:153656
|
|
increased blastoma incidence |
J:153656
|
|
increased carcinoma incidence |
J:153656
|
|
increased hemangioma incidence |
J:153656
|
|
increased hemangiosarcoma incidence |
J:153656
|
|
increased hepatocellular carcinoma incidence |
J:153656
|
|
increased liver adenoma incidence |
J:153656
|
|
increased liver tumor incidence |
J:153656
|
|
increased lung carcinoma incidence |
J:153656
|
|
increased lymphoma incidence |
J:153656
|
|
increased melanoma incidence |
J:153656
|
|
increased pheochromocytoma incidence |
J:153656
|
|
increased sarcoma incidence |
J:153656
|
|
increased skin squamous cell carcinoma incidence |
J:153656
|
|
increased squamous cell carcinoma incidence |
J:153656
|
|
increased T cell derived lymphoma incidence |
J:153656
|
|
premature death |
J:153656
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
Hprt1tm1(sb-Onco-Array)Peli/Hprt1+
involves: 129S7/SvEvBrd
|
decreased birth body size |
J:166283
|
|
increased hemangioma incidence |
J:166283
|
|
increased hemangiosarcoma incidence |
J:166283
|
|
increased lung adenocarcinoma incidence |
J:166283
|
|
increased lung adenoma incidence |
J:166283
|
|
increased lymphoma incidence |
J:166283
|
|
increased medulloblastoma incidence |
J:166283
|
|
increased rhabdomyosarcoma incidence |
J:166283
|
|
increased skin squamous cell carcinoma incidence |
J:166283
|
|
increased tumor incidence |
J:166283
|
|
perinatal lethality, incomplete penetrance |
J:166283
|
|
postnatal growth retardation |
J:166283
|
|
postnatal lethality, incomplete penetrance |
J:166283
|
|
premature death |
J:166283
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+
Hprt1tm1(sb-Onco-Array)Peli/Y
involves: 129S7/SvEvBrd
|
decreased birth body size |
J:166283
|
|
increased hemangioma incidence |
J:166283
|
|
increased hemangiosarcoma incidence |
J:166283
|
|
increased lung adenocarcinoma incidence |
J:166283
|
|
increased lung adenoma incidence |
J:166283
|
|
increased lymphoma incidence |
J:166283
|
|
increased medulloblastoma incidence |
J:166283
|
|
increased rhabdomyosarcoma incidence |
J:166283
|
|
increased skin squamous cell carcinoma incidence |
J:166283
|
|
increased tumor incidence |
J:166283
|
|
perinatal lethality, incomplete penetrance |
J:166283
|
|
postnatal growth retardation |
J:166283
|
|
postnatal lethality, incomplete penetrance |
J:166283
|
|
premature death |
J:166283
|
Gt(ROSA)26Sortm1(Sirt1)Ktm/Gt(ROSA)26Sor+
Tg(Agrp-cre)1Gsb/0
involves: 129 * C57BL/6J * FVB/N
|
normal
adipose tissue phenotype |
J:209418
|
|
normal
behavior/neurological phenotype |
J:209418
|
|
decreased food intake |
J:209418
|
|
decreased susceptibility to age related obesity |
J:209418
|
|
normal
growth/size/body region phenotype |
J:209418
|
|
normal
homeostasis/metabolism phenotype |
J:209418
|
|
increased body weight |
J:209418
|
|
increased food intake |
J:209418
|
|
increased response to leptin |
J:209418
|
Gt(ROSA)26Sortm1(Sirt1)Ktm/Gt(ROSA)26Sor+
Tg(Pomc1-cre)16Lowl/0
involves: 129 * C57BL/6J * FVB/N
|
normal
behavior/neurological phenotype |
J:209418
|
|
decreased circulating thyroxine level |
J:209418
|
|
decreased epididymal fat pad weight |
J:209418
|
|
decreased locomotor activity |
J:209418
|
|
decreased susceptibility to age related obesity |
J:209418
|
|
decreased susceptibility to induced hypothermia |
J:209418
|
|
decreased total body fat amount |
J:209418
|
|
normal
growth/size/body region phenotype |
J:209418
|
|
normal
homeostasis/metabolism phenotype |
J:209418
|
|
increased adipose tissue noradrenaline turnover |
J:209418
|
|
increased energy expenditure |
J:209418
|
|
increased oxygen consumption |
J:209418
|
|
increased response to leptin |
J:209418
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/?
involves: 129X1/SvJ
|
normal
neoplasm |
J:114992
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Tg(Nes-cre)1Kln/0
involves: 129X1/SvJ * C57BL/6 * SJL
|
abnormal lateral geniculate nucleus morphology |
J:147427
|
|
abnormal thalamus morphology |
J:147427
|
|
increased brain size |
J:147427
|
|
neonatal lethality, complete penetrance |
J:147427
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129X1/SvJ * C57BL/6J * CBA/J
|
abnormal cardiac outflow tract development |
J:135134
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:135134
|
|
increased cardiac neural crest cell number |
J:135134
|
|
persistent truncus arteriosus |
J:135134
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129X1/SvJ * C57BL/6
|
abnormal pulmonary alveolus morphology |
J:264185
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Olig3tm1(cre)Ynka/Olig3+
involves: 129X1/SvJ * C57BL/6 * SJL
|
abnormal lateral geniculate nucleus morphology |
J:147427
|
|
abnormal thalamus morphology |
J:147427
|
|
normal
nervous system phenotype |
J:147427
|
|
prenatal lethality, incomplete penetrance |
J:147427
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Nkx3-2tm1(cre)Wez/Nkx3-2+
involves: 129S7/SvEvBrd * 129X1/SvJ
|
abnormal intestine development |
J:199664
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Tg(Pdgfra-cre/ERT)467Dbe/0
involves: 129X1/SvJ * C57BL/6 * SJL
|
abnormal pulmonary alveolus morphology |
J:264185
|
|
emphysema |
J:264185
|
|
overexpanded pulmonary alveolus |
J:264185
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Hk2tm1.1Uku/Hk2+
Tg(GFAP-cre)25Mes/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N
|
increased medulloblastoma incidence |
J:210113
|
|
premature death |
J:210113
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Hk2tm1.1Uku/Hk2tm1.1Uku
Tg(GFAP-cre)25Mes/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N
|
abnormal neuronal precursor proliferation |
J:210113
|
|
abnormal tumor vascularization |
J:210113
|
|
decreased tumor growth/size |
J:210113
|
|
increased medulloblastoma incidence |
J:210113
|
|
increased tumor latency |
J:210113
|
|
premature death |
J:210113
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Olig2tm2(TVA,cre)Rth/Olig2+
involves: 129 * 129X1/SvJ
|
increased medulloblastoma incidence |
J:139574
|
|
premature death |
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Shhtm2(cre/ERT2)Cjt/Shh+
involves: 129S6/SvEvTac * 129X1/SvJ
|
normal
neoplasm |
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tg(Atoh1-cre/Esr1*)14Fsh/0
involves: 129X1/SvJ * FVB/N
|
abnormal cerebellum external granule cell layer morphology |
J:139574
|
|
increased medulloblastoma incidence |
J:139574
|
|
premature death |
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tg(GFAP-cre)25Mes/0
involves: 129X1/SvJ * FVB/N
|
increased medulloblastoma incidence |
J:139574
|
|
premature death |
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tg(Krt1-5-cre/ERT)1Ipc/0
involves: 129X1/SvJ * C57BL/6 * SJL
|
increased basal cell carcinoma incidence |
J:158915
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
Tlx3tm1(cre)Qima/Tlx3+
involves: 129X1/SvJ
|
increased medulloblastoma incidence |
J:139574
|
|
premature death |
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm2(EGFP/cre)Alj
Pgbd5tm1.1Aken/Pgbd5tm1.1Aken
involves: 129 * C57BL/6J * C57BL/6NTac * SW
|
increased medulloblastoma incidence |
J:346387
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/?
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129X1/SvJ * C57BL/6J * CBA/J
|
abnormal face development |
J:89445
|
|
abnormal head development |
J:89445
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/?
Tg(CAG-cre/Esr1*)5Amc/?
involves: 129X1/SvJ * C57BL/6 * CBA
|
abnormal pancreas morphology |
J:114992
|
|
gastric polyps |
J:114992
|
|
increased basal cell carcinoma incidence |
J:114992
|
|
increased medulloblastoma incidence |
J:114992
|
|
increased rhabdomyosarcoma incidence |
J:114992
|
|
intestine polyps |
J:114992
|
|
premature death |
J:114992
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/?
Tg(Pbsn-cre)4Prb/?
involves: 129X1/SvJ * C57BL/6 * DBA/2
|
normal
endocrine/exocrine gland phenotype |
J:114992
|
Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/Gt(ROSA)26Sor+
Tg(Nes-cre)1Kln/0
involves: 129 * C57BL/6 * SJL
|
no abnormal phenotype detected |
J:150777
|
Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/Gt(ROSA)26Sortm1(SNCA*A53T)Djmo
involves: 129 * C57BL/6J
|
no abnormal phenotype detected |
J:147332
|
Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/Gt(ROSA)26Sortm1(SNCA*A53T)Djmo
7630403G23RikTg(Th-cre)1Tmd/7630403G23Rik+
involves: 129 * C57BL/6 * SJL
|
no abnormal phenotype detected |
J:150777
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
involves: C57BL/6 * DBA/2
|
abnormal prostate gland morphology |
J:239660
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Pten+
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:239660
|
|
increased prostate intraepithelial neoplasia incidence |
J:239660
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:239660
|
Gt(ROSA)26Sortm1(SRF/VP16)Antu/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal cone electrophysiology |
J:172655
|
|
abnormal eye electrophysiology |
J:172655
|
|
abnormal ocular fundus morphology |
J:172655
|
|
abnormal optic nerve morphology |
J:172655
|
|
abnormal retina blood vessel morphology |
J:172655
|
|
abnormal retina photoreceptor morphology |
J:172655
|
|
abnormal retina pigment epithelium morphology |
J:172655
|
|
abnormal rod electrophysiology |
J:172655
|
|
decreased body weight |
J:172655
|
|
disorganized retina layers |
J:172655
|
|
lipofuscinosis |
J:172655
|
|
retina degeneration |
J:172655
|
|
retina photoreceptor degeneration |
J:172655
|
Gt(ROSA)26Sortm1(SRF/VP16)Antu/Gt(ROSA)26Sortm1(SRF/VP16)Antu
involves: 129S1/Sv * 129X1/SvJ
|
abnormal cone electrophysiology |
J:172655
|
|
abnormal eye electrophysiology |
J:172655
|
|
abnormal ocular fundus morphology |
J:172655
|
|
abnormal optic nerve morphology |
J:172655
|
|
abnormal retina blood vessel morphology |
J:172655
|
|
abnormal retina inner nuclear layer morphology |
J:172655
|
|
abnormal retina photoreceptor morphology |
J:172655
|
|
abnormal retina pigment epithelium morphology |
J:172655
|
|
abnormal rod electrophysiology |
J:172655
|
|
decreased body weight |
J:172655
|
|
disorganized retina layers |
J:172655
|
|
lipofuscinosis |
J:172655
|
|
retina degeneration |
J:172655
|
|
retina outer nuclear layer degeneration |
J:172655
|
|
retina photoreceptor degeneration |
J:172655
|
Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv/Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv
involves: C57BL/6
|
abnormal T-helper 17 cell differentiation |
J:205858
|
Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv/Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv
Tg(Agrp-cre)1Gsb/?
involves: C57BL/6 * FVB/N
|
abnormal glucose homeostasis |
J:133218
|
|
decreased circulating adrenaline level |
J:133218
|
|
decreased circulating glucose level |
J:133218
|
|
decreased circulating insulin level |
J:133218
|
|
decreased circulating noradrenaline level |
J:133218
|
|
decreased gonadal fat pad weight |
J:133218
|
|
improved glucose tolerance |
J:133218
|
|
increased locomotor activity |
J:133218
|
|
increased oxygen consumption |
J:133218
|
|
polyphagia |
J:133218
|
|
slow postnatal weight gain |
J:133218
|
Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv/Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv
Tg(Cd4-cre)1Cwi/0
involves: C57BL/6 * DBA/2
|
decreased lung compliance |
J:205858
|
|
increased airway resistance |
J:205858
|
|
increased circulating interleukin-17 level |
J:205858
|
|
increased interleukin-17 secretion |
J:205858
|
|
increased lung elastance |
J:205858
|
|
increased regulatory T cell number |
J:205858
|
|
increased T-helper 1 cell number |
J:205858
|
|
increased T-helper 17 cell number |
J:205858
|
|
lung inflammation |
J:205858
|
|
premature death |
J:205858
|
Gt(ROSA)26Sortm1(Stat3*A661C*N663C)Sbkv/?
Tg(Fabp4-cre/ERT2)1Ipc/0
Tyk2tm1Shmd/Tyk2tm1Shmd
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
normal
adipose tissue phenotype |
J:195099
|
|
normal
homeostasis/metabolism phenotype |
J:195099
|
Gt(ROSA)26Sortm1(Tbx1/GFP)Bem/Gt(ROSA)26Sor+
Foxg1tm1(cre)Skm/Foxg1+
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
abnormal cochlea morphology |
J:204435
|
|
abnormal common crus morphology |
J:204435
|
|
abnormal endolymphatic duct morphology |
J:204435
|
|
abnormal forebrain morphology |
J:204435
|
|
abnormal frontonasal prominence morphology |
J:204435
|
|
abnormal geniculate ganglion morphology |
J:204435
|
|
abnormal glossopharyngeal ganglion morphology |
J:204435
|
|
abnormal nasal placode morphology |
J:204435
|
|
abnormal optic vesicle formation |
J:204435
|
|
abnormal trigeminal ganglion morphology |
J:204435
|
|
abnormal vagus ganglion morphology |
J:204435
|
|
absent lateral semicircular canal |
J:204435
|
|
absent utricle |
J:204435
|
|
absent vestibular saccule |
J:204435
|
|
athymia |
J:204435
|
|
cochlear ganglion degeneration |
J:204435
|
|
perinatal lethality, complete penetrance |
J:204435
|
|
vestibular ganglion degeneration |
J:204435
|
Gt(ROSA)26Sortm1(Tbx1/GFP)Bem/Gt(ROSA)26Sor+
Tbx1tm1Bld/Tbx1tm6(cre)Bld
involves: 129S7/SvEvBrd * C57BL/6 * SJL
|
abnormal cochlea morphology |
J:204435
|
|
abnormal vestibular saccule morphology |
J:204435
|
|
double outlet right ventricle |
J:204435
|
|
normal
hearing/vestibular/ear phenotype |
J:204435
|
|
ventricular septal defect |
J:204435
|
Gt(ROSA)26Sortm1(Tbx1/GFP)Bem/Gt(ROSA)26Sor+
Tg(Pax2-cre)1Akg/0
involves: 129 * C57BL/6 * SJL
|
abnormal cochlea morphology |
J:204435
|
|
abnormal common crus morphology |
J:204435
|
|
abnormal endolymphatic duct morphology |
J:204435
|
|
abnormal semicircular canal morphology |
J:204435
|
|
absent lateral semicircular canal |
J:204435
|
|
absent utricle |
J:204435
|
|
absent vestibular saccule |
J:204435
|
|
perinatal lethality, complete penetrance |
J:204435
|
Gt(ROSA)26Sortm1(Tbx1/GFP)Bem/Gt(ROSA)26Sor+
Tbx1tm6(cre)Bld/Tbx1+
involves: 129 * C57BL/6 * SJL
|
normal
cardiovascular system phenotype |
J:204435
|
|
normal
hearing/vestibular/ear phenotype |
J:204435
|
Gt(ROSA)26Sortm1(Tbx1/GFP)Bem/Gt(ROSA)26Sortm1(Tbx1/GFP)Bem
Tbx1tm1Bld/Tbx1tm6(cre)Bld
involves: 129S7/SvEvBrd * C57BL/6 * SJL
|
double outlet right ventricle |
J:204435
|
|
persistent truncus arteriosus |
J:204435
|
|
ventricular septal defect |
J:204435
|
Gt(ROSA)26Sortm1(Tbx1/GFP)Bem/Gt(ROSA)26Sortm1(Tbx1/GFP)Bem
Tbx1tm6(cre)Bld/Tbx1+
involves: 129 * C57BL/6 * SJL
|
double outlet right ventricle |
J:204435
|
|
persistent truncus arteriosus |
J:204435
|
|
postnatal lethality, complete penetrance |
J:204435
|
|
ventricular septal defect |
J:204435
|
Gt(ROSA)26Sortm1(tetO-RNAi:Hivep3)Glm/Gt(ROSA)26Sor+
Not Specified
|
increased bone mass |
J:201597
|
|
increased bone volume |
J:201597
|
|
increased compact bone thickness |
J:201597
|
|
increased osteoblast cell number |
J:201597
|
Gt(ROSA)26Sortm1(tetO-Sox9)Msan/Gt(ROSA)26Sor+
Tg(SFTPC-rtTA)5Jaw/0
Not Specified
|
abnormal cell differentiation |
J:202984
|
|
abnormal pulmonary alveolus epithelium morphology |
J:202984
|
|
perinatal lethality, complete penetrance |
J:202984
|
Gt(ROSA)26Sortm1(tetO-Sox9)Msan/Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy
Shhtm1(EGFP/cre)Cjt/Shh+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal lung morphology |
J:202984
|
|
lung cyst |
J:202984
|
|
small lung |
J:202984
|
Gt(ROSA)26Sortm1(Tfrc*)Nca/Gt(ROSA)26Sor+
Hfetm2Nca/Hfetm2Nca
involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N
|
increased circulating iron level |
J:133221
|
|
increased liver iron level |
J:133221
|
Gt(ROSA)26Sortm1(Tfrc*)Nca/Gt(ROSA)26Sor+
Tfrctm3.1Nca/Tfrctm3.1Nca
Tg(Vil1-cre)20Syr/0
involves: 129S4/SvJae * C57BL/6 * CD-1 * DBA/2
|
abnormal digestive system morphology |
J:224823
|
|
postnatal lethality, incomplete penetrance |
J:224823
|
Gt(ROSA)26Sortm1(Tfrc*)Nca/Gt(ROSA)26Sortm1(Tfrc*)Nca
involves: 129S4/SvJae * FVB/N
|
increased circulating iron level |
J:133221
|
|
increased heart iron level |
J:133221
|
|
increased liver iron level |
J:133221
|
Gt(ROSA)26Sortm1(Tgfbr1*)Crm/Gt(ROSA)26Sor+
Tg(Col1a2-cre/ERT,-ALPP)7Cpd/0
involves: 129S7/SvEvBrd * C57BL/6 * DBA/2
|
abnormal artery morphology |
J:134135
|
|
abnormal blood vessel morphology |
J:134135
|
|
abnormal blood vessel physiology |
J:134135
|
|
abnormal dermal layer morphology |
J:134135
|
|
abnormal kidney arterial blood vessel morphology |
J:134135
|
|
abnormal lung vasculature morphology |
J:134135
|
|
abnormal skin condition |
J:134135
|
|
decreased body weight |
J:134135
|
|
decreased subcutaneous adipose tissue amount |
J:134135
|
|
renal interstitial fibrosis |
J:134135
|
|
sparse hair |
J:134135
|
|
thick dermal layer |
J:134135
|
|
thick skin |
J:134135
|
|
thin epidermis |
J:134135
|
|
vascular smooth muscle hypertrophy |
J:134135
|
Gt(ROSA)26Sortm1(Thy1-FBXL2)Wata/Gt(ROSA)26Sor+
Tg(Thy1-PSEN1*M146V,-APP*Swe)10Arte/0
involves: C57BL/6 * C57BL/6N * CBA
|
amyloid beta deposits |
J:182731
|
Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0
involves: 129 * C57BL/6 * DBA/2
|
prostate gland ventral lobe hyperplasia |
J:200002
|
Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2
|
abnormal prostate gland physiology |
J:200002
|
|
distended abdomen |
J:200002
|
|
enlarged prostate gland |
J:200002
|
|
increased prostate gland adenocarcinoma incidence |
J:200002
|
|
increased prostate intraepithelial neoplasia incidence |
J:200002
|
|
penis prolapse |
J:200002
|
|
premature death |
J:200002
|
Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key
Tg(Pbsn-cre)4Prb/0
involves: 129 * C57BL/6 * DBA/2
|
prostate gland ventral lobe hyperplasia |
J:200002
|
Gt(ROSA)26Sortm1(Trpv1,ECFP)Mde/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6
|
circling |
J:136582
|
Gt(ROSA)26Sortm1(Trpv1,ECFP)Mde/Gt(ROSA)26Sor+
Trpv1tm1Jul/Trpv1tm1Jul
Tg(Mrgpra3-GFP/cre)#Xzd/0
involves: 129P2/OlaHsd * 129X1/SvJ
|
hypoalgesia |
J:197482
|
|
increased pruritus |
J:197482
|
|
increased thermal nociceptive threshold |
J:197482
|
Gt(ROSA)26Sortm1(Trpv1,ECFP)Mde/Gt(ROSA)26Sor+
Tg(Nes-cre)1Wme/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
abnormal single cell response |
J:136582
|
|
normal
behavior/neurological phenotype |
J:136582
|
|
circling |
J:136582
|
|
increased susceptibility to neuronal excitotoxicity |
J:136582
|
Gt(ROSA)26Sortm1(tTA)Roos/?
Lhx3tm1(cre)Slp/Lhx3+
Tg(tetO-SOD1*G93A,-luc)1Roos/0
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6
|
abnormal ventral spinal root morphology |
J:138761
|
|
decreased body weight |
J:138761
|
|
decreased motor neuron number |
J:138761
|
|
normal
nervous system phenotype |
J:138761
|
Gt(ROSA)26Sortm1(tTA)Roos/?
Lhx3tm1(cre)Slp/Lhx3+
Tg(tetO-SOD1,-luc)1Roos/0
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6
|
normal
growth/size/body region phenotype |
J:138761
|
|
normal
nervous system phenotype |
J:138761
|
Gt(ROSA)26Sortm1(tTA)Roos/?
Tg(tetO/CMV-Dek,-luc)317Siwe/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
|
no abnormal phenotype detected |
J:261249
|
Gt(ROSA)26Sortm1(tTA,CMV*1-Rheb,-EGFP)Gtm/Gt(ROSA)26Sor+
Not Specified
|
no abnormal phenotype detected |
J:176586
|
Gt(ROSA)26Sortm1(tTA,CMV*1-Rheb,-EGFP)Gtm/Gt(ROSA)26Sor+
Not Specified
|
normal
nervous system phenotype |
J:176586
|
Gt(ROSA)26Sortm1(tTA,CMV*1-Rheb,-EGFP)Gtm/Gt(ROSA)26Sor+
Tg(GFAP-cre)#Gtm/0
involves: C57BL/6 * CBA
|
abnormal astrocyte physiology |
J:176586
|
|
normal
growth/size/body region phenotype |
J:176586
|
|
normal
nervous system phenotype |
J:176586
|
Gt(ROSA)26Sortm1(tTA,tetO-Mir21)Fjsl/Gt(ROSA)26Sor+
Tg(Nes-cre)1Wmz/0
involves: C57BL/6 * C57BL/6J * SJL/J
|
abnormal bone marrow morphology |
J:163919
|
|
abnormal spleen morphology |
J:163919
|
|
abnormal thymus corticomedullary boundary morphology |
J:163919
|
|
abnormal thymus morphology |
J:163919
|
|
abnormal tumor morphology |
J:163919
|
|
anemia |
J:163919
|
|
decreased erythrocyte cell number |
J:163919
|
|
decreased hemoglobin content |
J:163919
|
|
decreased leukocyte cell number |
J:163919
|
|
enlarged lymph nodes |
J:163919
|
|
enlarged spleen |
J:163919
|
|
enlarged thymus |
J:163919
|
|
hindlimb paresis |
J:163919
|
|
hunched posture |
J:163919
|
|
increased lymphoma incidence |
J:163919
|
|
increased tumor incidence |
J:163919
|
|
intermingled spleen red and white pulp |
J:163919
|
|
premature death |
J:163919
|
|
respiratory distress |
J:163919
|
|
ruffled hair |
J:163919
|
Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/Gt(ROSA)26Sor+
Tg(Nes-cre)1Wmz/0
involves: 129 * C57BL/6 * FVB/N * SJL/J
|
abnormal coat appearance |
J:185598
|
|
abnormal immune system morphology |
J:185598
|
|
ataxia |
J:185598
|
|
enlarged liver |
J:185598
|
|
enlarged lymph nodes |
J:185598
|
|
enlarged spleen |
J:185598
|
|
hindlimb paresis |
J:185598
|
|
hunched posture |
J:185598
|
|
increased apoptosis |
J:185598
|
|
increased B cell derived lymphoma incidence |
J:185598
|
|
increased spleen weight |
J:185598
|
|
increased spleen white pulp amount |
J:185598
|
|
normal
nervous system phenotype |
J:185598
|
|
premature death |
J:185598
|
|
respiratory distress |
J:185598
|
|
thymus hyperplasia |
J:185598
|
|
tumor regression |
J:185598
|
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J
|
increased pancreatic ductal adenocarcinoma incidence |
J:140423
|
|
premature death |
J:140423
|
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129S6/SvEvTac * C57BL/6J
|
increased incidence of induced tumors |
J:140423
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:140423
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:140423
|
Gt(ROSA)26Sortm1(uprt)Tnr/Gt(ROSA)26Sortm1(uprt)Tnr
C57BL/6-Gt(ROSA)26Sortm1(uprt)Tnr
|
no abnormal phenotype detected |
J:82809
|
Gt(ROSA)26Sortm1(Vegfa*)Jhai/Gt(ROSA)26Sor+
Tg(Col2a1-cre)1Bhr/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * ICR * SJL
|
abnormal bone marrow cavity morphology |
J:156474
|
|
abnormal bone ossification |
J:156474
|
|
abnormal bone structure |
J:156474
|
|
abnormal long bone diaphysis morphology |
J:156474
|
|
abnormal long bone morphology |
J:156474
|
|
abnormal rib morphology |
J:156474
|
|
decreased width of hypertrophic chondrocyte zone |
J:156474
|
|
perinatal lethality, complete penetrance |
J:156474
|
Gt(ROSA)26Sortm1(Vegfa*)Jhai/Gt(ROSA)26Sor+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129S1/Sv * 129X1/SvJ * CD-1 * ICR
|
abnormal bone ossification |
J:156474
|
|
abnormal bone structure |
J:156474
|
Gt(ROSA)26Sortm1(Vegfa*)Jhai/Gt(ROSA)26Sor+
Kdrtm1Wag/Kdrtm1Wag
Tg(Col2a1-cre)1Bhr/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * ICR * SJL
|
abnormal blood vessel morphology |
J:156474
|
|
abnormal bone structure |
J:156474
|
|
abnormal long bone diaphysis morphology |
J:156474
|
|
abnormal skeleton development |
J:156474
|
|
increased bone mass |
J:156474
|
|
normal
skeleton phenotype |
J:156474
|
Gt(ROSA)26Sortm1(Wnk1)Clhu/Gt(ROSA)26Sor+
Kdrtm1(cre)Sato/Kdr+
Wnk1Gt(OST38262)Lex/Wnk1Gt(OST38262)Lex
involves: 129S1/Sv * 129S5/SvEvBrd
|
abnormal embryo development |
J:152906
|
|
normal
cardiovascular system phenotype |
J:152906
|
Gt(ROSA)26Sortm1(Wnk1)Clhu/Gt(ROSA)26Sor+
Wnk1Gt(OST38262)Lex/Wnk1Gt(OST38262)Lex
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S5/SvEvBrd * C57BL/6 * CBA
|
embryonic lethality during organogenesis |
J:152906
|
Gt(ROSA)26Sortm1(Wnk1)Clhu/Gt(ROSA)26Sor+
Wnk1Gt(OST38262)Lex/Wnk1Gt(OST38262)Lex
Tg(Tek-cre)12Flv/0
involves: 129S5/SvEvBrd * C3H * C57BL/6
|
abnormal embryo development |
J:152906
|
|
normal
cardiovascular system phenotype |
J:152906
|
|
neonatal lethality, complete penetrance |
J:152906
|
Gt(ROSA)26Sortm1(Wnt4)Bhr/Gt(ROSA)26Sor+
Tg(Col2a1-cre)1Bhr/0
involves: 129S7/SvEvBrd * C57BL/6 * SJL
|
abnormal bone marrow morphology |
J:129327
|
|
abnormal cartilage morphology |
J:129327
|
|
abnormal chondrocyte morphology |
J:129327
|
|
abnormal craniofacial bone morphology |
J:129327
|
|
abnormal pubis morphology |
J:129327
|
|
axial skeleton hypoplasia |
J:129327
|
|
decreased body weight |
J:129327
|
|
decreased chondrocyte proliferation |
J:129327
|
|
decreased locomotor activity |
J:129327
|
|
delayed endochondral bone ossification |
J:129327
|
|
disorganized long bone epiphyseal plate |
J:129327
|
|
disproportionate dwarf |
J:129327
|
|
domed cranium |
J:129327
|
|
increased width of hypertrophic chondrocyte zone |
J:129327
|
|
kyphosis |
J:129327
|
|
long incisors |
J:129327
|
|
short limbs |
J:129327
|
|
short lumbar vertebrae |
J:129327
|
|
short nasal bone |
J:129327
|
|
small frontal bone |
J:129327
|
|
small occipital bone |
J:129327
|
Gt(ROSA)26Sortm1.1(Aco1*)Mwh/Gt(ROSA)26Sortm1.1(Aco1*)Mwh
B6.129P2(129S1)-Gt(ROSA)26Sortm1.1(Aco1*)Mwh
|
abnormal erythropoiesis |
J:196374
|
|
decreased erythrocyte cell number |
J:196374
|
|
decreased hematocrit |
J:196374
|
|
decreased hemoglobin content |
J:196374
|
|
normal
homeostasis/metabolism phenotype |
J:196374
|
|
increased intestinal iron level |
J:196374
|
|
increased liver iron level |
J:196374
|
|
increased mean corpuscular hemoglobin |
J:196374
|
|
increased mean corpuscular volume |
J:196374
|
|
increased spleen iron level |
J:196374
|
|
normal
mortality/aging |
J:196374
|
Gt(ROSA)26Sortm1.1(Alb-PCSK9)Mby/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6N
|
normal
growth/size/body region phenotype |
J:280156
|
|
increased circulating cholesterol level |
J:280156
|
|
increased circulating LDL cholesterol level |
J:280156
|
Gt(ROSA)26Sortm1.1(birA)Mejr/Gt(ROSA)26Sortm1.1(birA)Mejr
Tbx20tm2Ccai/Tbx20tm2Ccai
involves: 129P2/OlaHsd
|
no abnormal phenotype detected |
J:198628
|
Gt(ROSA)26Sortm1.1(CAG-ATP1A3*D591V,-EGFP)Bcgen/Gt(ROSA)26Sor+
involves: C57BL/6
|
abnormal eye physiology |
J:319361
|
|
decreased a-wave amplitude |
J:319361
|
|
decreased b-wave amplitude |
J:319361
|
Gt(ROSA)26Sortm1.1(CAG-cas9*,-EGFP)Fezh/Gt(ROSA)26Sortm1.1(CAG-cas9*,-EGFP)Fezh
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm1.1(CAG-COX8A/Dendra2)Dcc/Gt(ROSA)26Sor+
Mfn1tm2Dcc/Mfn1tm2Dcc
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: 129 * 129S6/SvEvTac * C57BL/6J * SJL/J
|
no abnormal phenotype detected |
J:188347
|
Gt(ROSA)26Sortm1.1(CAG-COX8A/Dendra2)Dcc/Gt(ROSA)26Sor+
Mfn2tm3Dcc/Mfn2tm3Dcc
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: 129 * 129S6/SvEvTac * C57BL/6J * SJL/J
|
abnormal axonal transport |
J:188347
|
|
abnormal dopaminergic neuron morphology |
J:188347
|
|
abnormal innervation |
J:188347
|
|
abnormal mitochondrial morphology |
J:188347
|
|
abnormal striatum morphology |
J:188347
|
|
bradykinesia |
J:188347
|
|
decreased body size |
J:188347
|
|
decreased body weight |
J:188347
|
|
decreased locomotor activity |
J:188347
|
|
decreased vertical activity |
J:188347
|
|
hunched posture |
J:188347
|
|
kyphosis |
J:188347
|
|
loss of dopaminergic neurons |
J:188347
|
|
neurodegeneration |
J:188347
|
|
premature death |
J:188347
|
Gt(ROSA)26Sortm1.1(CAG-COX8A/Dendra2)Dcc/Gt(ROSA)26Sor+
MffGt(AZ0438)Wtsi/MffGt(AZ0438)Wtsi
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * C57BL/6J
|
abnormal mitochondrial morphology |
J:301349
|
|
abnormal sperm connecting piece morphology |
J:301349
|
|
abnormal sperm midpiece morphology |
J:301349
|
|
abnormal sperm mitochondrial sheath morphology |
J:301349
|
|
abnormal sperm principal piece morphology |
J:301349
|
|
abnormal spermatid morphology |
J:301349
|
|
asthenozoospermia |
J:301349
|
|
decreased fertilization frequency |
J:301349
|
|
decreased mitochondrial number |
J:301349
|
|
kinked sperm flagellum |
J:301349
|
Gt(ROSA)26Sortm1.1(CAG-COX8A/Dendra2)Dcc/Gt(ROSA)26Sortm1.1(CAG-COX8A/Dendra2)Dcc
involves: 129S6/SvEvTac * C57BL/6
|
no abnormal phenotype detected |
J:183306
|
Gt(ROSA)26Sortm1.1(CAG-EGFP)Fsh/Gt(ROSA)26Sor+
Nkx6-2tm1Qiu/Nkx6-2tm1(cre/ERT2)Fsh
involves: 129S6/SvEvTac * C57BL/6 * Swiss Webster
|
abnormal brain interneuron morphology |
J:155164
|
Gt(ROSA)26Sortm1.1(CAG-EGFP/Rpl10a,-birA)Wtp/Gt(ROSA)26Sortm1.1(CAG-EGFP/Rpl10a,-birA)Wtp
involves: 129S4/SvJae * C57BL/6J
|
no abnormal phenotype detected |
J:101977,
J:201159
|
Gt(ROSA)26Sortm1.1(CAG-Fto)Rdc/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL
|
abnormal circulating lipid level |
J:166829
|
|
abnormal hormone level |
J:166829
|
|
decreased adiponectin level |
J:166829
|
|
decreased circulating LDL cholesterol level |
J:166829
|
|
increased abdominal fat pad weight |
J:166829
|
|
increased body weight |
J:166829
|
|
increased circulating free fatty acids level |
J:166829
|
|
increased circulating HDL cholesterol level |
J:166829
|
|
increased circulating leptin level |
J:166829
|
|
increased circulating triglyceride level |
J:166829
|
|
increased food intake |
J:166829
|
|
increased lean body mass |
J:166829
|
|
increased susceptibility to diet-induced obesity |
J:166829
|
|
increased total body fat amount |
J:166829
|
Gt(ROSA)26Sortm1.1(CAG-Fto)Rdc/Gt(ROSA)26Sortm1.1(CAG-Fto)Rdc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL
|
abnormal circulating lipid level |
J:166829
|
|
abnormal hormone level |
J:166829
|
|
decreased adiponectin level |
J:166829
|
|
decreased circulating LDL cholesterol level |
J:166829
|
|
decreased circulating leptin level |
J:166829
|
|
impaired glucose tolerance |
J:166829
|
|
increased abdominal fat pad weight |
J:166829
|
|
increased body weight |
J:166829
|
|
increased circulating free fatty acids level |
J:166829
|
|
increased circulating HDL cholesterol level |
J:166829
|
|
increased circulating insulin level |
J:166829
|
|
increased circulating triglyceride level |
J:166829
|
|
increased energy expenditure |
J:166829
|
|
increased food intake |
J:166829
|
|
increased lean body mass |
J:166829
|
|
increased susceptibility to diet-induced obesity |
J:166829
|
|
increased total body fat amount |
J:166829
|
Gt(ROSA)26Sortm1.1(CAG-Insc/GFP)Jakn/Gt(ROSA)26Sor+
involves: C57BL/6
|
increased neuronal precursor cell number |
J:178712
|
Gt(ROSA)26Sortm1.1(CAG-Mirc20)Eem/Gt(ROSA)26Sor+
Nkx2-5tm1(cre)Rjs/Nkx2-5+
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal myocardial fiber morphology |
J:233994
|
|
abnormal myocardial fiber physiology |
J:233994
|
|
decreased cardiac muscle contractility |
J:233994
|
|
decreased myocardial fiber size |
J:233994
|
|
enlarged heart |
J:233994
|
|
increased cardiomyocyte apoptosis |
J:233994
|
|
increased fetal cardiomyocyte proliferation |
J:233994
|
|
increased heart weight |
J:233994
|
|
premature death |
J:233994
|
Gt(ROSA)26Sortm1.1(CAG-Mirc20)Eem/Gt(ROSA)26Sor+
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+
involves: 129 * C57BL/6 * FVB/N
|
abnormal myocardial fiber morphology |
J:233994
|
|
abnormal myocardial fiber physiology |
J:233994
|
|
abnormal response to cardiac infarction |
J:233994
|
|
decreased cardiomyocyte apoptosis |
J:233994
|
|
decreased myocardial fiber size |
J:233994
|
|
increased heart weight |
J:233994
|
|
increased myocardial fiber number |
J:233994
|
Gt(ROSA)26Sortm1.1(CAG-PLS3,-GFP)Bwir/Gt(ROSA)26Sor+
Smn1tm1Hung/Smn1+
Tg(SMN2)2Hung/0
B6N.Cg-Gt(ROSA)26Sortm1.1(CAG-PLS3,-GFP)Bwir Smn1tm1Hung Tg(SMN2)2Hung
|
abnormal motor neuron morphology |
J:193844
|
|
abnormal neuromuscular synapse morphology |
J:193844
|
Gt(ROSA)26Sortm1.1(CAG-PLS3,-GFP)Bwir/Gt(ROSA)26Sor+
Smn1tm1Hung/Smn1tm1Hung
Tg(SMN2)2Hung/0
B6N.Cg-Gt(ROSA)26Sortm1.1(CAG-PLS3,-GFP)Bwir Smn1tm1Hung Tg(SMN2)2Hung
|
abnormal motor capabilities/coordination/movement |
J:193844
|
|
abnormal motor neuron morphology |
J:193844
|
|
abnormal neuromuscular synapse morphology |
J:193844
|
|
abnormal proprioceptive neuron morphology |
J:193844
|
|
decreased body weight |
J:193844
|
|
impaired righting response |
J:193844
|
|
increased skeletal muscle fiber size |
J:193844
|
|
premature death |
J:193844
|
Gt(ROSA)26Sortm1.1(CAG-PLS3,-GFP)Bwir/Gt(ROSA)26Sor+
Smn1tm1Hung/Smn1tm1Hung
Tg(SMN2)2Hung/0
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N
|
abnormal colon morphology |
J:193844
|
|
abnormal heart morphology |
J:193844
|
|
abnormal intestinal mucosa morphology |
J:193844
|
|
abnormal lung morphology |
J:193844
|
|
abnormal motor capabilities/coordination/movement |
J:193844
|
|
abnormal pulmonary alveolus morphology |
J:193844
|
|
abnormal pulmonary interalveolar septum morphology |
J:193844
|
|
abnormal small intestinal villus morphology |
J:193844
|
|
abnormal small intestine morphology |
J:193844
|
|
abnormal synaptic vesicle number |
J:193844
|
|
decreased body weight |
J:193844
|
|
decreased small intestinal villus size |
J:193844
|
|
emphysema |
J:193844
|
|
impaired righting response |
J:193844
|
|
normal
nervous system phenotype |
J:193844
|
|
premature death |
J:193844
|
|
small heart |
J:193844
|
|
thin interventricular septum |
J:193844
|
Gt(ROSA)26Sortm1.1(CAG-PSTPIP1)Dtg/Gt(ROSA)26Sor+
involves: BALB/cJ * C57BL/6
|
normal
immune system phenotype |
J:196002
|
Gt(ROSA)26Sortm1.1(CAG-SPAST*C448Y)Baas/Gt(ROSA)26Sor+
involves: C57BL/6N
|
abnormal axon morphology |
J:273408
|
|
abnormal axonal transport |
J:273408
|
|
abnormal corticospinal tract morphology |
J:273408
|
|
abnormal gait |
J:273408
|
|
abnormal spinal cord morphology |
J:273408
|
|
axon degeneration |
J:273408
|
|
limb grasping |
J:273408
|
|
tremors |
J:273408
|
|
weight loss |
J:273408
|
Gt(ROSA)26Sortm1.1(CAG-SPAST*C448Y)Baas/Gt(ROSA)26Sortm1.1(CAG-SPAST*C448Y)Baas
involves: C57BL/6N
|
abnormal axon morphology |
J:273408
|
|
abnormal axonal transport |
J:273408
|
|
abnormal corticospinal tract morphology |
J:273408
|
|
abnormal gait |
J:273408
|
|
abnormal spinal cord morphology |
J:273408
|
|
axon degeneration |
J:273408
|
|
limb grasping |
J:273408
|
|
tremors |
J:273408
|
|
weight loss |
J:273408
|
Gt(ROSA)26Sortm1.1(CAG-tdTomato,-EGFP)Pjen/Gt(ROSA)26Sortm1.1(CAG-tdTomato,-EGFP)Pjen
B6.Cg-Gt(ROSA)26Sortm1.1(CAG-tdTomato,-EGFP)Pjen
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm1.1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sortm1.1(CAG-Trp53*,-EGFP)Medz
involves: C57BL/6
|
decreased thymocyte apoptosis |
J:158953
|
Gt(ROSA)26Sortm1.1(CAG-Upp1,-GFP)Gp/Gt(ROSA)26Sor+
involves: C57BL/6 * FVB/N
|
decreased fatty acid beta-oxidation |
J:195165
|
|
microvesicular hepatic steatosis |
J:195165
|
Gt(ROSA)26Sortm1.1(CAG-Venus,-Sdk2)Jrs/Gt(ROSA)26Sor+
Sdk2tm1.1(cre/ERT2)Jrs/Sdk2tm1.1(cre/ERT2)Jrs
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2
|
abnormal eye electrophysiology |
J:225578
|
Gt(ROSA)26Sortm1.1(CAG-YFP/DROSHA*E1147K)Gess/Gt(ROSA)26Sortm1.1(CAG-YFP/DROSHA*E1147K)Gess
Tg(Six2-EGFP/cre)1Amc/0
involves: 129S6/SvEvTac * C57BL/6 * CD-1
|
abnormal nephrogenic zone morphology |
J:321428
|
|
abnormal renal tubule morphology |
J:321428
|
|
absent kidney |
J:321428
|
|
glomerulosclerosis |
J:321428
|
|
increased kidney apoptosis |
J:321428
|
|
increased urine protein level |
J:321428
|
|
normal
mortality/aging |
J:321428
|
|
normal
neoplasm |
J:321428
|
|
postnatal growth retardation |
J:321428
|
|
renal hypoplasia |
J:321428
|
Gt(ROSA)26Sortm1.1(CMV-luc,-ALPP)Cklr/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
no abnormal phenotype detected |
J:157754
|
Gt(ROSA)26Sortm1.1(Ctnna3,EGFP)Jvh/Gt(ROSA)26Sortm1.1(Ctnna3,EGFP)Jvh
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
abnormal placenta physiology |
J:187209
|
|
decreased trophoblast giant cell number |
J:187209
|
|
increased trophoblast giant cell number |
J:187209
|
|
normal
mortality/aging |
J:187209
|
Gt(ROSA)26Sortm1.1(DUX4*)Plj/Gt(ROSA)26Sor+
B6(Cg)-Gt(ROSA)26Sortm1.1(DUX4*)Plj
|
alopecia |
J:256652
|
|
decreased body weight |
J:256652
|
|
enlarged lymph nodes |
J:256652
|
|
enlarged popliteal lymph nodes |
J:256652
|
|
normal
muscle phenotype |
J:256652
|
|
postnatal growth retardation |
J:256652
|
Gt(ROSA)26Sortm1.1(DUX4*)Plj/Gt(ROSA)26Sor+
Tg(ACTA1-cre)79Jme/0
involves: C57BL/6 * SJL
|
abnormal limb morphology |
J:256652
|
|
abnormal spinal cord morphology |
J:256652
|
|
decreased fetal size |
J:256652
|
|
perinatal lethality |
J:256652
|
|
small thoracic cage |
J:256652
|
Gt(ROSA)26Sortm1.1(DUX4*)Plj/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/0
involves: C57BL/6 * CBA
|
embryonic lethality, complete penetrance |
J:256652
|
Gt(ROSA)26Sortm1.1(DUX4*)Plj/Gt(ROSA)26Sor+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * C57BL/6
|
alopecia |
J:256652
|
|
ataxia |
J:256652
|
|
enlarged lymph nodes |
J:256652
|
|
enlarged popliteal lymph nodes |
J:256652
|
|
impaired righting response |
J:256652
|
|
kyphosis |
J:256652
|
|
retarded hair growth |
J:256652
|
|
seizures |
J:256652
|
|
tremors |
J:256652
|
Gt(ROSA)26Sortm1.1(DUX4*)Plj/Gt(ROSA)26Sor+
Pax7tm1(cre/ERT2)Gaka/?
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl
|
no abnormal phenotype detected |
J:256652
|
Gt(ROSA)26Sortm1.1(DUX4*)Plj/Gt(ROSA)26Sor+
Tg(ACTA1-cre/Esr1*)2Kesr/0
involves: C3H * C57BL/6
|
ataxia |
J:256652
|
|
centrally nucleated skeletal muscle fibers |
J:256652
|
|
decreased grip strength |
J:256652
|
|
decreased skeletal muscle fiber size |
J:256652
|
|
dystrophic muscle |
J:256652
|
|
increased acute inflammation |
J:256652
|
|
increased variability of skeletal muscle fiber size |
J:256652
|
|
myopathy |
J:256652
|
|
skeletal muscle fibrosis |
J:256652
|
|
skeletal muscle necrosis |
J:256652
|
|
weight loss |
J:256652
|
Gt(ROSA)26Sortm1.1(DUX4*)Plj/Gt(ROSA)26Sortm1.1(DUX4*)Plj
B6(Cg)-Gt(ROSA)26Sortm1.1(DUX4*)Plj
|
abnormal defecation |
J:256652
|
|
alopecia |
J:256652
|
|
decreased body weight |
J:256652
|
|
normal
muscle phenotype |
J:256652
|
|
preputial gland inflammation |
J:256652
|
|
rectal prolapse |
J:256652
|
Gt(ROSA)26Sortm1.1(FLII)Hdc/Gt(ROSA)26Sortm1.1(FLII)Hdc
involves: 129S1/Sv * 129X1/SvJ * BALB/c
|
impaired wound healing |
J:168970
|
Gt(ROSA)26Sortm1.1(Loxl2)Acan/Gt(ROSA)26Sortm1.1(Loxl2)Acan
Not Specified
|
abnormal epididymis epithelium morphology |
J:220689
|
|
abnormal epididymis morphology |
J:220689
|
|
abnormal keratinocyte differentiation |
J:220689
|
|
abnormal seminiferous tubule morphology |
J:220689
|
|
abnormal tumor pathology |
J:220689
|
|
decreased tumor latency |
J:220689
|
|
epididymis fibrosis |
J:220689
|
|
epididymis hypertrophy |
J:220689
|
|
epididymis inflammation |
J:220689
|
|
increased epididymal cell proliferation |
J:220689
|
|
increased epididymal epithelium cell proliferation |
J:220689
|
|
increased incidence of tumors by chemical induction |
J:220689
|
|
increased inflammatory response |
J:220689
|
|
male infertility |
J:220689
|
|
spermatocele |
J:220689
|
|
testis degeneration |
J:220689
|
Gt(ROSA)26Sortm1.1(Lyn/Celsr1/EGFP)Rodr/Gt(ROSA)26Sor+
involves: FVB/N
|
abnormal anterior visceral endoderm cell migration |
J:170681
|
Gt(ROSA)26Sortm1.1(Lyn/Celsr1/EGFP)Rodr/Gt(ROSA)26Sortm1.1(Lyn/Celsr1/EGFP)Rodr
involves: FVB/N
|
abnormal anterior visceral endoderm cell migration |
J:170681
|
Gt(ROSA)26Sortm1.1(Maml1/EGFP)Hri/?
Foxa2tm3.1(icre)Heli/Foxa2+
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
abnormal pancreas development |
J:184814
|
|
abnormal pancreatic beta cell differentiation |
J:184814
|
Gt(ROSA)26Sortm1.1(Mir26a-1)Coh/?
involves: 129 * C57BL/6
|
abnormal endocrine pancreas development |
J:201964
|
|
increased pancreatic islet number |
J:201964
|
Gt(ROSA)26Sortm1.1(Mir26a-1)Coh/Gt(ROSA)26Sor+
Tg(Ins2-cre)25Mgn/0
involves: C57BL/6 * DBA
|
decreased circulating insulin level |
J:286108
|
|
decreased fasting circulating glucose level |
J:286108
|
|
decreased insulin secretion |
J:286108
|
|
decreased pancreatic beta cell mass |
J:286108
|
|
decreased susceptibility to diet-induced obesity |
J:286108
|
|
improved glucose tolerance |
J:286108
|
|
increased insulin sensitivity |
J:286108
|
|
small pancreatic islets |
J:286108
|
Gt(ROSA)26Sortm1.1(MYC/ERT2)Gev/Gt(ROSA)26Sortm1.1(MYC/ERT2)Gev
involves: C57BL/6 * FVB/N
|
increased apoptosis |
J:142030
|
|
increased cell proliferation |
J:142030
|
Gt(ROSA)26Sortm1.1(Otx2)Daac/Gt(ROSA)26Sor+
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
decreased susceptibility to dopaminergic neuron neurotoxicity |
J:166896
|
Gt(ROSA)26Sortm1.1(Otx2)Daac/Gt(ROSA)26Sortm1.1(Otx2)Daac
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
decreased dopaminergic neuron number |
J:166896
|
|
decreased susceptibility to dopaminergic neuron neurotoxicity |
J:166896
|
Gt(ROSA)26Sortm1.1(Otx2)Daac/Gt(ROSA)26Sortm1.1(Otx2)Daac
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
Tg(CAG-Otx2,-GFP)21Asim/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
decreased dopaminergic neuron number |
J:166896
|
|
decreased susceptibility to dopaminergic neuron neurotoxicity |
J:166896
|
Gt(ROSA)26Sortm1.1(PDGFB)Cbet/Gt(ROSA)26Sortm1.1(PDGFB)Cbet
involves: 129X1/SvJ * C57BL/6 * SJL
|
abnormal embryonic hematopoiesis |
J:138069
|
|
abnormal vitelline vascular remodeling |
J:138069
|
Gt(ROSA)26Sortm1.1(Phc2*,EGFP)Hko/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ
|
cervical vertebral fusion |
J:204987
|
|
cervical vertebral transformation |
J:204987
|
|
increased rib number |
J:204987
|
|
lumbar vertebral transformation |
J:204987
|
|
thoracic vertebral transformation |
J:204987
|
|
vertebral transformation |
J:204987
|
Gt(ROSA)26Sortm1.1(rtTA2S*M2)Whsu/Gt(ROSA)26Sor+
Ncstntm1.1Akli/Ncstntm1.1Akli
Tg(tetO-cre)1Jaw/0
involves: 129 * 129S6/SvEvTac * C57BL/6
|
hydronephrosis |
J:227748
|
|
increased urinary bladder carcinoma incidence |
J:227748
|
|
ureter obstruction |
J:227748
|
Gt(ROSA)26Sortm1.1(rtTA2S*M2)Whsu/Gt(ROSA)26Sortm1.1(rtTA2S*M2)Whsu
involves: 129S6/SvEvTac
|
no abnormal phenotype detected |
J:99718
|
Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy/Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy
Smn1tm1Msd/Smn1+
Tg(SMN2)#Ahmb/Tg(SMN2)#Ahmb
Tg(SMN2*delta7)4299Ahmb/Tg(SMN2*delta7)4299Ahmb
Tg(tetO-SMN2,-luc)#aAhmb/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * FVB
|
abnormal ear morphology |
J:174960
|
|
abnormal intestine morphology |
J:174960
|
|
normal
behavior/neurological phenotype |
J:174960
|
|
decreased body size |
J:174960
|
|
decreased locomotor activity |
J:174960
|
|
normal
nervous system phenotype |
J:174960
|
|
postnatal lethality, complete penetrance |
J:174960
|
|
premature death |
J:174960
|
Gt(ROSA)26Sortm1.1(rtTA,tetO-cre)Bkmn/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ
|
no abnormal phenotype detected |
J:159515
|
Gt(ROSA)26Sortm1.1(Sall1)Ryn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6
|
decreased body weight |
J:162052
|
Gt(ROSA)26Sortm1.1(Sstr3/GFP)Bky/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac * FVB/N
|
asthenozoospermia |
J:199240
|
|
hairpin sperm flagellum |
J:199240
|
|
male infertility |
J:199240
|
|
normal
reproductive system phenotype |
J:199240
|
Gt(ROSA)26Sortm1.1(Ubc-BCL3)Sbn/Gt(ROSA)26Sor+
Cd79atm1(cre)Reth/Cd79a+
involves: BALB/c * C57BL/6
|
decreased B cell proliferation |
J:207111
|
|
decreased follicular B cell number |
J:207111
|
|
decreased marginal zone B cell number |
J:207111
|
|
increased follicular B cell number |
J:207111
|
Gt(ROSA)26Sortm1.1(Ubc-ROCK1*)Dnsh/Gt(ROSA)26Sor+
Tg(NPHS2-icre/ERT2)1Dnsh/0
involves: C57BL/6
|
abnormal podocyte foot process morphology |
J:182287
|
|
albuminuria |
J:182287
|
|
expanded mesangial matrix |
J:182287
|
|
podocyte foot process effacement |
J:182287
|
Gt(ROSA)26Sortm1.1(Wls/YFP)Mbtr/Gt(ROSA)26Sor+
involves: C57BL/6
|
decreased neutrophil cell number |
J:202499
|
Gt(ROSA)26Sortm1.1Fia/Gt(ROSA)26Sor+
involves: 129/Sv * C57BL/6
|
no abnormal phenotype detected |
J:114455
|
Gt(ROSA)26Sortm1.1Hjf/Gt(ROSA)26Sor+
involves: C57BL/6
|
no abnormal phenotype detected |
J:117041
|
Gt(ROSA)26Sortm1.1Hjf/Gt(ROSA)26Sortm1.1Hjf
involves: C57BL/6
|
no abnormal phenotype detected |
J:117041
|
Gt(ROSA)26Sortm1.1Ksvo/Gt(ROSA)26Sortm1.1Ksvo
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm1.1Lrsn/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
no abnormal phenotype detected |
J:176022
|
Gt(ROSA)26Sortm1.1Sia/Gt(ROSA)26Sortm1.1Sia
involves: C57BL/6 * CBA * FVB/N
|
no abnormal phenotype detected |
J:173653
|
Gt(ROSA)26Sortm1.2(CAG-PLS3,-GFP)Bwir/Gt(ROSA)26Sor+
B6N.Cg-Gt(ROSA)26Sortm1.1(CAG-PLS3,-GFP)Bwir
|
decreased bone resorption |
J:267292
|
|
decreased bone trabecula number |
J:267292
|
|
decreased osteoclast cell number |
J:267292
|
|
increased bone stiffness |
J:267292
|
|
increased bone strength |
J:267292
|
|
increased bone trabecular spacing |
J:267292
|
|
increased compact bone thickness |
J:267292
|
Gt(ROSA)26Sortm1.2(CAG-tdTomato,-EGFP)Pjen/Gt(ROSA)26Sortm1.2(CAG-tdTomato,-EGFP)Pjen
B6.Cg-Gt(ROSA)26Sortm1.2(CAG-tdTomato,-EGFP)Pjen
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm1.3(CAG-mTFP1)Imayo/Gt(ROSA)26Sortm1.3(CAG-mTFP1)Imayo
involves: 129S6/SvEvTac
|
no abnormal phenotype detected |
J:182745
|
Gt(ROSA)26Sortm1.3(CAG-tdTomato,-EGFP)Pjen/Gt(ROSA)26Sortm1.3(CAG-tdTomato,-EGFP)Pjen
B6.Cg-Gt(ROSA)26Sortm1.3(CAG-tdTomato,-EGFP)Pjen
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm1Afst/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
no abnormal phenotype detected |
J:154134
|
Gt(ROSA)26Sortm1Fan/Gt(ROSA)26Sor+
Tg(T-cre)1Lwd/0
involves: C3H * C57BL/6 * C57BL/6J
|
cervical vertebral fusion |
J:197427
|
Gt(ROSA)26Sortm1Fan/Gt(ROSA)26Sortm1Fan
Tg(T-cre)1Lwd/0
involves: C3H * C57BL/6 * C57BL/6J
|
abnormal axial skeleton morphology |
J:197427
|
|
abnormal intervertebral disk morphology |
J:197427
|
|
abnormal posture |
J:197427
|
|
abnormal spinal cord morphology |
J:197427
|
|
decreased somite size |
J:197427
|
|
fused dorsal root ganglion |
J:197427
|
|
impaired somite development |
J:197427
|
|
kinked tail |
J:197427
|
|
neonatal lethality, complete penetrance |
J:197427
|
|
vertebral fusion |
J:197427
|
Gt(ROSA)26Sortm1Fia/Gt(ROSA)26Sor+
Nf1tm1Fcr/Nf1tm1Par
Tg(Tek-cre)1Ywa/0
involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal dorsal root ganglion morphology |
J:114455
|
|
abnormal spleen morphology |
J:114455
|
|
prenatal lethality, complete penetrance |
J:114455
|
Gt(ROSA)26Sortm1Fia/Gt(ROSA)26Sor+
Nf1tm1Par/Nf1tm1Par
Tg(Fabp7-cre,-lacZ)3Gtm/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA
|
decreased body weight |
J:138868
|
|
decreased circulating growth hormone level |
J:138868
|
|
small adenohypophysis |
J:138868
|
Gt(ROSA)26Sortm1Fia/Gt(ROSA)26Sor+
Hprt1tm1(CMV-cre)Brd/Hprt1+
Nf1tm1Fcr/Nf1tm1Fcr
involves: 129S/SvEv * 129S/SvEvBrd
|
abnormal dorsal root ganglion morphology |
J:114455
|
|
abnormal enzyme/coenzyme level |
J:114455
|
|
abnormal somatic sensory system morphology |
J:114455
|
|
abnormal sympathetic ganglion morphology |
J:114455
|
|
adrenal medulla hyperplasia |
J:114455
|
|
prenatal lethality, incomplete penetrance |
J:114455
|
Gt(ROSA)26Sortm1Fia/Gt(ROSA)26Sortm1Fia
Hprt1tm1(CMV-cre)Brd/Hprt1+
Nf1tm1Fcr/Nf1tm1Fcr
involves: 129S/SvEv * 129S/SvEvBrd
|
abnormal somatic sensory system morphology |
J:114455
|
Gt(ROSA)26Sortm1Hjf/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(CMV-cre)1Cgn/0
involves: 129X1/SvJ * BALB/cJ * C57BL/6
|
no abnormal phenotype detected |
J:117041
|
Gt(ROSA)26Sortm1Hjf/?
Tg(Lck-cre)548Jxm/0
involves: C57BL/6 * SJL
|
no abnormal phenotype detected |
J:117041
|
Gt(ROSA)26Sortm1Iaai/Gt(ROSA)26Sor+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * C57BL/6
|
abnormal bone marrow cell physiology |
J:196407
|
Gt(ROSA)26Sortm1Iaai/Gt(ROSA)26Sortm9(cre/ESR1)Arte
involves: C57BL/6 * C57BL/6NTac
|
abnormal bone marrow cell physiology |
J:196407
|
Gt(ROSA)26Sortm1Joe/Gt(ROSA)26Sortm1Joe
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
|
no abnormal phenotype detected |
J:135149
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA
|
abnormal leukocyte morphology |
J:202090
|
|
abnormal thymus physiology |
J:202090
|
|
anemia |
J:202090
|
|
arrested B cell differentiation |
J:202090
|
|
decreased B cell number |
J:202090
|
|
decreased double-positive T cell number |
J:202090
|
|
decreased mature B cell number |
J:202090
|
|
decreased pre-B cell number |
J:202090
|
|
decreased pro-B cell number |
J:202090
|
|
distended abdomen |
J:202090
|
|
enlarged kidney |
J:202090
|
|
enlarged liver |
J:202090
|
|
enlarged lymph nodes |
J:202090
|
|
enlarged spleen |
J:202090
|
|
enlarged thymus |
J:202090
|
|
increased acute lymphoblastic leukemia incidence |
J:202090
|
|
increased CD8-positive, alpha-beta T cell number |
J:202090
|
|
increased inflammatory response |
J:202090
|
|
increased large unstained cell number |
J:202090
|
|
increased leukocyte cell number |
J:202090
|
|
increased single-positive T cell number |
J:202090
|
|
intermingled spleen red and white pulp |
J:202090
|
|
intestinal inflammation |
J:202090
|
|
kidney inflammation |
J:202090
|
|
lethargy |
J:202090
|
|
liver inflammation |
J:202090
|
|
meningitis |
J:202090
|
|
premature death |
J:202090
|
|
respiratory distress |
J:202090
|
|
stomach inflammation |
J:202090
|
|
thrombocytopenia |
J:202090
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+
Tg(MMTV-cre)4Mam/0
involves: C57BL/6J * C57BL/6N * FVB/N
|
abnormal leukocyte morphology |
J:202090
|
|
abnormal thymus physiology |
J:202090
|
|
anemia |
J:202090
|
|
arrested B cell differentiation |
J:202090
|
|
decreased B cell number |
J:202090
|
|
decreased double-positive T cell number |
J:202090
|
|
decreased mature B cell number |
J:202090
|
|
decreased pre-B cell number |
J:202090
|
|
decreased pro-B cell number |
J:202090
|
|
distended abdomen |
J:202090
|
|
enlarged kidney |
J:202090
|
|
enlarged liver |
J:202090
|
|
enlarged lymph nodes |
J:202090
|
|
enlarged spleen |
J:202090
|
|
enlarged thymus |
J:202090
|
|
increased acute lymphoblastic leukemia incidence |
J:202090
|
|
increased CD8-positive, alpha-beta T cell number |
J:202090
|
|
increased inflammatory response |
J:202090
|
|
increased large unstained cell number |
J:202090
|
|
increased leukocyte cell number |
J:202090
|
|
increased single-positive T cell number |
J:202090
|
|
intermingled spleen red and white pulp |
J:202090
|
|
intestinal inflammation |
J:202090
|
|
kidney inflammation |
J:202090
|
|
lethargy |
J:202090
|
|
liver inflammation |
J:202090
|
|
meningitis |
J:202090
|
|
premature death |
J:202090
|
|
respiratory distress |
J:202090
|
|
stomach inflammation |
J:202090
|
|
thrombocytopenia |
J:202090
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+
Tg(Lck-icre)3779Nik/0
involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2
|
normal
immune system phenotype |
J:202090
|
|
normal
neoplasm |
J:202090
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo
Tg(MMTV-cre)4Mam/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB
|
abnormal common lymphocyte progenitor cell morphology |
J:202090
|
|
increased hematopoietic stem cell number |
J:202090
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo
Tg(Mx1-cre)1Cgn/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA
|
abnormal common lymphocyte progenitor cell morphology |
J:202090
|
|
increased hematopoietic stem cell number |
J:202090
|
Gt(ROSA)26Sortm1Lrsn/Gt(ROSA)26Sor+
Prkntm1Roo/Prkntm1Roo
Slc6a3tm1(cre)Lrsn/Slc6a3+
Tfamtm1Lrsn/Tfamtm1Lrsn
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
|
abnormal axonal transport |
J:176022
|
|
abnormal neuron morphology |
J:176022
|
|
loss of dopaminergic neurons |
J:176022
|
Gt(ROSA)26Sortm1Lrsn/Gt(ROSA)26Sor+
Slc6a3tm1(cre)Lrsn/Slc6a3+
Tfamtm1Lrsn/Tfamtm1Lrsn
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal locomotor behavior |
J:176022
|
|
abnormal mitochondrial physiology |
J:176022
|
|
abnormal neuron morphology |
J:176022
|
|
loss of dopaminergic neurons |
J:176022
|
|
muscle hypertonia |
J:176022
|
|
weight loss |
J:176022
|
Gt(ROSA)26Sortm1Lrsn/Gt(ROSA)26Sor+
Mfn2tm1.1Arte/Mfn2tm1.1Arte
Slc6a3tm1(cre)Lrsn/Slc6a3+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal dopaminergic neuron morphology |
J:188337
|
|
abnormal dorsal striatum morphology |
J:188337
|
|
abnormal mitochondrial shape |
J:188337
|
|
decreased mitochondrial number |
J:188337
|
|
increased mitochondrial size |
J:188337
|
Gt(ROSA)26Sortm1Maoh/Gt(ROSA)26Sortm1Maoh
involves: 129P2/OlaHsd * C57BL/6
|
no abnormal phenotype detected |
J:173808
|
Gt(ROSA)26Sortm1Phep/Gt(ROSA)26Sortm1Phep
involves: 129P2/OlaHsd * C57BL/6J
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm1Sho/Gt(ROSA)26Sor+
Wt1tm1(EGFP/cre)Wtp/Wt1+
Zfpm2tm1Sho/Zfpm2tm1Sho
involves: 129S1/Sv * 129S4/SvJaeSor
|
normal
cardiovascular system phenotype |
J:150452
|
Gt(ROSA)26Sortm1Sho/0
Itga5tm2Hyn/Itga5tm1Hyn
Itgavtm1Hyn/Itgavtm2Hyn
Tg(Tek-cre)1Ywa/0
involves: 129 * C57BL/6 * SJL
|
abnormal ascending aorta morphology |
J:161850
|
|
lethality throughout fetal growth and development, complete penetrance |
J:161850
|
|
patent ductus arteriosus |
J:161850
|
|
retroesophageal right subclavian artery |
J:161850
|
|
vascular ring |
J:161850
|
|
ventricular septal defect |
J:161850
|
Gt(ROSA)26Sortm1Sho/0
Itga5tm2Hyn/Itga5tm1Hyn
Itgavtm2Hyn/Itgav+
Tg(Tek-cre)1Ywa/0
involves: 129 * C57BL/6 * SJL
|
patent ductus arteriosus |
J:161850
|
|
postnatal lethality, incomplete penetrance |
J:161850
|
|
ventricular septal defect |
J:161850
|
Gt(ROSA)26Sortm1Sia/Gt(ROSA)26Sortm1Sia
involves: C57BL/6 * CBA
|
no abnormal phenotype detected |
J:173653
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Pax3Sp-d/Pax3Sp-d
Tg(Prrx1-cre)1Cjt/0
involves: 129S4/SvJaeSor * C57BL/6J * SJL/J
|
abnormal diaphragm morphology |
J:231793
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Mef2ctm1Eno/Mef2ctm1Jjs
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6J * CBA/J
|
normal
embryo phenotype |
J:122483
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Msx2tm1Rilm/Msx2tm1Rilm
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S4/SvJae * C57BL/6J * CBA/J
|
fused cornea and lens |
J:184697
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Pgap2clpex/Pgap2clpex
involves: 129S4/SvJaeSor * A/J * C57BL/6J * CBA/J
|
abnormal lateral nasal prominence morphology |
J:277316
|
|
abnormal medial nasal prominence morphology |
J:277316
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Ptf1atm1(cre)Cvw/Ptf1atm2Macd
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ
|
abnormal pancreas development |
J:125691
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Pms2tm2(cre)Lisk/Pms2tm2(cre)Lisk
involves: 129S4/SvJae * 129S4/SvJaeSor
|
abnormal mismatch repair |
J:204653
|
|
increased lung tumor incidence |
J:204653
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
HhatTg(TFAP2A-cre)1Will/HhatTg(TFAP2A-cre)1Will
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * CBA
|
abnormal cranial ganglia morphology |
J:190013
|
|
abnormal trigeminal ganglion morphology |
J:190013
|
|
small trigeminal ganglion |
J:190013
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Ndufs4tm1Rpa/Ndufs4tm1Rpa
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6
|
decreased locomotor activity |
J:161393
|
|
impaired coordination |
J:161393
|
|
limb grasping |
J:161393
|
|
respiratory distress |
J:161393
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tg(Sftpc-cre)1Blh/0
involves: 129S4/SvJaeSor * C57BL/6 * DBA/2
|
lung cyst |
J:170336
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Nr2f2tm2.1Tsa/Nr2f2tm2.1Tsa
Prox1tm3(cre/ERT2)Gco/Prox1+
involves: 129S1/Sv * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6
|
abnormal lymphatic vessel morphology |
J:158959
|
|
edema |
J:158959
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tbx5tm1.2Jse/Tbx5tm1.2Jse
Tg(Kcne1-cre/ERT2)1Imos/0
involves: 129S4/SvJaeSor * CD-1
|
normal
cardiovascular system phenotype |
J:190765
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Hsd11b2tm1(cre)Anft/Hsd11b2+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * SJL
|
no abnormal phenotype detected |
J:118075
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tg(Thy1-cre/ERT2,-EYFP)VGfng/0
involves: C57BL/6 * SJL
|
no abnormal phenotype detected |
J:122791
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tg(Thy1-cre/ERT2,-EYFP)AGfng/0
involves: C57BL/6 * SJL
|
no abnormal phenotype detected |
J:122791
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tg(Nphs1-cre)33Mska/0
Tg(Nphs1-IL2RA)18Mska/0
involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * DBA/2
|
abnormal glomerular capsule parietal layer morphology |
J:126591
|
|
abnormal podocyte morphology |
J:126591
|
|
abnormal renal glomerulus morphology |
J:126591
|
|
glomerulosclerosis |
J:126591
|
|
increased kidney cell proliferation |
J:126591
|
|
mesangiolysis |
J:126591
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tg(Ggt1-cre)M3Egn/?
involves: 129S4/SvJaeSor * C57BL/6 * SJL
|
no abnormal phenotype detected |
J:111660
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Isl1tm2Sev/Isl1tm2Sev
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA
|
abnormal dorsal root ganglion morphology |
J:141110
|
|
abnormal sensory neuron innervation pattern |
J:141110
|
|
abnormal trigeminal ganglion morphology |
J:141110
|
|
decreased chemical nociceptive threshold |
J:141110
|
|
dorsal root ganglion hypoplasia |
J:141110
|
|
neonatal lethality, complete penetrance |
J:141110
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Hesx1tm1(cre)Jpmb/Hesx1+
involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6 * FVB/N
|
no abnormal phenotype detected |
J:142649
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Hesx1tm1(cre)Jpmb/Hesx1tm1Icar
involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6
|
abnormal optic vesicle formation |
J:135132
|
|
abnormal telencephalon development |
J:135132
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Hesx1tm1(cre)Jpmb/Hesx1tm2Jpmb
involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6 * FVB/N
|
decreased forebrain size |
J:142649
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Hesx1tm1(cre)Jpmb/Hesx1tm3Jpmb
involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6 * FVB/N
|
decreased forebrain size |
J:142649
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Hprt1tm1(Pbsn*-cre/ERT2)Jir/Hprt1+
involves: 129P2/OlaHsd * 129S4/SvJaeSor
|
no abnormal phenotype detected |
J:144541
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tbx18tm4(cre)Akis/Tbx18+
Wt1tm1Jae/Wt1tm1Jae
involves: 129S4/SvJae
|
abnormal epicardium development |
J:147421
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Ptpn11tm1.1Rbns/Ptpn11tm1.1Rbns
H2az2Tg(Wnt1-cre)11Rth/H2az2+
B6.Cg-Ptpn11tm1.1Rbns Gt(ROSA)26Sortm1Sor H2az2Tg(Wnt1-cre)11Rth
|
decreased cardiac neural crest cell number |
J:150835
|
|
impaired cranial neural crest cell differentiation |
J:150835
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Pax7tm1.1Fan/Pax7tm2.1(cre/ERT2)Fan
involves: 129 * C57BL/6 * SJL
|
abnormal muscle regeneration |
J:150962
|
|
abnormal myogenesis |
J:150962
|
|
normal
muscle phenotype |
J:150962
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Resttm1.1Yasu/Resttm1.1Yasu
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * CBA/J
|
abnormal melanoblast morphology |
J:230341
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tg(Cck-cre)CKres/0
involves: 129S4/SvJaeSor * C57BL/6
|
decreased survivor rate |
J:154361
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tbx1tm3.1Bld/Tbx1tm6(cre)Bld
involves: 129S4/SvJaeSor * 129S7/SvEvBrd
|
abnormal lymphatic vessel morphology |
J:159824
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Sox11tm1.1Vlf/Sox11tm1.1Vlf
Sox4tm1Vlf/Sox4tm1Vlf
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129 * C57BL/6 * C57BL/6J * CBA/J
|
abnormal pharyngeal arch development |
J:175338
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tg(Tex101-icre)2Lzj/0
involves: 129S4/SvJaeSor * C57BL/6 * SJL
|
normal
reproductive system phenotype |
J:168353
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Id3tm2.1Zhu/Id3tm2.1Zhu
Tg(Lck-cre)#Zhu/0
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * SJL
|
decreased T cell number |
J:172701
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Pdss2tm1.1Jdhu/Pdss2tm1.2Jdhu
Tg(Pcp2-cre)3555Jdhu/0
involves: 129 * C3H/HeNCr MMTV- * C57BL/6N * FVB/N
|
abnormal gait |
J:179845
|
|
abnormal motor coordination/balance |
J:179845
|
|
ataxia |
J:179845
|
|
decreased Purkinje cell number |
J:179845
|
|
impaired balance |
J:179845
|
|
increased neuron apoptosis |
J:179845
|
|
Purkinje cell degeneration |
J:179845
|
|
short stride length |
J:179845
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Srctm1Mul/Srctm1Mul
Tg(MMTV-cre)7Mul/0
Tg(MMTV-PyVT)#Mul/0
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * FVB/N
|
normal
neoplasm |
J:181822
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Recktm2.2Noda/Recktm3.1(cre/ERT2)Noda
involves: 129S4/SvJaeSor * C57BL/6 * FVB/N
|
abnormal limb development |
J:184585
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Nhlh2tm2Thbr/Nhlh2tm2Thbr
Tg(Gnrh1-cre)1Dlc/0
involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6 * CBA
|
decreased neuron number |
J:199640
|
|
ectopic neuron |
J:199640
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Pms2tm2(cre)Lisk/Pms2tm2(cre)Lisk
involves: 129S4/SvJaeSor
|
abnormal mismatch repair |
J:204653
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Meis2tm1.1Zkoz/Meis2tm1.1Zkoz
Tfap2atm1(cre)Moon/Tfap2a+
involves: 129 * C57BL/6J
|
abnormal cardiac neural crest cell morphology |
J:229604
|
|
abnormal cardiac outflow tract development |
J:229604
|
|
abnormal cartilage morphology |
J:229604
|
|
abnormal facial nerve morphology |
J:229604
|
|
abnormal heart valve morphology |
J:229604
|
|
abnormal hyoid bone morphology |
J:229604
|
|
abnormal mandible morphology |
J:229604
|
|
abnormal otic capsule morphology |
J:229604
|
|
abnormal palate morphology |
J:229604
|
|
abnormal parietal bone morphology |
J:229604
|
|
abnormal tongue muscle morphology |
J:229604
|
|
abnormal trigeminal nerve morphology |
J:229604
|
|
abnormal vestibulocochlear nerve morphology |
J:229604
|
|
absent interparietal bone |
J:229604
|
|
decreased cornea thickness |
J:229604
|
|
decreased tongue size |
J:229604
|
|
double outlet right ventricle |
J:229604
|
|
failure of eyelid fusion |
J:229604
|
|
neonatal lethality, complete penetrance |
J:229604
|
|
short mandible |
J:229604
|
|
small trigeminal ganglion |
J:229604
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Snrpbem1Lajm/Snrpb+
Tmem163Tg(ACTB-cre)2Mrt/Tmem163+
involves: 129S4/SvJaeSor * C57BL/6J * CD1 * FVB/N
|
decreased cranial neural crest cell number |
J:326544
|
|
increased cranial neural crest cell apoptosis |
J:326544
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
involves: 129S4/SvJaeSor
|
no abnormal phenotype detected |
J:64292
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Rb1tm2Brn/Rb1tm2Brn
involves: 129 * 129S4/SvJaeSor * C57BL/6 * FVB
|
normal
neoplasm |
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N
|
increased nervous system tumor incidence |
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Slc1a3tm1(cre/ERT2)Mgoe/Slc1a3+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJaeSor
|
increased astrocytoma incidence |
J:229481
|
|
increased glioma incidence |
J:229481
|
|
increased oligodendroglioma incidence |
J:229481
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJaeSor
|
increased astrocytoma incidence |
J:229481
|
|
increased glioma incidence |
J:229481
|
|
increased oligodendroglioma incidence |
J:229481
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB
|
increased astrocytoma incidence |
J:204385
|
|
increased glioma incidence |
J:204385
|
|
increased oligodendroglioma incidence |
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptf1atm1.1(cre)Cvw/Ptf1atm1.1(cre)Cvw
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * Black Swiss
|
abnormal digestive system development |
J:78710
|
|
abnormal pancreas development |
J:78710
|
|
absent pancreatic acini |
J:78710
|
|
increased retina ganglion cell number |
J:115271
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N
|
increased nervous system tumor incidence |
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Tg(NPHS2-rtTA2*M2)1Jbk/Tg(NPHS2-rtTA2*M2)1Jbk
Tg(tetO-cre)LC1Bjd/0
involves: 129S4/SvJaeSor * BALB/c * C57BL/6 * FVB/N
|
normal
renal/urinary system phenotype |
J:285673
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Tg(NPHS2-rtTA2*M2)1Jbk/Tg(NPHS2-rtTA2*M2)1Jbk
Tg(tetO-cre)LC1Bjd/Tg(tetO-cre)LC1Bjd
involves: 129S4/SvJaeSor * BALB/c * C57BL/6 * FVB/N
|
aneuploidy |
J:285673
|
|
decreased podocyte number |
J:285673
|
|
decreased renal glomerulus number |
J:285673
|
|
glomerulosclerosis |
J:285673
|
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:285673
|
|
increased urine protein level |
J:285673
|
|
podocyte foot process effacement |
J:285673
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Tg(PODXL-rtTA*M2)#Mjmr/Tg(PODXL-rtTA*M2)#Mjmr
Tg(tetO-cre)LC1Bjd/Tg(tetO-cre)LC1Bjd
involves: 129S/Sv * 129S4/SvJaeSor * BALB/c * C57BL/6J
|
normal
renal/urinary system phenotype |
J:285673
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Tg(Slc26a5-cre)#Jnz/0
involves: 129S4/SvJaeSor * C57BL/6 * FVB/NJ
|
no abnormal phenotype detected |
J:92297
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm2(icre/ERT2)Jphe
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6
|
no abnormal phenotype detected |
J:135150
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm7(SMO*/YFP)Amc
Tg(CAG-cre/Esr1*)5Amc/0
chimera involves: 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA * Swiss Webster
|
abnormal brain development |
J:165962
|
|
polydactyly |
J:165962
|
Gt(ROSA)26Sortm1Sor/?
Ptf1atm1(cre)Hnak/Ptf1atm1(cre)Hnak
involves: 129S4/SvJaeSor
|
abnormal retina layer morphology |
J:119184
|
|
abnormal retina neuronal layer morphology |
J:119184
|
|
absent amacrine cells |
J:119184
|
|
absent retina inner plexiform layer |
J:119184
|
|
neonatal lethality, complete penetrance |
J:119184
|
Gt(ROSA)26Sortm1Sor/?
Wnt7btm2Amc/Wnt7btm2.1Amc
Tg(Hoxb7-cre)13Amc/0
involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6
|
dilated kidney collecting duct |
J:142685
|
Gt(ROSA)26Sortm1Uga/Gt(ROSA)26Sortm1Uga
Tg(Thy1-cre)703Vaw/0
involves: C3H * C57BL/6 * C57BL/6J
|
abnormal neuron morphology |
J:179833
|
|
abnormal synaptic transmission |
J:179833
|
|
reduced long-term potentiation |
J:179833
|
Gt(ROSA)26Sortm2(ATF4)Myz/Gt(ROSA)26Sortm2(ATF4)Myz
Tg(Myh11-icre/ERT2)1Soff/?
either: D2.Cg-Atf4tm1.1Cmad Tg(Myh11-icre/ERT2)1Soff or B6.Cg-Atf4tm1.1Cmad Tg(Myh11-icre/ERT2)1Soff
|
calcified aorta |
J:237331
|
|
normal
homeostasis/metabolism phenotype |
J:237331
|
|
increased cardiomyocyte apoptosis |
J:237331
|
Gt(ROSA)26Sortm2(CAG-Dsred2/EGFP)Luo/Gt(ROSA)26Sortm1(Notch3*)Sfr
Notch3tm1.1(cre/ERT2)Sat/Notch3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6NTac
|
decreased mammary gland epithelial cell proliferation |
J:201985
|
Gt(ROSA)26Sortm2(CAG-Dsred2/EGFP)Luo/Gt(ROSA)26Sortm2(CAG-Dsred2/EGFP)Luo
involves: 129S1/Sv * 129X1/SvJ
|
reduced female fertility |
J:113338
|
Gt(ROSA)26Sortm2(CAG-EGFP)Npa/Gt(ROSA)26Sor+
BALB/c-Gt(ROSA)26Sortm2(CAG-EGFP)Npa
|
no abnormal phenotype detected |
J:184312
|
Gt(ROSA)26Sortm2(CAG-EYFP)Hze/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NCr
|
no abnormal phenotype detected |
J:155793
|
Gt(ROSA)26Sortm2(CAG-HIST1H2BB/EGFP)Zjh/Gt(ROSA)26Sortm2(CAG-HIST1H2BB/EGFP)Zjh
involves: 129S4/SvJae * C57BL/6
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm2(CAG-Lancl1)Pfw/Gt(ROSA)26Sor+
Tg(Ddx4-cre)1Dcas/0
involves: C57BL/6 * FVB
|
abnormal male germ cell apoptosis |
J:324139
|
|
abnormal redox activity |
J:324139
|
|
abnormal sperm progressive motility |
J:324139
|
|
abnormal spermatogenesis |
J:324139
|
|
decreased cellular sensitivity to oxidative stress |
J:324139
|
|
increased sperm motility |
J:324139
|
|
increased sperm number |
J:324139
|
Gt(ROSA)26Sortm2(CAG-Lancl1)Pfw/Gt(ROSA)26Sortm2(CAG-Lancl1)Pfw
Tg(Nes-cre)1Kln/0
involves: C57BL/6 * SJL
|
decreased susceptibility to neuronal excitotoxicity |
J:214805
|
Gt(ROSA)26Sortm2(CAG-Lin28b,-luc)Jhsc/Gt(ROSA)26Sor+
Tg(Dbh-icre)1Gsc/0
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6
|
increased neuroblastoma incidence |
J:241988
|
Gt(ROSA)26Sortm2(CAG-Mir128-2)Ans/Gt(ROSA)26Sor+
Tg(Camk2a-cre)2Gsc/0
involves: BALB/cJ * C57BL/6J * FVB/N
|
decreased locomotor activity |
J:205260
|
Gt(ROSA)26Sortm2(CAG-Mir128-2)Ans/Gt(ROSA)26Sor+
Mir128-2tm1.1Ans/Mir128-2tm1.1Ans
Tg(Camk2a-cre)2Gsc/0
involves: BALB/cJ * C57BL/6J * FVB/N
|
no abnormal phenotype detected |
J:205260
|
Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
|
abnormal B cell differentiation |
J:179036
|
|
abnormal marginal zone B cell physiology |
J:179036
|
|
abnormal spleen marginal zone morphology |
J:179036
|
|
decreased B cell number |
J:179036
|
|
decreased B-1a cell number |
J:179036
|
|
decreased B-2 B cell number |
J:179036
|
|
decreased follicular B cell number |
J:179036
|
|
decreased IgG1 level |
J:179036
|
|
decreased IgG3 level |
J:179036
|
|
decreased IgM level |
J:179036
|
|
decreased spleen B cell follicle size |
J:179036
|
|
decreased spleen germinal center number |
J:179036
|
|
decreased transitional stage T2 B cell number |
J:179036
|
|
increased B cell proliferation |
J:179036
|
|
increased marginal zone B cell number |
J:179036
|
|
increased spleen weight |
J:179036
|
|
increased T cell number |
J:179036
|
|
increased transitional stage T1 B cell number |
J:179036
|
Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
|
abnormal B cell differentiation |
J:179036
|
|
abnormal spleen marginal zone morphology |
J:179036
|
|
decreased follicular B cell number |
J:179036
|
|
decreased mature B cell number |
J:179036
|
|
decreased pre-B cell number |
J:179036
|
|
decreased transitional stage T2 B cell number |
J:179036
|
|
increased marginal zone B cell number |
J:179036
|
|
increased transitional stage T1 B cell number |
J:179036
|
Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor+
Cd79atm1(cre)Reth/Cd79a+
involves: 129S6/SvEvTac * BALB/c * C57BL/6J
|
arrested B cell differentiation |
J:179036
|
|
decreased B cell number |
J:179036
|
|
decreased splenocyte number |
J:179036
|
|
increased bone marrow cell number |
J:179036
|
|
increased T cell number |
J:179036
|
Gt(ROSA)26Sortm2(CAG-Nr5a1)Fjd/Gt(ROSA)26Sor+
Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal decidualization |
J:269597
|
|
abnormal endometrial gland development |
J:269597
|
|
abnormal endometrial gland morphology |
J:269597
|
|
abnormal endometrium morphology |
J:269597
|
|
abnormal uterus morphology |
J:269597
|
|
enlarged endometrial glands |
J:269597
|
|
enlarged uterine horn |
J:269597
|
|
female infertility |
J:269597
|
|
uterus cyst |
J:269597
|
|
uterus inflammation |
J:269597
|
Gt(ROSA)26Sortm2(CAG-PSTPIP1*)Dtg/Gt(ROSA)26Sor+
Commd10Tg(Vav1-icre)A2Kio/Commd10+
involves: C57BL/6 * C57BL/10 * CBA/Ca
|
normal
behavior/neurological phenotype |
J:196002
|
|
normal
growth/size/body region phenotype |
J:196002
|
|
normal
immune system phenotype |
J:196002
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Ptentm2Mak/Ptentm2Mak
Tg(RasE)290Biat/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
increased lung tumor incidence |
J:226601
|
|
increased pancreas tumor incidence |
J:226601
|
|
premature death |
J:226601
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Tg(GFP/KRAS2/ALPP)1Brn/0
involves: 129P2/OlaHsd * FVB/N
|
increased keratoacanthoma incidence |
J:127226
|
|
increased lung tumor incidence |
J:127226
|
|
increased lymphoma incidence |
J:127226
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Tg(RasE)290Biat/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
increased lung adenocarcinoma incidence |
J:226601
|
|
increased lung tumor incidence |
J:226601
|
|
increased pancreas tumor incidence |
J:226601
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:226601
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:226601
|
|
increased sebaceous gland tumor incidence |
J:226601
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/0
Tg(Sftpc-Grem1)105Mmyl/0
involves: 129P2/OlaHsd * C57BL/6N
|
abnormal pulmonary alveolar system morphology |
J:82809
|
|
lung inflammation |
J:82809
|
|
pulmonary fibrosis |
J:82809
|
|
thick pulmonary interalveolar septum |
J:82809
|
Gt(ROSA)26Sortm2(DTA)Riet/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129P2/OlaHsd * C57BL/6J * CBA/J
|
abnormal facial nerve morphology |
J:157532
|
Gt(ROSA)26Sortm2(DTA)Riet/Gt(ROSA)26Sor+
Cnptm1(cre)Kan/Cnp+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
absent oligodendrocytes |
J:110983
|
|
axon degeneration |
J:110983
|
|
demyelination |
J:110983
|
|
paraparesis |
J:110983
|
|
postnatal lethality, complete penetrance |
J:110983
|
|
tremors |
J:110983
|
|
weight loss |
J:110983
|
Gt(ROSA)26Sortm2(DTA)Riet/Gt(ROSA)26Sor+
Tg(PLAT-cre)116Sdu/0
involves: 129P2/OlaHsd
|
abnormal parasympathetic ganglion morphology |
J:157532
|
Gt(ROSA)26Sortm2(DTA)Riet/Gt(ROSA)26Sortm2(DTA)Riet
involves: 129P2/OlaHsd
|
no abnormal phenotype detected |
J:110983
|
Gt(ROSA)26Sortm2(DTA)Riet/Gt(ROSA)26Sortm2(DTA)Riet
Tg(Gdf9-icre)5092Coo/0
involves: 129P2/OlaHsd * C57BL/6
|
absent oocytes |
J:157008
|
|
normal
mortality/aging |
J:157008
|
Gt(ROSA)26Sortm2(Foxo1)Jnk/Gt(ROSA)26Sor+
Pdpk1tm1Maka/Pdpk1tm1Maka
Tg(CAG-cat,-lacZ)11Miya/0
Tg(Pomc1-cre)16Lowl/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
|
increased body weight |
J:162892
|
|
increased food intake |
J:162892
|
|
increased total body fat amount |
J:162892
|
Gt(ROSA)26Sortm2(GFP/tetX)Gld/Gt(ROSA)26Sor+
Tg(Nes-cre)1Kln/0
involves: C57BL/6 * SJL
|
abnormal CNS synaptic transmission |
J:147245
|
Gt(ROSA)26Sortm2(GFP/tetX)Gld/Gt(ROSA)26Sor+
Sim1tm1.1(cre)Gld/Sim1+
involves: C57BL/6 * SJL
|
abnormal CNS synaptic transmission |
J:147245
|
Gt(ROSA)26Sortm2(Gli2*)Flng/Gt(ROSA)26Sor+
Ihhtm1Amc/Ihhtm1Amc
involves: 129S1/Sv * 129X1/SvJ
|
abnormal long bone epiphyseal plate proliferative zone |
J:154905
|
|
abnormal long bone hypertrophic chondrocyte zone |
J:154905
|
|
abnormal osteoblast differentiation |
J:154905
|
|
disorganized long bone epiphyseal plate |
J:154905
|
Gt(ROSA)26Sortm2(Gli2*)Flng/Gt(ROSA)26Sor+
Ihhtm1Amc/Ihhtm1Amc
Tg(Col2a1-cre)3Amc/0
involves: 129S1/Sv * 129X1/SvJ
|
abnormal long bone epiphyseal plate proliferative zone |
J:154905
|
|
abnormal long bone hypertrophic chondrocyte zone |
J:154905
|
|
abnormal osteoblast differentiation |
J:154905
|
|
abnormal perichondrium morphology |
J:154905
|
|
disorganized long bone epiphyseal plate |
J:154905
|
|
perinatal lethality, complete penetrance |
J:154905
|
|
normal
skeleton phenotype |
J:154905
|
Gt(ROSA)26Sortm2(Gli2*)Flng/Gt(ROSA)26Sor+
Tg(Col2a1-cre)3Amc/0
involves: 129X1/SvJ
|
abnormal cartilage development |
J:154905
|
|
abnormal long bone epiphyseal plate proliferative zone |
J:154905
|
|
decreased body size |
J:154905
|
|
decreased length of long bones |
J:154905
|
|
decreased width of hypertrophic chondrocyte zone |
J:154905
|
|
increased width of hypertrophic chondrocyte zone |
J:154905
|
Gt(ROSA)26Sortm2(H1/tetO-RNAi:Kdm1a)Arte/Gt(ROSA)26Sor+
involves: C57BL/6
|
abnormal bone marrow cell morphology/development |
J:192055
|
|
abnormal erythropoiesis |
J:192055
|
|
abnormal granulocyte differentiation |
J:192055
|
|
abnormal megakaryocyte morphology |
J:192055
|
|
abnormal megakaryocyte progenitor cell morphology |
J:192055
|
|
abnormal monocyte differentiation |
J:192055
|
|
abnormal platelet morphology |
J:192055
|
|
abnormal proerythroblast morphology |
J:192055
|
|
anemia |
J:192055
|
|
decreased erythroid progenitor cell number |
J:192055
|
|
enlarged spleen |
J:192055
|
|
normal
hematopoietic system phenotype |
J:192055
|
|
increased circulating erythropoietin level |
J:192055
|
|
increased erythroid progenitor cell number |
J:192055
|
|
increased hematopoietic stem cell number |
J:192055
|
|
increased hematopoietic stem cell proliferation |
J:192055
|
|
increased leukocyte cell number |
J:192055
|
|
increased mean platelet volume |
J:192055
|
|
increased megakaryocyte cell number |
J:192055
|
Gt(ROSA)26Sortm2(H1/tetO-RNAi:lacZ)Jcbr/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6
|
normal
growth/size/body region phenotype |
J:176266
|
|
normal
homeostasis/metabolism phenotype |
J:176266
|
Gt(ROSA)26Sortm2(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
enlarged prostate gland anterior lobe |
J:170965
|
|
increased prostate gland tumor incidence |
J:170965
|
|
increased prostate gland weight |
J:170965
|
|
prostate gland hyperplasia |
J:170965
|
Gt(ROSA)26Sortm2(HIF1A/luc)Kael/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac
|
no abnormal phenotype detected |
J:118308
|
Gt(ROSA)26Sortm2(HOXC9)Odk/Gt(ROSA)26Sortm2(HOXC9)Odk
Gli1tm3(cre/ERT2)Alj/Gli1+
involves: 129S6/SvEvTac
|
normal
craniofacial phenotype |
J:201472
|
Gt(ROSA)26Sortm2(ITK/Syk)Hjum/Gt(ROSA)26Sor+
Tg(Lck-cre)I57Jxm/0
involves: 129S6/SvEvTac * ICR
|
abnormal circulating cytokine level |
J:207306
|
|
abnormal cytokine secretion |
J:207306
|
|
abnormal immunoglobulin level |
J:207306
|
|
abnormal liver morphology |
J:207306
|
|
abnormal spleen morphology |
J:207306
|
|
enlarged spleen |
J:207306
|
|
normal
immune system phenotype |
J:207306
|
|
increased activated T cell number |
J:207306
|
|
increased CD4-positive, alpha-beta T cell number |
J:207306
|
|
increased circulating interferon-gamma level |
J:207306
|
|
increased circulating interleukin-2 level |
J:207306
|
|
increased circulating interleukin-4 level |
J:207306
|
|
increased circulating interleukin-6 level |
J:207306
|
|
increased circulating interleukin-10 level |
J:207306
|
|
increased circulating tumor necrosis factor level |
J:207306
|
|
increased IgA level |
J:207306
|
|
increased IgG level |
J:207306
|
|
increased IgM level |
J:207306
|
|
increased inflammatory response |
J:207306
|
|
increased interferon-gamma secretion |
J:207306
|
|
increased interleukin-2 secretion |
J:207306
|
|
increased interleukin-4 secretion |
J:207306
|
|
increased interleukin-6 secretion |
J:207306
|
|
increased interleukin-10 secretion |
J:207306
|
|
increased mature B cell number |
J:207306
|
|
increased plasma cell number |
J:207306
|
|
increased tumor necrosis factor secretion |
J:207306
|
Gt(ROSA)26Sortm2(ITK/Syk)Hjum/Gt(ROSA)26Sor+
Tg(Cd4-cre)1Cwi/0
involves: 129S6/SvEvTac * C57BL/6 * DBA/2
|
abnormal circulating cytokine level |
J:207306
|
|
abnormal cytokine secretion |
J:207306
|
|
abnormal immunoglobulin level |
J:207306
|
|
abnormal liver morphology |
J:207306
|
|
abnormal spleen morphology |
J:207306
|
|
enlarged spleen |
J:207306
|
|
normal
immune system phenotype |
J:207306
|
|
increased activated T cell number |
J:207306
|
|
increased CD4-positive, alpha-beta T cell number |
J:207306
|
|
increased circulating interferon-gamma level |
J:207306
|
|
increased circulating interleukin-2 level |
J:207306
|
|
increased circulating interleukin-4 level |
J:207306
|
|
increased circulating interleukin-6 level |
J:207306
|
|
increased circulating interleukin-10 level |
J:207306
|
|
increased circulating tumor necrosis factor level |
J:207306
|
|
increased IgA level |
J:207306
|
|
increased IgG level |
J:207306
|
|
increased IgM level |
J:207306
|
|
increased inflammatory response |
J:207306
|
|
increased interferon-gamma secretion |
J:207306
|
|
increased interleukin-2 secretion |
J:207306
|
|
increased interleukin-4 secretion |
J:207306
|
|
increased interleukin-6 secretion |
J:207306
|
|
increased interleukin-10 secretion |
J:207306
|
|
increased mature B cell number |
J:207306
|
|
increased plasma cell number |
J:207306
|
|
increased tumor necrosis factor secretion |
J:207306
|
Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/c * C57BL/6
|
abnormal B cell activation |
J:137122
|
|
abnormal B cell physiology |
J:137122
|
|
abnormal class switch recombination |
J:137122
|
|
abnormal humoral immune response |
J:137122
|
|
abnormal T cell activation |
J:137122
|
|
enlarged inguinal lymph nodes |
J:137122
|
|
enlarged liver |
J:137122
|
|
enlarged spleen |
J:137122
|
|
increased B cell derived lymphoma incidence |
J:137122
|
|
increased B cell number |
J:137122
|
|
increased B cell proliferation |
J:137122
|
|
increased follicular B cell number |
J:137122
|
|
increased marginal zone B cell number |
J:137122
|
|
increased spleen B cell follicle size |
J:137122
|
|
increased spleen weight |
J:137122
|
|
increased T cell number |
J:137122
|
Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/Gt(ROSA)26Sor+
Tg(Cr2-cre)3Cgn/0
involves: BALB/c * C57BL/6
|
abnormal immune system morphology |
J:137122
|
|
abnormal immune system physiology |
J:137122
|
Gt(ROSA)26Sortm2(Mib1)Jlp/Gt(ROSA)26Sor+
Tg(Myh6-cre)2182Mds/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
cardiovascular system phenotype |
J:338889
|
Gt(ROSA)26Sortm2(Mirn150)Rsky/Gt(ROSA)26Sor+
involves: C57BL/6 * SJL/J
|
decreased mature B cell number |
J:127234
|
Gt(ROSA)26Sortm2(Mirn150)Rsky/Gt(ROSA)26Sortm2(Mirn150)Rsky
involves: C57BL/6 * SJL/J
|
decreased B-1 B cell number |
J:127234
|
|
decreased B-2 B cell number |
J:127234
|
|
decreased CD4-positive, alpha-beta T cell number |
J:127234
|
|
decreased CD8-positive, alpha-beta T cell number |
J:127234
|
|
increased B cell apoptosis |
J:127234
|
Gt(ROSA)26Sortm2(myc*T58A)Rcse/Gt(ROSA)26Sortm2(myc*T58A)Rcse
Tg(Wap-cre)11738Mam/0
involves: 129 * C57BL/6 * SJL
|
abnormal branching of the mammary ductal tree |
J:169403
|
|
abnormal involution of the mammary gland |
J:169403
|
|
abnormal mammary gland alveolus morphology |
J:169403
|
|
abnormal mammary gland epithelium physiology |
J:169403
|
|
aneuploidy |
J:169403
|
|
chromosomal instability |
J:169403
|
|
decreased tumor-free survival time |
J:169403
|
|
increased brain tumor incidence |
J:169403
|
|
increased mammary adenocarcinoma incidence |
J:169403
|
|
increased pituitary gland tumor incidence |
J:169403
|
|
mammary gland alveolar hyperplasia |
J:169403
|
|
mammary gland hyperplasia |
J:169403
|
|
polyploidy |
J:169403
|
Gt(ROSA)26Sortm2(Nfatc2*)Rao/Gt(ROSA)26Sor+
Tg(CMV-cre)1Cgn/0
involves: BALB/cJ
|
abnormal hematopoietic system morphology/development |
J:148341
|
|
prenatal lethality, incomplete penetrance |
J:148341
|
Gt(ROSA)26Sortm2(Nfatc2*)Rao/Gt(ROSA)26Sor+
Tg(Cd4-cre)1Cwi/0
involves: C57BL/6 * DBA/2
|
abnormal interferon level |
J:148341
|
|
abnormal T cell activation |
J:148341
|
Gt(ROSA)26Sortm2(Notch2)Ryn/Gt(ROSA)26Sor+
Six2tm1(tTA,tetO-EGFP/cre)Amc/Six2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6J
|
abnormal kidney development |
J:185844
|
|
abnormal metanephric ureteric bud development |
J:185844
|
|
abnormal nephrogenic zone morphology |
J:185844
|
|
absent metanephric mesenchyme |
J:185844
|
|
dilated proximal convoluted tubule |
J:185844
|
|
dilated renal tubule |
J:185844
|
|
impaired branching involved in ureteric bud morphogenesis |
J:185844
|
|
neonatal lethality, complete penetrance |
J:185844
|
|
renal glomerulus cyst |
J:185844
|
|
small kidney |
J:185844
|
Gt(ROSA)26Sortm2(NOTCH3*C455R)Sat/Gt(ROSA)26Sor+
Notch3Gt(PST033)Byg/Notch3Gt(PST033)Byg
Tg(Tagln-cre)1Her/0
involves: 129 * C57BL/6 * SJL
|
abnormal vascular smooth muscle morphology |
J:171887
|
|
increased susceptibility to ischemic brain injury |
J:171887
|
Gt(ROSA)26Sortm2(OVA/EGFP)Dwir/Gt(ROSA)26Sor+
Albtm1(cre/ERT2)Mtz/Alb+
involves: 129P2/OlaHsd * 129S2/SvPas
|
abnormal hepatocyte physiology |
J:173806
|
Gt(ROSA)26Sortm2(OVA/EGFP)Dwir/Gt(ROSA)26Sor+
Tg(TcraTcrb)1100Mjb/0
Albtm1(cre/ERT2)Mtz/Alb+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
increased circulating alanine transaminase level |
J:173806
|
Gt(ROSA)26Sortm2(Pax3)Joe/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA
|
cleft palate |
J:137730
|
Gt(ROSA)26Sortm2(Pax3)Joe/Gt(ROSA)26Sor+
Pax3tm1(cre)Joe/Pax3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
decreased palatal length |
J:137730
|
|
normal
limbs/digits/tail phenotype |
J:137730
|
|
normal
muscle phenotype |
J:137730
|
Gt(ROSA)26Sortm2(Pax3)Joe/Gt(ROSA)26Sortm2(Pax3)Joe
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
no abnormal phenotype detected |
J:137730
|
Gt(ROSA)26Sortm2(Pax3)Joe/Gt(ROSA)26Sortm2(Pax3)Joe
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA
|
abnormal craniofacial morphology |
J:137730
|
|
abnormal eyelid morphology |
J:137730
|
|
abnormal palate morphology |
J:137730
|
Gt(ROSA)26Sortm2(Pax3)Joe/Gt(ROSA)26Sortm2(Pax3)Joe
Pax3tm1(cre)Joe/Pax3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal bone mineralization |
J:137730
|
|
abnormal bone ossification |
J:137730
|
|
abnormal craniofacial bone morphology |
J:137730
|
|
abnormal eyelid development |
J:137730
|
|
abnormal forelimb morphology |
J:137730
|
|
abnormal osteoblast differentiation |
J:137730
|
|
abnormal pterygoid process morphology |
J:137730
|
|
abnormal secondary palate development |
J:137730
|
|
absent alisphenoid bone |
J:137730
|
|
absent eyelids |
J:137730
|
|
absent pterygoid process |
J:137730
|
|
alisphenoid bone hypoplasia |
J:137730
|
|
cleft palate |
J:137730
|
|
decreased tympanic ring size |
J:137730
|
|
failure of eyelid fusion |
J:137730
|
|
failure of palatal shelf elevation |
J:137730
|
|
hypaxial muscle hypoplasia |
J:137730
|
|
normal
limbs/digits/tail phenotype |
J:137730
|
|
normal
muscle phenotype |
J:137730
|
|
normal
nervous system phenotype |
J:137730
|
|
postnatal lethality |
J:137730
|
Gt(ROSA)26Sortm2(Pax3)Joe/Gt(ROSA)26Sortm2(Pax3)Joe
Pax3tm1(cre)Joe/Pax3tm1(cre)Joe
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
postnatal lethality |
J:137730
|
Gt(ROSA)26Sortm2(Pik3ca)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)1Mam/0
involves: 129S6/SvEvTac * FVB/N
|
no abnormal phenotype detected |
J:170898
|
Gt(ROSA)26Sortm2(Pik3ca)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)#Tfln/0
involves: 129S6/SvEvTac
|
no abnormal phenotype detected |
J:170898
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Pdpk1tm1Mlw/Pdpk1tm1Mlw
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129S4/SvJae * 129S6/SvEvTac
|
normal
endocrine/exocrine gland phenotype |
J:197054
|
|
normal
neoplasm |
J:197054
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Pdpk1tm1Mlw/Pdpk1tm1Mlw
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129S6/SvEvTac
|
normal
endocrine/exocrine gland phenotype |
J:197054
|
|
normal
neoplasm |
J:197054
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129S6/SvEvTac
|
enlarged pancreas |
J:197054
|
|
increased carcinoma incidence |
J:197054
|
|
increased pancreas weight |
J:197054
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:197054
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:197054
|
|
pancreatic acinar-to-ductal metaplasia |
J:197054
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+
Tg(Cela1-cre/ERT)1Dam/0
involves: 129S6/SvEvTac
|
increased pancreatic intraepithelial neoplasia incidence |
J:197054
|
|
pancreatic acinar-to-ductal metaplasia |
J:197054
|
Gt(ROSA)26Sortm2(Rnf187)Jhai/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Vil1-cre)20Syr/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2
|
abnormal enterocyte proliferation |
J:173145
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
TgTn(sb-T2/Onc)68Dla/0
involves: C57BL/6 * DBA/2 * FVB/N
|
abnormal liver morphology |
J:147264
|
|
increased hepatocellular carcinoma incidence |
J:147264
|
|
increased liver adenoma incidence |
J:147264
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Trp53tm3Tyj/Trp53+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
TgTn(sb-T2/Onc)68Dla/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
|
abnormal liver morphology |
J:147264
|
|
increased hepatocellular carcinoma incidence |
J:147264
|
|
increased liver adenoma incidence |
J:147264
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Tg(Vil1-cre)20Syr/0
TgTn(sb-T2/Onc)68Dla/0
involves: C57BL/6 * DBA/2 * FVB/N
|
increased gastrointestinal tumor incidence |
J:146887
|
|
increased intestinal adenoma incidence |
J:146887
|
|
increased small intestine adenocarcinoma incidence |
J:146887
|
|
premature death |
J:146887
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Tg(Vil1-cre)20Syr/0
TgTn(sb-T2/Onc)76Dla/0
involves: C57BL/6 * DBA/2 * FVB/N
|
increased gastrointestinal tumor incidence |
J:146887
|
|
increased intestinal adenoma incidence |
J:146887
|
|
increased small intestine adenocarcinoma incidence |
J:146887
|
|
premature death |
J:146887
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0
involves: 129 * C57BL/6 * C57BL/6J
|
abnormal skin condition |
J:153656
|
|
increased susceptibility to infection |
J:153656
|
|
liver cirrhosis |
J:153656
|
|
muscle degeneration |
J:153656
|
Gt(ROSA)26Sortm2(Sirt1)Ktm/Gt(ROSA)26Sor+
Tg(Agrp-cre)1Gsb/0
involves: 129 * C57BL/6J * FVB/N
|
normal
adipose tissue phenotype |
J:209418
|
|
normal
behavior/neurological phenotype |
J:209418
|
|
normal
growth/size/body region phenotype |
J:209418
|
|
normal
homeostasis/metabolism phenotype |
J:209418
|
Gt(ROSA)26Sortm2(Sirt1)Ktm/Gt(ROSA)26Sor+
Tg(Pomc1-cre)16Lowl/0
involves: 129 * C57BL/6J * FVB/N
|
normal
adipose tissue phenotype |
J:209418
|
|
normal
behavior/neurological phenotype |
J:209418
|
|
normal
growth/size/body region phenotype |
J:209418
|
|
normal
homeostasis/metabolism phenotype |
J:209418
|
Gt(ROSA)26Sortm2(SNCA*119)Djmo/Gt(ROSA)26Sor+
Tg(Nes-cre)1Kln/0
involves: 129 * C57BL/6 * SJL
|
no abnormal phenotype detected |
J:150777
|
Gt(ROSA)26Sortm2(SNCA*119)Djmo/Gt(ROSA)26Sortm2(SNCA*119)Djmo
involves: 129 * C57BL/6J
|
no abnormal phenotype detected |
J:147331
|
Gt(ROSA)26Sortm2(SNCA*119)Djmo/Gt(ROSA)26Sortm2(SNCA*119)Djmo
7630403G23RikTg(Th-cre)1Tmd/7630403G23Rik+
involves: 129 * C57BL/6
|
decreased dopamine level |
J:150777
|
|
increased circulating noradrenaline level |
J:150777
|
|
increased serotonin level |
J:150777
|
Gt(ROSA)26Sortm2(SNCA*119)Djmo/Gt(ROSA)26Sortm2(SNCA*119)Djmo
7630403G23RikTg(Th-cre)1Tmd/7630403G23Rik+
involves: 129 * C57BL/6 * SJL
|
decreased dopamine level |
J:150777
|
|
increased noradrenaline level |
J:150777
|
|
increased serotonin level |
J:150777
|
Gt(ROSA)26Sortm2(Sp8)Lma/Gt(ROSA)26Sor+
Tg(Msx2-cre)5Rem/0
involves: C57BL/6 * CBA
|
normal
limbs/digits/tail phenotype |
J:223057
|
Gt(ROSA)26Sortm2(Sp8)Lma/Gt(ROSA)26Sor+
Sp8tm1Smb/Sp8tm1Smb
Tg(Msx2-cre)5Rem/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA
|
abnormal autopod morphology |
J:223057
|
|
abnormal limb morphology |
J:223057
|
Gt(ROSA)26Sortm2(Sp8)Lma/Gt(ROSA)26Sor+
Shhtm1(EGFP/cre)Cjt/Shh+
Not Specified
|
normal
limbs/digits/tail phenotype |
J:223057
|
Gt(ROSA)26Sortm2(SS18)Mrc/Gt(ROSA)26Sortm2(SS18)Mrc
Hprt1tm1(CAG-cre)Mnn/Hprt1tm1(CAG-cre)Mnn
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
prenatal lethality, complete penetrance |
J:120967
|
Gt(ROSA)26Sortm2(SS18)Mrc/Gt(ROSA)26Sortm2(SS18)Mrc
Myf5tm1(cre)Mrc/Myf5tm1(cre)Mrc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
decreased body size |
J:120967
|
|
increased sarcoma incidence |
J:120967
|
|
increased tumor incidence |
J:120967
|
|
postnatal lethality, incomplete penetrance |
J:120967
|
Gt(ROSA)26Sortm2(SS18)Mrc/Gt(ROSA)26Sortm2(SS18)Mrc
Myf6tm1(cre)Mrc/Myf6tm1(cre)Mrc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal skeletal muscle morphology |
J:120967
|
|
centrally nucleated skeletal muscle fibers |
J:120967
|
|
myopathy |
J:120967
|
|
normal
neoplasm |
J:120967
|
|
premature death |
J:120967
|
Gt(ROSA)26Sortm2(SS18)Mrc/Gt(ROSA)26Sortm2(SS18)Mrc
Pax3tm1(cre)Joe/Pax3tm1(cre)Joe
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
embryonic lethality during organogenesis, complete penetrance |
J:120967
|
Gt(ROSA)26Sortm2(SS18)Mrc/Gt(ROSA)26Sortm2(SS18)Mrc
Pax7tm1(cre)Mrc/Pax7tm1(cre)Mrc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
lethality throughout fetal growth and development, complete penetrance |
J:120967
|
Gt(ROSA)26Sortm2(tTA,CMV*1-KIAA1549/BRAF,-EGFP)Gtm/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6
|
abnormal neuronal stem cell physiology |
J:204469
|
|
increased neuronal stem cell self-renewal |
J:204469
|
Gt(ROSA)26Sortm2(tTA,CMV*1-KIAA1549/BRAF,-EGFP)Gtm/Gt(ROSA)26Sor+
Tg(GFAP-cre)#Gtm/0
involves: 129S6/SvEvTac * C57BL/6 * CBA
|
normal
nervous system phenotype |
J:204469
|
Gt(ROSA)26Sortm2(tTA,CMV*1-KIAA1549/BRAF,-EGFP)Gtm/Gt(ROSA)26Sor+
Ifi208Tg(Cspg4-cre)1Akik/Ifi208+
involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL
|
normal
nervous system phenotype |
J:204469
|
Gt(ROSA)26Sortm2(tTA,CMV*1-KIAA1549/BRAF,-EGFP)Gtm/Gt(ROSA)26Sor+
Tg(Fabp7-cre,-lacZ)3Gtm/0
involves: 129S6/SvEvTac * C57BL/6 * CBA
|
abnormal digestive system morphology |
J:204469
|
|
abnormal digestive system physiology |
J:204469
|
|
abnormal hindgut morphology |
J:204469
|
|
enlarged stomach |
J:204469
|
|
increased astrocyte number |
J:204469
|
|
normal
nervous system phenotype |
J:204469
|
|
premature death |
J:204469
|
Gt(ROSA)26Sortm2(Ubc-GPR52)Kohi/Gt(ROSA)26Sor+
Tg(Gpr52-cre)116FKohi/0
involves: 129S/SvEv * C57BL/6J
|
normal
behavior/neurological phenotype |
J:214470
|
|
normal
growth/size/body region phenotype |
J:214470
|
|
impaired behavioral response to methamphetamine |
J:214470
|
|
normal
nervous system phenotype |
J:214470
|
Gt(ROSA)26Sortm2(VEGFB*)Dlam/Gt(ROSA)26Sor+
Tg(Thy1-cre)1Dlam/0
involves: 129 * C57BL/6 * FVB
|
abnormal developmental vascular remodeling |
J:172783
|
|
normal
nervous system phenotype |
J:172783
|
Gt(ROSA)26Sortm2(Wnt1/GFP)Amc/Gt(ROSA)26Sor+
Tg(Hoxb7-cre)13Amc/0
Wnt9btm1.1Amc/Wnt9btm1.1Amc
involves: 129X1/SvJ * C57BL/6 * CBA
|
normal
renal/urinary system phenotype |
J:100575
|
Gt(ROSA)26Sortm2(Wnt1/GFP)Amc/Gt(ROSA)26Sor+
Wnt9btm1.1Amc/Wnt9btm1.1Amc
involves: 129X1/SvJ * C57BL/6 * CBA
|
abnormal kidney collecting duct morphology |
J:100575
|
|
abnormal kidney development |
J:100575
|
|
abnormal Mullerian duct morphology |
J:100575
|
|
neonatal lethality |
J:100575
|
Gt(ROSA)26Sortm2(Wnt1/GFP)Amc/Gt(ROSA)26Sor+
Pbx1tm1Koss/Pbx1tm1Koss
Pbx2tm1Mlc/Pbx2+
Tg(Tcfap2a-cre)1Will/0
involves: 129P2/OlaHsd * 129S/Sv * 129X1/SvJ
|
normal
craniofacial phenotype |
J:178316
|
Gt(ROSA)26Sortm2.1(CAG-EGFP)Maoh/Gt(ROSA)26Sortm2.1(CAG-EGFP)Maoh
involves: 129P2/OlaHsd * C57BL/6
|
no abnormal phenotype detected |
J:173808
|
Gt(ROSA)26Sortm2.1(CAG-EGFP,-DTA*G128D)Pjen/Gt(ROSA)26Sortm2.1(CAG-EGFP,-DTA*G128D)Pjen
B6.Cg-Gt(ROSA)26Sortm2.1(CAG-EGFP,-DTA*G128D)Pjen/J
|
male infertility |
J:101977
|
Gt(ROSA)26Sortm2.1(CAG-PSTPIP1*)Dtg/Gt(ROSA)26Sor+
involves: BALB/cJ * C57BL/6
|
circling |
J:196002
|
|
decreased birth body size |
J:196002
|
|
decreased body weight |
J:196002
|
|
increased circulating interleukin-1 alpha level |
J:196002
|
|
increased circulating interleukin-1 beta level |
J:196002
|
|
increased circulating tumor necrosis factor level |
J:196002
|
|
normal
integument phenotype |
J:196002
|
|
normal
nervous system phenotype |
J:196002
|
|
postnatal growth retardation |
J:196002
|
|
prenatal lethality, incomplete penetrance |
J:196002
|
|
normal
skeleton phenotype |
J:196002
|
Gt(ROSA)26Sortm2.1(Cd74/MOG)Awai/Gt(ROSA)26Sor+
involves: C57BL/6 * BALB/cJ
|
abnormal humoral immune response |
J:140751
|
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:140751
|
Gt(ROSA)26Sortm2.1(Mirn150)Rsky/Gt(ROSA)26Sor+
involves: C57BL/6 * SJL/J
|
decreased mature B cell number |
J:127234
|
Gt(ROSA)26Sortm2.1(Mirn150)Rsky/Gt(ROSA)26Sortm2.1(Mirn150)Rsky
involves: C57BL/6 * SJL/J
|
arrested B cell differentiation |
J:127234
|
|
arrested T cell differentiation |
J:127234
|
|
decreased B-1 B cell number |
J:127234
|
|
decreased B-2 B cell number |
J:127234
|
|
decreased lymphocyte cell number |
J:127234
|
|
increased B cell apoptosis |
J:127234
|
Gt(ROSA)26Sortm2.1(MYC/ERT)Hsc/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJaeSor
|
increased cell proliferation |
J:89756
|
Gt(ROSA)26Sortm2.1(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0
involves: 129 * C57BL/6 * C57BL/6J
|
increased hemolymphoid system tumor incidence |
J:153656
|
|
increased leukemia incidence |
J:153656
|
|
increased T cell derived lymphoma incidence |
J:153656
|
|
premature death |
J:153656
|
Gt(ROSA)26Sortm2.1Ksvo/Gt(ROSA)26Sortm2.1Ksvo
involves: 129S6/SvEvTac * C57BL/6J
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm2.1Sia/Gt(ROSA)26Sortm2.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm2.2Ksvo/Gt(ROSA)26Sortm2.2Ksvo
involves: 129S6/SvEvTac * C57BL/6J
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm2Bet/Gt(ROSA)26Sortm2Bet
involves: BALB/c
|
no abnormal phenotype detected |
J:174261
|
Gt(ROSA)26Sortm2Bet/Gt(ROSA)26Sortm2Bet
Speer6-ps1Tg(Alb-cre)21Mgn/?
involves: BALB/c * C57BL/6 * DBA
|
abnormal bile duct development |
J:174261
|
|
abnormal bile duct morphology |
J:174261
|
|
abnormal intrahepatic bile duct morphology |
J:174261
|
|
abnormal liver morphology |
J:174261
|
|
decreased hepatocyte number |
J:174261
|
|
increased hepatocyte proliferation |
J:174261
|
|
increased liver weight |
J:174261
|
Gt(ROSA)26Sortm2Iaai/Gt(ROSA)26Sor+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * C57BL/6
|
abnormal bone marrow cell physiology |
J:196407
|
Gt(ROSA)26Sortm2Jake/Gt(ROSA)26Sor+
Tg(Gfap-cre)#Mvs/0
involves: BALB/c * C57BL/6 * C57BL/6NHsd
|
abnormal astrocyte morphology |
J:192021
|
|
abnormal astrocyte physiology |
J:192021
|
|
abnormal response to injury |
J:192021
|
Gt(ROSA)26Sortm2Nat/Gt(ROSA)26Sor+
involves: 129 * C57BL/6
|
no abnormal phenotype detected |
J:155417
|
Gt(ROSA)26Sortm2Sho/Gt(ROSA)26Sor+
Sp8tm1Smb/Sp8tm1Smb
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J * CBA/J
|
abnormal nasal pit morphology |
J:200761
|
|
decreased cranial neural crest cell proliferation |
J:200761
|
|
increased cranial neural crest cell apoptosis |
J:200761
|
|
increased embryonic neuroepithelium apoptosis |
J:200761
|
|
increased head mesenchyme apoptosis |
J:200761
|
Gt(ROSA)26Sortm2Sho/Gt(ROSA)26Sor+
Leprtm1.1Chua/Leprtm1.1Chua
Ntstm1(cre)Mgmj/Nts+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * FVB/N
|
abnormal nervous system electrophysiology |
J:176657
|
Gt(ROSA)26Sortm2Sho/Gt(ROSA)26Sor+
Ntstm1(cre)Mgmj/Nts+
involves: 129S4/SvJaeSor * C57BL/6 * FVB
|
normal
nervous system phenotype |
J:176657
|
Gt(ROSA)26Sortm2Sho/Gt(ROSA)26Sor+
Lef1tm1Hhx/Lef1tm1Hhx
Tg(GZMB-cre)1Jcb/0
involves: 129S4/SvJaeSor * C57BL/6 * FVB/N
|
abnormal memory T cell physiology |
J:189838
|
|
decreased CD8-positive, alpha-beta T cell number |
J:189838
|
Gt(ROSA)26Sortm2Sho/?
Tg(Lck-cre)548Jxm/0
involves: 129S4/SvJaeSor * C57BL/6 * SJL
|
no abnormal phenotype detected |
J:117041
|
Gt(ROSA)26Sortm2Sia/Gt(ROSA)26Sortm2Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Thl/Trp53tm1Thl
Tyrc-Brd/Tyrc-Brd
involves: 129/Sv * 129S4/SvJae * C57BL/6
|
increased glioblastoma incidence |
J:172585
|
|
increased tumor growth/size |
J:172585
|
|
premature death |
J:172585
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tyrc-Brd/Tyrc-Brd
involves: 129/Sv * 129S4/SvJae * C57BL/6
|
increased glioblastoma incidence |
J:172585
|
|
premature death |
J:172585
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+
Tyrc-Brd/Tyrc-Brd
involves: 129/Sv * C57BL/6
|
normal
mortality/aging |
J:172585
|
|
normal
neoplasm |
J:172585
|
Gt(ROSA)26Sortm2Wbaa/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6
|
no abnormal phenotype detected |
J:177475
|
Gt(ROSA)26Sortm3(CAG-Chrm3*,-mCitrine)Ute/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm3(CAG-EGFP/Dsred2)Luo/Gt(ROSA)26Sortm3(CAG-EGFP/Dsred2)Luo
involves: 129S1/Sv * 129X1/SvJ
|
premature death |
J:113339
|
|
reduced fertility |
J:113339
|
Gt(ROSA)26Sortm3(CAG-EYFP)Hze/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NCr
|
no abnormal phenotype detected |
J:155793
|
Gt(ROSA)26Sortm3(CAG-EYFP)Hze/Gt(ROSA)26Sor+
Stat5atm2Mam Stat5btm1Mam/Del(11Stat5a-Stat5b)1Mam
Tg(Mx1-cre)1Cgn/0
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
abnormal CD4-positive T cell differentiation |
J:204829
|
Gt(ROSA)26Sortm3(CAG-EYFP)Hze/Gt(ROSA)26Sor+
Hiratm1c(EUCOMM)Wtsi/Hiratm1d(EUCOMM)Wtsi
Tg(Myh6-cre)2182Mds/0
B6.Cg-Gt(ROSA)26Sortm3(CAG-EYFP)Hze Hiratm1c(EUCOMM)Wtsi/Hiratm1d(EUCOMM)Wtsi Tg(Myh6-cre)2182Mds
|
abnormal blood circulation |
J:231593
|
|
abnormal cardiac muscle contractility |
J:231593
|
|
abnormal cardiovascular system physiology |
J:231593
|
|
abnormal heart morphology |
J:231593
|
|
abnormal myocardial fiber morphology |
J:231593
|
|
abnormal myocardial fiber physiology |
J:231593
|
|
abnormal sarcolemma morphology |
J:231593
|
|
cardiac fibrosis |
J:231593
|
|
congestive heart failure |
J:231593
|
|
decreased cardiac output |
J:231593
|
|
decreased cardiac stroke volume |
J:231593
|
|
myocardial fiber degeneration |
J:231593
|
|
oxidative stress |
J:231593
|
Gt(ROSA)26Sortm3(CAG-flpo/ERT2)Alj/Gt(ROSA)26Sor+
Npm1tm1Trow/Npm1+
B6.Cg-Gt(ROSA)26Sortm3(CAG-flpo/ERT2)Alj Npm1tm1Trow
|
abnormal bone marrow cell physiology |
J:272803
|
|
abnormal bone marrow hematopoietic cell morphology |
J:272803
|
|
decreased hematopoietic stem cell number |
J:272803
|
|
increased granulocyte monocyte progenitor cell number |
J:272803
|
Gt(ROSA)26Sortm3(CAG-flpo/ERT2)Alj/Gt(ROSA)26Sortm3(CAG-flpo/ERT2)Alj
involves: 129S6/SvEvTac * C57BL/6
|
no abnormal phenotype detected |
J:186310
|
Gt(ROSA)26Sortm3(CAG-Il17a)Awai/Gt(ROSA)26Sor+
Tg(Cd4-cre)1Cwi/0
involves: C57BL/6 * DBA/2
|
abnormal immune system physiology |
J:144710
|
|
abnormal neutrophil physiology |
J:144710
|
|
increased circulating interleukin-17 level |
J:144710
|
|
increased granulocyte number |
J:144710
|
|
increased interleukin-17 secretion |
J:144710
|
Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky/Gt(ROSA)26Sor+
Tg(CD2-icre)4Kio/0
involves: C57BL/6 * C57BL/10 * CBA/Ca
|
decreased marginal zone B cell number |
J:133215
|
|
increased B-1a cell number |
J:133215
|
Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky/Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky
Tg(CD2-icre)4Kio/0
involves: C57BL/6 * C57BL/10 * CBA/Ca
|
abnormal B cell activation |
J:133215
|
|
abnormal B cell morphology |
J:133215
|
|
abnormal CD4-positive, alpha beta T cell morphology |
J:133215
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:133215
|
|
abnormal glomerular mesangium morphology |
J:133215
|
|
abnormal immune system morphology |
J:133215
|
|
abnormal immune system physiology |
J:133215
|
|
abnormal immunoglobulin level |
J:133215
|
|
abnormal spleen marginal zone morphology |
J:133215
|
|
abnormal T cell activation |
J:133215
|
|
abnormal T cell differentiation |
J:133215
|
|
decreased marginal zone B cell number |
J:133215
|
|
decreased spleen red pulp amount |
J:133215
|
|
enlarged lymph nodes |
J:133215
|
|
expanded mesangial matrix |
J:133215
|
|
extramedullary hematopoiesis |
J:133215
|
|
normal
immune system phenotype |
J:133215
|
|
increased anti-double stranded DNA antibody level |
J:133215
|
|
increased anti-single stranded DNA antibody level |
J:133215
|
|
increased B cell number |
J:133215
|
|
increased B cell proliferation |
J:133215
|
|
increased B-1a cell number |
J:133215
|
|
increased CD4-positive, alpha-beta T cell number |
J:133215
|
|
increased CD8-positive, alpha-beta T cell number |
J:133215
|
|
increased germinal center B cell number |
J:133215
|
|
increased IgG2a level |
J:133215
|
|
increased IgG2b level |
J:133215
|
|
increased IgG3 level |
J:133215
|
|
increased IgM level |
J:133215
|
|
increased lymphocyte cell number |
J:133215
|
|
increased mesangial cell number |
J:133215
|
|
increased spleen weight |
J:133215
|
|
increased spleen white pulp amount |
J:133215
|
|
increased urine protein level |
J:133215
|
|
intermingled spleen red and white pulp |
J:133215
|
|
lymph node hyperplasia |
J:133215
|
|
pale kidney |
J:133215
|
|
premature death |
J:133215
|
|
renal glomerulus hypertrophy |
J:133215
|
|
spleen hyperplasia |
J:133215
|
Gt(ROSA)26Sortm3(CAG-Shox2)Fawa/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Meis2tm1.1Zkoz/Meis2tm1.1Zkoz
involves: 129S6/SvEvTac * C57BL/6J * CBA/J
|
absent palate bones |
J:286823
|
|
cleft secondary palate |
J:286823
|
|
neonatal lethality, complete penetrance |
J:286823
|
|
submucous cleft palate |
J:286823
|
Gt(ROSA)26Sortm3(CAG-tdTomato,-EGFP*)Zjh/Gt(ROSA)26Sortm3(CAG-tdTomato,-EGFP*)Zjh
involves: 129S4/SvJae * C57BL/6
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm3(CMV-EGFP)Npa/Gt(ROSA)26Sor+
BALB/c-Gt(ROSA)26Sortm3(CMV-EGFP)Npa
|
no abnormal phenotype detected |
J:184312
|
Gt(ROSA)26Sortm3(Gli3)Amc/Gt(ROSA)26Sor+
Tg(Prrx1-cre)1Cjt/0
involves: 129 * C57BL/6J * CBA * SJL/J * Swiss Webster
|
decreased bone mineral density |
J:143454
|
|
polydactyly |
J:143454
|
|
short limbs |
J:143454
|
Gt(ROSA)26Sortm3(H1/tetO-RNAi:Mir143)Jcbr/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6
|
normal
endocrine/exocrine gland phenotype |
J:176266
|
|
normal
growth/size/body region phenotype |
J:176266
|
|
normal
homeostasis/metabolism phenotype |
J:176266
|
|
impaired glucose tolerance |
J:176266
|
|
increased circulating insulin level |
J:176266
|
|
insulin resistance |
J:176266
|
Gt(ROSA)26Sortm3(HIF1A*)Kael/Gt(ROSA)26Sor+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * BALB/c * C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:144666
|
|
microvesicular hepatic steatosis |
J:144666
|
|
normal
mortality/aging |
J:144666
|
Gt(ROSA)26Sortm3(HIF1A*)Kael/Gt(ROSA)26Sor+
Tg(KRT14-cre)1Ipc/0
involves: 129S6/SvEvTac * BALB/c * C57BL/6 * SJL
|
normal
integument phenotype |
J:144666
|
Gt(ROSA)26Sortm3(HIF1A*)Kael/Gt(ROSA)26Sortm4(HIF2A*)Kael
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * BALB/c * C57BL/6 * DBA
|
abnormal blood vessel morphology |
J:144666
|
|
abnormal liver morphology |
J:144666
|
|
normal
growth/size/body region phenotype |
J:144666
|
|
hepatic steatosis |
J:144666
|
|
increased hematocrit |
J:144666
|
|
increased hepatocyte proliferation |
J:144666
|
|
increased liver weight |
J:144666
|
|
premature death |
J:144666
|
|
reddish skin |
J:144666
|
|
reticulocytosis |
J:144666
|
Gt(ROSA)26Sortm3(Irf4)Evdr/Gt(ROSA)26Sor+
Tg(Ucp1-cre)1Evdr/0
involves: 129 * C57BL/6J * FVB
|
abnormal adipose tissue development |
J:214637
|
|
abnormal cellular respiration |
J:214637
|
|
abnormal white fat cell size |
J:214637
|
|
normal
behavior/neurological phenotype |
J:214637
|
|
browned white adipose tissue morphology |
J:214637
|
|
decreased body fat mass |
J:214637
|
|
decreased body weight |
J:214637
|
|
decreased epididymal fat pad weight |
J:214637
|
|
decreased inguinal fat pad weight |
J:214637
|
|
improved glucose tolerance |
J:214637
|
|
increased carbon dioxide production |
J:214637
|
|
increased energy expenditure |
J:214637
|
|
increased insulin sensitivity |
J:214637
|
|
increased oxygen consumption |
J:214637
|
Gt(ROSA)26Sortm3(myc*S62A)Rcse/Gt(ROSA)26Sortm3(myc*S62A)Rcse
Tg(Wap-cre)11738Mam/0
involves: 129 * C57BL/6 * SJL
|
abnormal branching of the mammary ductal tree |
J:169403
|
|
abnormal mammary gland alveolus morphology |
J:169403
|
|
aneuploidy |
J:169403
|
|
chromosomal instability |
J:169403
|
|
increased brain tumor incidence |
J:169403
|
|
polyploidy |
J:169403
|
Gt(ROSA)26Sortm3(NOTCH3*R1031C)Sat/Gt(ROSA)26Sor+
Tg(Tagln-cre)1Her/0
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal aorta morphology |
J:171887
|
|
abnormal brain vasculature morphology |
J:171887
|
|
abnormal vascular smooth muscle morphology |
J:171887
|
Gt(ROSA)26Sortm3(NOTCH3*R1031C)Sat/Gt(ROSA)26Sor+
Notch3Gt(PST033)Byg/Notch3Gt(PST033)Byg
Tg(Tagln-cre)1Her/0
involves: 129 * C57BL/6 * SJL
|
increased susceptibility to ischemic brain injury |
J:171887
|
Gt(ROSA)26Sortm3(phiC31*)Sor/Gt(ROSA)26Sortm3(phiC31*)Sor
involves: 129S4/SvJaeSor
|
no abnormal phenotype detected |
J:128069
|
Gt(ROSA)26Sortm3(RNAi:Fabp4)Mrl/Gt(ROSA)26Sor+
B6NTac.Cg-Gt(ROSA)26Sortm3(RNAi:Fabp4)Mrl
|
abnormal eating behavior |
J:177476
|
|
decreased body weight |
J:177476
|
|
normal
homeostasis/metabolism phenotype |
J:177476
|
|
increased body weight |
J:177476
|
|
increased total body fat amount |
J:177476
|
Gt(ROSA)26Sortm3(rtTA,tetO-cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129 * C57BL/6
|
no abnormal phenotype detected |
J:155417
|
Gt(ROSA)26Sortm3(Runx2)Flng/Gt(ROSA)26Sor+
Runx2tm1Mjo/Runx2tm1Mjo
Tg(Col2a1-cre)3Amc/0
involves: 129X1/SvJ
|
abnormal bone marrow cavity morphology |
J:180304
|
|
abnormal bone ossification |
J:180304
|
|
normal
skeleton phenotype |
J:180304
|
Gt(ROSA)26Sortm3(Runx2)Flng/Gt(ROSA)26Sortm3(Runx2)Flng
involves: 129X1/SvJ
|
no abnormal phenotype detected |
J:180304
|
Gt(ROSA)26Sortm3(Runx2)Flng/Gt(ROSA)26Sortm3(Runx2)Flng
Ihhtm1Amc/Ihhtm1Amc
Tg(Col2a1-cre)3Amc/0
involves: 129S1/Sv * 129X1/SvJ
|
abnormal bone ossification |
J:180304
|
|
abnormal bone structure |
J:180304
|
|
abnormal long bone epiphyseal plate morphology |
J:180304
|
|
abnormal long bone hypertrophic chondrocyte zone |
J:180304
|
|
abnormal osteoblast differentiation |
J:180304
|
Gt(ROSA)26Sortm3(Runx2)Flng/Gt(ROSA)26Sortm3(Runx2)Flng
Runx2tm1Mjo/Runx2tm1Mjo
Tg(Col2a1-cre)3Amc/0
involves: 129X1/SvJ
|
abnormal bone ossification |
J:180304
|
|
normal
skeleton phenotype |
J:180304
|
Gt(ROSA)26Sortm3(Snai2)Jhai/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
embryonic lethality |
J:194078
|
|
hemorrhage |
J:194078
|
|
pallor |
J:194078
|
Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/Gt(ROSA)26Sortm3(SNCA*E46K)Djmo
involves: 129 * C57BL/6J
|
no abnormal phenotype detected |
J:147333
|
Gt(ROSA)26Sortm3(SS18/EGFP)Mrc/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal cell death |
J:147728
|
Gt(ROSA)26Sortm3(SS18/EGFP)Mrc/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
Hprt1tm1(CAG-cre)Mnn/Hprt1tm1(CAG-cre)Mnn
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal embryonic tissue morphology |
J:120967
|
|
prenatal lethality, complete penetrance |
J:120967
|
Gt(ROSA)26Sortm3(SS18/EGFP)Mrc/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
Myf5tm1(cre)Mrc/Myf5tm1(cre)Mrc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal muscle development |
J:120967
|
|
decreased body size |
J:120967
|
|
increased sarcoma incidence |
J:120967
|
|
increased tumor incidence |
J:120967
|
|
postnatal lethality, incomplete penetrance |
J:120967
|
Gt(ROSA)26Sortm3(SS18/EGFP)Mrc/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
Myf6tm1(cre)Mrc/Myf6tm1(cre)Mrc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
myopathy |
J:120967
|
|
normal
neoplasm |
J:120967
|
|
postnatal lethality, complete penetrance |
J:120967
|
Gt(ROSA)26Sortm3(SS18/EGFP)Mrc/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
Pax3tm1(cre)Joe/Pax3tm1(cre)Joe
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
embryonic lethality during organogenesis, complete penetrance |
J:120967
|
Gt(ROSA)26Sortm3(SS18/EGFP)Mrc/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
Pax7tm1(cre)Mrc/Pax7tm1(cre)Mrc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal muscle development |
J:120967
|
|
lethality throughout fetal growth and development, complete penetrance |
J:120967
|
Gt(ROSA)26Sortm3(tetO-EGFP,-RNAi:T)Bgh/Gt(ROSA)26Sor+
chimera involves: C57BL/6 or (129S6/SvEvTac x C57BL/6NCr)F1
|
abnormal tail development |
J:173434
|
|
truncated notochord |
J:173434
|
Gt(ROSA)26Sortm3(tetO-EGFP,-RNAi:T)Bgh/Gt(ROSA)26Sor
involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NCr * NMRI
|
abnormal digestive system morphology |
J:190628
|
|
abnormal lumbar vertebrae morphology |
J:190628
|
|
abnormal neural tube closure |
J:190628
|
|
abnormal notochord morphology |
J:190628
|
|
abnormal paraxial mesoderm morphology |
J:190628
|
|
abnormal renal/urinary system morphology |
J:190628
|
|
abnormal rostral-caudal axis patterning |
J:190628
|
|
abnormal somite development |
J:190628
|
|
abnormal tail morphology |
J:190628
|
|
abnormal vertebral column morphology |
J:190628
|
|
absent caudal vertebrae |
J:190628
|
|
anal atresia |
J:190628
|
|
anal stenosis |
J:190628
|
|
caudal vertebral transformation |
J:190628
|
|
decreased paraxial mesoderm size |
J:190628
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:190628
|
|
hypospadia |
J:190628
|
|
kinked neural tube |
J:190628
|
|
neonatal lethality, complete penetrance |
J:190628
|
|
notochord degeneration |
J:190628
|
|
rectal atresia |
J:190628
|
|
rectourethral fistula |
J:190628
|
|
respiratory distress |
J:190628
|
|
small sacral vertebrae |
J:190628
|
|
spina bifida occulta |
J:190628
|
|
truncated notochord |
J:190628
|
Gt(ROSA)26Sortm3(tetO-Mir193)Arte/Gt(ROSA)26Sor+
involves: 129 * BALB/c * C57BL/6
|
abnormal kidney morphology |
J:197989
|
|
abnormal podocyte slit diaphragm morphology |
J:197989
|
|
abnormal renal glomerulus morphology |
J:197989
|
|
abnormal renal tubule morphology |
J:197989
|
|
albuminuria |
J:197989
|
|
glomerulosclerosis |
J:197989
|
|
kidney cyst |
J:197989
|
|
podocyte foot process effacement |
J:197989
|
|
premature death |
J:197989
|
|
renal tubule atrophy |
J:197989
|
Gt(ROSA)26Sortm3(tetO-Mir193)Arte/Gt(ROSA)26Sortm3(tetO-Mir193)Arte
involves: 129 * BALB/c * C57BL/6
|
abnormal kidney morphology |
J:197989
|
|
abnormal podocyte slit diaphragm morphology |
J:197989
|
|
abnormal renal glomerulus morphology |
J:197989
|
|
abnormal renal tubule morphology |
J:197989
|
|
albuminuria |
J:197989
|
|
glomerulosclerosis |
J:197989
|
|
kidney cyst |
J:197989
|
|
podocyte foot process effacement |
J:197989
|
|
premature death |
J:197989
|
|
renal tubule atrophy |
J:197989
|
Gt(ROSA)26Sortm3.1(CAG-EYFP)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr
|
no abnormal phenotype detected |
J:155793
|
Gt(ROSA)26Sortm3.1(CAG-Il17a)Awai/Gt(ROSA)26Sor+
involves: BALB/c * C57BL/6
|
anemia |
J:144710
|
|
decreased hematocrit |
J:144710
|
|
decreased hemoglobin content |
J:144710
|
|
decreased mean corpuscular hemoglobin |
J:144710
|
|
decreased mean corpuscular volume |
J:144710
|
|
increased granulocyte number |
J:144710
|
|
increased interleukin-17 secretion |
J:144710
|
|
postnatal growth retardation |
J:144710
|
|
skin inflammation |
J:144710
|
Gt(ROSA)26Sortm3.1(CAG-mCFP)Maoh/Gt(ROSA)26Sortm3.1(CAG-mCFP)Maoh
involves: 129P2/OlaHsd * C57BL/6
|
no abnormal phenotype detected |
J:173808
|
Gt(ROSA)26Sortm3.1(CAG-SORL1)Tew/Gt(ROSA)26Sor+
Not Specified
|
abnormal nervous system morphology |
J:213687
|
Gt(ROSA)26Sortm3.1(CAG-SORL1)Tew/Gt(ROSA)26Sor+
Tg(APPV717F)109Ili/0
Not Specified
|
abnormal nervous system morphology |
J:213687
|
Gt(ROSA)26Sortm3.1(CAG-SORL1)Tew/Gt(ROSA)26Sortm3.1(CAG-SORL1)Tew
Not Specified
|
abnormal nervous system morphology |
J:213687
|
|
decreased survivor rate |
J:213687
|
|
perinatal lethality, incomplete penetrance |
J:213687
|
Gt(ROSA)26Sortm3.1Sia/Gt(ROSA)26Sortm3.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm3Dym/Gt(ROSA)26Sortm3Dym
either: 129S4/SvJaeSor-Gt(ROSA)26Sortm3Dym or (involves: 129S4/SvJaeSor * C57BL/6J)
|
normal
mortality/aging |
J:128980
|
Gt(ROSA)26Sortm3Sia/Gt(ROSA)26Sortm3Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Srsf3tm1Pjln/Srsf3tm1Pjln
involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J * CBA/J
|
abnormal cranial neural crest cell morphology |
J:308882
|
|
decreased cranial neural crest cell apoptosis |
J:308882
|
|
decreased cranial neural crest cell proliferation |
J:308882
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1a(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
Tg(Mef2c-cre)2Blk/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N
|
abnormal heart right ventricle outflow tract morphology |
J:335489
|
|
absent heart right ventricle |
J:335489
|
|
enlarged heart |
J:335489
|
|
heart right ventricle hypoplasia |
J:335489
|
|
ventricular septal defect |
J:335489
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1a(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
Tg(Sox10-cre)1Wdr/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N * CBA
|
normal
cardiovascular system phenotype |
J:335489
|
|
cleft chin |
J:335489
|
|
cleft palate |
J:335489
|
|
facial cleft |
J:335489
|
|
frontal bone hypoplasia |
J:335489
|
|
nasal bone hypoplasia |
J:335489
|
|
short mandible |
J:335489
|
|
temporal bone squamous part hypoplasia |
J:335489
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1a(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
Tg(Wnt1-cre/Esr1*)10Rth/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N
|
decreased heart left ventricle wall thickness |
J:335489
|
|
embryonic lethality during organogenesis, complete penetrance |
J:335489
|
|
flat forehead |
J:335489
|
|
increased vascular permeability |
J:335489
|
|
lethality throughout fetal growth and development |
J:335489
|
|
persistent truncus arteriosus |
J:335489
|
|
pharyngeal arch artery hypoplasia |
J:335489
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Hnrnpltm1.1Tmo/Hnrnpltm1.1Tmo
Tg(Lck-cre)548Jxm/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA
|
abnormal T cell differentiation |
J:188749
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Kdm6atm1.1Kaig/Y
Pax7tm2.1(cre/ERT2)Fan/Pax7+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
impaired skeletal muscle regeneration |
J:232700
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Pikfyvetm2.1Tssk/Pikfyvetm2.1Tssk
Tg(Tyr-cre/ERT2)13Bos/0
involves: C57BL/6 * C57BL/6J
|
diluted coat color |
J:262141
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Pfkfb3tm1Pec/Pfkfb3tm1Pec
Tg(Cdh5-cre/ERT2)1Rha/0
involves: 129S1/Sv * 129X1/SvJ
|
abnormal retina vasculature morphology |
J:200070
|
|
decreased endothelial cell proliferation |
J:200070
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Pfkfb3tm1Pec/Pfkfb3tm1Pec
Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA
|
abnormal retina vasculature morphology |
J:200070
|
|
decreased endothelial cell proliferation |
J:200070
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1c(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
Tg(Mef2c-cre)2Blk/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N
|
abnormal heart right ventricle outflow tract morphology |
J:335489
|
|
absent heart right ventricle |
J:335489
|
|
enlarged heart |
J:335489
|
|
heart right ventricle hypoplasia |
J:335489
|
|
ventricular septal defect |
J:335489
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1c(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
Tg(Sox10-cre)1Wdr/0
Not Specified
|
cardiovascular system phenotype |
J:335489
|
|
cleft chin |
J:335489
|
|
cleft palate |
J:335489
|
|
facial cleft |
J:335489
|
|
frontal bone hypoplasia |
J:335489
|
|
nasal bone hypoplasia |
J:335489
|
|
short mandible |
J:335489
|
|
temporal bone squamous part hypoplasia |
J:335489
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1c(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
Tg(Wnt1-cre/Esr1*)10Rth/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N
|
decreased heart left ventricle wall thickness |
J:335489
|
|
embryonic lethality during organogenesis, complete penetrance |
J:335489
|
|
flat forehead |
J:335489
|
|
increased vascular permeability |
J:335489
|
|
lethality throughout fetal growth and development |
J:335489
|
|
persistent truncus arteriosus |
J:335489
|
|
pharyngeal arch artery hypoplasia |
J:335489
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1aem1Knwea/Polr1atm1c(EUCOMM)Hmgu
Tg(Sox10-cre)1Wdr/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N * CBA
|
cleft palate |
J:335489
|
|
facial cleft |
J:335489
|
|
midline cleft upper lip |
J:335489
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1aem1Knwea/Polr1atm1c(EUCOMM)Hmgu
Tg(Wnt1-cre/Esr1*)10Rth/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N
|
normal
cardiovascular system phenotype |
J:335489
|
|
facial cleft |
J:335489
|
|
flat forehead |
J:335489
|
|
lethality throughout fetal growth and development |
J:335489
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1d(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
Tg(Mef2c-cre)2Blk/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N
|
abnormal heart right ventricle outflow tract morphology |
J:335489
|
|
absent heart right ventricle |
J:335489
|
|
enlarged heart |
J:335489
|
|
heart right ventricle hypoplasia |
J:335489
|
|
ventricular septal defect |
J:335489
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1d(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
Tg(Sox10-cre)1Wdr/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N * CBA
|
cardiovascular system phenotype |
J:335489
|
|
cleft chin |
J:335489
|
|
cleft palate |
J:335489
|
|
facial cleft |
J:335489
|
|
frontal bone hypoplasia |
J:335489
|
|
nasal bone hypoplasia |
J:335489
|
|
short mandible |
J:335489
|
|
temporal bone squamous part hypoplasia |
J:335489
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Polr1atm1d(EUCOMM)Hmgu/Polr1atm1c(EUCOMM)Hmgu
Tg(Wnt1-cre/Esr1*)10Rth/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N
|
decreased heart left ventricle wall thickness |
J:335489
|
|
embryonic lethality during organogenesis, complete penetrance |
J:335489
|
|
flat forehead |
J:335489
|
|
increased vascular permeability |
J:335489
|
|
lethality throughout fetal growth and development |
J:335489
|
|
persistent truncus arteriosus |
J:335489
|
|
pharyngeal arch artery hypoplasia |
J:335489
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo
involves: 129S1/Sv * 129X1/SvJ
|
no abnormal phenotype detected |
J:124702
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/?
Pdzrn3tm1.1Ysa/Pdzrn3tm1.1Ysa
Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NCrlj * CBA * CBA/JNCrlj
|
abnormal retina blood vessel morphology |
J:222522
|
|
abnormal retina blood vessel pattern |
J:222522
|
|
abnormal retina vasculature morphology |
J:222522
|
|
normal
vision/eye phenotype |
J:222522
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/?
Smotm2Amc/Smotm2Amc
Tg(Tagln-cre)1Jjl/0
involves: 129S1/Sv * 129X1/SvJ * FVB/N
|
normal
cardiovascular system phenotype |
J:204743
|
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/?
Tg(BGLAP-cre)1Clem/?
Trip11tm1.1Psmi/Trip11tm1.2Psmi
involves: 129/Sv * C57BL/6 * FVB/NJ
|
abnormal Golgi stack morphology |
J:253969
|
|
normal
skeleton phenotype |
J:253969
|
Gt(ROSA)26Sortm4(attB/attP)Sor/Gt(ROSA)26Sortm4(attB/attP)Sor
involves: 129S4/SvJaeSor
|
no abnormal phenotype detected |
J:128069
|
Gt(ROSA)26Sortm4(CAG-EGFP*)Nat/Gt(ROSA)26Sortm4(CAG-EGFP*)Nat
involves: 129 * C57BL/6
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
Tg(Tal1-tTA)19Dgt/0
Tg(tetO-BCR/ABL1)2Dgt/0
TgTn(pb-sb-GrOnc)#aGsva/0
involves: 129P2/OlaHsd * C57BL/6 * CBA/J * DBA/2 * FVB/N
|
abnormal hematopoietic stem cell physiology |
J:227558
|
|
decreased hemoglobin content |
J:227558
|
|
increased basophil cell number |
J:227558
|
|
increased chronic myelocytic leukemia incidence |
J:227558
|
|
increased granulocyte number |
J:227558
|
|
increased hematopoietic stem cell number |
J:227558
|
|
increased leukocyte cell number |
J:227558
|
|
increased liver weight |
J:227558
|
|
increased myeloid cell number |
J:227558
|
|
increased spleen weight |
J:227558
|
|
premature death |
J:227558
|
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
Tg(tetO-BCR/ABL1)2Dgt/0
TgTn(pb-sb-GrOnc)#aGsva/0
involves: 129P2/OlaHsd * C57BL/6 * CBA/J * FVB/N
|
increased leukemia incidence |
J:227558
|
|
premature death |
J:227558
|
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Npm1tm1Gsva/Npm1+
TgTn(pb-sb-GrOnc)#aGsva/0
Tg(Mx1-cre)1Cgn/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
increased acute promyelocytic leukemia incidence |
J:172071
|
|
increased B cell derived lymphoma incidence |
J:172071
|
|
increased hemangiosarcoma incidence |
J:172071
|
|
increased leukemia incidence |
J:172071
|
|
increased lymphoma incidence |
J:172071
|
|
premature death |
J:172071
|
Gt(ROSA)26Sortm4(CAG-lacZ,-EGFP)Dym/Gt(ROSA)26Sor+
Shhtm1(EGFP/cre)Cjt/Shh+
involves: C57BL/6
|
abnormal skin morphology |
J:132568
|
|
thin epidermis |
J:132568
|
Gt(ROSA)26Sortm4(EEF1A1-EGFP)Npa/Gt(ROSA)26Sor+
BALB/c-Gt(ROSA)26Sortm4(EEF1A1-EGFP)Npa
|
no abnormal phenotype detected |
J:184312
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
involves: C57BL/6
|
abnormal tumor latency |
J:194308
|
|
abnormal tumor morphology |
J:194308
|
|
increased incidence of tumors by chemical induction |
J:194308
|
|
increased tumor growth/size |
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: C57BL/6J * CBA/J
|
embryonic lethality, complete penetrance |
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/?
involves: C57BL/6 * SJL
|
embryonic lethality, complete penetrance |
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
Tg(Prrx1-cre)1Cjt/?
involves: C57BL/6 * SJL
|
abnormal limb morphology |
J:194308
|
|
lethality throughout fetal growth and development, complete penetrance |
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
Pax7tm1(cre)Mrc/Pax7+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal craniofacial morphology |
J:194308
|
|
lethality throughout fetal growth and development, complete penetrance |
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
Pax3tm1(cre)Joe/Pax3+
involves: C57BL/6
|
embryonic lethality, complete penetrance |
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
Myf5tm1(cre)Mrc/Myf5+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
decreased body size |
J:194308
|
|
myopathy |
J:194308
|
|
premature death |
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
Bmi1tm1(cre/ERT)Mrc/Bmi1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
increased tumor incidence |
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
Tg(Prrx1-cre/ERT2)1Mlgn/?
involves: C57BL/6
|
increased tumor incidence |
J:194308
|
|
myopathy |
J:194308
|
Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc/Gt(ROSA)26Sor+
Pax7tm1(cre/ERT2)Gaka/Pax7+
involves: 129S6/SvEvTac * C57BL/6
|
myopathy |
J:194308
|
|
normal
neoplasm |
J:194308
|
Gt(ROSA)26Sortm4(H1/tetO-RNAi:Ezh2)Arte/Gt(ROSA)26Sor+
C57BL/6-Gt(ROSA)26Sortm4(H1/tetO-RNAi:Ezh2)Arte
|
abnormal mammary gland development |
J:202724
|
|
abnormal mammary gland duct morphology |
J:202724
|
|
decreased body size |
J:202724
|
|
decreased mammary gland epithelial cell proliferation |
J:202724
|
|
impaired mammary gland growth during pregnancy |
J:202724
|
|
prenatal lethality, complete penetrance |
J:202724
|
|
small lymph nodes |
J:202724
|
Gt(ROSA)26Sortm4(H1/tetO-RNAi:Ezh2)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * FVB
|
abnormal mammary gland development |
J:202724
|
|
prenatal lethality, complete penetrance |
J:202724
|
Gt(ROSA)26Sortm4(H1/tetO-RNAi:Mir145)Jcbr/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6
|
normal
growth/size/body region phenotype |
J:176266
|
|
normal
homeostasis/metabolism phenotype |
J:176266
|
Gt(ROSA)26Sortm4(HIF2A*)Kael/Gt(ROSA)26Sor+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * BALB/c * C57BL/6 * DBA
|
abnormal blood vessel morphology |
J:144666
|
|
abnormal liver morphology |
J:144666
|
|
normal
growth/size/body region phenotype |
J:144666
|
|
hepatic steatosis |
J:144666
|
|
increased hematocrit |
J:144666
|
|
increased hepatocyte proliferation |
J:144666
|
|
increased liver weight |
J:144666
|
|
premature death |
J:144666
|
|
reddish skin |
J:144666
|
|
reticulocytosis |
J:144666
|
Gt(ROSA)26Sortm4(HIF2A*)Kael/Gt(ROSA)26Sor+
Tg(KRT14-cre)1Ipc/0
involves: 129S6/SvEvTac * BALB/c * C57BL/6 * SJL
|
alopecia |
J:144666
|
|
decreased body size |
J:144666
|
|
dilated vasculature |
J:144666
|
|
epidermal hyperplasia |
J:144666
|
|
increased keratinocyte proliferation |
J:144666
|
|
increased vascular permeability |
J:144666
|
|
reddish skin |
J:144666
|
Gt(ROSA)26Sortm4(HIF2A*)Kael/Gt(ROSA)26Sor+
Tg(Myh6-cre)2182Mds/0
involves: 129S6/SvEvTac * FVB/N
|
abnormal heart left ventricle morphology |
J:179490
|
|
cardiac fibrosis |
J:179490
|
|
decreased heart ventricle muscle contractility |
J:179490
|
|
dilated cardiomyopathy |
J:179490
|
|
increased angiogenesis |
J:179490
|
|
liver vascular congestion |
J:179490
|
|
pulmonary vascular congestion |
J:179490
|
Gt(ROSA)26Sortm4(HIF2A*)Kael/Gt(ROSA)26Sortm4(HIF2A*)Kael
Tg(Vil1-cre/ERT2)23Syr/0
involves: 129S6/SvEvTac * C57BL/6 * DBA/2
|
normal
growth/size/body region phenotype |
J:307422
|
|
increased susceptibility to colitis induced morbidity/mortality |
J:307422
|
|
normal
mortality/aging |
J:307422
|
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal spleen morphology |
J:167612
|
|
decreased germinal center B cell number |
J:167612
|
|
enlarged spleen |
J:167612
|
|
increased B cell number |
J:167612
|
|
increased IgG1 level |
J:167612
|
|
increased IgM level |
J:167612
|
|
increased plasma cell number |
J:167612
|
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
Ighg1tm1(cre)Cgn/Ighg1+
Prdm1tm2Masu/Prdm1tm2Masu
involves: 129P2/OlaHsd * C57BL/6
|
abnormal germinal center B cell physiology |
J:167612
|
|
abnormal plasma cell differentiation |
J:167612
|
|
decreased IgG1 level |
J:167612
|
|
decreased survivor rate |
J:167612
|
|
increased B cell derived lymphoma incidence |
J:167612
|
|
increased germinal center B cell number |
J:167612
|
|
premature death |
J:167612
|
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sortm4(Ikbkb)Rsky
Igh-Jtm1Cgn/Ightm4Cgn
Tg(Cr2-cre)3Cgn/0
involves: 129P2/OlaHsd * C57BL/6
|
increased B cell number |
J:157297
|
Gt(ROSA)26Sortm4(RNAi:Gsk3a,Gsk3b)Rkuhn/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
decreased body weight |
J:133340
|
|
transmission ratio distortion |
J:133340
|
Gt(ROSA)26Sortm4(Snai1)Jhai/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
abnormal embryo development |
J:194078
|
|
embryonic lethality during organogenesis, complete penetrance |
J:194078
|
Gt(ROSA)26Sortm4(tetO-RNAi:T)Bgh/Gt(ROSA)26Sor+
chimera involves: C57BL/6 or (129S6/SvEvTac x C57BL/6NCr)F1
|
abnormal neural tube morphology |
J:173434
|
|
absent allantois |
J:173434
|
|
absent notochord |
J:173434
|
|
caudal body truncation |
J:173434
|
|
embryonic lethality during organogenesis, complete penetrance |
J:173434
|
|
impaired somite development |
J:173434
|
Gt(ROSA)26Sortm4(Wnt7a)Amc/?
Tg(Nes-cre)1Kln/0
involves: C57BL/6 * SJL
|
abnormal vascular endothelial cell morphology |
J:142352
|
Gt(ROSA)26Sortm4(Wnt7b)Flng/Gt(ROSA)26Sor+
Tg(Col1a1-cre)1Ack/0
involves: FVB/N
|
abnormal bone marrow cavity morphology |
J:208766
|
|
abnormal bone structure |
J:208766
|
|
abnormal tibia morphology |
J:208766
|
|
decreased osteoclast cell number |
J:208766
|
|
decreased trabecular bone volume |
J:208766
|
|
enlarged spleen |
J:208766
|
|
increased bone mass |
J:208766
|
|
increased bone mineral density |
J:208766
|
|
increased bone ossification |
J:208766
|
|
increased bone resorption |
J:208766
|
|
increased circulating osteocalcin level |
J:208766
|
|
increased circulating type I collagen C-terminal telopeptide level |
J:208766
|
|
increased osteoblast cell number |
J:208766
|
|
increased spleen weight |
J:208766
|
|
increased trabecular bone volume |
J:208766
|
Gt(ROSA)26Sortm4(Wnt7b)Flng/Gt(ROSA)26Sor+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: CD-1
|
abnormal bone marrow cavity morphology |
J:208766
|
|
abnormal bone structure |
J:208766
|
|
abnormal long bone morphology |
J:208766
|
|
decreased length of long bones |
J:208766
|
|
delayed chondrocyte differentiation |
J:208766
|
|
increased bone mass |
J:208766
|
|
increased bone mineral density |
J:208766
|
|
increased osteoblast cell number |
J:208766
|
Gt(ROSA)26Sortm4(Wnt7b)Flng/Gt(ROSA)26Sor+
Rptortm1Rueg/Rptor+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129S1/Sv * 129X1/SvJ * CD-1
|
abnormal bone marrow cavity morphology |
J:208766
|
|
increased bone mass |
J:208766
|
Gt(ROSA)26Sortm4(Wnt7b)Flng/Gt(ROSA)26Sor+
Rptortm1Rueg/Rptortm1Rueg
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129S1/Sv * 129X1/SvJ * CD-1
|
abnormal bone marrow cavity morphology |
J:208766
|
|
abnormal bone structure |
J:208766
|
|
increased osteoblast cell number |
J:208766
|
Gt(ROSA)26Sortm4(Wnt7b)Flng/Gt(ROSA)26Sor+
Tg(Runx2-rtTA*M2)#Flng/0
Tg(tetO-cre)1Jaw/0
involves: 129 * C57BL/6
|
abnormal bone structure |
J:208766
|
|
decreased osteoclast cell number |
J:208766
|
|
increased bone mineral density |
J:208766
|
|
increased bone ossification |
J:208766
|
|
increased osteoblast cell number |
J:208766
|
|
increased trabecular bone mass |
J:208766
|
|
increased trabecular bone volume |
J:208766
|
Gt(ROSA)26Sortm4.1(CAG-mCitrine)Maoh/Gt(ROSA)26Sortm4.1(CAG-mCitrine)Maoh
involves: 129P2/OlaHsd * C57BL/6
|
no abnormal phenotype detected |
J:173808
|
Gt(ROSA)26Sortm4.1Sia/Gt(ROSA)26Sortm4.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm4Sia/Gt(ROSA)26Sortm4Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm5(ACTB-tTA)Luo/Gt(ROSA)26Sor+
Tg(Col2a1-cre)1Bhr/0
Tg(tetO/CMV-Col2a1*R992C,-GFP)#Afe/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6J * SJL
|
abnormal bone collagen fibril morphology |
J:216945
|
|
abnormal chondrocyte morphology |
J:216945
|
|
abnormal chondrocyte physiology |
J:216945
|
|
abnormal cranium size |
J:216945
|
|
abnormal head size |
J:216945
|
|
abnormal long bone epiphyseal plate morphology |
J:216945
|
|
abnormal long bone hypertrophic chondrocyte zone |
J:216945
|
|
abnormal primary cilium morphology |
J:216945
|
|
abnormal vertebrae morphology |
J:216945
|
|
decreased body length |
J:216945
|
|
decreased body size |
J:216945
|
|
decreased length of long bones |
J:216945
|
|
disorganized long bone epiphyseal plate |
J:216945
|
|
increased diameter of femur |
J:216945
|
|
increased diameter of tibia |
J:216945
|
|
short femur |
J:216945
|
|
short tibia |
J:216945
|
Gt(ROSA)26Sortm5(ASPSCR1/TFE3)Mrc/Gt(ROSA)26Sor+
Tg(Prrx1-cre/ERT2)1Mlgn/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
increased organ/body region tumor incidence |
J:217462
|
Gt(ROSA)26Sortm5(ASPSCR1/TFE3)Mrc/Gt(ROSA)26Sortm1(cre/ERT)Nat
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
enlarged occipital bone |
J:217462
|
|
increased sarcoma incidence |
J:217462
|
|
increased tumor incidence |
J:217462
|
Gt(ROSA)26Sortm5(CAG-EGFP,-lacZ)Dym/?
Tg(Fev-flpe)1Dym/?
Tg(Hoxa2-cre)1Dym/?
Not Specified
|
no abnormal phenotype detected |
J:136096
|
Gt(ROSA)26Sortm5(CAG-flpo)Zjh/Gt(ROSA)26Sortm5(CAG-flpo)Zjh
involves: 129S4/SvJae * C57BL/6
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm5(CAG-Mdm4,-EGFP)Jhai/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
no abnormal phenotype detected |
J:194078
|
Gt(ROSA)26Sortm5(CAG-Sun1/sfGFP)Nat/Gt(ROSA)26Sortm5(CAG-Sun1/sfGFP)Nat
involves: 129 * C57BL/6
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm5(Etv4/en,-GFP)Amc/Gt(ROSA)26Sor+
Shhtm1Amc/Shhtm2Amc
Tg(Prrx1-cre)1Cjt/0
involves: 129 * C57BL/6 * CBA * SJL/J * Swiss Webster
|
abnormal digit morphology |
J:149478
|
Gt(ROSA)26Sortm5(Etv4/en,-GFP)Amc/Gt(ROSA)26Sor+
Tg(Prrx1-cre)1Cjt/0
involves: 129 * C57BL/6 * CBA * SJL/J * Swiss Webster
|
abnormal limb morphology |
J:149478
|
|
polydactyly |
J:149478
|
|
polyphalangy |
J:149478
|
Gt(ROSA)26Sortm5(H1/tetO-RNAi:Ezh2)Arte/Gt(ROSA)26Sor+
C57BL/6-Gt(ROSA)26Sortm5(H1/tetO-RNAi:Ezh2)Arte
|
abnormal mammary gland development |
J:202724
|
|
abnormal mammary gland duct morphology |
J:202724
|
|
decreased body size |
J:202724
|
|
decreased mammary gland epithelial cell proliferation |
J:202724
|
|
impaired mammary gland growth during pregnancy |
J:202724
|
|
prenatal lethality, complete penetrance |
J:202724
|
|
small lymph nodes |
J:202724
|
Gt(ROSA)26Sortm5(H1/tetO-RNAi:Ezh2)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * FVB
|
abnormal mammary gland development |
J:202724
|
|
prenatal lethality, complete penetrance |
J:202724
|
Gt(ROSA)26Sortm5(tetO-RNAi:T)Bgh/Gt(ROSA)26Sor+
chimera involves: C57BL/6 or (129S6/SvEvTac x C57BL/6NCr)F1
|
abnormal mesoderm development |
J:173434
|
|
abnormal neural tube morphology |
J:173434
|
|
absent allantois |
J:173434
|
|
absent notochord |
J:173434
|
|
caudal body truncation |
J:173434
|
|
embryonic lethality during organogenesis, complete penetrance |
J:173434
|
|
impaired somite development |
J:173434
|
|
truncated notochord |
J:173434
|
Gt(ROSA)26Sortm5(Wnt5a)Flng/Gt(ROSA)26Sortm5(Wnt5a)Flng
Tg(Col1a1-cre)1Ack/0
involves: FVB/N
|
normal
skeleton phenotype |
J:208766
|
Gt(ROSA)26Sortm5(Wnt5a)Flng/?
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: C57BL/6J * CBA/J
|
abnormal craniofacial morphology |
J:208766
|
|
embryonic lethality |
J:208766
|
Gt(ROSA)26Sortm5.1(CAG-mOrange)Maoh/Gt(ROSA)26Sortm5.1(CAG-mOrange)Maoh
involves: 129P2/OlaHsd * C57BL/6
|
no abnormal phenotype detected |
J:173808
|
Gt(ROSA)26Sortm5.1Sia/Gt(ROSA)26Sortm5.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm5Mom/?
Or8a1tm28(cre)Mom/?
involves: 129P2/OlaHsd * C57BL/6
|
abnormal olfactory sensory neuron physiology |
J:233447
|
|
normal
taste/olfaction phenotype |
J:233447
|
Gt(ROSA)26Sortm5Sia/Gt(ROSA)26Sortm5Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NCr
|
no abnormal phenotype detected |
J:155793
|
Gt(ROSA)26Sortm6(tetO-dTomato,-Ctnnb1*)Bgh/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6
|
abnormal cell physiology |
J:187862
|
Gt(ROSA)26Sortm6(Vegfa*)Jhai/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
embryonic lethality |
J:194078
|
Gt(ROSA)26Sortm6.1(CAG-tdTomato)Maoh/Gt(ROSA)26Sortm6.1(CAG-tdTomato)Maoh
involves: 129P2/OlaHsd * C57BL/6
|
no abnormal phenotype detected |
J:173808
|
Gt(ROSA)26Sortm6.1Sia/Gt(ROSA)26Sortm6.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm6Dym/?
Smotm2Amc/Smotm2Amc
Sox9tm3(cre)Crm/Sox9+
involves: 129S7/SvEvBrd * 129X1/SvJ
|
abnormal temporomandibular joint morphology |
J:153743
|
|
small mandibular condyloid process |
J:153743
|
Gt(ROSA)26Sortm6Sia/Gt(ROSA)26Sortm6Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm7(CAG-mCherry,-EGFP/tetX)Dym/Gt(ROSA)26Sor+
Tmem163Tg(ACTB-cre)2Mrt/0
Tg(ACTFLPe)9205Dym/0
involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL
|
perinatal lethality |
J:154944
|
Gt(ROSA)26Sortm7(CAG-mCherry,-EGFP/tetX)Dym/Gt(ROSA)26Sor+
Tmem163Tg(ACTB-cre)2Mrt/0
Tg(Fev-flpe)1Dym/0
involves: 129S6/SvEvTac * FVB/N
|
abnormal axon morphology |
J:154944
|
|
abnormal breathing pattern |
J:231745
|
|
abnormal oxygen consumption |
J:231745
|
|
decreased anxiety-related response |
J:154944
|
|
decreased body size |
J:231745
|
|
decreased heart rate |
J:231745
|
|
enhanced contextual conditioning behavior |
J:154944
|
|
hypopnea |
J:231745
|
|
increased exploration in new environment |
J:154944
|
|
increased prepulse inhibition |
J:154944
|
|
increased pulmonary ventilation |
J:231745
|
|
increased susceptibility to induced morbidity/mortality |
J:231745
|
|
increased tidal volume |
J:231745
|
Gt(ROSA)26Sortm7(CAG-mCherry,-EGFP/tetX)Dym/Gt(ROSA)26Sor+
En1tm2(cre)Wrst/En1+
Tg(ACTFLPe)9205Dym/0
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * SJL
|
perinatal lethality |
J:154944
|
Gt(ROSA)26Sortm7(CAG-mCherry,-EGFP/tetX)Dym/Gt(ROSA)26Sor+
En1tm2(cre)Wrst/En1+
Tg(Fev-flpe)1Dym/0
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ
|
abnormal axon morphology |
J:154944
|
|
normal
behavior/neurological phenotype |
J:154944
|
|
decreased anxiety-related response |
J:154944
|
Gt(ROSA)26Sortm7(CAG-mCherry,-EGFP/tetX)Dym/Gt(ROSA)26Sor+
Tg(ACTFLPe)9205Dym/0
Tg(Atoh1-cre)1Bfri/0
involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL
|
abnormal ear physiology |
J:154944
|
|
abnormal excitatory postsynaptic currents |
J:154944
|
|
abnormal gait |
J:154944
|
|
abnormal synaptic vesicle recycling |
J:154944
|
|
impaired balance |
J:154944
|
|
impaired coordination |
J:154944
|
|
short stride length |
J:154944
|
Gt(ROSA)26Sortm7(CAG-mCherry,-EGFP/tetX)Dym/Gt(ROSA)26Sor+
Tg(ACTFLPe)9205Dym/0
Tg(Pcp2-cre)2Mpin/0
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * SJL
|
tremors |
J:154944
|
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/Gt(ROSA)26Sor+
Tg(CAG-cre/Esr1*)5Amc/0
B6.Cg-Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky Tg(CAG-cre/Esr1*)5Amc
|
abnormal blood vessel morphology |
J:264410
|
|
abnormal limb morphology |
J:264410
|
|
abnormal spleen morphology |
J:264410
|
|
abnormal vein morphology |
J:264410
|
|
dilated vasculature |
J:264410
|
|
enlarged lymphatic vessel |
J:264410
|
|
hepatic steatosis |
J:264410
|
|
increased cell proliferation |
J:264410
|
|
increased classified tumor incidence |
J:264410
|
|
internal hemorrhage |
J:264410
|
|
kidney cyst |
J:264410
|
|
liver hemorrhage |
J:264410
|
|
postnatal lethality, incomplete penetrance |
J:264410
|
|
premature death |
J:264410
|
|
renal fibrosis |
J:264410
|
|
scoliosis |
J:264410
|
|
skeletal muscle hypertrophy |
J:264410
|
|
visceromegaly |
J:264410
|
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky
Tg(Cr2-cre)3Cgn/0
involves: C57BL/6
|
neonatal lethality, complete penetrance |
J:157297
|
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky
Ighg1tm1(cre)Cgn/Ighg1+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal class switch recombination |
J:191824
|
|
increased B cell derived lymphoma incidence |
J:191824
|
|
increased germinal center B cell number |
J:191824
|
|
premature death |
J:191824
|
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/?
Ptpn11tm1.1Wbm/Ptpn11tm1.1Wbm
Tg(Dhh-cre)1Mejr/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
|
abnormal myelination |
J:207470
|
Gt(ROSA)26Sortm7(SMO*/YFP)Amc/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA * Swiss Webster
|
abnormal brain development |
J:165962
|
|
abnormal frontonasal prominence morphology |
J:165962
|
Gt(ROSA)26Sortm7.1(CAG-EGFP/RNAi:Tyr)Maoh/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal coat/hair pigmentation |
J:173808
|
|
abnormal ear pigmentation |
J:173808
|
|
choroidal neovascularization |
J:173808
|
Gt(ROSA)26Sortm7.1Sia/Gt(ROSA)26Sortm7.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm7Sia/Gt(ROSA)26Sortm7Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm8(Aifm1)Jhai/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
normal
mortality/aging |
J:194078
|
Gt(ROSA)26Sortm8(Map2k1*,EGFP)Rsky/Gt(ROSA)26Sor+
Tg(Cd4-cre)1Cwi/0
Traf3ip3tm1c(KOMP)Wtsi/Traf3ip3tm1c(KOMP)Wtsi
involves: C57BL/6 * C57BL/6N * DBA/2
|
normal
immune system phenotype |
J:226431
|
Gt(ROSA)26Sortm8(Map2k1*,EGFP)Rsky/Gt(ROSA)26Sortm8(Map2k1*,EGFP)Rsky
Igh-Jtm1Cgn/Ightm4Cgn
Tg(Cr2-cre)3Cgn/0
involves: 129P2/OlaHsd * C57BL/6
|
decreased mature B cell number |
J:157297
|
Gt(ROSA)26Sortm8(Map2k1*,EGFP)Rsky/?
Ptpn11tm1.1Wbm/Ptpn11tm1.1Wbm
Tg(Dhh-cre)1Mejr/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
|
hypermyelination |
J:207470
|
Gt(ROSA)26Sortm8(Map2k1*,EGFP)Rsky/?
Tg(Dhh-cre)1Mejr/0
involves: C57BL/6 * FVB/N
|
normal
nervous system phenotype |
J:207470
|
Gt(ROSA)26Sortm8(RNAi:Crhr1)Rkuhn/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6J
|
decreased anxiety-related response |
J:151155
|
|
decreased circulating corticosterone level |
J:151155
|
Gt(ROSA)26Sortm8.1Sia/Gt(ROSA)26Sortm8.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm8Sia/Gt(ROSA)26Sortm8Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm9(Aifm1*)Jhai/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
normal
mortality/aging |
J:194078
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NCr
|
no abnormal phenotype detected |
J:155793
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
involves: 129 * C57BL/6NCrl * FVB/N
|
increased metastatic potential |
J:245611
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:245611
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Prdm1tm1Clme/Prdm1tm1Clme
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
involves: 129 * C57BL/6NCrl * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:245611
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:245611
|
|
premature death |
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Syngap1tm1.1Geno/Syngap1+
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NCr
|
abnormal CNS synaptic transmission |
J:193208
|
|
abnormal glutamate-mediated receptor currents |
J:193208
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Hmga2tm1.1Mmw/Hmga2+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * FVB/N
|
increased metastatic potential |
J:245611
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Rn7sktm1.1Mfrye/Rn7sktm1.1Mfrye
Tg(KRT14-cre/ERT)20Efu/0
involves: 129 * C57BL/6NCrl * CBA * CD-1 * SJL
|
abnormal epidermal layer morphology |
J:331226
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * C57BL/6
|
enlarged lymph nodes |
J:170965
|
|
enlarged spleen |
J:170965
|
|
hunched posture |
J:170965
|
|
increased acute lymphoblastic leukemia incidence |
J:170965
|
|
increased spleen weight |
J:170965
|
|
premature death |
J:170965
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Rnf2tm1Mvi/Rnf2tm1Mvi
involves: 129S/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal neuron differentiation |
J:154927
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Ripk3tm1Arte/Ripk3tm1Arte
involves: C57BL/6NTac
|
abnormal crypts of Lieberkuhn morphology |
J:209137
|
|
abnormal intestine physiology |
J:209137
|
|
abnormal lymphocyte morphology |
J:209137
|
|
blunted small intestinal villi |
J:209137
|
|
diarrhea |
J:209137
|
|
fused small intestinal villi |
J:209137
|
|
intestinal edema |
J:209137
|
|
intestinal inflammation |
J:209137
|
|
normal
mortality/aging |
J:209137
|
|
thymus atrophy |
J:209137
|
|
weight loss |
J:209137
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Map3k14tm1.1Gne/Map3k14tm1.1Gne
B6(Cg)-Map3k14tm1.1Gne Gt(ROSA)26Sortm9(cre/ESR1)Arte
|
abnormal immunoglobulin level |
J:240453
|
|
decreased B cell number |
J:240453
|
|
decreased B cell proliferation |
J:240453
|
|
decreased germinal center B cell number |
J:240453
|
|
decreased IgA level |
J:240453
|
|
decreased IgG1 level |
J:240453
|
|
decreased IgM level |
J:240453
|
|
decreased Peyer's patch number |
J:240453
|
|
normal
immune system phenotype |
J:240453
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Pkn2tm1c(KOMP)Wtsi/Pkn2tm1c(KOMP)Wtsi
involves: C57BL/6N * C57BL/6NTac
|
abnormal embryo morphology |
J:229595
|
|
abnormal embryo turning |
J:229595
|
|
abnormal mesenchyme morphology |
J:229595
|
|
abnormal mesoderm morphology |
J:229595
|
|
abnormal mitosis |
J:229595
|
|
abnormal vascular development |
J:229595
|
|
absent pharyngeal arches |
J:229595
|
|
decreased fibroblast proliferation |
J:229595
|
|
decreased mitotic index |
J:229595
|
|
hemorrhage |
J:229595
|
|
increased embryonic tissue cell apoptosis |
J:229595
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Pcgf5tm1.1Aiwa/Pcgf5tm1.1Aiwa
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Pcgf5tm1.1Aiwa
|
normal
hematopoietic system phenotype |
J:248956
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/?
Tnfaip3tm1Homy/Tnfaip3tm1Homy
involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac
|
abnormal blood cell morphology/development |
J:212681
|
|
abnormal circulating cytokine level |
J:212681
|
|
abnormal circulating interleukin level |
J:212681
|
|
abnormal liver morphology |
J:212681
|
|
normal
hematopoietic system phenotype |
J:212681
|
|
increased apoptosis |
J:212681
|
|
increased circulating interferon-gamma level |
J:212681
|
|
increased circulating interleukin-1 beta level |
J:212681
|
|
increased circulating interleukin-6 level |
J:212681
|
|
increased circulating tumor necrosis factor level |
J:212681
|
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:212681
|
|
pale spleen |
J:212681
|
|
thymus atrophy |
J:212681
|
Gt(ROSA)26Sortm9(EGFP/Rpl10a)Amc/Gt(ROSA)26Sortm9(EGFP/Rpl10a)Amc
involves: 129S4/SvJae * C57BL/6
|
no abnormal phenotype detected |
J:206130
|
Gt(ROSA)26Sortm9(Rac1*,EGFP)Rsky/Gt(ROSA)26Sor+
Ptf1atm1(cre)Hnak/Ptf1a+
involves: C57BL/6
|
normal
endocrine/exocrine gland phenotype |
J:197054
|
|
normal
neoplasm |
J:197054
|
Gt(ROSA)26Sortm9(Rac1*,EGFP)Rsky/Gt(ROSA)26Sortm9(Rac1*,EGFP)Rsky
Igh-Jtm1Cgn/Ightm4Cgn
Tg(Cr2-cre)3Cgn/0
involves: 129P2/OlaHsd * C57BL/6
|
decreased mature B cell number |
J:157297
|
Gt(ROSA)26Sortm9.1Sia/Gt(ROSA)26Sortm9.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm9Sia/Gt(ROSA)26Sortm9Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm10(Gata2)Jhai/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
embryonic lethality |
J:194078
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
involves: BALB/cJ
|
abnormal B cell morphology |
J:181546
|
|
increased B cell proliferation |
J:181546
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ
|
enlarged spleen |
J:181546
|
|
increased B cell number |
J:181546
|
|
premature death |
J:181546
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ
|
enlarged liver |
J:181546
|
|
enlarged spleen |
J:181546
|
|
increased B cell derived lymphoma incidence |
J:181546
|
|
increased B cell number |
J:181546
|
|
increased plasmacytoma incidence |
J:181546
|
|
premature death |
J:181546
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/cJ
|
abnormal B cell differentiation |
J:181546
|
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:181546
|
|
abnormal immune system physiology |
J:181546
|
|
decreased B cell number |
J:181546
|
|
decreased mature B cell number |
J:181546
|
|
decreased pre-B cell number |
J:181546
|
|
enlarged spleen |
J:181546
|
|
increased B cell number |
J:181546
|
|
increased B cell proliferation |
J:181546
|
|
increased CD4-positive, alpha-beta T cell number |
J:181546
|
|
increased CD8-positive, alpha-beta T cell number |
J:181546
|
|
increased pro-B cell number |
J:181546
|
|
increased susceptibility to induced morbidity/mortality |
J:181546
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6
|
normal
neoplasm |
J:181546
|
Gt(ROSA)26Sortm10.1Sia/Gt(ROSA)26Sortm10.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm10Sia/Gt(ROSA)26Sortm10Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm11(CAG-Braf*/ERT2)Rkuhn/Gt(ROSA)26Sortm11(CAG-Braf*/ERT2)Rkuhn
involves: 129S6/SvEvTac * C57BL/6J
|
no abnormal phenotype detected |
J:196873
|
Gt(ROSA)26Sortm11(Gata3)Jhai/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
normal
mortality/aging |
J:194078
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
involves: C57BL/6
|
abnormal B cell morphology |
J:181546
|
|
increased B cell proliferation |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
enlarged spleen |
J:181546
|
|
increased B cell number |
J:181546
|
|
premature death |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
enlarged liver |
J:181546
|
|
enlarged spleen |
J:181546
|
|
increased B cell derived lymphoma incidence |
J:181546
|
|
increased B cell number |
J:181546
|
|
increased plasmacytoma incidence |
J:181546
|
|
premature death |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell differentiation |
J:181546
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:181546
|
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:181546
|
|
abnormal immune system physiology |
J:181546
|
|
decreased B cell number |
J:181546
|
|
decreased mature B cell number |
J:181546
|
|
decreased pre-B cell number |
J:181546
|
|
enlarged spleen |
J:181546
|
|
increased B cell number |
J:181546
|
|
increased B cell proliferation |
J:181546
|
|
increased CD4-positive, alpha-beta T cell number |
J:181546
|
|
increased CD8-positive, alpha-beta T cell number |
J:181546
|
|
increased interferon-gamma secretion |
J:181546
|
|
increased pro-B cell number |
J:181546
|
|
increased susceptibility to induced morbidity/mortality |
J:181546
|
|
increased tumor necrosis factor secretion |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
normal
neoplasm |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre/ERT2)Rsky/Cd19+
involves: 129P2/OlaHsd * C57BL/6J
|
abnormal T cell physiology |
J:217520
|
|
enlarged spleen |
J:217520
|
|
increased activated T cell number |
J:217520
|
|
increased B cell number |
J:217520
|
|
increased CD4-positive, alpha-beta T cell number |
J:217520
|
|
increased CD8-positive, alpha-beta T cell number |
J:217520
|
Gt(ROSA)26Sortm11.1Sia/Gt(ROSA)26Sortm11.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm11Sia/Gt(ROSA)26Sortm11Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm12(CD2*)Rsky/Gt(ROSA)26Sor+
Myctm2Fwa/Myctm2Fwa
Ighg1tm1(cre)Cgn/Ighg1+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6
|
decreased spleen germinal center size |
J:188564
|
Gt(ROSA)26Sortm12.1Sia/Gt(ROSA)26Sor+
Haus6tm1.2Sdwb/Haus6tm1.2Sdwb
B6.Cg-Haus6tm1.2Sdwb Gt(ROSA)26Sortm12.1Sia
|
abnormal mitotic spindle morphology |
J:235084
|
Gt(ROSA)26Sortm12.1Sia/Gt(ROSA)26Sortm12.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm12Sia/Gt(ROSA)26Sortm12Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky/Gt(ROSA)26Sor+
Myctm2Fwa/Myctm2Fwa
Ighg1tm1(cre)Cgn/Ighg1+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6
|
normal
immune system phenotype |
J:188564
|
Gt(ROSA)26Sortm13.1Sia/Gt(ROSA)26Sortm13.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm13Sia/Gt(ROSA)26Sortm13Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NCr
|
no abnormal phenotype detected |
J:155793
|
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Rr271em1Mgn/Rr271+
Sox17tm2(EGFP/cre)Mgn/Sox17+
involves: 129S6/SvEvTac * C57BL/6NCrl * CD-1
|
decreased embryo size |
J:328045
|
|
failure of initiation of embryo turning |
J:328045
|
|
truncated foregut |
J:328045
|
Gt(ROSA)26Sortm14.1Sia/Gt(ROSA)26Sortm14.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm14Jhai/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
normal
mortality/aging |
J:194078
|
Gt(ROSA)26Sortm14Sia/Gt(ROSA)26Sortm14Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm15.1Sia/Gt(ROSA)26Sortm15.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm15Sia/Gt(ROSA)26Sortm15Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm16.1Sia/Gt(ROSA)26Sortm16.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm16Jhai/Gt(ROSA)26Sor+
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCr * CBA
|
normal
cellular phenotype |
J:195147
|
Gt(ROSA)26Sortm16Sia/Gt(ROSA)26Sortm16Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm17.1Sia/Gt(ROSA)26Sortm17.1Sia
involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm17Sia/Gt(ROSA)26Sortm17Sia
involves: C57BL/6NCrlj * CBA/JNCrlj
|
no abnormal phenotype detected |
J:180918
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL
|
increased T cell derived lymphoma incidence |
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Cd4-cre)1Cwi/0
involves: C57BL/6 * CD-1 * DBA/2
|
increased T cell acute lymphoblastic leukemia incidence |
J:263520
|
|
premature death |
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Tek-cre)1Ywa/0
involves: C57BL/6 * CD-1 * SJL
|
increased T cell acute lymphoblastic leukemia incidence |
J:263520
|
|
increased thymus tumor incidence |
J:263520
|
|
premature death |
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL
|
increased leukemia incidence |
J:263520
|
|
increased T cell derived lymphoma incidence |
J:263520
|
|
increased thymoma incidence |
J:263520
|
Gt(ROSA)26Sortm18.1Sia/Gt(ROSA)26Sor+
involves: C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:196795
|
Gt(ROSA)26Sortm19.1Sia/Gt(ROSA)26Sor+
involves: C57BL/6NCrlj * CBA/JNCrlj * FVB/N
|
no abnormal phenotype detected |
J:196795
|
Gt(ROSA)26Sortm31(H1/tetO-RNAi:Insr)Arte/Gt(ROSA)26Sor+
involves: C57BL/6
|
hyperglycemia |
J:151686
|
|
insulin resistance |
J:151686
|
Gt(ROSA)26Sortm35.1(CAG-aop3/GFP)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr
|
no abnormal phenotype detected |
J:172633
|
Gt(ROSA)26Sortm37(H1/tetO-RNAi:Tafazzin)Arte/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6J
|
abnormal heart left ventricle morphology |
J:167527
|
|
abnormal myocardial fiber morphology |
J:167527
|
|
abnormal sarcomere morphology |
J:167527
|
|
abnormal skeletal muscle fiber morphology |
J:167527
|
|
decreased body weight |
J:167527
|
|
decreased cardiac muscle contractility |
J:167527
|
|
dilated heart left ventricle |
J:167527
|
|
increased mitochondrial fission |
J:167527
|
|
increased mitochondrial number |
J:167527
|
Gt(ROSA)26Sortm37(H1/tetO-RNAi:Tafazzin)Arte/?
Not Specified
|
abnormal mitochondrial morphology |
J:176041
|
|
abnormal mitochondrial physiology |
J:176041
|
|
decreased heart left ventricle muscle contractility |
J:176041
|
|
impaired skeletal muscle contractility |
J:176041
|
Gt(ROSA)26Sortm38.1(CAG-GCaMP3)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr
|
no abnormal phenotype detected |
J:171735
|
Gt(ROSA)26Sortm39.1(CAG-hop/EYFP)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr
|
no abnormal phenotype detected |
J:172634
|
Gt(ROSA)26Sortm39.1(CAG-hop/EYFP)Hze/Gt(ROSA)26Sor+
Shox2tm1.1(cre)Oki/Shox2+
involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6
|
abnormal nervous system physiology |
J:209344
|
Gt(ROSA)26Sortm40.1(CAG-aop3/EGFP)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * C57BL/6NCr
|
no abnormal phenotype detected |
J:191265
|
Gt(ROSA)26Sortm47(HTT)Arte/Gt(ROSA)26Sor+
Not Specified
|
decreased locomotor activity |
J:243843
|
|
decreased vertical activity |
J:243843
|
|
impaired coordination |
J:243843
|
|
nervous system inclusion bodies |
J:243843
|
|
premature death |
J:243843
|
Gt(ROSA)26Sortm48(HTT)Arte/Gt(ROSA)26Sor+
Not Specified
|
abnormal medium spiny neuron morphology |
J:243843
|
|
decreased locomotor activity |
J:243843
|
|
decreased vertical activity |
J:243843
|
|
impaired coordination |
J:243843
|
|
nervous system inclusion bodies |
J:243843
|
|
premature death |
J:243843
|
Gt(ROSA)26Sortm49(HTT)Arte/Gt(ROSA)26Sor+
Not Specified
|
decreased locomotor activity |
J:243843
|
|
decreased vertical activity |
J:243843
|
|
impaired coordination |
J:243843
|
|
premature death |
J:243843
|
Gt(ROSA)26Sortm50(HTT)Arte/Gt(ROSA)26Sor+
Not Specified
|
decreased vertical activity |
J:243843
|
|
impaired coordination |
J:243843
|
|
premature death |
J:243843
|
Gt(ROSA)26Sortm51(HTT)Arte/Gt(ROSA)26Sor+
Not Specified
|
premature death |
J:243843
|
Gt(ROSA)26Sortm65.1(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm66.1(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * C57BL/6NCr
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm75.1(CAG-tdTomato*)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm80.1(CAG-COP4*L132C/EYFP)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm95.1(CAG-GCaMP6f)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm95.1(CAG-GCaMP6f)Hze/Gt(ROSA)26Sor+
Piezo2tm1c(KOMP)Wtsi/Piezo2tm1c(KOMP)Wtsi
involves: 129S6/SvEvTac * C57BL/6NCrl
|
abnormal CNS synaptic transmission |
J:266637
|
|
abnormal nociception after inflammation |
J:266637
|
|
abnormal touch escape response |
J:266637
|
|
ataxia |
J:266637
|
Gt(ROSA)26Sortm96(CAG-GCaMP6s)Hze/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6
|
no abnormal phenotype detected |
J:101977
|
Gt(ROSA)26Sortm407(H1/tetO-RNAi:Large)Arte/Gt(ROSA)26Sor+
B6.Cg-Gt(ROSA)26Sortm407(H1/tetO-RNAi:Large)Arte
|
abnormal basement membrane morphology |
J:206057
|
|
abnormal neuromuscular synapse morphology |
J:206057
|
|
centrally nucleated skeletal muscle fibers |
J:206057
|
|
dystrophic muscle |
J:206057
|
|
enhanced skeletal muscle regeneration |
J:206057
|
|
increased susceptibility to injury |
J:206057
|
|
limb grasping |
J:206057
|
|
normal
muscle phenotype |
J:206057
|
|
skeletal muscle endomysial fibrosis |
J:206057
|
|
skeletal muscle necrosis |
J:206057
|
Hand2tm1Dsr/Hand2tm2.1Dsr
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Isl1tm1(cre)Tmj/Isl1+
involves: 129S4/SvJaeSor * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6
|
abnormal heart development |
J:169213
|
Hand2tm1Dsr/Hand2tm2.1Dsr
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Tg(Tbx1-cre)#Dsr/0
involves: 129 * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6
|
abnormal cardiac outflow tract development |
J:169213
|
|
decreased heart right ventricle size |
J:169213
|
Hdac1tm1.1Mrl/Hdac1tm1.1Mrl
Hdac2tm1.1Rdp/Hdac2tm1.1Rdp
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal mitosis |
J:197818
|
|
decreased fibroblast proliferation |
J:197818
|
|
early cellular replicative senescence |
J:197818
|
Hif1atm3Rsjo/Hif1atm3Rsjo
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
Hprt1tm1(Pck1-cre)Vhh/Y
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ
|
abnormal cell differentiation |
J:130751
|
|
decreased susceptibility to injury |
J:130751
|
|
kidney inflammation |
J:130751
|
|
renal fibrosis |
J:130751
|
Hoxb1tm1.1Mist/Hoxb1tm1.1Mist
Tg(Hoxb1-cre)r4Mist/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * CD-1
|
abnormal brainstem morphology |
J:197162
|
|
abnormal cochlear outer hair cell morphology |
J:197162
|
|
abnormal cochlear VIII nucleus morphology |
J:197162
|
|
abnormal organ of Corti morphology |
J:197162
|
|
abnormal pons morphology |
J:197162
|
|
abnormal susceptibility to hearing loss |
J:197162
|
|
increased or absent threshold for auditory brainstem response |
J:197162
|
|
increased susceptibility to age-related hearing loss |
J:197162
|
Hoxb1tm1Mist/Hoxb1tm1Mist
Tg(Hoxb1-cre)r4Mist/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * CD-1
|
abnormal brainstem morphology |
J:197162
|
|
abnormal cochlear outer hair cell morphology |
J:197162
|
|
abnormal cochlear VIII nucleus morphology |
J:197162
|
|
abnormal organ of Corti morphology |
J:197162
|
|
abnormal pons morphology |
J:197162
|
|
increased or absent threshold for auditory brainstem response |
J:197162
|
|
increased susceptibility to age-related hearing loss |
J:197162
|
Hprt1tm4(CAG-Tbx18*,-Venus)Akis/Y
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Tbx18tm4(cre)Akis/Tbx18+
involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * NMRI
|
abnormal epicardium development |
J:210076
|
Hprt1tm6(CAG-fat-1)Geno/Y
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal fatty acids level |
J:213660
|
Hsp90aa1tm1.2Udon/Hsp90aa1tm1.2Udon
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac * FVB/N
|
abnormal male germ cell apoptosis |
J:187954
|
|
arrest of spermatogenesis |
J:187954
|
|
azoospermia |
J:187954
|
|
decreased testis weight |
J:187954
|
|
small testis |
J:187954
|
|
testicular atrophy |
J:187954
|
Htatsf1tm1Jakn/Htatsf1tm1Jakn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6J
|
abnormal pluripotent precursor cell morphology |
J:271373
|
Htr2ctm2Jke/Y
Tg(Pomc1-cre)16Lowl/0
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * FVB/N
|
abnormal nervous system electrophysiology |
J:207704
|
Il13tm1(YFP/cre)Lky/Il13+
Il4tm1(CD2)Mmrs/Il4+
Gt(ROSA)26Sortm1(DTA)Lky/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae
|
decreased eosinophil cell number |
J:178986
|
|
increased susceptibility to parasitic infection |
J:178986
|
Itchtm1.1Alta/Itchtm1.1Alta
Gt(ROSA)26Sortm1Hjf/Gt(ROSA)26Sor+
Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:204685
|
|
increased inflammatory response |
J:204685
|
Itgb1tm1Mll/Itgb1tm1Mll
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Tg(Nes-cre/Esr1*)1Kuan/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB
|
abnormal Bergmann glial cell morphology |
J:191222
|
|
abnormal cerebellar foliation |
J:191222
|
|
abnormal cerebellum external granule cell layer morphology |
J:191222
|
|
abnormal cerebellum fissure morphology |
J:191222
|
|
abnormal cerebellum lobule morphology |
J:191222
|
|
ectopic cerebellar granule cells |
J:191222
|
Jag1tm1Frad/Jag1tm1Frad
Tg(Cdh5-cre)7Mlia/0
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129 * 129S4/SvJaeSor * FVB/N
|
abnormal atrioventricular cushion morphology |
J:189213
|
|
abnormal cardiac epithelial to mesenchymal transition |
J:189213
|
Kdm6atm1.1Afst/Y
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NTac
|
normal
hematopoietic system phenotype |
J:196401
|
Kdm6atm1.1Afst/Kdm6atm1.1Afst
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NTac
|
abnormal bone marrow cell morphology/development |
J:196401
|
|
abnormal bone structure |
J:196401
|
|
abnormal erythropoiesis |
J:196401
|
|
abnormal granulocyte morphology |
J:196401
|
|
abnormal hematopoietic stem cell physiology |
J:196401
|
|
abnormal megakaryocyte morphology |
J:196401
|
|
anemia |
J:196401
|
|
decreased common myeloid progenitor cell number |
J:196401
|
|
decreased erythrocyte cell number |
J:196401
|
|
decreased erythroid progenitor cell number |
J:196401
|
|
decreased hemoglobin content |
J:196401
|
|
decreased leukocyte cell number |
J:196401
|
|
decreased mean corpuscular volume |
J:196401
|
|
enlarged spleen |
J:196401
|
|
extramedullary hematopoiesis |
J:196401
|
|
increased B cell number |
J:196401
|
|
increased spleen weight |
J:196401
|
|
spontaneous chromosome breakage |
J:196401
|
|
thrombocytopenia |
J:196401
|
|
weight loss |
J:196401
|
Kdrtm1Wag/Kdrtm1Wag
Nfatc1tm1.1(cre)Bz/Nfatc1+
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6
|
abnormal angiogenesis |
J:193198
|
|
abnormal coronary artery morphology |
J:193198
|
Kittm1.1(cre)Jmol/Kittm2.1(cre/Esr1*)Jmol
Gt(ROSA)26Sortm1(CAG-lacZ,-EGFP)Glh/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J * FVB
|
abnormal heart development |
J:210584
|
|
neonatal lethality, complete penetrance |
J:210584
|
Kittm1.1(cre)Jmol/Kittm2.1(cre/Esr1*)Jmol
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J
|
abnormal heart development |
J:210584
|
|
neonatal lethality, complete penetrance |
J:210584
|
Kmt2btm1Afst/Kmt2btm1.1Afst
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6
|
female infertility |
J:166778
|
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae
|
abnormal colon goblet cell morphology |
J:132357
|
|
abnormal intestinal epithelium morphology |
J:132357
|
|
abnormal large intestine crypts of Lieberkuhn morphology |
J:132357
|
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Tg(Flt3-cre)#Ccb/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
anemia |
J:247853
|
|
decreased B cell number |
J:247853
|
|
decreased double-negative T cell number |
J:247853
|
|
decreased double-positive T cell number |
J:247853
|
|
decreased hematopoietic stem cell number |
J:247853
|
|
decreased T cell number |
J:247853
|
|
hepatosplenomegaly |
J:247853
|
|
increased dendritic cell number |
J:247853
|
|
increased leukemia incidence |
J:247853
|
|
increased leukocyte cell number |
J:247853
|
|
increased monocyte cell number |
J:247853
|
|
premature death |
J:247853
|
|
thrombocytopenia |
J:247853
|
|
thymus atrophy |
J:247853
|
|
weight loss |
J:247853
|
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm3(CAG-luc)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae
|
increased lung tumor incidence |
J:141383
|
Krastm4Tyj/Kras+
Tg(Cdh5-cre/ERT2)1Rha/0
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6NCrl * FVB
|
normal
cardiovascular system phenotype |
J:312482
|
|
postnatal lethality |
J:312482
|
Krastm4Tyj/Kras+
Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+
Tg(Pdx1-cre)6Tuv/0
TgTn(sb-T2/Onc)#Dla/0
involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N
|
increased pancreas tumor incidence |
J:186717
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:186717
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:186717
|
|
premature death |
J:186717
|
Krastm5Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sortm1(cre/ERT2)Tyj
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased sarcoma incidence |
J:172206
|
Lcp2tm1Gak/Lcp2tm2Gak
Tg(Pf4-icre)Q3Rsko/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal lymphatic vessel morphology |
J:162815
|
|
abnormal Peyer's patch morphology |
J:162815
|
|
abnormal platelet activation |
J:162815
|
Lcp2tm1Gak/Lcp2tm2Gak
Tg(VAV1-cre)1Graf/0
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal lymphatic vessel morphology |
J:162815
|
|
intestinal edema |
J:162815
|
Lef1tm1Hhx/Lef1tm1Hhx
Tcf7tm1Cle/Tcf7tm1Cle
Gt(ROSA)26Sortm2Sho/Gt(ROSA)26Sor+
Tg(GZMB-cre)1Jcb/0
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N
|
abnormal memory T cell physiology |
J:189838
|
|
decreased CD8-positive, alpha-beta T cell number |
J:189838
|
|
decreased tumor necrosis factor secretion |
J:189838
|
Lgr5tm1(cre/ERT2)Fjs/Lgr5tm2(Hbegf/EGFP)Fjs
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N
|
normal
digestive/alimentary phenotype |
J:177145
|
|
neonatal lethality, complete penetrance |
J:177145
|
Mc4rtm2Lowl/Mc4rtm2Lowl
Chattm1(cre)Lowl/Chat+
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
involves: 129S6/SvEvTac * C57BL/6NCr
|
abnormal nervous system electrophysiology |
J:193452
|
|
normal
nervous system phenotype |
J:193452
|
Mcl1tm1Dmta/Mcl1+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
B6.Cg-Mcl1tm1Dmta Gt(ROSA)26Sortm9(cre/ESR1)Arte
|
decreased germinal center B cell number |
J:166069
|
|
decreased memory B cell number |
J:166069
|
Mcl1tm1Dmta/Mcl1tm1Dmta
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
B6.Cg-Mcl1tm1Dmta Gt(ROSA)26Sortm9(cre/ESR1)Arte
|
abnormal B cell differentiation |
J:166069
|
|
absent germinal center B cells |
J:166069
|
|
absent memory B cells |
J:166069
|
|
decreased naive B cell number |
J:166069
|
Men1tm1.2Ctre/Men1tm1.2Ctre
Pax3tm1(cre)Joe/Pax3+
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac
|
normal
cardiovascular system phenotype |
J:127545
|
|
normal
digestive/alimentary phenotype |
J:127545
|
Mesp2tm1Ysa/Mesp2tm10Ysa
Gt(ROSA)26Sor/?
involves: 129 * C57BL/6 * CBA
|
failure of somite differentiation |
J:120635
|
Mir148atm2942.1Arte/Mir148atm2942.1Arte
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
abnormal B cell physiology |
J:307366
|
|
abnormal plasmablast number |
J:307366
|
|
decreased plasma cell number |
J:307366
|
|
impaired humoral immune response |
J:307366
|
|
increased plasma cell number |
J:307366
|
Mirc14tm1.1Czc/Mirc14tm1.1Czc
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
either: (involves: 129P2/OlaHsd * 129S4/SvJae * 129S4/SvJaeSor) or (involves: 129P2/OlaHsd * 129S4/SvJae * 129S4/SvJaeSor * C57BL/6)
|
decreased double-positive T cell number |
J:188125
|
|
thymus hypoplasia |
J:188125
|
Mllt11tm1c(KOMP)Mbp/Mllt11tm1c(KOMP)Mbp
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Cux2tm1.1(cre)Mull/Cux2+
involves: C57BL/6 * C57BL/6J * C57BL/6N
|
abnormal neurite morphology |
J:324710
|
|
abnormal stratification in cerebral cortex |
J:324710
|
Myctm2Fwa/Myctm2Fwa
Gt(ROSA)26Sortm1Sor/?
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * CBA
|
abnormal coronal suture morphology |
J:121871
|
|
abnormal frontal bone morphology |
J:121871
|
|
abnormal malleus morphology |
J:121871
|
|
short nasal bone |
J:121871
|
|
small malleus |
J:121871
|
|
small malleus manubrium |
J:121871
|
Myo18atm1c(KOMP)Wtsi/Myo18atm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N
|
normal
immune system phenotype |
J:277320
|
Myo18atm1c(KOMP)Wtsi/Myo18atm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Tnnt2-cre)5Blh/0
involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * C57BL/6N * DBA/2
|
lethality throughout fetal growth and development, complete penetrance |
J:277320
|
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
abnormal male germ cell apoptosis |
J:195140
|
|
abnormal male germ cell morphology |
J:195140
|
|
abnormal small intestine morphology |
J:195140
|
|
chromosomal instability |
J:195140
|
|
decreased body length |
J:195140
|
|
decreased litter size |
J:195140
|
|
decreased testis weight |
J:195140
|
|
normal
hematopoietic system phenotype |
J:195140
|
|
increased B cell derived lymphoma incidence |
J:195140
|
|
increased cellular sensitivity to ionizing radiation |
J:195140
|
|
increased hepatocellular carcinoma incidence |
J:195140
|
|
increased leukemia incidence |
J:195140
|
|
increased mortality induced by ionizing radiation |
J:195140
|
|
increased T cell derived lymphoma incidence |
J:195140
|
|
increased thymocyte apoptosis |
J:195140
|
|
increased tumor incidence |
J:195140
|
|
oligozoospermia |
J:195140
|
|
reduced male fertility |
J:195140
|
|
normal
reproductive system phenotype |
J:195140
|
|
small testis |
J:195140
|
|
testis degeneration |
J:195140
|
Nap1l2tm2.1Ucr/Y
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
|
abnormal neural tube morphology |
J:82809
|
Nap1l2tm2.1Ucr/Nap1l2tm2.1Ucr
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
|
abnormal neural tube morphology |
J:82809
|
Nfatc1tm1Glm/Nfatc1tm1Glm
Gt(ROSA)26Sortm1Sho/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * CBA
|
abnormal cardiac outflow tract development |
J:185683
|
Nfatc1tm1Glm/Nfatc1tm1Glm
Tg(Tek-cre)1Ywa/0
Gt(ROSA)26Sortm1Sho/Gt(ROSA)26Sor+
involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * SJL
|
abnormal cardiac outflow tract development |
J:185683
|
Nkx2-2tm2.1Suss/Nkx2-2tm2.1Suss
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Ins2-cre)23Herr/0
involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * CBA/J * SJL
|
abnormal pancreatic beta cell differentiation |
J:177838
|
Nkx2-2tm2.1Suss/Nkx2-2tm2.1Suss
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Pdx1-cre/Esr1*)#Dam/0
involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * CBA * SJL
|
abnormal pancreatic beta cell differentiation |
J:177838
|
Nkx6-1tm1Jlr/Nkx6-1tm1.1Msan
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Tg(Ins2-cre)25Mgn/0
involves: 129 * C57BL/6 * DBA * SJL
|
abnormal pancreatic beta cell differentiation |
J:195153
|
|
decreased pancreatic beta cell number |
J:195153
|
|
increased pancreatic delta cell number |
J:195153
|
Nle1tm1Cba/Nle1tm1.1Cota
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S2/SvPas
|
abnormal bone marrow cell morphology/development |
J:204063
|
|
abnormal common lymphocyte progenitor cell morphology |
J:204063
|
|
abnormal hematopoietic stem cell physiology |
J:204063
|
|
abnormal immune system organ morphology |
J:204063
|
|
abnormal intestinal epithelium morphology |
J:204063
|
|
abnormal ribosome biogenesis |
J:204063
|
|
decreased bone marrow cell number |
J:204063
|
|
decreased common myeloid progenitor cell number |
J:204063
|
|
decreased granulocyte number |
J:204063
|
|
decreased macrophage cell number |
J:204063
|
|
decreased NK cell number |
J:204063
|
|
decreased T cell number |
J:204063
|
|
normal
hematopoietic system phenotype |
J:204063
|
|
impaired hematopoiesis |
J:204063
|
|
premature death |
J:204063
|
|
spleen hypoplasia |
J:204063
|
|
thymus hypoplasia |
J:204063
|
Nle1tm1Cba/Nle1tm1.1Cota
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas
|
normal
hematopoietic system phenotype |
J:204063
|
Nodaltm1.1Ysa/Nodaltm1.1Ysa
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
abnormal male germ cell morphology |
J:191052
|
Notch1tm1Agt/Notch1tm1Agt
Tg(Cdh5-cre)7Mlia/0
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129 * 129S4/SvJaeSor * FVB/N
|
abnormal atrioventricular cushion morphology |
J:189213
|
|
abnormal cardiac epithelial to mesenchymal transition |
J:189213
|
Nr4a2tm1.1Pcn/Nr4a2tm1.1Pcn
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
abnormal regulatory T cell morphology |
J:205658
|
|
abnormal T-helper 1 cell differentiation |
J:205658
|
|
abnormal T-helper 17 cell differentiation |
J:205658
|
Nrbp1tm1.1Dja/Nrbp1tm1.1Dja
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J
|
abnormal crypts of Lieberkuhn morphology |
J:184685
|
|
abnormal enterocyte proliferation |
J:184685
|
|
abnormal intestinal enteroendocrine cell morphology |
J:184685
|
|
abnormal intestinal goblet cell morphology |
J:184685
|
|
abnormal intestinal mucosa morphology |
J:184685
|
|
abnormal intestine morphology |
J:184685
|
|
abnormal liver morphology |
J:184685
|
|
decreased tumor-free survival time |
J:184685
|
|
distended stomach |
J:184685
|
|
ectopic Paneth cells |
J:184685
|
|
increased gastrointestinal tumor incidence |
J:184685
|
|
increased leukemia incidence |
J:184685
|
|
increased lung carcinoma incidence |
J:184685
|
|
increased lymphoma incidence |
J:184685
|
|
increased tumor incidence |
J:184685
|
|
intestinal edema |
J:184685
|
Nrbp1tm1.1Dja/Nrbp1tm1.2Dja
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J
|
abnormal crypts of Lieberkuhn morphology |
J:184685
|
|
abnormal enterocyte proliferation |
J:184685
|
|
abnormal intestinal enteroendocrine cell morphology |
J:184685
|
|
abnormal intestinal goblet cell morphology |
J:184685
|
|
abnormal intestinal mucosa morphology |
J:184685
|
|
abnormal intestine morphology |
J:184685
|
|
abnormal liver morphology |
J:184685
|
|
decreased tumor-free survival time |
J:184685
|
|
distended stomach |
J:184685
|
|
ectopic Paneth cells |
J:184685
|
|
increased gastrointestinal tumor incidence |
J:184685
|
|
increased leukemia incidence |
J:184685
|
|
increased lung carcinoma incidence |
J:184685
|
|
increased lymphoma incidence |
J:184685
|
|
increased tumor incidence |
J:184685
|
|
intestinal edema |
J:184685
|
Nt5c2tm1.1Aafo/Nt5c2+
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
involves: 129 * C57BL/6 * SJL
|
abnormal bone marrow cell physiology |
J:257751
|
Ntrk2tm2Kln/Ntrk2tm2Kln
Slc1a3tm1(cre/ERT2)Mgoe/?
Gt(ROSA)26Sortm1Sor/?
involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * SJL
|
abnormal dendrite morphology |
J:143452
|
|
abnormal neuron differentiation |
J:143452
|
|
decreased locomotor activity |
J:143452
|
|
increased thigmotaxis |
J:143452
|
|
reduced long-term potentiation |
J:143452
|
Nubp2tm1c(EUCOMM)Hmgu/Nubp2tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Tg(Wnt1-GAL4)11Rth/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA/J
|
increased cranial neural crest cell apoptosis |
J:284772
|
Nup160tm1Mdan/Nup160tm1Mdan
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6
|
abnormal hematopoietic stem cell physiology |
J:301567
|
|
decreased hematopoietic stem cell proliferation |
J:301567
|
Odad3tm1c(EUCOMM)Hmgu/Odad3tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N
|
asthenozoospermia |
J:278798
|
|
oligozoospermia |
J:278798
|
P2ry6tm1Jabo/P2ry6tm1Jabo
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte P2ry6tm1Jabo
|
abnormal respiratory mucosa goblet cell morphology |
J:179177
|
|
increased eosinophil cell number |
J:179177
|
|
increased interferon-gamma secretion |
J:179177
|
|
increased interleukin-4 secretion |
J:179177
|
|
increased interleukin-5 secretion |
J:179177
|
|
increased interleukin-13 secretion |
J:179177
|
|
increased neutrophil cell number |
J:179177
|
|
lung inflammation |
J:179177
|
P2ry6tm1Jabo/P2ry6tm1Jabo
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129 * C57BL/6 * C57BL/6NTac
|
abnormal respiratory mucosa goblet cell morphology |
J:179177
|
|
decreased IgE level |
J:179177
|
|
decreased T cell apoptosis |
J:179177
|
|
increased eosinophil cell number |
J:179177
|
|
increased interferon-gamma secretion |
J:179177
|
|
increased interleukin-4 secretion |
J:179177
|
|
increased interleukin-5 secretion |
J:179177
|
|
increased interleukin-13 secretion |
J:179177
|
|
increased neutrophil cell number |
J:179177
|
|
increased T cell proliferation |
J:179177
|
|
lung inflammation |
J:179177
|
Pax7tm1(cre/ERT2)Gaka/Pax7+
Gt(ROSA)26Sortm1(DTA)Mrc/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6
|
decreased satellite cell number |
J:174914
|
|
impaired skeletal muscle regeneration |
J:174914
|
|
skeletal muscle fibrosis |
J:174914
|
Pde6batrd1/Pde6btm1Eye
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * 129S6/SvEvTac * BALB/cAnN * C3H/HeN * C57BL/6J
|
abnormal ocular fundus morphology |
J:200898
|
|
abnormal retina blood vessel morphology |
J:200898
|
|
abnormal retina cone cell morphology |
J:200898
|
|
decreased retina photoreceptor cell number |
J:200898
|
|
retina photoreceptor degeneration |
J:200898
|
|
normal
vision/eye phenotype |
J:200898
|
Pdgfratm8Sor/Pdgfratm8Sor
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal dorsal mesocardium morphology |
J:157946
|
|
dual inferior vena cava |
J:157946
|
|
total anomalous pulmonary venous connection |
J:157946
|
Pdpk1tm1.1Mlw/Pdpk1tm1.1Mlw
Rag2tm1Fwa/Rag2tm1Fwa
Tnfrsf4tm2(cre)Nik/Tnfrsf4+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129S/SvEv * 129X1/SvJ * C57BL/6
|
abnormal keratinocyte differentiation |
J:226194
|
|
dermatitis |
J:226194
|
|
epidermal hyperplasia |
J:226194
|
|
premature death |
J:226194
|
Pdpk1tm1.1Mlw/Pdpk1tm1.1Mlw
Tnfrsf4tm2(cre)Nik/Tnfrsf4+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
involves: 129X1/SvJ * C57BL/6
|
abnormal hypodermis fat layer morphology |
J:226194
|
|
abnormal keratinocyte differentiation |
J:226194
|
|
abnormal regulatory T cell number |
J:226194
|
|
abnormal T cell physiology |
J:226194
|
|
cachexia |
J:226194
|
|
dermatitis |
J:226194
|
|
enlarged lymph nodes |
J:226194
|
|
enlarged spleen |
J:226194
|
|
epidermal hyperplasia |
J:226194
|
|
hair follicle degeneration |
J:226194
|
|
hyperkeratosis |
J:226194
|
|
impaired skin barrier function |
J:226194
|
|
premature death |
J:226194
|
|
premature hair loss |
J:226194
|
|
scaly skin |
J:226194
|
|
skin fibrosis |
J:226194
|
|
skin hyperplasia |
J:226194
|
|
skin lesions |
J:226194
|
|
thick skin |
J:226194
|
Pi4katm1.1Arte/Pi4katm1.1Arte
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6NTac
|
abnormal cecum morphology |
J:188779
|
|
abnormal digestive system morphology |
J:188779
|
|
abnormal duodenum morphology |
J:188779
|
|
abnormal gastric parietal cell morphology |
J:188779
|
|
abnormal intestine morphology |
J:188779
|
|
abnormal stomach mucosa morphology |
J:188779
|
|
distended stomach |
J:188779
|
|
premature death |
J:188779
|
Pi4katm2.1Arte/Pi4ka+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6NTac
|
abnormal coat appearance |
J:188779
|
|
abnormal digestive system morphology |
J:188779
|
|
abnormal spleen morphology |
J:188779
|
|
decreased body weight |
J:188779
|
|
hunched posture |
J:188779
|
|
premature death |
J:188779
|
Pi4katm2.1Arte/Pi4katm2.1Arte
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6NTac
|
abnormal coat appearance |
J:188779
|
|
abnormal digestion |
J:188779
|
|
abnormal digestive system morphology |
J:188779
|
|
abnormal large intestine crypts of Lieberkuhn morphology |
J:188779
|
|
abnormal large intestine morphology |
J:188779
|
|
abnormal small intestinal villus morphology |
J:188779
|
|
abnormal small intestine crypts of Lieberkuhn morphology |
J:188779
|
|
decreased body size |
J:188779
|
|
diarrhea |
J:188779
|
|
hunched posture |
J:188779
|
|
premature death |
J:188779
|
|
unresponsive to tactile stimuli |
J:188779
|
Pitx2tm1.1Sac/Pitx2tm2Sac
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Gt(ROSA)26Sortm1Sor/?
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6 * CBA
|
abnormal eye development |
J:104125
|
|
abnormal eye muscle development |
J:104125
|
|
abnormal eye pigmentation |
J:104125
|
|
abnormal optic stalk morphology |
J:104125
|
|
abnormal retina pigmentation |
J:104125
|
|
absent optic nerve |
J:104125
|
|
absent sclera |
J:104125
|
|
anophthalmia |
J:104125
|
|
decreased cornea stroma thickness |
J:104125
|
Pkd1tm1Gztn/Pkd1tm1Gztn
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S/Sv * 129S7/SvEvBrd * C57BL/6
|
abnormal kidney physiology |
J:162080
|
|
polycystic kidney |
J:162080
|
Pkd1tm2Ggg/Pkd1tm2Ggg
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
increased kidney weight |
J:213263
|
Pknox1tm2.1Fbla/Pknox1tm2.1Fbla
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd
|
decreased pre-B cell number |
J:192251
|
|
increased pro-B cell number |
J:192251
|
Prmt5tm2c(EUCOMM)Wtsi/Prmt5tm2c(EUCOMM)Wtsi
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/SvlmJ * C57BL/6Brd * C57BL/6N * SJL
|
decreased embryo size |
J:201152
|
|
embryonic growth retardation |
J:201152
|
|
pallor |
J:201152
|
Psmd11tm1.1Qit/Psmd11tm1.1Qit
Gt(ROSA)26Sortm3(CAG-Cre/ERT2)Dsa/Gt(ROSA)26Sor+
Tg(ACTFLPe)9205Dym/0
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
increased apoptosis |
J:301736
|
Ptch1tm1Hahn/Ptch1+
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6
|
premature death |
J:149148
|
Ptch1tm1Hahn/Ptch1+
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6
|
epidermal cyst |
J:149148
|
|
increased fibroma incidence |
J:149148
|
|
increased tumor incidence |
J:149148
|
|
premature death |
J:149148
|
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
decreased tumor growth/size |
J:158915
|
|
increased basal cell carcinoma incidence |
J:158915
|
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6
|
increased basal cell carcinoma incidence |
J:149148
|
|
increased tumor incidence |
J:149148
|
|
premature death |
J:149148
|
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal double-negative T cell morphology |
J:127207
|
|
abnormal hematopoietic system morphology/development |
J:127207
|
|
abnormal thymus lobule morphology |
J:127207
|
|
decreased B cell number |
J:127207
|
|
decreased double-positive T cell number |
J:127207
|
|
decreased immature B cell number |
J:127207
|
|
decreased lymphocyte cell number |
J:127207
|
|
decreased pre-B cell number |
J:127207
|
|
decreased transitional stage B cell number |
J:127207
|
|
increased B cell number |
J:127207
|
|
increased basal cell carcinoma incidence |
J:149148
|
|
increased double-negative T cell number |
J:127207
|
|
increased mature B cell number |
J:127207
|
|
increased neutrophil cell number |
J:127207
|
|
increased single-positive T cell number |
J:127207
|
|
increased tumor incidence |
J:149148
|
|
premature death |
J:149148
|
|
thymus hypoplasia |
J:127207
|
Rac1tm1Djk/Rac1tm1Djk
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Tg(Mef2c-cre)2Blk/0
involves: 129 * BALB/c * C57BL/6 * C57BL/6J
|
abnormal interventricular septum muscular part morphology |
J:315097
|
|
decreased cell migration |
J:315097
|
Rad50tm1Jpt/Rad50tm3Jpt
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129/Sv * C57BL/6
|
abnormal intestine morphology |
J:209141
|
|
postnatal lethality, complete penetrance |
J:209141
|
Rag1tm1.1Sadu/Rag1tm1.1Sadu
Trdctm1Mal/Trdctm1Mal
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * BALB/c * C57BL/6
|
absent gamma-delta T cells |
J:187400
|
|
decreased gamma-delta T cell number |
J:187400
|
|
increased gamma-delta T cell number |
J:187400
|
|
small thymus |
J:187400
|
Rbfox2tm1.1Dblk/Rbfox2tm1.1Dblk
E2f1Tg(Wnt1-cre)2Sor/E2f1+
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
involves: 129S/Sv * 129X1/SvJ * C57BL/6J
|
normal
cellular phenotype |
J:279139
|
|
normal
embryo phenotype |
J:279139
|
Rbfox2tm1.1Dblk/Rbfox2tm1.1Dblk
Pax3tm1(cre)Joe/0
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J
|
normal
cellular phenotype |
J:279139
|
|
normal
embryo phenotype |
J:279139
|
Rbpjtm1Hon/Rbpjtm1.1Hon
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ptf1atm2(cre/ESR1)Cvw/Ptf1a+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
normal
endocrine/exocrine gland phenotype |
J:180310
|
Rbpjtm1Hon/Rbpjtm1.1Hon
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Hes1tm1(cre/ERT2)Lcm/Hes1+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
abnormal centroacinar cell of Langerhans morphology |
J:180310
|
|
abnormal pancreas physiology |
J:180310
|
|
normal
endocrine/exocrine gland phenotype |
J:180310
|
|
increased pancreatic acinar cell number |
J:180310
|
Rem2tm1c(EUCOMM)Hmgu/Rem2tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6N * C57BL/6NCrl
|
decreased dendritic spine density |
J:263600
|
Resttm1.1Bban/Rest+
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * C57BL/6J
|
cochlear hair cell degeneration |
J:265659
|
|
impaired hearing |
J:265659
|
|
increased or absent threshold for auditory brainstem response |
J:265659
|
Riok2tm1c(KOMP)Wtsi/Riok2+
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6N
|
anemia |
J:305794
|
|
decreased erythrocyte cell number |
J:305794
|
|
decreased hematocrit |
J:305794
|
|
decreased hemoglobin content |
J:305794
|
Rr96tm1.1Tich/Rr96+
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129 * 129S4/SvJae * C57BL/6
|
abnormal T cell differentiation |
J:191711
|
Rr96tm1.1Tich/Rr96+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
involves: 129 * 129S4/SvJae * C57BL/6
|
abnormal CD4-positive T cell differentiation |
J:191711
|
Rr96tm1.1Tich/Rr96tm1.1Tich
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(rtTA*M2)Jae
involves: 129 * 129S4/SvJae * C57BL/6
|
abnormal T cell differentiation |
J:191711
|
Scxtm1Eno/Scxtm1Eno
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
either: (involves: 129S4/SvJaeSor * 129S7/SvEvBrd * Swiss) or (involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6)
|
abnormal ectoplacental cone morphology |
J:55991
|
|
abnormal egg cylinder morphology |
J:55991
|
|
abnormal extraembryonic tissue morphology |
J:55991
|
|
abnormal parietal endoderm morphology |
J:55991
|
|
abnormal visceral endoderm morphology |
J:55991
|
|
absent mesoderm |
J:55991
|
|
embryonic growth arrest |
J:55991
|
|
embryonic growth retardation |
J:55991
|
|
embryonic lethality between somite formation and embryo turning, incomplete penetrance |
J:55991
|
|
failure of primitive streak formation |
J:55991
|
|
failure to gastrulate |
J:55991
|
Sdhbtm1c(EUCOMM)Hmgu/Sdhbtm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
Tg(Ins2-cre)23Herr/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * CBA/J
|
abnormal pancreatic beta cell physiology |
J:326592
|
Sdhctm1c(EUCOMM)Wtsi/Sdhctm1c(EUCOMM)Wtsi
Gt(ROSA)26Sortm1.1(rtTA,tetO-cre)Bkmn/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6N
|
abnormal blood homeostasis |
J:284745
|
|
abnormal muscle physiology |
J:284745
|
|
abnormal tricarboxylic acid cycle |
J:284745
|
|
decreased circulating glucose level |
J:284745
|
|
decreased circulating insulin level |
J:284745
|
|
decreased energy expenditure |
J:284745
|
|
decreased grip strength |
J:284745
|
|
decreased locomotor activity |
J:284745
|
|
decreased vertical activity |
J:284745
|
|
impaired coordination |
J:284745
|
|
increased body fat mass |
J:284745
|
|
increased circulating creatine kinase level |
J:284745
|
|
lactic acidosis |
J:284745
|
|
normal
neoplasm |
J:284745
|
|
premature death |
J:284745
|
|
weight loss |
J:284745
|
Setd4tm1c(KOMP)Wtsi/Setd4tm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6 * C57BL/6N
|
abnormal tumor pathology |
J:297725
|
|
decreased apoptosis |
J:297725
|
|
decreased mortality induced by ionizing radiation |
J:297725
|
|
decreased tumor growth/size |
J:297725
|
|
increased metastatic potential |
J:297725
|
|
increased tumor latency |
J:297725
|
Setd4tm1c(KOMP)Wtsi/Setd4tm1c(KOMP)Wtsi
Trp53tm1Brn/Trp53+
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6N
|
abnormal tumor latency |
J:297725
|
|
normal
neoplasm |
J:297725
|
Setd4tm1c(KOMP)Wtsi/Setd4tm1c(KOMP)Wtsi
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6N
|
abnormal tumor latency |
J:297725
|
|
decreased metastatic potential |
J:297725
|
|
decreased tumor latency |
J:297725
|
|
increased mortality induced by gamma-irradiation |
J:297725
|
|
increased tumor growth/size |
J:297725
|
Sh2d1atm1.1Knic/Y
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129X1/SvJ * C57BL/6
|
abnormal NK T cell physiology |
J:196692
|
|
decreased circulating interleukin-4 level |
J:196692
|
|
decreased interferon-gamma secretion |
J:196692
|
|
normal
immune system phenotype |
J:196692
|
Sh2d1atm1.1Knic/Sh2d1atm1.1Knic
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129X1/SvJ * C57BL/6
|
abnormal NK T cell physiology |
J:196692
|
|
decreased circulating interleukin-4 level |
J:196692
|
|
decreased interferon-gamma secretion |
J:196692
|
|
normal
immune system phenotype |
J:196692
|
Sh2d1atm2.1Cpt/Y
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
abnormal germinal center B cell physiology |
J:189126
|
|
abnormal humoral immune response |
J:189126
|
|
decreased IgG level |
J:189126
|
|
decreased IgM level |
J:189126
|
|
normal
immune system phenotype |
J:189126
|
Sh2d1atm2.1Cpt/Sh2d1atm2.1Cpt
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
abnormal germinal center B cell physiology |
J:189126
|
|
abnormal humoral immune response |
J:189126
|
|
decreased IgG level |
J:189126
|
|
decreased IgM level |
J:189126
|
|
normal
immune system phenotype |
J:189126
|
Sh3kbp1tm1Kuro/Sh3kbp1tm1Kuro
Cd79atm1(cre)Reth/Cd79a+
Gt(ROSA)26Sortm4(Ikbkb)Rsky/?
involves: BALB/c * C57BL/6 * NZB
|
decreased B-1a cell number |
J:176805
|
|
normal
immune system phenotype |
J:176805
|
Slc17a6tm1.1Thna/Slc17a6tm1.1Thna
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Slc6a3tm1(cre)Xz/Slc6a3+
involves: 129/Sv * 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J
|
abnormal dopaminergic neuron morphology |
J:167767
|
|
abnormal excitatory postsynaptic currents |
J:167767
|
|
decreased dopamine level |
J:167767
|
|
impaired behavioral response to cocaine |
J:167767
|
Slc34a2tm1.1Scc/Slc34a2tm1.1Scc
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129 * C57BL/6 * C57BL/6NTac
|
abnormal feces composition |
J:166317
|
|
abnormal intestinal absorption |
J:166317
|
|
calcified pulmonary alveolus |
J:166317
|
|
decreased physiological sensitivity to xenobiotic |
J:166317
|
|
decreased urine calcium level |
J:166317
|
|
decreased urine phosphate level |
J:166317
|
Smarca4tm1.2Pcn/Smarca4tm1.2Pcn
Nfatc1tm1.1(cre)Bz/Nfatc1+
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ
|
abnormal semilunar valve morphology |
J:226941
|
Smarce1tm1Tich/Smarce1tm2.1Tich
Gt(ROSA)26Sortm3(CAG-flpo/ERT2)Alj/Gt(ROSA)26Sor+
Tg(Cd4-cre)1Cwi/0
involves: 129S6/SvEvTac * C57BL/6 * DBA/2
|
normal
immune system phenotype |
J:194195
|
Smg6tm1.1Zqw/Smg6tm1.1Zqw
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae
|
abnormal cell morphology |
J:222980
|
|
abnormal cell physiology |
J:222980
|
|
abnormal telomere morphology |
J:222980
|
|
normal
cellular phenotype |
J:222980
|
Smotm2Amc/Smotm2.1Amc
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+
involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J * CBA/J
|
decreased cardiac neural crest cell number |
J:135134
|
|
impaired cardiac neural crest cell differentiation |
J:135134
|
Sptlc2tm1Yhir/Sptlc2tm1Yhir
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac
|
abnormal circulating protein level |
J:202954
|
|
abnormal intestinal mucosa morphology |
J:202954
|
|
abnormal large intestine crypts of Lieberkuhn morphology |
J:202954
|
|
abnormal pancreatic acinar cell zymogen granule morphology |
J:202954
|
|
abnormal small intestinal villus morphology |
J:202954
|
|
abnormal small intestine crypts of Lieberkuhn morphology |
J:202954
|
|
abnormal spleen morphology |
J:202954
|
|
abnormal stomach mucosa morphology |
J:202954
|
|
abnormal thymus morphology |
J:202954
|
|
cellular necrosis |
J:202954
|
|
decreased bone marrow cell number |
J:202954
|
|
decreased lymphocyte cell number |
J:202954
|
|
decreased spleen weight |
J:202954
|
|
decreased thymus weight |
J:202954
|
|
increased adrenal gland weight |
J:202954
|
|
increased blood urea nitrogen level |
J:202954
|
|
increased circulating alanine transaminase level |
J:202954
|
|
increased circulating serum albumin level |
J:202954
|
|
increased erythrocyte cell number |
J:202954
|
|
increased hematocrit |
J:202954
|
|
increased hemoglobin content |
J:202954
|
|
increased neutrophil cell number |
J:202954
|
|
reticulocytopenia |
J:202954
|
|
sebaceous gland atrophy |
J:202954
|
Syktm1.1(cre)Fkfr/Syktm1.1(cre)Fkfr
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sortm1(EYFP)Cos
involves: 129S1/Sv * 129X1/SvJ
|
abnormal blood vessel morphology |
J:159112
|
|
abnormal liver development |
J:159112
|
|
abnormal lymphangiogenesis |
J:159112
|
|
decreased leukocyte cell number |
J:159112
|
|
decreased liver weight |
J:159112
|
|
increased leukocyte cell number |
J:159112
|
|
liver hypoplasia |
J:159112
|
Taf1btm1c(EUCOMM)Hmgu/Taf1btm1c(EUCOMM)Hmgu
Trp53tm1Tyj/Trp53tm1Tyj
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm1(cre/ERT)Nat
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * C57BL/6N
|
abnormal nucleolus morphology |
J:321558
|
Tbx4tm1.2Pa/Tbx4tm1.2Pa
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N
|
abnormal autopod morphology |
J:117423
|
|
abnormal digit morphology |
J:117423
|
|
abnormal limb bud morphology |
J:117423
|
|
abnormal metatarsal bone morphology |
J:117423
|
|
abnormal pelvic girdle bone morphology |
J:117423
|
|
absent femur |
J:117423
|
|
embryonic lethality during organogenesis, complete penetrance |
J:117423
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:117423
|
|
failure of chorioallantoic fusion |
J:117423
|
|
fused phalanges |
J:117423
|
|
hindlimb oligodactyly |
J:117423
|
|
normal
limbs/digits/tail phenotype |
J:117423
|
|
short femur |
J:117423
|
|
short fibula |
J:117423
|
|
short hindlimb |
J:117423
|
Tcf7l2tm3.1(cre/ERT2)Mrc/Tcf7l2+
Gt(ROSA)26Sortm1(DTA)Mrc/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal muscle morphology |
J:174914
|
|
abnormal muscle regeneration |
J:174914
|
|
decreased satellite cell number |
J:174914
|
Tektm1.1Vlcg/Tektm1.1Vlcg
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/?
Tg(tetO-cre)1Jaw/0
involves: 129 * C57BL/6NCr
|
abnormal anterior eye segment morphology |
J:217296
|
|
buphthalmos |
J:217296
|
|
increased cornea size |
J:217296
|
|
increased eye anterior chamber depth |
J:217296
|
Telo2tm1Tdl/Telo2tm1.1Tdl
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129 * 129P2/OlaHsd * C57BL/6J
|
abnormal cell cycle |
J:141633
|
|
abnormal DNA repair |
J:141633
|
|
early cellular replicative senescence |
J:141633
|
Telo2tm1Tdl/Telo2tm1.1Tdl
Trp53tm1Tyj/Trp53tm1Tyj
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129 * 129P2/OlaHsd * 129S2/SvPas * C57BL/6J
|
abnormal cell cycle |
J:141633
|
Tg(VAV1-cre)1Graf/?
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/?
Trip11tm1.1Psmi/Trip11tm1.2Psmi
involves: 129/Sv * C57BL/6
|
normal
immune system phenotype |
J:253969
|
|
normal
skeleton phenotype |
J:253969
|
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(Tie1-cre)9Ref/?
Gt(ROSA)26Sortm1Sor/?
involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6J
|
abnormal visceral yolk sac morphology |
J:128498
|
|
abnormal vitelline vasculature morphology |
J:128498
|
|
absent vitelline blood vessels |
J:128498
|
|
embryonic growth retardation |
J:128498
|
|
embryonic lethality during organogenesis, complete penetrance |
J:128498
|
|
pericardial effusion |
J:128498
|
Tgfbr2tm1Karl/Tgfbr2tm1Karl
Tg(Tagln-cre)1Her/?
Gt(ROSA)26Sortm1Sor/?
involves: 129 * C57BL/6 * SJL
|
abnormal heart morphology |
J:128498
|
|
abnormal vitelline vasculature morphology |
J:128498
|
|
delayed brain development |
J:128498
|
|
delayed heart development |
J:128498
|
|
embryonic growth retardation |
J:128498
|
|
lethality throughout fetal growth and development, complete penetrance |
J:128498
|
|
pale yolk sac |
J:128498
|
Tgfbr2tm1Karl/Tgfbr2tm1Karl
Tg(Tie1-cre)9Ref/?
Gt(ROSA)26Sortm1Sor/?
involves: 129 * 129S1/Sv * 129X1/SvJ * C57BL/6J
|
abnormal pharyngeal arch morphology |
J:128498
|
|
abnormal vitelline vasculature morphology |
J:128498
|
|
absent vitelline blood vessels |
J:128498
|
|
embryonic growth retardation |
J:128498
|
|
embryonic lethality during organogenesis, complete penetrance |
J:128498
|
|
pericardial effusion |
J:128498
|
Trim71tm1695Arte/Trim71tm1695Arte
Tg(tetO-cre)1Jaw/0
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Trim71tm1695Arte Tg(tetO-cre)1Jaw
|
abnormal neural tube morphology |
J:335575
|
Trip11tm1.1Psmi/Trip11tm1.2Psmi
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/?
Tg(CAG-cre/Esr1*)5Amc/?
involves: 129/Sv * C57BL/6 * SJL/J
|
abnormal Golgi vesicle transport |
J:253969
|
Trip11tm1.1Psmi/Trip11tm1.2Psmi
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/?
Tg(Col2a1-cre)1Bhr/?
involves: 129/Sv * C57BL/6 * SJL/J
|
abnormal chondrocyte morphology |
J:253969
|
|
abnormal Golgi stack morphology |
J:253969
|
|
chondrodystrophy |
J:253969
|
|
decreased length of long bones |
J:253969
|
|
delayed bone mineralization |
J:253969
|
|
delayed endochondral bone ossification |
J:253969
|
|
domed cranium |
J:253969
|
|
impaired lung alveolus development |
J:253969
|
|
perinatal lethality, complete penetrance |
J:253969
|
|
short limbs |
J:253969
|
|
short snout |
J:253969
|
|
small thoracic cage |
J:253969
|
Trp53tm1Att/Trp53tm1Att
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
involves: 129S4/SvJae
|
decreased apoptosis |
J:173395
|
Trp53tm1Brn/Trp53+
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
decreased tumor latency |
J:297725
|
|
increased mortality induced by gamma-irradiation |
J:297725
|
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
decreased tumor latency |
J:297725
|
|
increased mortality induced by gamma-irradiation |
J:297725
|
Trp53tm3Att/Trp53tm3Att
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
involves: 129S4/SvJae
|
normal
cellular phenotype |
J:173395
|
Trp53tm4Att/Trp53tm4Att
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
involves: 129S4/SvJae
|
decreased apoptosis |
J:173395
|
Tsc1tm1Djk/Tsc1tm1Djk
Gt(ROSA)26Sortm1Sho/Gt(ROSA)26Sor+
involves: 129S4/SvJae * 129S4/SvJaeSor
|
abnormal brain morphology |
J:221022
|
|
abnormal brain ventricle morphology |
J:221022
|
|
abnormal neuron morphology |
J:221022
|
|
abnormal postnatal subventricular zone morphology |
J:221022
|
|
cachexia |
J:221022
|
|
enlarged lateral ventricles |
J:221022
|
|
hunched posture |
J:221022
|
|
hydrocephaly |
J:221022
|
|
increased brain size |
J:221022
|
|
premature death |
J:221022
|
Tsixtm1.1Awu/Tsix+
Tg(CAG-EGFP)50Osb/0
Gt(ROSA)26Sortm1(rtTA)Awu/Gt(ROSA)26Sortm1(rtTA)Awu
involves: 129P2/OlaHsd * 129S4/SvJae * C3H/HeSlc * C57BL/6J * C57BL/6Slc
|
abnormal capillary morphology |
J:174672
|
|
abnormal DNA methylation |
J:174672
|
|
abnormal dosage compensation, by inactivation of X chromosome |
J:174672
|
|
abnormal imprinting |
J:174672
|
|
abnormal placenta labyrinth morphology |
J:174672
|
|
abnormal trophoblast giant cell morphology |
J:174672
|
|
abnormal trophoblast layer morphology |
J:174672
|
|
absent placental labyrinth |
J:174672
|
|
absent spongiotrophoblast |
J:174672
|
|
decreased capillary density |
J:174672
|
|
embryonic growth retardation |
J:174672
|
|
increased trophoblast giant cell number |
J:174672
|
|
small placenta |
J:174672
|
Tsixtm1.1Awu/Y
Tg(CAG-EGFP)50Osb/0
Gt(ROSA)26Sortm1(rtTA)Awu/Gt(ROSA)26Sortm1(rtTA)Awu
involves: 129P2/OlaHsd * 129S4/SvJae * C3H/HeSlc * C57BL/6J * C57BL/6Slc
|
no abnormal phenotype detected |
J:174672
|
Tsixtm1.1Awu/Tsixtm1.1Awu
Tg(CAG-EGFP)50Osb/0
Gt(ROSA)26Sortm1(rtTA)Awu/Gt(ROSA)26Sortm1(rtTA)Awu
involves: 129P2/OlaHsd * 129S4/SvJae * C3H/HeSlc * C57BL/6J * C57BL/6Slc
|
no abnormal phenotype detected |
J:174672
|
Ttc21btm2c(KOMP)Wtsi/Ttc21baln
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * A/J * C57BL/6N
|
abnormal kidney morphology |
J:213263
|
|
abnormal loop of Henle morphology |
J:213263
|
|
decreased kidney epithelial cell primary cilium length |
J:213263
|
|
dilated proximal convoluted tubule |
J:213263
|
|
increased blood urea nitrogen level |
J:213263
|
|
increased kidney cell proliferation |
J:213263
|
|
increased kidney weight |
J:213263
|
|
polycystic kidney |
J:213263
|
Ucp2tm2.1Lowl/Ucp2tm2.1Lowl
Gt(ROSA)26Sortm1(CAG-Kcnj11*,-GFP)Nich/?
Tg(Pmch-cre)1Lowl/0
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * FVB/NJ
|
impaired glucose tolerance |
J:167906
|
Ufl1tm1c(EUCOMM)Wtsi/Ufl1tm1c(EUCOMM)Wtsi
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C3H * C57BL/6 * C57BL/6N
|
abnormal autophagy |
J:238253
|
|
abnormal bone marrow cell physiology |
J:238253
|
|
anemia |
J:238253
|
|
decreased erythrocyte cell number |
J:238253
|
|
decreased erythroid progenitor cell number |
J:238253
|
|
decreased granulocyte number |
J:238253
|
|
decreased hematocrit |
J:238253
|
|
decreased hemoglobin content |
J:238253
|
|
decreased leukocyte cell number |
J:238253
|
|
decreased lymphocyte cell number |
J:238253
|
|
decreased monocyte cell number |
J:238253
|
|
pancytopenia |
J:238253
|
|
premature death |
J:238253
|
|
thrombocytopenia |
J:238253
|
|
weight loss |
J:238253
|
Vgll4tm1b(EUCOMM)Hmgu/Vgll4tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
involves: 129S6/SvEvTac * C57BL/6NCrl * CBA * SJL
|
abnormal heart development |
J:273437
|
Vipas39tm1c(KOMP)Mbp/Vipas39tm1c(KOMP)Mbp
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6J * C57BL/6N
|
abnormal tendon collagen fibril morphology |
J:236095
|
|
alopecia |
J:236095
|
|
dry skin |
J:236095
|
|
normal
growth/size/body region phenotype |
J:236095
|
|
scaly skin |
J:236095
|
Vps33btm1.1Arte/Vps33btm1.1Arte
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6J
|
abnormal megakaryocyte morphology |
J:222766
|
|
abnormal tendon collagen fibril morphology |
J:236095
|
|
alopecia |
J:236095
|
|
decreased dendritic cell number |
J:222766
|
|
decreased lymphocyte cell number |
J:222766
|
|
decreased mean platelet volume |
J:222766
|
|
decreased platelet aggregation |
J:222766
|
|
decreased platelet alpha-granule number |
J:222766
|
|
dry skin |
J:222766,
J:236095
|
|
enlarged spleen |
J:222766
|
|
extramedullary hematopoiesis |
J:222766
|
|
normal
growth/size/body region phenotype |
J:236095
|
|
increased bleeding time |
J:222766
|
|
increased macrophage cell number |
J:222766
|
|
increased megakaryocyte cell number |
J:222766
|
|
increased monocyte cell number |
J:222766
|
|
increased neutrophil cell number |
J:222766
|
|
scaly skin |
J:222766,
J:236095
|
|
skin lesions |
J:222766
|
|
thrombocytosis |
J:222766
|
Wapltm1.1Jmpt/Wapltm1.2Jmpt
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129 * C57BL/6 * C57BL/6NTac * SJL
|
abnormal cell cycle |
J:205429
|
|
abnormal mitosis |
J:205429
|
|
absent fibroblast proliferation |
J:205429
|
Wbp1ltm2c(EUCOMM)Hmgu/Wbp1ltm2c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6N * SJL
|
abnormal bone marrow cell physiology |
J:284781
|
Wnt1tm1.1Mze/Wnt1tm1.1Mze
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
En1tm2(cre)Wrst/En1+
involves: 129 * C57BL/6N
|
abnormal hindbrain morphology |
J:194842
|
|
abnormal innervation |
J:194842
|
|
abnormal midbrain morphology |
J:194842
|
|
abnormal rhombomere morphology |
J:194842
|
|
decreased neuron number |
J:194842
|
|
decreased neuronal precursor cell number |
J:194842
|
Wnt1tm1.1Mze/Wnt1tm1.1Mze
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Shhtm1(EGFP/cre)Cjt/Shh+
involves: 129S6/SvEvTac * C57BL/6N
|
abnormal midbrain morphology |
J:194842
|
|
decreased neuron number |
J:194842
|
|
premature neuronal precursor differentiation |
J:194842
|
Wnt1tm1.1Mze/Wnt1tm1.1Mze
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Tg(Wnt1-cre/ERT)1Alj/0
involves: 129S6/SvEvTac * C57BL/6N * Swiss Webster
|
abnormal midbrain morphology |
J:194842
|
Xpo7tm1c(KOMP)Wtsi/Xpo7tm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129S4/SvJae * C57BL/6N
|
decreased hematocrit |
J:331429
|
Zfp809tm1c(KOMP)Wtsi/Zfp809tm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N
|
abnormal cell physiology |
J:219938
|
Zfp830tm2.1Cota/Zfp830tm2.2Cota
Gt(ROSA)26Sortm2(cre/ERT2)Brn/?
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6
|
decreased cell proliferation |
J:171647
|
|
early cellular replicative senescence |
J:171647
|
Zfxtm1.1Reiz/Y
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
involves: 129/Sv * 129S6/SvEvTac
|
abnormal common lymphocyte progenitor cell morphology |
J:149654
|
|
abnormal hematopoietic system physiology |
J:149654
|
|
decreased hematopoietic stem cell number |
J:149654
|
Zfyve21tm2c(EUCOMM)Wtsi/Zfyve21tm2c(EUCOMM)Wtsi
Tg(Cdh5-cre/ERT2)1Rha/0
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N
|
abnormal body weight |
J:350543
|
|
abnormal glomerular endothelium fenestra morphology |
J:350543
|
|
abnormal glomerular filtration barrier function |
J:350543
|
|
abnormal kidney physiology |
J:350543
|
|
abnormal peritubular capillary morphology |
J:350543
|
|
abnormal renal filtration |
J:350543
|
|
abnormal renal glomerulus morphology |
J:350543
|
|
abnormal renal water homeostasis |
J:350543
|
|
decreased body weight |
J:350543
|
|
decreased circulating serum albumin level |
J:350543
|
|
decreased podocyte number |
J:350543
|
|
decreased renal glomerular filtration rate |
J:350543
|
|
edema |
J:350543
|
|
increased circulating creatinine level |
J:350543
|
|
increased glomerular capsule space |
J:350543
|
|
increased vascular permeability |
J:350543
|
Analysis Tools
Excel File